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CHAPTER I 
INTRODUCTION 
In terest in the components and functions of the fibrinolytic  
ensayme system  or plaam inogen^plasm in system  has been stim ulated  
largely  by the availability of activators and inhibitors of this system , 
as preparations suitable for u se  in man* A dm inistration of these  
substances as therapeutic agents in man has lead to m ore fundamental 
understanding of the physiological function of the fibrinolytic enzym e 
system  and the biochem ical abnorm alities which accompany pathological 
activity of this sy stem . This th esis  is  concerned with the study of 
certain  aspects of plasm inogen activation and its  inhibition*
Acute and frequently life-»threatening haem ostatic defects may 
be precipitated in part or wholly by d isordered activity of the 
fibrinolytic enayme system  and there is  increasing evidence that 
inhibitors of the system  may have value in the therapy of such states*  
Studies made for this th esis  included investigation of two compounds 
which p o ssess  activity as fibrinolytic inhibitors (chapters 4 and 5).
A number of c lin ica l tr ia ls  and individual w ell-docum ented  
cases have served  to estab lish  the feasib ility  and usefu lness of 
plasm inogen activators in the treatm ent of thrombo^embolic vascu lar  
d isea se . Up to the present tim e , the m ost frequently e m p l o y e d
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activator has been the bacteria l protein, streptokinase* This 
activator has certain  disadvantages, in particular its  antigenicity.
On the other hand, urokinase, the activator prepared from  human 
urine, has presum ed non-antigenicity. However, early preparations 
p o ssessed  marked throm boplastic activ ity . R ecently a com m ercial 
preparation of urokinase has been made available for tr ia l by 
clin ical in vestigators. One of the chapters of this th esis  describ es  
studies made with this preparation with a view to defining any 
coagulative properties it might p o sse ss  and includes investigation of 
its  effect on plasm inogen activation  in vivo (chapter 6).
The physiological role of the fibrinolytic enzym e system  is  
considered by many authorities to be the maintenance of a patent 
vasculature. One hypothesis concerning the development of 
ath erosc lerosis  links plasm a lipid  lev e ls  with the coagulation system  
and the fibrinolytic enzym e system . The hypothesis suggests that 
high plasm a lipid lev e ls  may accelerate  clotting and inhibit ly s is  
thus perm itting the in creased  occurrence and p ersisten ce  of 
intravascular fibrin. It is  thought that such fibrin can becom e 
incorporated in the subendothelial layer of the arteria l wall leading  
to the development of a th erosclerotic  plaques. The effect of fat
- 3 -
feeding on blood clotting, fib rin o lysis and p latelet aggregation  
was investigated as part of the work for this th esis  (chapter 7).
In chapter 8 of this th e s is , an account is  presented  of 
detailed investigation of the b iochem ical abnorm alities occurring in 
the defibrination syndrome; the patients studied had a variety  of 
associated  clin ica l disorders* It is  gene rally Ibelieved that abnormal 
fib rin o lysis may contribute in  part at lea st to the coagulation defect 
associated  with som e defibrination syndromes*
The th esis  is  presented in Z volum es. The fir s t  contains 
the text and references and the second figures and tab les . The 
text begins with an h istorica l introduction to the fibrinolytic enzyme 
System  and an account of current concepts of its  components and 
functions. There follow s a description  of the methods used  in the 
work for this th esis  and thereafter the presentation and d iscussion  
of the investigative work m entioned above. The figures are numbered  
in order of their introduction in the text and the tables are arranged  
s im ila r ly .
CHAPTER 2 
THE FIBRINOLYTIC ENZYME SYSTEM 
H istorica l Introduction 
Current extensive knowledge of components and functions of 
the fibrinolytic enzym e system  has largely  accum ulated over the past 
two decades although the ea r lie st  observations of fib rin o lysis appear to 
have been made nearly 200 years ago by Morgagni (1769) and Hunter 
(1794), In their w ritings is  recorded the finding of post-m ortem  
fluidity of blood in ca ses  of sudden death# Half a century la ter , Denis 
(1838) noted that washed human fibrin clots would d isso lve  in alkaline 
solution, P ld sz  (1873) dem onstrated that fibrin was rendered insoluble  
following re%)eated sa lt extraction and concluded that the substance 
responsible for d issolution  had been eluted during the p ro cess. He 
suggested  that the d issolving agent might be a tryptic enzym e, D astre  
(1893) called  the spontaneous dissolution  of whole blood c lo ts , fib rin o lysis , 
and attributed the phenomenon to enzym es attached to fibrin .
D elezenne and P ozersk i (1903) confirm ed the ea r lier  observations 
of Denys and de Marbaix (1889) that proteolytic activity appeared in serum  
m ixed with chloroform  and also  found that this activity disappeared on 
addition of untreated serum , They concluded that the effect of 
chloroform  might be to destroy proteolytic inhibitors.
Holf ( 1904) reported that the incoagulability of blood observed  
after peptone injection was associa ted  with a m arked in crease  in 
fibrinolytic activity and suggested  that the source of the substance 
producing fib rin olysis might be the vascu lar w all,
■ %t w ill be seen  that th ese  early  observations and hypotheses 
concerning the nature of fib rin o lysis  foreshadowed findings-made after  
the lapse of many,yearsk
A fundamental d iscovery in the fie ld  of fib rin o lysis  was made 
by T illett and Garner (1933) who showed that rapid ly s is  of human plasm a  
clots occurred  if they w ere form ed in. the-presence of culture filtra tes of 
certain  strains of haem olytic strep tococci. They thought that such culture 
filtra tes contained an enzym e with a d irect proteolytic effect on fibrin# 
However# Mil stone (1941) dem onstrated that the effect of the streptococcal 
substance was dependent on a factor contained in the globulin fraction of 
human serum  since pure human fibrin w as resistan t to ly s is  by the 
streptococcal substance alone but was rapidly ly sed  in its  presence on 
addition of a sm all amount of human serum  globulins. He named this 
a ccesso ry  component contained in human serum  globulins 'lytic factor'#  
Kaplan (1944) thought that 'lytic factor' was the sam e agent as 
the proteolytic substance which appeared in serum  on addition of chloroform .
C hristensen (1945) and C hristensen and MacLeod (1945) extended this 
observation and postulated that the streptococcal substance was a kinase 
which activated a globulin precursor of the fibrinolytic enzyme of 
human blood.
T hese workers a lso  proposed the term inology now m ost widely  
used by w orkers in the field  of fib r in o ly sis . They called  the streptococcal 
substance, streptokinase. The globulin precursor of the active 
fibrinolytic enzym e was named plasm inogen and the active enzym e, plasm in  
The enzym e system  responsib le for the phenomenon of fibrinolysis was 
called  the plasminogen*-x^asmin system  or fibrinolytic enzym e system .
Components and Functions of the F ibrinolytic  
Enzyme (System
There are four principal components of the fibrinolytic enzym e 
system : plasminogen# plasmin# activators and inhibitors (jfigure 1).
P lasm inogen . Plasm inogen is  the circulating plasm a precursor of the 
proteolytic enzym e plasmin* Kowalski et al# (1958) have suggested  that 
idasm inogen thought to be identical with plasm a plasminogen# is  present 
in various tissu es; C hristensen (1954) has dem onstrated plasm inogen in  
certain exudates and transudates and Lodi et al. (1961) its presence in  
lymph.
im 'J  m
The site  o£ plasm inogen synthesis in the body is  not definitely  
known although Barnhart and Riddle (1963) using a fluorescent antibody 
technique, have shown that eosinophils contain and may produce 
plasm inogen.
Plasm inogen is  a beta globulin but since absolutely pure 
preparations have not yet been obtained, its  characterisation  rem ains 
inadequate, Shulman et al* (1958) and Singher (I960) have shown that 
the plasm inogen m olecule contains about 8 hexose groups suggesting  
that it is  a glycoprotein# The form er workers have found a m olecular  
weight for plasm inogen of 143,000, More recently D avies and Englert 
(I960) and Hagan et a l. (I960) have reported it to be 83,000.
The m ost widely used  methods of preparation of plasm inogen have 
been evolved from  that of Kline (1953), This method is  based on two 
properties of plasm inogen, its  m arked acid resistan ce  (von Kaulla,
1949) and its  concentration in Cohn fraction III (C hristensen and Sm ith,
1950)which is  used as starting m ateria l. Such acid-fractionated  
plasm inogen is  sparingly soluble and unstable at neutral pH, More 
recently , A lkjaersig (1964), has produced, using D EA E*cellulose  
chromatography, a stable plasm inogen preparation of high sp ecific  
activity which is  readily soluble at neutral pH* Reports on sim ilar
preparations have been made by D avies and Englert (i960), Hagan 
et ai* (i960), De rechin (1962), De rechin ot a l, (1962), Wallen 
(1962 a, b), Hink and McDonald (1963), and Robbins and Sum maria
(1963). In this method basic amino acid s, such as lysin e or epsilon  
am inocaproic acid (EACA) are used  as se lec tive  effluents or to enhance 
solubility and prevent co-precip itation  of plasm inogen during the 
purification procedure* A com m ercial preparation of th is type has 
been made available recently (A*B, Kabi, Stockholm)*
Conversion of P lasm inogen to P lasm in  Troll and Sherry (1955) and 
A lkjaersig et a l. (1958 a ,b) have shown that the conversion of 
plasm inogen to plasm in (plasm inogen activation) is  a fir st-o rd er  
enzym atic step which involves the splitting of peptide bonds, probably 
ly sin e and/or arginine bonds since the e ste r s  of these amino acids are  
also  sp lit by plasm inogen activators and they act as com petitive  
inliibitors of plasm inogen activation.
A ctivators and procedures which activate plasm inogen to plasm in  
may be divided into four m ain groups. Certain activators, including 
urokinase and tissu e  activators, bring about d irect conversion of 
plasm inogen to plasm in. Som e substances appear to convert an inert 
proactivator to activator. T his group includes streptokinase euid tissu e
îysokinases* Proactivator has been postulated as an activity and has 
not yet been identified. It is  thought that proactivator may be plasm inogen  
its e lf  (Be Renzo# I960), Yerfatraete (1966) has ouggested that plasm in  
is  the proactivator and that a etreptbkinase-plasm in com plex p o sse sse s  
the property of plasm inogen activation, M acfarlane (1964) has suggested  
that the hypothesis concerning proactivator a r ise s  out of d ifferences in 
sp ec ies  sp ecific ity  of activator , . The third group of activating  
procedures includes adm inistration of certain substances, among them  
adrenaline and nicotinic acid* not th em selves plasm inogen activators*  
which appear to tr igger activator re lease  into the blood stream . The 
fourth group com prises a variety  of procedures which bring about 
plasm inogen activation in v itr o * T hese procedures include diktion of 
plasm a, addition of chloroform  to plasm a and trypsin  activation.
T issu e Activator Astrup and P erm in  (1947) dem onstrated that 
fibrinolytic activity present in t is su e s  is  due to plasm inogen activator 
activity and not to a fibrinolytic enzyme* T issu e activator may be 
prepared by potassium  thiocyanate extraction of human or animal tissu e  
(Astrup and Stage# 1952), T issu e  activator is  relatively  stable 
esp ecia lly  at acid pH (Astrup and Sterndorff * 1956)* M ullertz (1953) 
considers that tissues contain lysok in ases which, like streptokinase# 
activate an inert proactivator, Abe and Astrup (i960) have shown that
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converBion of p lasm inogen  to p la sm in  by a  tM ocyanato ac tiv a to r 
e x tra c t  ol pig h e a r t  is  a  slow , possib ly  s to ic h io m e tr ic , reaction*
A ctivator activity i$ present4m  m oat tissues#  Uterus#' adremal's, 
lymph modes, prostate and lung are particularly rich in activator  
comtemt while there is  mono im norm al liv er  and placemta (Albrechstem,
19BT), Using an autoradiographic technique, Todd (19S9) has dem onstrated  
the presence o l activator in  t is su e s  c lo se ly  related to the endothelium  
of veins and pulmonary arteries# Baron and Barnett (I960) have shown 
that plasm inogen activator Is produced by a continuous m etabolic  
p rocess and re leased  into the supernatant by a variety  ol prim ary and 
continuous human ce ll cultures* Lack and A ll (1964) have produced  
evidence to suggest that t issu e  activator is  concentrated in the lysosom al 
fraction of tis su e  homogenates* Lack (1964) suggests that local anoxia 
may influence the re lea se  of t issu e  activator and that this re lea se  may 
be responsible for the in creased  plasm a fibrinolytic activity found after  
sudden death, in response to loca l ischaem ia  and after anaphylaxis*
Blood Activator Under physiological conditions, plasm inogen activator 
activity can be detected in shed blood (Fearnley and Tweed, 1953)* 
Plasm inogen activator can be separated from  plasm a by precipitation  
of the euglobulins which a lso  contain plasm inogen, a quarter of the
fibrinogen but with only tra ces of fibrinoiytic inhibitory activity
(Kowalski et a l., 1959). F lû te (I960) iso la ted  by electrop h oresis a
fraction of norm al plasm a which behaved as a la b ile  ^ plasminogen
activator; F earnley et al* (1952) showed that there was a rapid lo s s
of fibrinolytic activator activity from  blood sam ples' stored  at room-
0tem perature. The lo s s  was le e s  at 4 'G* and the activ ity  stabilised'by  
fibrin formation; -Flute (1963) considers that blood - activator ' is  a  
lyeokinase;
■ Increase- in -physio logical fibrinolytic activity m ay  be - brought 
about by# among o th ers, e x e rc ise  and adrenaline injection (Biggs et a l . , 
1947; Ogston and F ullerton , 1961), e lec tr ic  shock (Fantl and Sim on, 
1948) - and'anaesthesia- (von Kaulla# 1947). The concept of -strebs as a 
stim ulant to in c r e a se  phyBiological fibrinolytic activity i s  now generally  
accepted. F letch er et al* (1964) have shown that the jincreasod plasm a  
activator activity induced in vivo by nicotinic aSid injection has a h a lf-  
life  in the circulation of between 14 and 15 niinutes.
The source of blood activator has not been estab lished , i^waan 
et alt (1957 a, b) found an in crease  in fibrinolytic activity in iso la ted  
venous segm ents following the paravenous injection of acetyl choline, 
adrenaline and serotonin and concluded that the activity was re leased
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fro m  vein  w alls  by a cho linerg ic-e ffec to ïr m ech an ism  since  the effect 
w as M ocked by atropine# Kwaan e t al# (1958:a^l^have put fo rw ard  the 
hypo thesis  th a t loca l a c tiv a to r  re le a se  fro m  the v e sse l w all m ay be a 
re sp o n se  to intravas:cdtlar th rom bosis#  They su g g est th a t se ro to n in  
re le a s e d  fro m  aggregating  p la te le ts  m ay be the stim u lus fo r i ts  
p roduc tion . The w ork  of Todd (1959), m entioned  p rev io u sly , lends 
support to the  view tha t v e in  w alls  m ay be the so u rce  of ac tiv a to r 
appearing  in  blood. G hal^rabarti e t a l. (1963) found th a t tra u m a  to the 
w all of an u n o b stru c ted  vein  exposed  a t op era tio n  re su lte d  in  in c re a se d  
p la sm a  a c tiv a to r  ac tiv ity  u p s tre a m  from , the s ite  of tra u m a . T hese  
w o rk e rs  a lso  showed th a t n o n -fib rin o ly tic  p la sm a  in tro d u ced  in to  the 
lum en  of an iso la te d  venous segm en t rap id ly  developed fib rin o ly tic  
activity* They co n sid e red  th a t re le a s e  of a c tiv a to r  fro m  the vein  w alls  
w as a reaso n ab le  exp lanation  fo r th e ir  resu lts*  M ore recen tly  W arren
(1964), using  a  h is to ch em ica l technique s im ila r  to  th a t of Todd (1959), 
found evidence of a c tiv a to r  ac tiv ity  in  c lose  a sso c ia tio n  w ith the  endothelium  
of v e in s , venu les and sm a ll a r te r ie s  including the vas a  vas o ru m .
U rok inase  U rok inase  is  the physio log ical a c tiv a to r  w hich has been 
iao la téd  fro m  hum an u r in e , in v estig a tio n  of a  p re p a ra tio n  of u ro k in ase  
w as p a r t  of the w ork  fo r th is  thesia and the p ro p e r tie s  of th is  a c tiv a to r
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a re  d isc u sse d  in  ch ap te r 6,
A ctiv a to rs  in  S ec re tio n s  P lasm in o g en  ac tiv a to r ac tiv ity  has been  
d em o n stra ted  in  m ilk  (A strup  and S te rn d o rff , 1963), sem ina l flu id  
(von K au lla  and S h e ttle s , 1953), sa liv a  (A lb reehsten  and T h^ysen , 1955) 
and te a r s  (s to rm , 1955)*
B a c te r ia l A c tiv a to rs  T hese  include s trep to k in ase  and s taphy lok inase . 
S trep to k in ase  S trep to k in ase  is  p re se n t in  cu ltu re  f i l t r a te s  of c e r ta in  
s tra in s  of haem oiy tic  strep tococci*  F le tc h e r  and Johnson  (1957) 
d e sc rib e d  a  p u rifica tio n  p ro c e s s  w hich m ade p o ss ib le  th e  in tr  a v a sc u la r  
ad m in is tra tio n  of s tre p to k in a se  p re p a ra tio n s  in  man* S trep to k in ase  is  
a  b a c te r ia l  p ro te in  of m o le c u la r  w eight about 50,000 and exhibits 
an tigenic  p ro p e r tie s  (F le tc h e r  e t a l* , 1958).
C liff ton and Downie (1950) d em o n stra ted  the m ark e d  sp ec ie s  
v a r ia b ility  which o cc u rs  in  re sp o n se  to  s trep to k in ase  adm in istra tion*  
S trep to k in ase  re ad ily  b rin g s  about the  ac tiva tion  of hum an p lasm inogen , 
is  le s s  effective w ith ra b b it, dog, ca t and m onkey p lasm inogen  and bovine 
and p o rc ine  p lasm inogen  a re  a lm o st to ta lly  re s is ta n t  to i t .
S trep to k in ase  f i r s t  a c ts  s to ich io m e trica lly  w ith blood p ro a c tiv a to r  
(T ro ll and S h e rry , 1955)* T he concept of p ro  ac tiv a to r has been 
m entioned  ea rlie r*  T his re a c tio n  is  rap id  and the a c tiv a to r  so fo rm ed
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co nverts  p lasm inogen  to  p la sm in  by a  f i r s t - o r d e r  enzym atic  re a c tio n  
w ith re le a s e  of n itro g en -co n ta in in g  m o ie tie s  {A lkjaersig  et a l . ,  1958 b).
I t  has been u se d  ex tensive ly  as a  th rom bo ly tic  agent in  m an  
(see la te r ) .  I ts  e ffec tiv en ess  in  th is  re sp e c t w as e s tab lish ed  by 
Johnson and M cC arty  (19S9), In  a  con tro lled  t r i a l ,  m o n ito red  by 
venography , they d em o n stra ted  the  d isap p ea ran ce  of a r tif ic ia lly  induced 
th i’om bi in  the  fo re a rm  veins of hum an volunteer© , following sy s tem ic  
s trep to k in ase  in fusion . V eins containing th ro m b i in  con tro l su b jec ts  
not given s trep to k in ase  w ent o n to  fib ro sis*
A ntibodies to s trep to k in ase  a r e  d is tr ib u te d  w idely in  the 
population and depending on re c e n t o r  rem o te  s tre p to c o c c a l in fec tion , 
th e ir  lev e l v a r ie s  considerably* A p rim ing  dose of s tre p to k in a se , which 
can be a ssay ed , i© re q u ire d  to  n e u tra liz e  an tis trep to k in ase  antibody befo re  
s trep to k in ase  can  e x e rt i ts  p lasm inogen  ac tivating  effect {Johnson et a l . , 
1957).
Staphylokinase S taphylokinase is  a  s taphy lococcal exotoxin, and w as 
shown to  be a p lasm inogen  a c tiv a to r  (G erhoim  and F e rg u so n , 1949). In  
c e r ta in  re sp e c ts  i t  d iffe rs  f ro m  s tre p to k in a se . A lthough i t  p roduces 
ra p id  ac tiva tion  of p lasm inogen  at su ffic ien tly  high concen tra tions 
(D avidson, 1960), th e re  is  a  lim itin g  co ncen tra tion  above w hich it  exert©
an aBtiplasnTin-Uke effect (Sweet et àl*, 1965). I t  a lso  ap p e a rs  to 
ac tiva te  p lasm inogen  d ire c tly  in  c o n tra s t to streptoldfaaoe* L ack  
and T ow ers (1.962) have d em o n s tra ted  tha t stapliy lokinase is  antigenic* 
B ecause of the antiplasmin'^dike. effect of c u rre n tly  availab le  
p re p a ra tio n s  and becau se  in  o th e r  re sp e c ts  i t  has no-advantages 
co m pared  w ith  s trep to k in ase ,, i t  seem s unlikely th a t s taphy lok inase  w ill 
have value as  a th ro m b o ly tic  agent*. . ’ .
M on-enzym at!c A gents A drenaline  has.-already been m entioned  as 
in c re a s in g  spontaneous fib rin o ly tic  ac tiv ity  on in trav en o u s in jec tio n  
(Biggs et al.,1947)« A nother v a s o -ac tiv e  su b stan ce , nicotinic ac id , 
h as  been found to have a s im ila r  effect when a d m in is te re d  sy s tem ic  ally  
(Vfeiner et a l. ,1958). Both th e se  su b st ances produce in ten se  but 
tra n s ie n t r i s e s .  In th is  g roup  m u st be included  b a c te r ia l  pyrogen  
s in c e , when a d m in is te red  by the in travenous ro u te , it  haa an effec t on 
p la sm a  fib rin o ly tic  activity c lo se ly  resem b ling  th a t of ad rena line  and 
n ico tin ic  ac id  (M eneghini, 1949).
F e a rn le y  and h is  co lleagues have recen tly  in v estig a ted  v a rio u s  
drugs in  a s e a rc h  fo r a  substance  which would enhance physio log ical 
fib rin o ly tic  ac tiv ity . T olbu tam ide and ch lo rp ropam ide w ere  found to  
in c re a se  p la sm a  fib rin o ly tic  ac tiv ity  in  p a tien ts  w ith a th e ro s c le ro s is
16l a * *  .
(F çarn ldy  et a l-, I960) although the effec t is  te m p o ra ry  in  m any 
people* re s is ta n c e  developing a f te r  se v e ra l weeks* tre a tm e n t 
(F ea rn ley  and G hakrabarti#  1964)* A nother o ra l  an ti d iabetic  agent, 
phenfo rm in , has been  found to  give an in c re a s e  in  fib rin o ly tic  ac tiv ity  
w ithout provoking re s is ta n c e  (F ea rn ley  and C h a k ra b a rti, 1964)* 
T e s to s te ro n e  and andro lone , g iven by freq u en t in tra m u sc u la r  in jection , 
enhance fib rin o ly tic  ac tiv ity  and a s h o r t- l iv e d  effec t has been found 
using  anabolic s te ro id s , including  c lo fib ra te  (F ea rn ley  e t a l . , 1963),
The m o st potent effect has  been  d em o n stra ted  w ith c o r tic o s te ro id s  
(C h ak rab arti e t a l , , 1964)* A ll th ese  sub stan ces a re  fib rin o ly tic  ally  
in e r t  in  v itro  and the  m ech an ism  of th e ir  ac tion  in  vivo h as  not been  
elucidated*
Spontaneous A ctivation  P lasm in o g en  d isso lv ed  in  phosphate bu ffe r,
H 7 .6 , and 50 p e r  cen t g ly ce ro l and m ain ta ined  a t 30^G undergoes
v ir tu a lly  com plete a pont one ou s ac tiv a tio n , in  a  f i r s t - o r d e r  re a c tio n , in  
about 4 days. The re a c tio n  is  thought to be au toca ta ly tic  since i t  is  sa id  
to  occu r w ith a c tiv a to r - f re e  p re p a ra tio n s  (A lk jae rsig  et a l . ,  1956 a). 
A stru p  (I960) has su ggested  th a t spontaneous ac tiva tion  is  due to the 
p re se n c e  of sm all am ounts of a c tiv a to r  which con tam inate  the p repara tion*  
The m ech an ism  of ch lo ro fo rm -in d u ced  ac tiva tion  is  thought to be
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d es tru c tio n  of W iib lto rs  to f ib rin o ly s is  w ith subsequen t au toca ta ly tic  
ac tiva tion  (C h ris te n sen, 1946),
Yon K aulla  (1962) h as  suggested  tha t the in  v itro  p lasm inogen  
ac tiva tion  p roduced  by m any u re a  o r  u re th an e  d e riv a tiv e s  and 
hyda^otropic com pounds is  due to a s im ila r  m ech an ism .
T ry p sin  A ctivation  P u r if ie d  p lasm inogen  is  ac tiv a ted  by trypsin#  If 
the reac tio n  is  s ta b iliz e d  in  g ly ce ro l, the ac tiva tion  k in e tic s  a re  th o se  
of a  f i r s t - o r d e r  enzym atic  re a c tio n  (A lk jae rs ig  et a l# , 1958 b). T his 
m echan ism  has not been p ro v ed  to o ccu r in  v iv o .
P ld sm in  P lasm dn is  the p ro teo ly tic  enzym e w hich is  p roduced  fro m  its  
in ac tiv e  p re c u rs o r  p lasm inogen  by the ac tiva tion  p ro c ed u re s  a lre ad y  
d iscussed* A lk jae rs ig  et al* (1958 a , fo) stud ied  tlie re le a s e  of 
tr ic h lo ra c e tic  ac id  (TCA) so luble m o ie tie s  a f te r  au to ca ta ly tic  ac tiv a tio n  
in  g ly cero l and a f te r  s tre p to k in a se  and u ro k in ase  ac tiva tion . A fte r the 
fo rm e r , TCA soluble m a te r ia l  re p re se n te d  25 p a r  cen t of the o rig in a l 
p ro te in  and a f te r  the la t te r ,  the fig u re  w as 16 p e r  cen t. T hese 
o b se rv a tio n s  suggest th a t d iffe ren t ac tiva tion  p ro c ed u re s  m ay produce 
d iffe ring  m o lecu la r sp ec ie s  of p lasm in . The m o lecu la r w eight of p lasm in  
fo rm ed  spontaneously  fro m  p lasm inogen  has been sug g ested  to be 107,000 
(Shulman et a l# , I960).
-1 8 *
In v itro , plasm in has equal affinity for fibrinogen and fibrin  
(Katnoff, 1953)* Among other plasm a proteins susceptib le to digestion  
by plasm in are ACTH, glucagon* growth hormone (M irsky et a l. ,1959)* 
prothrombin (A lagille and S ou lier , 1956)* factor V (Greenwalt and 
Triantaphyllopoulos, 1954) antihaem ophilic globulin (A.H.G, )  (Lew is 
et al# ,1949) and certain  components of com plem ent (P illem er et al#, 
1953)# E isen  (1964) has suggested  that plasm in may be involved in the 
form ation of p lasm a kinins* such as bradykinin* from  their inactive  
alpha-2-globulin precursors#
Inhibitors of the F ibrinolytic Enzym e System  There are two groups of 
inhibitors of the fibrinolytic enzym e system ; those which inhibit the 
activation of plasm inogen ca lled  antiactivators * and those which inhibit 
the proteolytic activity of form ed plasmin* called  antiplasm ins #
P lasm a Antiactivator The separate existence of a physiological 
antiactivator in plasm a has not been established  since assay  system s  
at present available do not distinguish activator inhibition from  anti- 
plasm in activity# There is  som e evidence to suggest that compounds 
which inhibit activator activity are present in the circulating blood 
(Lewis and F erguson , 1951; J a c o b s 1955; Mullertz* 1957; 
P araskevas et al#, 1962; M cNicol at al#, 1963 a)#
^  y»**
Other Anti activators A number of aliphatic amino compounds, of which  
the moat potent is  EAOA, com petitively inhibit plasm inogen activation- 
T hese are review ed in  chapter 4 in  which an account ie given of 
aminomethyl cy clohexane carboxylic acid (AMCA), a m ore potent 
antiactivator than EAOA- The investigation of AMGA form ed part of 
the work for tliis thesis# A b rief account is  a lso  given in chapter 4 of 
p-am inom ethyl benzoic acid (PAMBA), which a lso  has antiactivator 
p rop erties.
Another compound, the polypeptide T rasy lo l, p o sse sse s  anti- 
activator activity and its  investigation  is  described  in chapter 5 as part 
of the work for this th e s is .
P lasm a Antiplasm in The ex istence of two separate antiplasm ins in  
plasm a has been estab lished  by the work of Norm an (1958) and Norm an  
and H ill (1958), According to electrophoretic m igration patterns, they 
have been designated alpha-1-globulin antiplasm in and alpha-2-globulin  
antiplasm in. The alphas2-p rotein  is  h ea t-stab le , acts rapidly and 
behaves as a com petitive inhibitor of plasm in. The a ipha-l-protein  is  
h eat-lab ile  and reacts m ore slow ly and non-dissociab ly . It is  generally  
agreed that antiplasm in lev e ls  In plasm a exceed  potential plasm in le v e ls ,  
F letcher (I960) has reported that p lasm a antiplasm in lev e ls  are 60 per
cent greater than potential p lasm in le v e ls , while Norm an (I960) has 
©itggeated that antiplasm in le v e l s .a r e .about 30 tim es greater.
P la te let Antiplasm in Johnson and Schneider (1953) have shown that 
platelets p o sse ss  antiplasm in activity .
Other Antiplasm ins There are numerous, compounds with antiplasm in  
activity w hich a re  chiefly of th eoretica l in terest. T hese include 
pancreatic trypsin  inhibitor and soya bean trypsin  inhibitor (C hristensen  
and M acleodi 1945)» quaternary am ines (Astrup and A lk jaersig , 1951), 
lauryl amine (Astrup and A lkjaersig , 1952), basic amino acids  
(M ullertz, 1954), their e s te r s  (T roll et al . ,  1954), heavy m etals  
(Kowalski and L at a lio , 1956), heparin (von Kaulla and McDonald, 1958) 
and toluidine blue (Lombardo, 1958) . Other antiplasm ins include BACA 
and AMCA., . T hese are d iscu ssed  in chapter 4 . T heir utility as anti- 
plasm ins is  restr icted  to in  v itro  work. T rasy lo l, the polype%)tid@ 
proteolytic inhibitor, m ay be a therapeutically useful antiplasm in. It 
i s  disc%%ssed in chapter 5.
The Antifibrinolytic E ffect of L ipids This effect was investigated  as 
part of the work for th is th esis  and is  d iscu ssed  in chapter 7* 
P hysiologic al F ibrinoly s is  Sherry and his co-w orkers have postulated  
an hypothesis to account for the largely  sp ecific  in vivo effect of the
fibrinolytic enzym e ay stem  -  that of lyaie of fibrin (A lkjaersig et al,y 
1959 a; Sherry et al,, 1959 a,b;  F letch er et al,y 1962 a). F igure 2 
la a schem atic representation of the hypothesis which has been ca lled  
the dual phase c o n c e #  of plasm inogen activation. According to the 
concept, plasm inogen, in  a p lasm a-clo t system , exists# in a 
physical sen se in a soluble and a gel phase, P lasm inogen in plasm a  
constitutes the soluble phase and'plasminogen in clot the gel phase. 
B ecause of th is physical distribution of plasminogen# the biochem ical 
effects of plasm inogen activation in each phase d iffer. When soluble 
phase plasm inogen is  activated to plasmin# it is  rapidly neutralized  by 
plasm a antiplasm in so that no appreciable p roteo lysis of plasm a proteins  
susceptib le to digestion by plasmin# is  detectable. It is  only when 
plasm a plasm inogen is  rapidly converted to plasm in and the antiplasm in  
m echanism  is  tem porarily  overwhelm ed that system ic  p roteolysis with a 
haem orrhagic state occu rs. Such hyperplasm inaem ic states are 
d iscu ssed  below* In the gel phase# activator# adsorbed to fibrin during 
its  formation# a lso  diffuses into the clot where plasm inogen is  in  
intim ate spatial relationship with fibrin and lev e ls  of antiplasm in are 
said  to be low (Sawyer et a l , , 1961), Thus free plasm in is  form ed in  
c lo se  proxim ity to its  substrate fibrin which is  then lysed .
Thez'G IB experim ental evidence which, though not conclusive, 
lends support to this hypothesis# Fibrinogen and fibrin have strong  
affin ities for plasm inogen (Blombadk and Blom back, 1956)* The 
preparation of fibrinogen free  from  plasm inogen is  eM eedingly  
difficult un less sp ecific  plasminogen**^solubilisiing agents are used  
(B ergstrom  ami Wallen# 1961)# Fibrinous deposits or thrombi are 
found to contain considerable quantities of plasminogen# Clots 
rendered plasrainogen*^poor rapidly talce up plasm inogen when exposed  
to plasma# Plasm inogen^enriched radioactive clots ly se  rapidly when 
im m ersed  in a medium containing activator and clot ly s is  rates are 
linearly  related to the logarithm  of either clot plasm inogen concentration  
or activator concentration (A lkjaersig et al# ,1959 a)* Using iso top ica lly -  
labelled  streptokinase prross^ (1963) has reported that this activator 
rapidly and deeply penetrates thrombus in contact with it .
I t  is  suggested  by S h e rry  e t a l, (1959 a) th a t an im p o rtan t 
function of p lasm a  p lasm inogen  m ay be to endow f ib r in  w ith a  m echan ism  
which can p rom ote  i ts  subsequen t lysis*
A nother hypo thetica l exp lanation  of the m ech an ism  involved in  
ly s is  of th rom bus is  th a t of A n ib rus and M arkus (I960). T hese  au tho rs 
be lieve  th a t sp ec ific ity  of p la sm in  fo r  f ib rin  is  c o n fe rre d  by m eans of a
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plasm in^antix^laem m  com plex , w hich m ay function  as a  r e s e rv o ir  of 
p lasm in  in  the circulation# C ircu la tin g  p ro te in s  a re  p ro tec te d  fro m  
p ro teo ly s is  by p lasm in  when i t  is  bound to antiplasm in* p la sm in  
becom es ava ilab le  when required , a t s ite s  of in tra v a sc u la r  f ib rin  
form ation*
The R ela tionsh ip  betw een the  F ib rin o ly tic  Fnaym e S ystem  and 
the C oagulation S ystem  A stru p  (1956) has suggested  th a t in  h ea lth , the 
fib rin o ly tic  ehaym e sy s te m  m ay be in  dynam ic eq u ilib riu m  w ith the  
coagulation system # He c o n s id e rs  th a t the la t te r  sy s tem  is  constan tly  
laying down f ib r in  d eposits  to se a l any s ite s  of t is su e  dam age in  the 
v a sc u la r  t r e e  and th a t, in  o rd e r  to  m ain ta in  v a sc u la r  patency , the 
fo rm e r  sy s tem  constan tly  rem o v es  such f ib rin  once the in teg rity  of the 
v e s se l w all has been resto red*
Duguid (195S) h as  a rgued  tha t p re s is tin g  m u ra l deposits  of f ib rin  
can becom e in c o rp o ra te d  in  the  a r te r ia l  w all thus fo rm ing  the b a s is  of 
an a th e ro sc le ro tic  p laq u e ,
A stru p  extended Duguid*e th eo ry  by suggesting  th a t in  d ise a se d  
s ta te s  accom panied  by reduction  in  fib rin o ly tic  ac tiv ity , re so lu tio n  of 
f ib rin  deposits  could be delayed  thus p e rm ittin g  the pathological p ro c e ss  
p roposed  by Duguid*
Evidence in favoui* of a dynamic equilibrium  of clotting and ly s is
is  conflicting* F e a rn le y  and Tw eed (1953) and Saw yer e t a l . (I960)
have d em o n etra ted  fib rin o ly tic  ac tiv ity  i n  p la s tn a  fro m  n o rm a l su b jec ts
w hich supporta  the view  th a t the fib rin o ly tic  enaym e sy s tem  is  constan tly
active  in  vivo. A m in o r reduction  in  fib rin o ly tic  ac tiv ity  h as  been
d e sc rib e d  in  c e r ta in  d ise a se d  s ta te s  a sso c ia te d  w ith th ro m b o s is , Hume
(1958), L ack n er and M erskey  (I960) and Jam es  e t al# (1961) have re p o rte d
d e c re a se d  fib rin o ly tic  ac tiv ity  a l te r  ca rd iac  in fa rc tio n , H oste l (1959)
has re p o rte d  s im ila#  findings in  p a tien ts  w ith in te rm itte n t
claud ication ; F  ranis e t al* (1961) in  p o s t-o p e ra tiv e  p a tien ts  and F e a rn le y
e t a l, (1963) in  p a tien ts  su ffe rin g  fro m  d iabetes m e llitu s , S m y rn io tis
e t a l , (1959) have found a  d e c re a se  in  u rin a ry  ac tiv a to r  ex c re tio n  in
p a tien ts  w ith c a n c e r .
If the concept of a  dynam ic equ ilib rium  w ere  t ru e ,  i t  m ight be
expected  th a t p a tien ts  w ith  haem orxdiagic d ia th eses  due to defic ien c ies
of clo tting  fa c to rs  would have d im in ished  p la sm a  fib rin o ly tic  ac tiv ity
to com pensa te  fo r th e ir  im p a ire d  coagulation* H ow ever, K am el e t a l,
(1963) have re p o rte d  th a t f ib rin o ly tic  ac tiv ity  is  n o rm a l in  pa tien ts
w ith  haem oph ilia , C h ris tm a s  d ise a se  and von W illebrand*s d isea se
131and R ausen et a l, (1961) have found th a t I- la b e lle d  fib rinogen
stirv ival is  n o rm al in  îiaam opliilic  patients* In add ition , G ordon e t al*
(1965) found th a t pro longed ad m in is tra tio n  of the fib rin o ly tic  in h ib ito r, 
EACA, to  a  group of h aem o p h iliacs  d id  not b ring  about an in c re a s e  in  
p la sm a  fib rinogen  levels#
F ro m  th ese  o b se rv a tio n s , i t  w ill be seen  th a t A s tru p 's  
hypothesis rem a in s  nnproven# T h ere  is  accum ulating  evidence to 
suggest tha t the coagulation  sy s te m  and the fib rin o ly tic  enzym e sy s te m  
have a  com plex in te r r e la t io n s h ip .  T his ev idence, rev iew ed  in  ch ap te r 
8 w hich is  concerned  w ith a  num ber of defib rina tion  syndrom es of d iffering  
ae tio lo g ie s , includes the findings tha t H agem an fa c to r  m ay ac tiv a te  
both sy s tem s; p la te le ts  p o s se s s  an tip lasm in  ac tiv ity ; pi*othrombin 
fa c to r V | an tihaem ophilic  globulin  (A .H .G . ) and fib rinogen  a re  
su scep tib le  to d igestion  by p la sm in  and fib rinogen  bi^eakdown p roduc ts  
m ay have an an tith rom b in  effect and inh ib it f ib r in  po lym erisation#  
Th€irapeutic T h rom bo lysis  The e a r l ie s t  o b serv a tio n s th a t a d m in is tra tio n  
of p lasm inogen  ac tiv a to r m ight b ring  about ly s is  of in  vivo th ro m b i w ere  
m ade by Johnson and T ille tt  (19SB) who found th a t th ro m b i p roduced  
in  the m arg in a l e a r  ve in s  of ra b b its  could by ly sed  by in tra v a sc u la r  
ad m in is tra tio n  of s trep tok inase#  In m an , the w ork  of Johnson and 
M cC arty  (19S9) p rev io u sly  m en tioned , e s tab lish ed  the value of sy s tem ic
str©ptokixxaBe in fusion  in  ly sing  a r tif ic ia lly  produced th ro m b i m  
the fo rearxn  veins of human, volunteers^-..'.The fe a s ib ility  and 
e ffec tiv en ess  of th ro m b o ly s is  in  m an  w ith s trep to k in ase  infusion  has 
been e s tab lish ed  by c lin ica l t r i a l s  (F le tc h e r  et al*, 1959 a ,b ;  D eutsch  
and F is c h e r ,  I960) and in  ind iv idual well-♦documented c a se s  of 
p e r ip h e ra l v a sc u la r  occ lusion  (A m ory e t al*, 1963; M cNicol e t a l* , 1963 h» 
Y e rs tr a e te  e t a l* , 1963)* C om pared  w ith s trep to k in ase  which is  
an tigen ic , u ro k in ase  has obvious a ttra c tio n s  as a  th ro m b o ly tic  agent 
and in chapter 6 of th is  th esis* is  descaribed in v estig a tio n  of a  com m ercial 
p re p a ra tio n  of u ro k in ase  w ith a  view  to es tab lish in g  its  su itab ility  fo r 
th is  p u rp o se .
Hypex^plaçminaemic S ta tes  D iso rd e re d  fib rin o ly tic  s ta te s  w ith a 
re su lta n t coagulation  defect o cc u r when la rg e  am ounts of p lasm inogen  
ac tiv a to r a re  re le a se d  in to  the  circulatio jx  bo  th a t conversion  o f  
p lasm inogen  to p lasm in  is  ra p id  and com plete* The % )lasm in-antiplasm in 
'buff e ring  * sy s tem  is  te m p o ra r ily  overw helm ed  and f re e  p lasm in  
ciz’c td a tes  -  hyperp lasm inaem ia*  The ensuing coagulation  defect is  
due in  p a r t  to d igestion  of p ro th ro m b in , fa c to r V and an tihaem ophilic  
globulin (A .H .G .) i in  p a r t  to  defective  fib rin  p o ly m erisa tio n  b rought 
about by c irc u la tio n  of fib rinogen  and f ib r in  breakdow n p roduc ts  and in
p a r t  to a c c e le ra te d  ly s is  of such f ib r in  thrombi aa do fo rm  (A lk jaersig  
0 t  a l . , 1962; Bang e t a l. ,1962; F le tc h e r  e t a l. ,1962 b)«
A number of s tep s  a re  involved in  f ib rin  gel fo rm a tio n . T h rom bin , 
a  highly spec ific  p ro teo ly tic  enzym e (B lom back and Y am ashm a, 1958), 
sp lits  off spec ific  pep tides fro m  fib rinogen , thus converting  i t  to f ib rin  
m onomer (S eheraga and Baskow sld,- 1957)* The f ib r in  po lym er I s  
fo rm ed  by condensation  of a  num ber of f ib rin  m onom ers and the v is ib le  
f ib rin  clo t is  then fo rm ed  in  a ge la tion  s tep , The c lo t is  re n d e re d  
inso luble  by the exx^ymatic ac tion  of fa c to r  XIII, w hich has  been 
p ostu la ted  to b ring  about the fo rm a tio n  of su lphydry l linkages betw een 
the po lym ers (Laki and G lad n er, 1964). Bang e t al# (1962) have shown, 
using the e le c tro n  m ic ro sc o p e , th a t c lo ts fo rm ed  in  the p re se n c e  of 
fib rinogen  and f ib rin  breakdow n p roducts  ax*e loose  and fria b le  and have 
an abmox'mal 'fray ed -ro p e*  a p p e a ran c e . The abno rm ality  is  due to  
rn co rp o ra tio n  w ithin  the f ib r in  %)olymer of bx^eakdowxi p roducts  w hich 
la ck  the c o r re c t  configuration  fo r  a  s tru c tu ra lly  sound polymex*# An 
an tith rom bin  effect of the p ro d u c ts  of fib rin  and fib rinogen  p ro teo ly s is  
h as  a lso  bean  o b serv ed  (H iew iarow ski and B at a lio , 195^7;
T rlan taphy llopou lo s, i 9.58).
H yper plus m inaem ic  s ta te s  have been re p o r te d  to occu r when
— 6 0  —
t is su e s  rich in activator have been handled esp ecia lly  during pulmonary 
surgery (Soulier et a l . , 1952) and surgery with extracorporeal circulation  
(von Kaulia and Swan, 1958); in association  with prostatic carcinom a  
particularly with m étastasés (Tagnon et a l . , 1952) and in c irrh osis  of 
the liver  (Kwaan et a l* , 1956). System ic p roteo lysis by plasm in may 
contribute to the coagulation defect which may com plicate certain  obstetric  
accidents, m ost com monly am niotic fluid em bolism , intrauterine death 
and accidental haem orrhage (Schneider, 1959). As w ill be d iscu ssed  in 
chapter 8 of this th es is , the gen esis  of defibrination syndrom es may be 
in part due to hyperplasm inaem ia and it is  possib le  that 'pure* hyper- 
plasm inaem ic states are rare , with the exception of that which is  
probably inevitable in patients receiving throm bolytic therapy#
As has been m entioned, the work for this th esis  has involved  
the investigation of two compounds which exhibit antifibrinolytic 
properties (AMCA and T rasy lo l), one of which a lso  p o sse sse s  anti­
coagulant and antitryptic activity# A com m ercial preparation of 
urokinase has been screen ed  for throm boplastic activity# The effect of 
fat feeding on clotting, ly s is  and platelet aggregation has been exam ined  
and finally a number of patients with the defibrination syndrome have 
been studied in an attempt to elucidate further the problem  of its  diagnosis 
and therapy.
CHAPTER 3
MATERIALS AND METHODS 
In  th is  ch ap te r is  p re se n te d  an account of the m a te r ia ls  and 
s tan d a rd  fib rin o ly tic  and coa-guiation m ethods u sed  in  the w ork fo r  
th is  th e s is ,  A b rie f  explanation*of the b a s is  fo r  each  m ethod, and 
so u rce s  of e r r o r  in  in te rp re ta tio n  of r e s u l ts ,  is  a lso  given# In c e r ta in  
ix istancee, i t  w as necessax^y to m odify a  num ber of the te s ts  fo r 
p a r tic u la r  ex p e rim en ts  # Such m odifications and m ethods dev ised  
o r u sed  fo r one p a r tic u la r  a sp e c t of the w ork  in  th is  th e s is  a re  se t 
out in the m ethods sec tio n  of the ap p ro p ria te  chapter#
A ssay  sy stem s a re  d e sc r ib e d  fo r p lasm inogen , p lasm inogen  
a c tiv a to rs  and fo r  fib rinogen , w hich, as f ib r in , is  the physio log ical 
s u b s tra te  fo r plasm in* P la s m a  fib rin o ly tic  inh ib ito r ac tiv ity  w as a lso  
m easured#  A m ethod  fo r  assay -o f s trep to k in ase  antibody is  given and 
the  th ro m b in  clo tting  time# w idely  u sed  as a m e a su re  of the coagulation  
defect due to h y p e rp la sm in ae m ia , is  described#
A b r ie f  accotint is  g iven of the o n e -s tag e  p ro th ro m b in  t im e , the 
p la sm a  re e a lc ilie a tio n  tim e  and the throm .boplastin  g en era tio n  test*
The a ssay  sy s tem s u sed  to d e te rm in e  lev e ls  of fa c to r  V , an tihaem ophilic  
globulin (A#H ,G#), C h ris tm a s  fa c to r  and H agem an ia e tè r  a re  ou tlined . 
The m ethod u sed  to  count p la te le ts  is  given and d e ta ils  of the sy s te m
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em ployed to a a eess  speed  of p la te le t agg regation  a re  p rov ided .
M a te r ia ls
S tre p to k in a se  ^ S trep to k in ase  .S treptodornaB e Vaxddaae (L ederle)
w as the p re p a ra tio n  em ployed.w ith  the exception  of one a e r ie s  of
experim ent8, described in  ch ap te r 7,, in .w hich the pre%)aratlon of
s trep to k in ase  tiaed w as ICabikinase p rov ided  by A. B. K ahi, Stockholm*
The stock  so lu tion  of the Taridaa.o. p re p a ra tio n  contained  .stx^eptokinase,
10,000 N .l .H .  un its /m l*  of 0*9 p e r  cent ea line . T h is .was s to re d  a t 
o4 C. and d ilu ted  in  0*9 per cent sa line  as required* The K abikinase 
p re p a ra tio n  w as highly p u rif ied  s trep to k in aae  in tended  fo r  in tra v a s c u la r  
adininlstx’ation and supp lied  as a pow der in am poules of 250,000 M .Î.H* 
units* /Fox" the  s e r ie s  of ex p e rim en ts  in  ch ap te r 7, one m l. am ounts 
containing 8,000 H .I .H , units w ere  reqxiired. A ccord ing ly , one 
am poule w as d isso lv ed  in  0*9 p e r  cen t sa line  to give a co n cen tra tio n  
of 8,000 H .Î .H . u n ite /m l. and th is  volum e was s to re d  at -EO^G.in one 
m l, am ounts and thaw ed im m ed ia te ly  befo re  use*
Urokinase Two p re p a ra tio n s  w ere  u sed , one p rov ided  by Leo 
L a b o ra to r ie s  L td . , C openhagen, and one by Abbott L a b o ra to r ie s ,
N orth  C hicago, Illinois*  The la t te r  p re p a ra tio n  is  d e sc rib ed  in  d e ta il 
in  chap te r 6, U rok inase  (Leo) w as a pu rified  p re p a ra tio n  iso la te d  fro m
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human urine# It was a s te r ile  yellow ish  white powder, freely
soluble in 0 .9  per cent saline# The potency of the preparation used
in the work for this th esis  was 5 ,000 Ploug units per m g. protein
(Ploug and Kjeldgaard, 1957). The fibrinolytic and coagulative properties
of th is preparation have been described  by M cNicol et a l. (1963 a).
Human Plasm inogen This was a purified preparation, soluble at
neutral pH, containing 0 .3  case in  u n its/m g. protein, supplied by A .B .
Kabi. The casein  unit of activity is  defined below.
Human P lasm in  This was prepared by the method of A lkjaersig et a l.
(1958 a), by spontaneous activation of Kabi human plasminogen* To
each flask  of human plasm inogen was added 10 m l. of 50 per cent
g ly cero l-sa lin e . The spontaneous activation to plasm in at 37^C, was
98 per cent com plete after 6 w eeks. Completion was a sse sse d  by
caseinolytic assay , described  below, of the preparation with and without
the addition of streptokinase, 2 ,000  u n its /m l. Without streptokinase
activation, the preparation contained 6 .1  casein  u n its /m l. and with
streptokinase activation, 6 .2  casein  u n its/m l.
Thrombin This was Thrombin Topical (Parke, D avis). A stock
solution of concentration 100 N#I*H. u n its /m l, was stored  in SO per
ocent g ly cero l-sa lin e  a t-20 C.and diluted in saline to the required working
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coB eentration .
T ry p a in  T h is  w as bovine try p s in  (L, L ight and Go. L t d , , G oinbrook). 
The p re p a ra tio n  w as tw ice c ry s ta ll is e d  and s a l t - f r e e .
C ase in  Solution T h is w as p re p a re d  as d e sc rib e d  by M cNicol and 
Douglas (1964^, by boiling 26 .gm. ca se in  (L , L igh t and Go, Ltd#) in  
600 m l, phosphate b u ffe r, 0# 1 M o la r, pH 7 .6 , fo r 20 m inutes# W hile
ho t, the pH of the so lu tion  w as ad ju s ted  to  7*6 and the so lu tion  f i l te re d ,
oI t  was then  d ia ly sed  fo r  24 h o u rs  w ith constan t s t i r r in g  a t 4 G, ag a in st 
4 l i t r e s  of phosphate b u ffe r, 0 ,1  M o lar, pH 7,6# The d la ly sa te  w as 
changed once a t 12 hours# The pH of the  ca se in  so lu tion  w as checked 
a t the end of d ia ly s is  and readjusted#  if n ec essa ry , to  7 ,6 , The so lu tion  
w as s to re d  a t 4^0*
P hosphate  B uffer The phosphate buffer of 0# 1 M o lar, pH 7 ,6  w as m ade 
up as  fo llow s;- N aH ^FO ^, 2 ,0 2 8  gm#; Ha^HPO^, 14*964 g m .;
N aC l, 9*0 gm , ; d is tille d  w a te r  to  1,000 m l.
H um an F ib rin o g en  T his w as p re p a re d  fro m  ex p ired  pooled bank p la sm a  
by a  phosphate buffer m ethod  (Biggs and M acfarlan e , 1962 a). The 
final co ncen tra tion  of fib rinogen  w as about 4 m g , /m l ,  of c i t r a te - s a l in e  
so lu tion .
131R adioactive Iodine ( I) T his w as obtained fro m  the R adidchem ical 
C en tre , A m er sham , as sodium  iod ide , in  0# 1 ml* d ilu te  sodium  
th io  su lphate •
R adioactive Io d ine-tagged  H um an F ib rin o g en  H um an fib rinogen  v/as
lab e lled  w ith rad io ac tiv e  iod ine by à m odification  of the m ethod of
Clem^ent and M cNicol (1959), (M cNicol and D ouglas, 1964^, To one to
two me* rad io ac tiv e  iodine w ere  added 0 ,025  ml* ,N* s tab le  iodine in
m ethanol; 0 ,025  m l , ,  0 ,0 1  N , H^SO^i 0 .025  ml* h ep a rin  (25 u n its /m l* )
and S m l, of human fibrinogen in c itra te -sa lin e . The m ixture was
allow ed to incubate  fo r  5 m inu tes at room  tem p era tu re*  It w as then
p a sse d  through a  ch lo rid e -p h ase  ion-exchange re s in  colum n, (A m berlite
IRA 400 (cl), B,D*H* L ab o ra to ry  C hem icals D iv ision , Poole) w ith 5 m l.
phosphate b u ffe r, 0*1 Molax", pH 7* 6* The tagged  fib rinogen  w as s to re d
oin  sm all amount© a t -20 C . C lo ttab le  rad io ac tiv ity  of th is  p re p a ra tio n  
v a r ie d  fro m  89 to 94 p e r  cen t.
A ce ty l-1 -L ysine  M ethyl E s te r  (AcLM e) T his w as a p re p a ra tio n  d rie d  
w ith phosphate bu ffe r, pH 7*6, and N aCl (Cyclo C hem ical C o rp o ra tio n , 
Los A ngeles, C alif*). Tw enty m g*/m l* in  d is til le d  w a te r  gave a 
so lu tion  of pH 7*6 containing 0*016 M olar AcLM e in  0*066 M olar 
phosphate buffer and 0*6 p e r  cen t NaCl*
(*>
C hrom otrop ic  A cid R eagent In a  1,000 xmL v o lu m etric  f la sk  
containing 200 m l. cold d istilled*w ater w ere  added 100 m l* , Z p e r  cent 
ch ro m o tro p ic  ac id  (4, 6 -d ihyd roxy -2 , 7^naphthalene d isu lphonic ac id , 
d isodium  sa lt  (Kodak L td*, London))). T his m ix tu re  w as p laced  in  an 
ice  bath and 600 ml* cold co n cen tra ted  H^SO^ added in  SO m l, a liq u o ts , 
allow ing 20 m inu tes betw een each  addition* T his w as allow ed to  stand  
16 h o u rs  a t brought up to  room  te m p e ra tu re , d is tille d  w a te r to
1,000 m l, added and  then  f i l te re d  th rough  a  m e d iu m ^ o rè , s in te re d  
g la ss  funnel* The so lu tion  w as .s to red  in  the  d a rk  at 4^G and w as 
d isca rd ed  if it  tu rn ed  brow n on stand ing .
E psilon  A m inocapro ic  A cid  (BAGA) T his w as a  2$ p e r  cen t so lu tion  
p rov ided  by Boots P u re  D rug Co* L t d . , N ottingham ,
P la sm a  Sam ples F la a m a  sam p les  w ere  ob tained  by m ixing , w ithout 
fro th ing , 9 volum es of whole blood, co llec ted  by c lean  venepunctu re , 
w ith I volum e of 3*8 p e r  cen t sodium  c itra te  and th e  p la sm a  se p a ra te d  
by cen trifuga tion  (600 g. fo r  10 m inu tes a t 4^Q). W here p la sm a  w as 
u sed  in  a s s a y s , no c o rre c tio n  of re su lts  w as m ade fo r  d ilu tion  by 
c itra te*
E x p ired  P oo led  Bank P la s m a  u sed  in  the w ork  fo r  th is  th e s is  had  a  
fib rinogen  content of 220 m g*/ 100 m l, and a  p lasm inogen  content of 
2* 2 ca se in  u n its /m l*
S ilicone G lassw are  G lassw are  w as s ilic o n e -co a te d  by the m ethod 
d esc rib ed  by B acie  (1956 a), using  a JO p e r  cen t (V/V) so lu tion  of 
s ilicone  M 441 (l#G*J. L t d , , M ancheste r) in  p e tro leu m  e th e r . The 
g la ssw are  w as w ashed  and r e - t r e a te d  fo r each  ex p e rim en t,
■ M ethods
P lasm inogen  A ssay  The m ethod u sed  w as the case in o ly tic  a ssa y  of 
R em m ert and Cohen (1949), as m odified  by A lk jae rs ig  e t a l , (1959 a).
In  th is  a s s a y , p la sm a  is  incubated  w ith ac id  to d e s tro y  an tip lasm in .
The ac id  is  n e u tra lis e d  w ith a lk a li and bu ffer, -S treptokinase is  added 
to convert p lasm inogen  to  p la sm in . C ase in  is  em ployed as su b s tra te  
fo r  the p lasm in  so form ed* The ensym atic  action  of p lasm in  on case in  
is  stopped by p re c ip ita tio n  of p ro te in  w ith tr ic h lo ra c e tic  ac id  (TGA),
TO A -so lub le  m o ie tie s , including ty ro s in e , re le a s e d  by the p ro teo ly tic  
ac tiv ity  of p lasm in  on c a se in , a re  in  the supernatant*  The am ount of 
ty ro s in e  re le a se d  fro m  the c a se in  is  a  m e a su re  of the am ount of p lasm in  
present*
To 0, 5 m l, p la sm a  w as added 0. 5 m l , , Vb N* H C l, The
p la sm a  w as incubated  w ith  th e  ac id  fo r  15 m inu tes at room  te m p e ra tu re
1and then  0, 5 m l* , /6  N , NaOH w as added follow ed by 1 ,0  m l, 
phosphate b u ffe r, 0*1 M o la r, pH 7*6* S trep to k in ase , 0 .5  m l, of a
so lu tion  containing 2 ,000  u n i ts /m L , w as next added* A fte r addition  
o£ 2 ,0  m l# , .5 p e r cent c a se in  so lu tion  and thorough mixing# the 
d igestion  m ix tu re  w as incubated  a t 37^0 fo r  62 m inutee# A liquo ts, 
each  of 2 .0  m l . , w ere  re m o v e d 'fro m  the d igestion  m ix tu re  a t 2 
m inu tes and 62 m inu tes and each  added to 2 m l . , 10 p e r  cen t TCÂ.
The su p en m tan t w as ob tained  by cen trifuga tion  (1 ,000  g . fo r  10 
m inu tes) and ty ro s in e  m e a su re d  by  addition of l.O  m l. of th e  su p ern a tan t 
to  5 .0  m l# , 0# 5 H . NaOH; 1 .5  m l# , B p e r  cen t TCA and l.B  m l. d ilu te 
(1:2) F o lin  C ioealteu  reagent# ' A fte r standing, fo r 15 m inu tes fo r  co lour 
developm ent, the op tica l density  of the 62 m inute sam ple  w as re a d  in  a 
sp ec tro p h o to m ete r (SPSOÛ, U nicam  In s tru m e n ts , C am bridge) a t 650 mp 
w ith the 2 m inute sam ple  a s  blank# T y ro sin e  re le a s e  w as re a d  off a  
s tan d a rd  curve* One ca se in  un it of p lasm inogen  re le a s e d  180 pgm# 
ty ro s in e /h o u r .
A ctiv a to r A ssay s  Ho d ire c t  a ssa y  fo r  a c tiv a to r in  biological flu ids is
available# F iv e  a ssa y  sy s tem s  a re  d e sc rib ed . The euglobulin  ly s is
and dilu te p lasm a  clo t ly s is  te s ts  m e a su re  p r im a r ily  p la sm a  a c tiv a to r
131activity# The fib rin  p la te  te s t  and the  rad io ac tiv e  iodine ( I) lab e lled  
clot a s sa y  m e a su re  the ab ility  of the te s t  p la sm a  o r  o th e r b io log ical 
flu id  to  lyae  p re fo rm ed  f ib r in . An a ssa y  sy s tem  fo r  u ro k in ase ,
em ploying the syn thetic  e s te r  A cLM e, is  a lso  described# T his a ssay  
sy s tem  is  u sefu l as a  b iochem ica l s tan d ard iza tio n  fo r co n cen tra ted  
so lu tions of p u re  u ro k in a se ,
Euglobulin L y sis  T e s t  In th is  te s t i  the p la sm a  euglobulin fra c tio n  is  
p re c ip ita te d  at pH 5 .4  and low ionic strength# The p re c ip ita te  con tains 
p lasm inogen  a c tiv a to r and p lasm inogen , a q u a r te r  of the p lasm a  
fib rinogen , but w ith only t r a c e s  of the p la sm a  an tip lasm in s w hich a re  
chiefly  in  the  su p ern a tan t (K ow alski et a l» , 1959). B ecause  an ti­
p lasm in  is  not p re se n t in  the c lo ts  m ade fro m  the euglobulin 
p îrecip itato , ly s is  tim e s  a r e  m uch s h o r te r  than  th o se  found w ith c lo ts  
m ade fro m  native  p la sm a . In  the p re se n c e  of n o rm a l concen tra tions 
of p la sm a  p lasm inogen  and probab ly  fib rinogen , the ly s is  tim e ie a 
m e a su re  of the p la sm a  a c tiv a to r  ac tiv ity . Low plasm inogen  
co n cen tra tio n s , even in  the  p re se n c e  of high ac tiv a to r  activity* lead  
to  pi’olonged euglobulin ly s is  t im e s  because  th e re  is  in su ffic ien t 
p ro te n tia l p la sm in  to  d ig est the f ib r in  of the clo t (M cNicol e t a l* , 1962^ a) 
and th e re  is  evidence to su g g est th a t an in c re a se d  co ncen tra tion  of 
fib rinogen , w hich as f ib r in  is  su b s tra te  fo r p la sm in , m ay also  
lengthen  the  ly s is  tim e  of the euglobulin  clot (Bang e t a l , , I960),
The m ethod  u sed  w as th a t of N ilsso n  and Glow (1962), A
* <p re c ip ita te  w as fo rm ed  by addition  of. 0* 5 m l, p la sm a  to 9* 5 m l 
0 .0 1 4  p e r  cen t ace tic  ac id , pH 5.4* A fter standing fo r 10 minuteB 
i%t 4^C, the p re c ip ita te  w as ob tained  by cen trifuga tion  (l,000g*  fo r  
10 m inu tes at 4^C). The su p ern a tan t w as d isc a rd e d  and the p re c ip ita te  
re  suspended  in  0. B ml* b arb itone  bu ffe r, pH 7 ,3  (sodium  diethyl 
barb ltono , 11,75 gm , ; H C l, O .lN * , 430 m l, ; N aC l, 14.67 gm , ; 
die ti lle d  w a te r to 1,000 m l . ) , . The re  suspended  p re c ip ita te  w as c lo tted  
w ith OiB m l, th ro m b in , 2 H .I .H . u n its /m l* , and the tim e  fo r ly s is  of 
the clo t o b se rv ed  a t 3 7^0 , R esu lts  of euglobulin ly s is  te s ts  m ay be 
e x p re sse d  in  m inu tes but w here  s ta t is t ic a l  an a ly s is  of re s u lts  is  
n ecessa ry ,-  in  un its  of ac tiv ity . F ib rin o ly tic  a c tiv a to r  ac tiv ity  is  
In v e rse ly  |sropo rtional to ly s is  tim e  (S herry  and A lk ja e rs ig , 1957) 
and using  th is  re la tio n sh ip  in  a  double lo g a rith m ic  p lo t, o b se rv ed  
ly s is  tim.es a re  e x p re s se d  as u n its  of ac tiv ity , a  ly s is  tim e  of 300 
m inu tes being a r b i t r a r i ly  a ss ig n ed  a  value of one un it of activity# To 
convert ly a is  tim e s  to  u n its , the  ly s is  tim e in  m inu tes is  divided in to  300. 
D ilute P la s m a  C lot L y s is  T e s t T h is  Is  a  d ilu tion  technique which 
depends on the  fac t th a t d ilu tion  favou rs fib rh io lysis. possib ly  by 
d ep ress in g  in h ib ito ry  ac tiv ity  (F ea rn ley  and L ac k n e r, 1955)*
The m ethod u sed  in  th is  th e s is  w as that of F e a rn le y  e t a l, (1957),
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m odified  to u se  p la sm a  in s te a d  of w hole blood. To 1# 7 m l,
phosphate bu ffe r, pH 7 ,4 , .containing 0 ,1  ml* th ro m b in  (50
im itaf ml* sa line) was added 0 ,3  m l, plasm a.. The th ro m b in  w as
added im m ed ia te ly  b e fo re  th e  plasrma,* The p la sm a  w as se p a ra te d
fro m  c itra te d  whole blood co llec ted  as d e sc rib e d  p rev io u sly , the
oc itra te d  whole blood hav ing  been kept on ic e , cen trifuged  at 4 C and
the p la sm a  added to the b u ffe r w ithout delay . C lotting o c c u rre d
' ow ithin  a m inute and the  tubes w ere  then  s to re d  f a r  30 m inu tes a t 4 C
o ■and t r a n s f e r r e d  fo r  B m inu tes to a  w a te rb a th  a t 37 C# Â.t th is  tim e# 
b r is k  ro ta tio n  of the tube betw een  the palm s of the  hands fre ed  the 
clo t fro m  the w all of the  tu b e . The c lo t w as then  o b se rv ed  at 37^C 
un til i ts  com plete  d isappearance ; which was the end -po in t. L y s is  tim e s  
in  healthy  su b jec t a during  the  day w e re  g re a te r  than  400 m in u tes . 
F ib r in  P la te  T ea t In  th is  t e s t  a  so lu tion  of fib rinogen  is  c lo tted  w ith 
thrombin in  a  p e rsp e x  d ish  resem bling  a P e t r i  d ish . T es t flu ids 
a re  p ipetted  on to the fib rim su rfa c e . P lasm inogen  is  alw ays 
a sso c ia te d  w ith the fib rinogen  u sed  fo r the te s t .  If the  te s t  flu id  
contains activator#  p lasm inogen  w ill be co nverted  to plasm in w hich 
then d igests  f ib rin  to p roduce ho les in  the fib rin  film . The a re a s  of 
ly s is  a re  not lineaiTy re la te d  to  ac tiv a to r concen tra tio n  and w here
s ta tis tic a l  an a ly s is  of re su lts  is  required# a s tan d a rd  curve mxiBt be 
run  with each batch  of te s t  flu id , ac tiv ity  in  each  sam ple  being a*ead 
off the cu rve  (S m yrn io tis e t a l,., 1959),
The m.ethofl u sed  in  th is  th e s is  w asram odification o£ th a t of 
N ils  son. and Glow (1963). B ovine. fib rinogen , B lom back fra c tio n  1 - 0  
(B lom back and Blomback# 1956), w as u sed . To 23. 7 m l, t r ie  bi^ffer,
0 * IS M o la r, pH 7 ,8 , was added 0 ,7  m l* , 0 ,1  p e r  cen t bovine fibrinogen# 
The fib rinogen  so lu tion  w as c lo tted  w ith 0 ,6  ml* th rom b in  (50 N .X .H . 
im its /m i. ), in  a p e rsp e x  d ish  of in te rn a l d iam e te r 11,5  cm . Sam ples 
of hum an p la sm a , resuspended , euglobulin  p reclp ita .te , o th e r b io logical 
fluid o r  hom ogenized t is s u e  w ere  app lied  In SO p l i t r e  am ounts to the 
su rfa ce  of the f ib rin . The p la te  w as then incubated  at 37^G fo r 16 h o u rs  
H oles m ade in  the plat© w here  fib rin  had been ly sed  w ere  then m e a su re d  
and re su lts  e x p re sse d  in  sq u a re  m ill im e tre s  a© the  product of two 
p e rp en d icu la r d ia m e te rs  of the a r e a  of lysis*
R esiispended euglobulin px’o c ip ita tes  p roduced  la rg e r  ho les than  
the  p la sm as  fro m  which they  w ere  p re p a re d  b ecause  p la sm a  an tip lasm in  
is  la rg e ly  d isc a rd e d  w ith the  su p ern a tan t (Kowalski e t a l. # 1959),
The p re c ip ita te  w as p re p a re d  by addition of G, 1 m l .  p lasm a  to 
1 ,9  m l . ,  0*014 p a r  cen t ac e tic  ac id , pH 5 ,4 , A fte r standing fo r 10
m inu tes at 4^C, the p re c ip ita te  w as ob tained  by cen trifuga tion  (1 ,000 g. 
fo r 10 m inu tes a t 4^0) and re su sp an d ed  in c i t ra te - s a l in e  so lu tion  (one 
volum e 3*8 p e r  cen t sodium  c itra te  and 9 volume© 0 ,9  p e r  cen t sa lin e ). 
R adioactive C lot A ssay  The m ethod  d esc rib ed  is  m odified  fro m  tha t of 
A lk jae rs ig  et a i, (19S9 a), (M cNicol and D ouglas, 1964)4. The a ssay
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depends on the re le a s e  of rad io ac tiv ity  fro m  1 -taggod  p la sm a  c lo ts , 
en rich ed  w ith p lasm inogen , when incubated  in  the p re se n ce  of a 
p lasm inogen  a c tiv a to r , PTasm inogen is  added to clo ts during th e ir  
fo rm atio n  to en su re  th a t they re m a in  sen sitiv e  to a c tiv a to r  a f te r  they 
have been w ashed  to rem ove b lank ra d io ac tiv ity . The clo ts a re  fo rm ed  
round s ta in le s s  s te e l w ire  s p i r a ls .  A fte r w ash ing , the  clo ts a re  
incubated  a t 37^C w ith the  te s t  p la sm a . R ad ioactiv ity  re le a se d  into 
the te s t  p lasm a  fro m  the c lo t in  a  s ta n d a rd  tim e is  a  m e a su re  of 
ac tiv a to r concen tra tio n  in  the te s t  p la sm a ,
131E x p ired  pooled bank p la sm a  w as t ra c e  lab e lled  w ith ' I-tag g ed  
fib rinogen  so th a t 10 m l, p la sm a  gave api^roxim ately 2 ,500  counts in  10 
seco n d s. To 0 .5  m l, lab e lled  p la sm a  was added 0 , 1 m l, p lasm inogen , 
6 c a se in  u n its /m l. The p lasm inogen  w as inso lub le  at n e u tra l pH and 
w as th e re fo re  not e lu ted  during  w ashing. The p la sm a  w as c lo tted  
w ith 0 ,1  m l, th ro m b in , 10 unit a /m l . ,  round  the  co rk sc re w  end
^  Cs
of a stain lesB  s tee l w ire  in  a 75 x 8 m m , te s t  tube and w ashed in  
X->hoaphate buffer# 0* I M olar* pH 7 ,6 , The m in im um  w ash ing ,tim e 
w as 60 laiîxmteB^ The te s t  p la sm a , 0*5 ml** w as inciib ate d w ith a 
rad ioac tive  clot fo r  30 m in u te s , The clo t was then  rem oved  on its  w ire  
sp ira l and rad io ac tiv ity  in  the te s t  so lution counted. R esu lts  w ere  
re co rd ed  a f te r  su b trac tio n  of background rad io ac tiv ity  and the mearn 
count fro m  two sa line  con tro l tubes in  which clo ts had bemn incubating* 
.Results w ere  e x p re sse d  e ith e r  as counts or* a f te r  ca lucu la tlon  of the 
spec ific  rad io ac tiv ity  of the f ib r in  as pgm^ fib rin  ly sed  I  m l.  of te s t  
solution I  h o u r.
A ssay  of U rok inase  w ith the  Synthetic  E ster*  AcLM e T his a ssay  
depends on the ab ility  of u ro k in ase  to sp lit AcLM e in to  a c e ty l- I- ly s in e  
and m ethyl a lcohol. The am ount of m ethyl alcohol l ib e ra te d  from  the 
syn thetic  s u b s tra te  is  m e a su re d  co lo rim etrica lly *  The m ethod is  not 
suffic ien tly  sen s itiv e  to m e a su re  u ro k in ase  in  u rin e  and is  u sefu l for 
b iochem ical s tan d a rd isa tio n  of co n cen tra ted  so lu tions of pure  u ro k in ase . 
The a ssay  sy s tem  w as th a t of S h e rry  e t a l ,  (1964), To 3 ,0  m l, 
A cLM e, 20 m g , / m l , ,  at 37^C w as added 0 .3  m l, u ro k in ase  d isso lv ed  
in  phosphate buffer, 0, 1 M o lar, pH 7 ,6 , The co n cen tra tio n  of the 
u ro k in ase  so lu tion  was not le s s  than  1,000 G ,T ,A , u n i ts /m l. The G .T .A .
unit is  defined in ch ap te r 6, At 1 minute# a one ml* aliquot was 
rem oved  into O.S m l , , 1.5 p e r  cent TCA and again at IS and 30 m inutes*
To 0. 5 ml* of each of th e se  spee im ens w as added 0 .1  m l# , 2 p e r  cen t 
p o tass iu m  perm an g an a te  (KMnO^) and a f te r  one minute# 0 . 1 m l , , 10 
p e r  cent w hich had  been  fre sh ly  prepared*  A fte r addition of
4*0 m l. chrom otropic ac id  reag en t and thorough m ixing, spec im ens 
w ere  p laced  in  a boiling w a te r bath  fo r IS m in u tes . A fte r a few m inu tes 
fo r cooling, co lour in ten sity  w as re a d  in  a a pec t  r  ophotom.ete r  (S. P . 500, 
Unlearn. In s tru m en ts) at: 580 mp, aga in st the one m inute spec im en  as 
blank*
A s tan d a rd  cu rve  was run  w ith each te s t  batch* The stock  
s tan d ard  w as a so lu tion  of m ethy l alcohol containing one \i m o la /m l . , 
m ade up in  0 .066  M olar phosphate bufiEer containing 5 p e r  cen t TCA*
The s tan d ard s  w ere  t re a te d  fro m  the point at w hich K'MnO. w as added.
In the w ork fo r th is  th e s is ,  0, S m l. of a  so lu tion  containing one \x m o la /m l, 
gave an op tical density  read ing  of 0 ,1 5 0 . The re su lts  w ere  calcuM ted 
fro m  the s tan d a rd  cu rv e  and e x p re sse d  as p m o les of m ethy l alcohol 
l ib e ra te d  p e r  m l, of enzym e so lu tion  pea* hou r.
F ib rin o g en  A ssay  The m ethod  d esc rib ed  is  m odified  from  th a t of
wntïïi IIII I......
Ratnoff and M enzie (1951) (M cNicol and D ouglas, 19644. In th is  m ethod 
plasm a fibrinogen is  clotted with an ex cess  of thrombin and the fibrin
form ed, after washing free from  other plasm a proteins, is  hydrolysed  
by boiling with sodium hydroxide* The tyrosine re leased  during 
hydrolysis is  estim ated co lorim etric  ally* It is  assum ed that there is  
a constant proportion of tyrosine in the fibrinogen m olecule (1*0:11* 7),
Into a IS m l. th ick-w alled  g lass te st  tube w ere placed *'0*2 ml.** 
g la ss  beads, of diam eter not greater than 0* 15 mm* ; 6*0 m l* , 0* 9 per 
cent saline; 0*2 ml*# 2#S per cent CaGl^» 0*2 m l. plasm a and finally  
0* 1 ml* thrombin, 100 N .I .H , u n its /m l. The tube was shaken without 
inversion  and the fibrin harvested  on the g lass beads. After standing 
for 30 minutes at 4^C, any further fibrin form ed was harvested on the glasi 
beads by shaking the te st  tube without inversion . The tube was then 
centrifuged (1,000 g, for 10 m inutes). The supernatant was discarded  
using a P asteur pipette and the g la ss  beads washed three tim es with
6 .0  m l . , 0 , 9  per cent sa lin e , with centrifugation (1 ,000 g* for 10 m inutes) 
after each washing and careful décantation of the sa lin e . To the g la ss  
beads and adherent fibrin was then added 0*4 m l * , 10 per cent NaOH 
and the tube boiled in a water bath for 20 m inutes. The tube was sea led  
with tinfoil to prevent evaporation. After cooling, the tyrosine re leased  
was estim ated  by addition of 2 ,0  m l . , 0 . 5  N# NaOH; 0 ,6  ml * , 5 per 
cent TCA and 0 .6  ml* dilute (1:2) F olin  G iocalteu reagent* After
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standing fo r 10 m inu tes to  p e rm it m axim um  co lour developm ent# the  
op tical density  w as re a d  in  a s pe c tr  ophotom ete r  (SP 500, Uni cam  
In s tru m en ts)  a t 650 mp,. ag a in s t a  re ag en t blank* The ch ief so u rce s  
of e r r o r  in  th is  a ssa y  a re  fa ilu re  to  w ash the g la ss  beads adequately , 
c a re le s s  décan ta tion  of sa lin e  w ashings and adherence  of f ib r in  to  the 
w alla of the  te s t  tube* O ptical density  read ings w ere  co n v e rted  fro m  
a  s tan d a rd  ty rp e in e  cu rv e  to mg* f ib r in o g e n /100 ml* plaem a*
A ssay  fo r  F ib rin o ly tic  In h ib ito r A ctiv ity : U rok inase  S ensitiv ity  T ea t 
In th is  test# p la sm a  is  c lo tted  in  the  p re se n ce  of a  s tan d a rd  am ount of 
the p lasm inogen  a c tiv a to r  urokinase* The ly s is  tim e s  of such s tan d a rd  
c lo ts p rov ide a  com p ara tiv e  m e a su re  of o v e ra ll f ib rin o ly tic  in h ib ito r 
le v e ls . U rok inase  is  em ployed ae a c tiv a to r  in  th is  sy s tem  b ecause  of 
i ts  p re su m e d  n o n -an tigen ic ity  and the  re la tiv e  un ifo rm ity  of the 
f ib rin o ly tic  re sp o n se  w hich i t  p ro d u ces  (F le tc h e r  e t a l . , 1965). It 
is  therefore assu m ed  th a t inh ib ito ry  ac tiv ity  ag a in s t u ro k in ase  is  due 
to  p la sm a  an tifib rin o ly tic  ac tiv ity  and not to  sp ec ific  antibody to 
u ro k in ase  as m ay o ccu r withi.the b a c te r ia l  p ro te in  a c tiv a to rs  
s trep to k in ase  and s tap h y lo ld n ase , an tibodies to  s trep to k in ase  and 
etaphylokinase being p re se n t in  v e ry  v a ria b le  t i t r e s  throughout the 
population* A ccord ingly , in  any one p a tien t, in  whom p lasm inogen  and
fib rinogen  lev e ls  a re  co n stan t, changes in  ly s is  tim e  in  the u ro k in ase  
sen s itiv ity  te a t  w ill re f le c t  v a r ia tio n s  in  fib rin o ly tic  inh ib ito r le v e ls .
Thcj t e s t i s  th e re fo re  u sefu l in  detec ting  any in c re a s e  in  fib rin o ly tic  
inh ib ition  w hich m ay be im p a rte d  to  %dasma by ad m in is tra tio n  of a  
fib rin o ly tic  inhibitor# S im ila rly  in  a  population w ith p lasm inogen  
and fib rinogen  lev e ls  w ithin  the  n o rm a l ra n g es , the s c a tte r  of ly s is  
tim e s  is  a  m easure , of •the s c a t te r  of in h ib ito r le v e ls .
The te s t  does not d is tin g u ish  betw een p la sm a  a n tiac tiv a to r 
ac tiv ity  and p la sm a  an tip la sm in  ac tiv ity  though w ith the re la tiv e ly  high 
co ncen tra tion  of u ro k in ase  inco^ 'porated  in  the te a t sy s tem , v a r ia tio n s  
in  ly s is  tim e s  a re  m o re  lik e ly  to be due to fluc tuations in  an tip lasm in  
activity*
In th is  a ssa y  sy s te m , m odified  ©lightly fro m  th a t of M cNicol 
e t a i. (1963 a), to  0 .2  m l. p la sm a  w as added 0 .3 2  m l. u ro k in ase  containing 
500 P loug u n its /m l. The m ix tu re  w as c lo tted  w ith th rom b in  0* 1 m l . ,
20 N .I .H . unit©/ml* T he ly s is  tim e  of the p la sm a  c lo t at 37^0 w as 
observed* R esu lts  m ay be e x p re s se d  as m inu tes o r  fo r s ta t is t ic a l  
an a ly s is  as un its  of ac tiv ity , one un it being defined as the re c ip ro c a l 
of a  ly s is  tim e of 10 m inutes*
S trep to k in ase  S en sitiv ity  T e s t T h is te s t  is  designed  to m e a su re  the
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concenti’ation  of etreptoldiaa^o which, would ueutrali^se p la sm a  
antibody to e trep to k in ase  and o th e r In h ib ito rs  and leave  su ffic ien t 
f re e  s trep to k in ase  to  p roduce à  p la sm a  clo t ly s is  tim e  of about 20 
m inu tes («Johnson e t al» » 19S7),
To 0 ,2  m l. p la sm a  in  each  of a  s e r ie s  of t e s t  tubes* 
s tre p to k in a se , 500 u n i t s /m l . , w as added in  volum es ranging
Mom  2 to 160 p l i t r e s  as m e a su re d  in  a  m ic ro b u re tte  (M icro ^m etric  
In s tru m en t C o . , C leveland , Ohio)* E ach  p la sm a / s trep to k in ase  
m h itu re  w as c lo tted  w ith th ro m b in , 0 .1  m l. (20 H .I .H . u n i t s /m l .) ,  
and incubated  a t 3?^C . The tim e  fo r  c lo t ly s is  to  occu r was o b se rv ed . 
The re q u ire d  concen tra tio n  of s trep to k in ase  w as ca lcu la ted  on the b a s is  
of the  plasm ia volum e to w hich i t  would be added.
T hrom bin  C lotting T im e T h is te s t  is  u sed  as an index of defective 
fib rin  p o ly m erisa tio n . H ow ever, evidence w ill be p re se n te d  in  
ch ap te r 8 th a t reduced  co n cen tra tio n  of fib rinogen  p e r  se  m ay prolong 
the th rom b in  clo tting  time*
The m ethod d e sc r ib e d  is  th a t of F le tc h e r  e t a l, (1959 a). To 
0 .1  ml* p la sm a  w as added 0* 3 m l. * th rom bin  ti tra t io n  mix* (S eegers 
and Sm ith , 1942). T h rom bin , 0 ,1  m l. ( 6 K ,I .H .  u n i ts /m l .)  w as 
added and the clo tting  tim e  of th is  m ix tu re  re c o rd e d  at 37^0 . The
tlirom bin  ti tra tio n  m ix  w as f re sh ly  p re p a re d  im m ed ia te ly  befo re  u se  
as followe;** 6 m l . , 0*9 p e r  cen t sa lin e , Z m l . , 0 .7  p e r  cent CaCl^;
Z m l* , 15 p e r  cent acacia# 1 m l, t r i s  bu ffe r, 0 .1  M o lar, pH 7.5* 
One>*Btage P ro th ro m b in  T im e T h is  te s t  w as c a r r ie d  out as d e sc rib ed  
by Douglas (1962), A fro z e n  sa line  e x tra c t of hum an b ra in  w as the  
b ra in  e x tra c t u sed  and the co n cen tra tio n  of the  0*025 M olar GaCl^ 
w as checked by ti tr a t io n .
P la sm a  d é c a lc if ic a tio n  T im e T his was m e a su re d  by the m ethod of 
Biggs and M acfarlane  (1962 b).
T h ro m b o p lastin  G en era tio n  T e a t T h is w as the m ethod  of B iggs and 
Douglas (1953). In m o st of the ex p e rim e n ts , the m ethod w as m odified  
by using  co m m erc ia l p la te le t su b stitu te  (B ell and A lton, 1954), 
supp lied  by Stayne L a b o ra to r ie s , L td . , High W ycom be, B ucks,
F a c to r  V A ssay  T his w as the  m ethod of Douglas and B iggs (1953) 
w ith the m odification  th a t c lo tting  tim e s  w ere  re c o rd e d  at 5 and 6 
m inu tes a f te r  the  s ta r t  of incubation .
A ntihaem ophilic  G lobulin (A .H .G *) and C h ris tm a s  F a c to r  A ssay s  T h ese  
w ere  c a r r ie d  out by a one**stage m ethod  (D ouglas, 1965) w hich depends 
on the clo tting  tim e of p la sm a  fro m  pa tien ts  w ith  high*»*grade 
haem oph ilia  o r  C h ris tm a s  d ise a se , which has been  m ax im ally  ‘^contact***
*activated** by kaolin» Goplialin (B ell and A lton, 1954) w as added to  
the su b a tra to  aya tem .
H agem an F a c to r  A ssay  T h is  m ethbd  (D ouglas, 1963)' depends on the 
re c a lc if ic a tio n  tim e  of the  te s t  p la sm a  m ixed  w ith  H agem an fa c to r  
defic ien t plasm a* A d ilu tion  cu rv e  w as m ade w ith  pooled n o rm a l 
p la sm a  and clo tting  tim e s  of the te s t  p la sm a  converted  tp  p e r  cen t 
Idagem an fa c to r  fro m  the curve» The sy s tem  w as m ax im ally  "con tact^  
activated** w ith kao lin  and cephalin  (B ell and A lton, 1954) w as added. 
P la te le t  Count The m ethod u sed  w as th a t d e sc rib e d  by D acie (1936 b)» 
P i a t e le t Ag g r  eg ation T h is w as m e a su re d  by a  m odification  of the 
C h an d le r 's  tube technique (C hand ler, 1958). C handler show ed th a t 
when whole Mood w as ro ta te d  in  a  c lo sed  loop of p la s tic  tubing, when 
i t  so lid ified , i ts  h is to lo g ica l s tru c tu re  c lo se ly  re se m b le d  a  patho log ical 
in  vivo a r te r ia l  th ro m b u s . T h is technique h as  bean  m odified  to u se  
platelet*^rich p la sm a  (Cunningham  et al» 1965). When p la te le t ’^ rich  
p la sm a  is  m ade to  flow round a C h an d le r 's  tube , the f i r s t  s tage  in  
fo rm atio n  of the th rom bus is  a  "snow-storm** effect p roduced  by p la te le t 
agg rega tion . T hese  p la te le t c lum ps eventually  co a le sce  to fo rm  the 
w hite head  of the th rom bus and a f te r  a  fu r th e r  in te rv a l, a  f ib rin  ta il  
fo rm s . U nder rig id ly  s ta n d a rd ise d  conditions, the tim e  betw een r e ­
ca lc ifica tio n  of the  p la sm a  and the  ap pearance  of the " sn o w -s to rm "  
effect is  m e a su re d .
The m ethod u sed  in  th is  th e s is  w as sligh tly  m odified  fro m  
th a t of Cmmingham  e t al* (1965)* N ine volum es of whole Mood w ere  
co llec ted  in  a s ilicone  cen trifu g e  tuba containing 1 v o lu m e ,- 3# 8 p e r  
cen t sodium  eitra.te and m ixed  w ithout fro th ing  using  a  n o n -w a te r-
w ettah le  sea l to avoid con tac t ac tiva tion  of the  blood during  mixing#
■ ’ • ■ 0  ' '
A fte r cen trifu g a tio n , (600 g* fo r 5 m inu tes a t 4 C, 10 m inu tes
a f te r  co llec tion ), 5 md. of the p la te le t- r ic h  p la sm a  w ere  t r a n s f e r r e d ,
using  a s ilicone  P a s te u r  p ip e tte , to a  C h an d le r 's  tube . The tube w as
m ade w ith t ra n s p a re n t  p la s tic  v inyl tubing of length  70 cm , and. in te rn a l
d iam e te r 1 .25 cm . (P o rtlan d  P la s t ic s  L td .,  H ythe, K en t). The tube
contained 10 m l# , 0 .9  p e r  cen t saline# T his m ix tu re  w as re c a lc if ie d
w ith 0. 5 m l# , 0 .2 5  M olar CaCl^ and a s top -w atch  s ta r te d . The tube w as
m ade a continuous loop w ith a  nylon adap to r and ro ta te d  on the tu rn tab le
of a  b lo o d -ce ll su spension  m ix e r  (M atburn L t d . , London), revolv ing  at
28. 5 r .p .m #  in  a  g la ss  «^fronted in cu b a to r a t 3 7^0 . The tim e fo r  the
"sn o w -s to rm "  appearance  to o cc u r a f te r  re c a lc if ic a tio n  was noted  and
taken  as the  tim e  fo r  p la te le t agg rega tion .
CH APTER 4
IN VITRO AND IN VIVO STUDIES OF AMINOMBTHYL
CYCLQHEXANE CARBQXYLIG ACID, A SYNTHETIC 
FIBRINOLYTIC INHIBITOR 
The possib le use of inhibitors of the fibrinolytic ©nayme 
system  for the treatm ent of haem ostatic failure due to pathological 
fibrinolytic activity (M cNicol and Douglas, 1964d) has stim ulated the 
search  for potent inhibitors of fib rin o lysis . In this chapter w ill be 
described the resu lts  of a laboratory and clin ica l appraisal of the 
synthetic amino acid inhibitor l-(am inom ethyl) cyelohexane-4- 
carboxylic acid (M itsubishi K asei Kogyo Company, 1961), the anti­
fibrinolytic effect of which was d iscovered  by Okamoto and Okamoto (1962).
A num ber of am ino com pounds have been shown to p o sse ss  
an tifib rin o ly tic  e ffec ts . In  v it ro , ly s in e  and o rn ith in e  inh ib it the 
ac tiva tion  of p lasm inogen  (MuUertss, 1954) and a rg in in e  and ly s in e  
e s te r s  com petitive ly  inh ib it th e  p ro teo ly tic  ac tiv ity  of p lasm in  and the  
ac tiva tion  of p lasm inogen  by u ro k in a se , s trep to k in ase  and try p s in  
(A lk jaersig  e t a l . , 1958 b). The syn thetic  am ino ac id  EAGA, which 
d iffe rs  fro m  ly s in e  in  the absence  of the a lpha-am ino  group , w as 
d isco v e red  by O kam oto and h is  a s so c ia te s  (M itsubish i K ase i Kogyo 
K abushikl K aish a  Com pany, 1957) and w as shown to  foe an effective
ü illib ito r of p lasm inogen  ac tiv a tio n  by Ablondi e t à l. (1959) and 
A lk jae rs ig  et a l . (1959 b).
S jo e rd sm a  and N ilsso n  (I960) in v estig a ted  a num ber of a lipha tic  
am ino com pounds and found ac tiv ity  as in h ib ito rs  of p lasm inogen  
ac tiva tion  am ong th o se  am ino ac id s w ith a ca rbon  chain  length  of 
4 -8  G a to m s. The m o s t po ten t w as the 6 -ca rb o n  com pound, EAGA*
The te rm in a l position  of the am ino  group ap p e a rs  to be c r i t ic a l  in  th a t 
w hile EAGA is  a potent in h ib ito ri n o rleuc ine  (a lp h a-am in o cap ro ic  acid) 
ia  inactive* L ikew ise the ca rboxy l group probably  is  im p o rtan t 
b ecause  the addition  of an a lpha-am ino  group to  EACA (a lp h a -ep s ilo n - 
am inocapro ic  ac id  o r  lysine) re su lts  in  im p a ire d  activity*
The se a rc h  fo r  a  m o re  potent fib rin o ly tic  in h ib ito r lead  to  the 
in v estig a tio n  of am ino com pounds w ith a  cyclic  s tru c tu re*  At the 
p re se n t t im e , the m o st po ten t of th e se  a re  am inom ethyl cyclohexane 
carboxy lic  ac id  and p -  am inom ethyl ben 2îoic ac id , (PAMBA), (Lohm ann 
e t aL  , 1964), O kam oto and O kam oto (1962) in itia lly  re p o rte d  th a t 
am inom ethyl cyclohexane c a r  boxy lie  ac id  had 10 to 30 tim e s  the ac tiv ity  
of EACA. A nim al tox ic ity  s tu d ie s , including acu te and ch ron ic  tox ic ity  
s tud ies and investig a tio n  of the  effect of lo n g - te rm  ad m in is tra tio n  on 
conception and foe ta l developm ent, w ere  re p o r te d  by M elander et a l, (1965),
w hose re su lts  ind ica ted  tha.t the  compomid w as co n sid erab ly  le s s  toxic 
to a d m in is te r  than  a re  the am ounts of EACA. in  c u r re n t use*
The u se  of EACA as a  fib rin o ly tic  in h ib ito r is  now w ell-  
docum ented. At co n cen tra tio n s  above 10 “M o lar, i t  com petitively  
inh ib its  p lasm inogen  ac tiva tion  and at concen tra tions above 10 M olar, 
i t  n on -com petitive ly  in îiib its the  p ro teo ly tic  ac tiv ity  of p lasm in  (Ablondi 
e t a l . , 1959; A lk jae rs ig  et a l . , 1959 b). E ffective blood lev e ls  of 
EAGA a re  m ain ta ined  by a daily  dose of the o rd e r  of 15 to 20 gm .
(M cNicol a t a l . , 1962^] .^ The d e c re a se  in  tox ic ity  and the a lleged  in c re a s e  
in  potency of am inom ethyl cyclohexane c a r  boxy lie  ac id  com pared  w ith 
EAGA would re p re s e n t  a  co n s id e rab le  advance in  the s e a rc h  fo r  a  m o re  
potent fib rin o ly tic  in h ib ito r and fo r  th is  re a so n , i ts  in v estig a tio n  w as 
u n d ertak en . M elander et ai* (1965) found th a t the syn thetic  pathw ays 
d e sc rib e d  in  the chem ica l l i te r a tu re  fo r  am inom ethyl cyclohexane 
carboxy lic  ac id  re su lt  in  a  m ix tu re  of iso m e rs  containing 10 to  25 p e r  
cent of one of th e se  is o m e rs  w hich p o sse s se s  the e n tire  an tifib rin o ly tic  
ac tiv ity  of the m ixture* G roth  and H ass el (1965) have shown th a t the 
trana iiâom er is  the ac tive  fo rm .
In  th is  account the follow ing asp ec ts  of the com pound have been 
studied: i ts  m ode of ac tion  as  an in h ib ito r of the fib rin o ly tic  enzym e
sy stem ; i ts  effect on the  try p s in o g e n -try p s in  sy s tem  and on the 
p ro teo ly tic  ac tiv ity  of pepsin ; i ts  e ffec t on the coagulation  sy stem ; 
and an a p p ra isa l of i ts  in  vivo potency#
In m any of the  e x p e rim e n ts , the effect of the com pound w as 
com pared  w ith th a t of EACA and in  one in  v itro  ex p e rim en t its  potency 
re la tiv e  to PAMBA w as dem onstrated#
M a te r ia ls
A m inom ethyl C yclohexane C arboxy lic  A cid T h e re  w ere  two p re p a ra tio n s  
A m ix tu re  of the  is o m e rs  containing betw een 10 and 25 p e r  cen t of the 
an tifib rin o ly tica lly  ac tive  is o m e r  is  obtained by a  syn thetic  p ro ced u re  
involving hydrogenation  of am inom ethyl benzoic ac id . T h is m ix tu re , 
which h a s  been ca lled  AMCHA, w as p rov ided  as a  10 p e r  cen t solution* 
The ac tive  is o m e r , s e p a ra te d  fro m  the m ix tu re  by ch rom atog raphy , 
has been ca lled  AMCA and w as a lso  prov ided  as a  10 p e r  cen t solution# 
The chem ica l fo rm u la  of the  com pound to g e th e r w ith th a t of EACA is  
shown in  fig u re  3,
T rypsinogen  and E n te ro k in aso  T h ese  w ere  p u rified  bovine 
p re p a ra tio n s  fro m  L . L ight and C o . , L td ,
P e p s in  T h is w as a  th re e  tim e s  c ry s ta ll iz e d  p re p a ra tio n  obtained  
fro m  the S igm a C hem ical C o#, St# L o u is , Mo,
XJyea-denatured H aem oglobin T h is  w as a tw ice c ry s ta ll iz e d  bovine 
p re p a ra tio n  fro m  the S igm a C hem ical Co,
M ethods
CaBeinolytic A ssay  In  the  ex p e rim en t c a r r ie d  out to m e a su re  
inh ib ition  by AMCHA and by EACA of case in o ly tic  ac tiv ity  of bank 
p la sm a , the final volum e of the d igestion  m ix tu re  w as in c re a se d  to
6 ,0  ml# by addition  of l.O  m l. of vary ing  co n cen tra tio n s of AMCHA o r  
EAGA, Saline w as su b s titu ted  fo r  in h ib ito r in  the con tro l ex p e rim en t.
In  the k ine tic  s tu d io s , the  m ethod w as m odified  by using 
p lasm inogen , p la sm in , try p s in o g en  o r  try p s in  in s te a d  of p la sm a . The 
ac id / a lka li tre a tm e n t was o h iitted  and the final volum e of the d igestion  
m ix tu re  w as SiO m l . , AMCHA o r EACA occupying a  volum e of 1 ,0  m l. 
and sa line  rep lac ing  in h ib ito r in  the  con tro l ex p e rim en t.
The k in e tic s  of inh ib ition  by AM ÇA of p lasm inogen  ac tiva tion  
w ere  in v estig a ted  using  a  m od ifica tion  of the technique d e sc rib e d  by 
A lk jaera ig  e t a l, (19S8 b). The d igestion  m ix tu re  w as 0 .5  m l, hum an 
p lasm inogen  of vary ing  co n c en tra tio n s , 0*5 m l. s tre p to k in a se ,
(50 N .I .H . u n i ts /m l ,)  and 0 .2  ml* AMCA o r sa lin e  in  the  co n tro l 
ex p e rim en t. The ac tiv a tio n  re a c tio n  w as allow ed to p ro ceed  fo r  one 
h o u r a t 37^C and the re a c tio n  stopped  by addition of Z m l . , 0.25H .H C1
which lo w ers  the pH of the d igestion  m ix tu re  to  2* At pH 2, p lasm in  
ia  s tab le , AMCA w as rem oved  by d ia ly s is  a t 4^G ag a in s t 0 .0 1 N .H C l. 
Stx 'eptoldnase w as d ena tu red  o r in ac tiv a ted  by p re c ip ita tio n  of p lasm in  
with 1.0 M olar HaCl at pH Z (T ro ll and S h e rry , 1955), The 
p re c ip ita te  w as w ashed  tw ice in  0 ,01  N .H C l containing 1.0 M olar N aCI, 
co llec ted  by cen trifu g a tio n , d isso lv ed  in  3 m l, d is tille d  w a te r and 
p lasm in  then a ssay e d  by the ca se in o ly tic  techn ique.
U rok inase  S ensitiv ity  T e s t T his w as m odified in o rd e r  to  exam ine the 
an tifib rin o ly tic  effect in  v itro  of AMCHA and AMCA com pared  w ith EACA. 
The fina l volum e of the te s t  m ix tu re  w as in c re a se d  to 0, 82 m l. to 
accom m odate in h ib ito r. In the  co n tro l ex p e rim en t, sa line  w as 
su b stitu ted  fo r in h ib ito r,
Eadm ation of P la s m a  L ev e ls  of AMCA T his m ethod w as m odified  fro m  
th a t of N ilsso n  et a l. (i960) and is  b ased  on the u ro k in ase  sen s itiv ity  
t e s t .  To 0 .2  m l, am ounts of c i tra te d  p la sm a , w ithdraw n fi*om the 
sub jec t im m ed ia te ly  befo re  in g estio n  of AMCA, w ere  added in c re a s in g  
concen tra tions of AMCA in  0 .2  m l. vo lum es, A sa lin e  con tro l w as 
a lso  p re p a re d . A fte r addition  of 0 .3 2  m l. u ro k in ase  (500 Ploug 
u n i ts /m l .)  and clo tting  w ith 0 .1  m l. th rom bin  (20 u n i t s /m l .) ,
the ly s is  tim e  at 37^C of each  clo t so fo rm ed  w as o b se rv ed , A con tro l
curve w as p re p a re d  by plo tting  on the a b sc is s a  the M olar concen tra tion  
o£ AMCA in each p la sm a  volum e aga in st the lo g a rith m  of the 
co rrespond ing  ly s is  tim e  in  seconds on the o rd in a te . A  l in e a r  
re la tio n sh ip  w as found. The concen tra tion  of AMCA in  p la sm a  
w ithdraw n fro m  the sub jec t at d iffe ren t tim es  a f te r  ingestion  of the 
drug w as e s tim a ted  by te s tin g  0 ,2  m l, am ounts of each  p la sm a  in  th is  
sy s tem  w ith 0, 2 m l, sa line  added to  ad just the volum e to tha t of the 
con tro l cu rve  sy s te m . The con cen tra tio n  of AMCA w as d e riv ed  by 
conversion  of the c lo t ly s is  tim e  in  seconds to  the co rrespond ing  
lo g a rith m  and read ing  off the con tro l curve the M olar concen tra tion  
of AMCA w hich, added to the p re - in g e s tio n  p la sm a , gave the sam e 
lo g a rith m .
A ssay  of P e p s in  A ctiv ity  The m ethod u sed  w as d e sc rib e d  by M cNicol
(1964) m odified  fro m  th a t of N o rth ro p  et a l, (1948), The su b s tra te  
u sed  w as u re a -d e n a tu re d  bovine haem oglobin . In  80 m l , , 0 ,0 5  M olar 
g lycine so lu tion  w ere  d isso lv ed  2 .5  g rn . , bovine haem oglobin . The pH 
w as ad ju sted  to 2 w ith about 20 m l , , 0 ,2  N .H C l, The su b s tra te  w as 
p re p a re d  im m ed ia te ly  befo re  u se . P e p s in  w as u sed  in  a  co ncen tra tion  
of 0 ,005  m g ,/m l .  To 4 m l, su b s tra te  was added 0 ,5  m l, in h ib ito r 
d ilu ted  in  sa lin e , A sa lin e  co n tro l w as a lso  p re p a re d , A fte r the
addition of 0 .5  m l, pepsin  so lu tion , the a ssay  m ix tu re  w as incubated  
oa t 37 G fo r 62 m in u tes . A liquots of 2 ,0  m l, w ere  rem oved  at 2 aiid 
62 m inu tes and added to  2 ,0  m l , , 10 p e r  cent NaOH w hich a r r e s t s  
enzym e ac tiv ity . A fte r cen trifu g a tio n  (1,000 g, fo r 10 m in u tes),
1 • 0 m l, of the  su p ern a tan t w as added to  4 . 0 m l , , 0 ,5  N .NaOH; 1, 5 m l , ,
5 p e r  cent TCA and 1 .5  m l, d ilu te (1:2) F olin  C iocalteu  reag en t. A fte r 
standing fo r 15 m inu tes fo r m ax im al co lour developm ent, the op tica l 
density  of the 62 m inute sam ple  w as re a d  at 650 mp,. in  a  
sp ec tro p h o to m ete r (SP500, Unicam.), aga in st the 2 m inu te sam ple  as 
blank.
G lycine w as u sed  as a  buffer because  addition of EACA 
o r  AMCHA to the ac id -haem og lob in  so lu tion  w ithout glycine ra is e d  
the pH out of the range in  w hich pepsin  is  ac tiv e , but w ith g lycine , 
addition of EACA o r  AMCHA did not sign ifican tly  a l te r  the pH, The 
d e ta ils  of th ese  effects a re  shown in  tab le  1, In th is  ex p erim en t,
0 .5  m i, of vary ing  co n cen tra tio n s of AMCHA o r  EACA w as added to
4 ,0  m l. ac id -haem oglob in  s u b s tra te . The co n cen tra tio n s  of AMCHA 
and EACA shown in tab le  1 w ere  ca lcu la ted  in  the fina l volum es of 4 . 5 m l. 
T h rom bop lastin  G enera tion  T e s t T h is was m odified  by in c re a s in g  the 
final volum e of the incubation  m ix tu re  by 0 ,3  m l. The additional 0, 3 ml*
volum e w as occupied  by vary ing  concen tra tions of AMCHA and in  
the con tro l expezdment^ sa lin e  w as su b stitu ted  fo r AMCHA.
O ther M a te r ia ls  and M ethods w ere  d e sc rib ed  in  ch ap te r 3.
R esu lts
Inhib ition  of the  C ase ino ly tic  A ctiv ity  of Bank P la s m a  by AMCHA T his
w as m e a su re d  in  a  ca se in o ly tic  a ssay  sy s tem . E xp ired  pooled bank
p la sm a  w as the so u rce  of hum an plasm inogen* The ac tiv a to r w as
s tre p to k in a se , 100 N .I .H . u n i t s /m l . ,  a  concen tra tion  which gave a
ly s is  tim e  of 7 m inu tes in  the s trep to k in ase  sen s itiv ity  te s t  w ith the
p la sm a . A ctivation  of p la sm a  p lasm inogen  by s trep to k in ase  was
oallow ed to p ro ceed  fo r  30 m inu tes a t 37 G. AMCHA w as added in  
vary ing  concen tra tio n s im m ed ia te ly  befo re  s tre p to k in a se  o r im m ed ia te ly  
a f te r  s tre p to k in a se , but p r io r  tp p lasm in  a s sa y . The re s u lts  of th ese  
ex p e rim en ts  a re  shown in  fig u re  4. It can be seen  th a t inh ib ition  by 
AMCHA of the ca se in o ly tic  ac tiv ity  of bank p la sm a  w as m uch m o re  
m ark e d  when AMCHA w as added befo re  ac tivation  than  when i t  w as 
added a f te r  ac tiva tion .
The s im ila r  re s u lts  o b se rv e d  when EACA w as te s te d  in  th is  
sy s te m  a re  shown in  f ig u re  $♦
C om parison  of f ig u re s  4 and 5 shows th a t in  th is  sy s tem , AMCHA
—ou **
had  tw ice the potency of EAGA* F o r  exam ple, when added x>rior 
to  s tre p to k in a se , 2 x  10 ^ M olar AMCHA o r  4 x 10 ^  M olar EAGA 
produced  20 p e r  cent inh ib ition  of ca se in o ly tic  ac tiv ity  and when 
added a f te r  s tre p to k in a se , 14 p e r  cent inh ib ition  w as o b serv ed  at a 
con cen tra tio n  of 3 x 10 ^ M olar AMCHA o r 6 x 10 M olar EAGA. 
Inhib ition  by AMCHA of the P ro te o ly tic  A ctiv ity  of P la sm in :K in e tic s  
of the R eaction  In th is  ex p e rim en t; c a se in  w as u sed  as su b s tra te  fo r  
hum an p lasm in . The co n cen tra tio n  of ca se in  in  the  d igestion  m ix tu re  
w as v a r ie d  sevenfold , the h ig h est concen tra tio n  being 2 p e r  cen t.
The concen tra tio n  of p lasm in  w as constan tly  1 .5  ca se in  u n its /m l. 
of the d igestion  m ix tu re  and th a t of AMCHA 0 ,2  M olar.
The data  a re  shown in  fig u re  6 as double re c ip ro c a l p lots 
(liinew eaver and B urk , 1934). T hese  p lo ts fu lfil the L in ew eav er- 
B urk  C rite ria  lo r  uncom petitive  inh ib ition  by AMCHA of the 
p ro teo ly tic  ac tiv ity  of p lasm in i
F ig u re  7 shows the da ta  ob tained  when EAGA w as in co rp o ra ted  
in  th is  exp erim en t a t a co n cen tra tio n  of 0*4 M olar. The double 
re c ip ro c a l p lo ts of fig u re  7 fu lfil the B in ew eav er-B u rk  c r i te r ia  fo r 
non -com petitive  in h ib itio n  by EACA of the p ro teo ly tic  ac tiv ity  of p lasm in .
Inliibition by AMCHA of P lasm in o g en  A ctivation  by S trep tok inase; 
K inetics of the R eac tion  T h ese  w ere  in v estig a ted  in  a case in o ly tic  
a ssay  sy s tem  in  w hich p u rified  hum an p lasm inogen  w as the su b s tra te  
fo r the ac tiv a to r s tre p to k in a se . The h ighest p lasm inogen  co ncen tra tion  
added w as 23 ca se in  u n i t s /m l . , and the co ncen tra tion  w as v a r ie d  te n ­
fo ld . The con cen tra tio n  of s trep to k in ase  w as 10 N .I .H . u n i ts /m l. of 
the d igestion  m ix tu re . The re s u l ts  a re  i l lu s tra te d  in  figu re  8 as double 
re c ip ro c a l p lo ts . AMCHA w as in c o rp o ra te d  at a  constan t concen tra tio n  
of 0 ,0 5  M olar im m ed ia te ly  b efo re  ac tiva tion  of p lasm inogen  w ith 
s trep to k in a se . T hese  p lo ts fu lfil the L in ew eav er-B u rk  c r i te r ia  fo r 
com petitive inh ib ition  by AMCHA of p lasm inogen  ac tiva tion  by 
Btr eptokinas e ,
At a su ffic ien tly  high co n cen tra tio n , the p re se n c e  of AMCHA 
would in te r fe re  w ith the  a ssa y  of p lasm in  fo rm ed  in  th is  ex p erim en t 
and hence the o b se rv ed  re su lts  would not re p re se n t the tru e  k inetic  a 
of inhib ition  of p lasm inogen  ac tiv a tio n . T able 6 shows the re su lts  of 
case ino ly tic  a s sa y s  in  w hich vary ing  concen tra tions of p lasm in  w ere  
a ssay e d  w ith AMCHA 0 .0 5  M olar and w ithout AMCHA. I t  can be seen  
th a t the p ro tob ly tic  ac tiv ity  of p lasm in , in  a range of concen tra tio n s  
app rox im ate ly  the sam e as th a t w hich could be p roduced  by ac tiva tion
' V A '
of the p lasm inogen  co n cen tra tio n s  u sed  in  the p rev ious ex p e rim en t, 
w as not in fluenced  by the p re se n c e  of 0*05 M olar AMCHA*
The re s u lts  of the  co rresp o n d in g  ex p e rim en ts  fo r  BACA a re  
shown in  tab le s  S and 6 and the  double re c ip ro c a l p lo ts  of fig u re  9 
i l lu s tr a te  th a t 0 . 1 M olar BACA com petitively  inh ib its  p lasm inogen  
ac tiva tion  by strep tok inase*  T h is  re su lt  is  q u a lita tiv e ly  in  ag reem en t 
w ith  th a t of A lk jaera ig  et al* (1959 b)*
The k in e tic s  of inh ib ition  by AMCA of p lasm inogen  ac tiva tion  by 
s trep to k in ase  w ere  s tu d ied  using  the  techn ique, m odified  fro m  th a t of 
A lk jae rs ig  et al* (1958 b)* The h ig h est co ncen tra tion  of p lasm inogen  
added w as 23 ca se in  un its /m l*  and the co n cen tra tio n  w as v a r ie d  sev en ­
fold* A ctivation  of the  p lasm inogen  w ith s trep to k in ase  40 N .I .H . u n its / 
m l. of the  d igestion  m ix tu re  w as allow ed to  p ro ceed  fo r  60 m inu tes a t 
37^G* The p lasm in  fo rm ed  a f te r  th is  tim e  w as a ssay e d  a f te r  rem oval 
of AMCA and inac tiva tion  o r  d én a tu ra tio n  of strep tok inase*  The re su lts  
a r e  shown as double re c ip ro c a l p lo ts  in  fig u re  10* AMCA w as in c o rp o ra te d  
a t a  constan t co n cen tra tio n  of 0*02 M olar * The p lo ts fu lfil the c r i t e r ia  
fo r com petitive  inh ib ition  by AMCA of p lasm inogen  activation* The 
ex p e rim en t a lso  con firm s the o b se rv a tio n s  m ade w ith AMCHA*
Inhibition  by AMCHA of the  P ro te o ly tic  A ctiv ity  of T rypsin : K inetics
of the R eaction  T h ese  w ere  s tud ied  by the technique a lread y  d e sc rib e d
fo r p lasm in , in  a ca se in o ly tic  a ssay  sy s tem . The range of co ncen tra tion  
of c a se in , the su b s tra te  fo r try p s in , w as v a r ie d  sevenfold , the m axim um  
co ncen tra tion  being Z p e r  cent* The concen tra tio n  of try p s in  w as 
0 ,0 8  m g, I  m l, of the d igestion  m ix tu re  and th a t of AMCHA, 0* 2 M o lar.
The re su lts  a re  shown in  f ig u re  11 as L in ew eav er-B u rk  plots * The 
p lo ts d em o n stra te  th a t AMCHA is  a non-^competitive in h ib ito r of the 
p ro teo ly tic  ac tiv ity  of try p s in -
F ig u re  12 shows the re su lts  of th is  ex p erim en t w ith 0 ,4  M olar 
EACA as the  in îiib ito r. The double re c ip ro c a l p lo ts d em o n stra te  the 
EACA inh ib its  try p p in  in a non*-competitive m an n er.
Inhib ition  by AMCHA of T ry p sin o g en A ctivation  by E n te ro k in ase ;
K inetics of the R eaction  The re su lts  of th is  ex p erim en t a re  shown in  
fig u re  13, A case in o ly tic  a ssa y  sy s tem  w as u sed , The final concen tra tion  
in  the d igestion  m ix tu re  of en te ro k in ase  was 1 ,25  m g, / m l, and the 
concen tra tion  of trypsinogon  w as v a r ie d  fiftyfo ld , the m axim um  
concen tra tion  being 0, 5 mg* / n il, A-MCHA w as in c o rp o ra te d  in  a 
co ncen tra tion  of 0 ,0 5  M o lar, The exp erim en t w as a lso  c a r r ie d  out in  
the p re se n ce  of 0. I M olar EACA and the s im ila r  r e s u l ts  obtained a re  
shown in  fig u re  14, The L in ew eav e r-B u rk  jdete  of fig u re s  13 and 14 
fu lfil the  c r i t e r ia  fo r com petitive  inhib ition  by AMCHA and by BACA of
trypszBOgen ac tivation  by enterokinase*
The co n cen tra tio n  o£ AMCHA and EACA u sed  in th ese  
exp erim en ts  did not inh ib it the p ro teo ly tic  activ ity  of try p s in  in  
concen tra tions ranging fro m  50 m g. / 100 it4 .  to 5 m g. / 100 m l, of 
the d igestion  m ix tu re , as shown in  tab le  10.
In  a ll th e se  ex p e rim en ts  i t  w ill be seen  tha t AMCHA had 
about tw ice the potency of EACA. It w ill be seen  too , in  the Idnetic  
ex p e rim e n ts , th a t the m odes of ac tion  of AMCHA and. of EACA w ere  
qua lita tive ly  s im ila r .
The E ffect of AMCHA on P e p s in  A ctiv ity  The re su lts  a re  shown in  
figu re  15. Inhib ition  of pepsin  began at an AMCHA concen tra tion  of 
5 X 10 M olar and 80 p e r  cen t inh ib ition  was seen  at an AMCHA 
concen tra tion  of 5 x  10 M o lar.
C om parison  of the effect of AMCHA on pepsin  ac tiv ity  w as m ade 
w ith EACA. and the re su lts  a re  shown In figui’e 16. Inh ib ition  of pepsin  
by EACA began at co n e en tra tio n sg rea te r than  2 x ID Mola.r EACA and 
SO p e r  cent inh ib ition  w as o b se rv e d  w ith 6 % 10 ^ M olar EAGA.
The A n tifib rino ly tic  E ffect of AMCHA and AMCA In V itro  In the k ine tic  
s tu d ie s , c a se in  w as the s h b s tra te  em ployed to a ssay  p làsm in  b ecau se  the 
u se  of the physio log ical su b s tra te  f ib rin  in such s tud ies g ives poor
' V O -
re p ro d u c ib ility . In  o rd e r  to  study the  an tifib rin o ly tic  effect of 
AMCHA and AMCA com pared  w ith th a t of BACA in  a sy s te m  in co rp o ra tin g  
f ib r in , vary ing  co n cen tra tio n s  of th e se  com pounds w ere  added to  bank 
p la sm a  and the ly s is  t im e s  of th e se  m ix tu res  o b se rv e d  in  the  u ro k in ase  
sen s itiv ity  tost* The re s u lts  a re  shown in  fig u re  17* In th is  sy s te m , 
in  te rm s  of M olar co n cen tra tio n , AMCA the ac tive  iso m e r  w as about 
ten  tim e s  m o re  potent than  AMCHA, the m ix tu re  of is o m e rs ,  and about 
one hundred  tim e s  m o re  po ten t than  BACA#
A s im ila r  ex p e rim en t w as c a r r ie d  out to  com pare  the a n ti-  
fib rin o ly tic  effect of AMCA w ith th a t of PAMBA# T hese  re s u lts  a re  
i l lu s tra te d  in  fig u re  18 w here  i t  w ill be seen  th a t AMCA w as 
app rox im ate ly  eigh teen  tim e s  m o re  potent than  PAMBA*
The E ffect of AMCHA on the C oagulation S ystem  B ecause of the 
com plex in te r - re la t io n sh ip  of blood coagulation w ith  the  fib rin o ly tic  
enzym e sy s tem , and to  exam ine the  p o ssib ility  th a t AMCHA m ight 
p roduce a h aem o sta tic  effect by influencing th ro m b o p las tin  g en era tio n  
o r  the th ro m b in -fib rin o g en  re a c tio n , the effect of AMCHA on the 
th ro m b o p las tin  g en e ra tio n  te s t ,  the o n e -s ta g e  p ro th ro m b in  tim e  and 
the th rom b in  clo tting  tim e  w as studied#
V arying co n cen tra tio n s  of AMCHA w ere  added to f re s h  n o rm a l
p la sm a  w hich w as te s te d  in  the  o n e -s ta g e  p ro th ro m b in  tim e and 
th ro m b in  clo tting  t im e . In  th e  th ro m b o p las tin  g en e ra tio n  te s t ,  AMCHA 
w as added to  the  incubation  m ix tu re . The re s u lts  a re  shown in  
tab le s  14 and IS, w here  i t  w ill be seen  th a t a t co n cen tra tio n s of 
AMCHA g re a te r  than  2, S x  10 M o lar, the o n e -s ta g e  p ro th ro m b in  tim e  
and the th ro m b in  clo tting  tim e  w ere  pro longed  and at a  co n cen tra tio n  
of 2* S X 10 M o la r, th e re  w as s lig h t im p a irm en t of th ro m b o p lastin  
generation*
In  Vivo E x p erim en ts  w ith  AMCHA and AMCA 
The an tifib rin o ly tic  effec t of AMCHA and AMCA w as in v es tig a ted  
in  healthy  adult vo lun teers#  In  the  f i r s t  ex p e rim e n ts , Z gm . of AMCHA 
w ere  in g ested  by the  su b jec t im m ed ia te ly  a f te r  w ithdraw al of a  co n tro l 
spec im en  of venous blood# T h e re a f te r  spec im ens w ere  w ithdraw n a t 
15 and 30 m inu tes and 1, 2, 3, 5, 7, 12, and 24 ho u rs  following ing estio n  
of AMCHA, T hese  p la sm a  sam p les  w ere  te s te d  in  the  u rok in ase  
sen s itiv ity  te s t  and th e  c lo t ly s is  tim e  of each spec im en  w as tak en  as  a  
m e a su re  of the  an tifib rin o ly tic  effect im p a rte d  to  th a t p la sm a  by the 
AMCHA ingested# The re s u l ts  a re  shown in  fig u re  19 along w ith the 
r e s u lts  of a  co n tro l ex p e rim en t c a r r ie d  out on a  d iffe ren t day* It can  
be seen  th a t, follow ing the  in g estio n  of AMCHA, th e re  w as a  d em o n strab le
- o  f -
antifibrinolytiG  effec t a t 1$ m in u te s , a  peak effec t a t 2 h o u rs  and 
th e re a f te r  a  m o re  g rad u a l d im inution  of the  effect o v e r the succeeding  
5 h o u rs  w ith re tu rn  to  the  p re - in g e s tio n  ly s is  tim e  betw een 7 and 12 
hours# In  the  con tro l ex p e rim e n t, th e re  w as neg lig ib le  d iu rnal
v a r ia tio n  of ly s is  tim e  in  the u ro k in ase  sen sitiv ity  test*
oA ll of the  p la sm a  sam p les  w ere  d ia lyaed  at 4 C w ith constan t 
s t i r r in g  fo r 36 ho u rs  ag a in st 0* 1 M olar phosphate b u ffe r, pH 7 .6 , 
w ith two changes of buffer# At the  end of d ia ly s is , th e re  had  been  a 
25 p e r  cen t volum e in c re a s e  of a ll spec im ens and each  spec im en  
had  a  ly s is  tim e  of about IB m inu tes in  the u ro k in ase  sen s itiv ity  test#  
U ndialyaed aliquots of a ll sam p les  w ere  diuted 25 pei" cen t w ith 0 . 1 
M olar phosphate  bu ffe r and a lso  te s te d  in  the u ro k in ase  sen s itiv ity  test# 
D ilu tion  by 25 p e r  cen t of the  p re - in g e s tio n  sam ple  re su lte d  in  a 
u ro k in ase  sen s itiv ity  te s t  of IB m inutes* The o th e r , und ialysed , 
d ilu ted  spec im ens a lso  gave p ro longed  ly s is  tim es  co m p ared  w ith th e ir  
undilu ted  values* F o r  exam ple , the two h o u r spec im en , tha t w ithdraw n 
a t the peak of the in h ib ito ry  e ffec t, had  a  ly s is  tim e  of 42 m inu tes when 
d ilu ted  and 39*5 m inu tes ünd ilu ted . D ia ly sis  had  th e re fo re  e lim in a ted  
the substance  producing the  in c re a s e d  an tifib rin o ly tic  effect* T h ese  
re su lts  a re  shown in  d e ta il in  tab le  16.
' V U '
The sam e su b jec t in g es ted  on d iffe ren t days 2 gm , BACA and 
1 gm . AMCHA# Specim ens of venous blood w ere  w ithdraw n a t the  
sam e tim e s  as in  the  p rev io u s  exp erim en t and the p la sm a  sam p les  
te s te d  as before* The re s u l ts  a r e  shown in  fig u re  20. I t  can  be seen  
th a t the effect of 2 gm . BACA and of I gm* AMCHA w as c lo se ly  
s im ila r ,  w ith  the  d iffe ren ce  th a t th e re  w as p ossib ly  a  sign ifican tly  
g re a te r  an tifib rin o ly tic  effect a t 7 h o u rs  in  the AMCHA ex p erim en t 
com pared  w ith the 7 ho u r value  in  the BACA e x p e rim e n t. In th is  
ex p e rim en t AMCHA had  in  vivo about tw ice the potency of EAGA.
D ia ly sis  of th e se  sp éc im en s in  the m an n er a lread y  d e sc rib e d  
e lim in a ted  the d iffe ren ces  in  c lo t ly s is  t im e s , as shown in  tab le  18,
The ac tive  is o m e r , AMCA, w as in v estig a ted  s im ila r ly . F ig u re  
21 shows the  e ffec t of in g estio n  of 200 m g. AMCA com p ared  w ith the 
effect of 2 gm . EAGA in g es ted  by the  sam e su b jec t on a  d iffe ren t day . 
With AMCA, th e re  w as d em o n strab le  an tifib rin o ly tic  ac tiv ity  a t IS 
m inu tes in  the u ro k in ase  sen s itiv ity  t e s t ,  m axim um  inh ib ito ry  effec t 
betw een 1 and S h o u rs , and a  slow  fa ll of inh ib ito ry  effec t to  p r e ­
ing estio n  ly s is  tim e s  betw een 12 and 24 hours* With EAGA on the 
o th e r  hand, peak in h ib ito ry  ac tiv ity  w as d em o n strab le  a t 2 h o u rs  and 
re tu rn  to p re - in g e s tio n  va lues o c c u rre d  betw een 5 and 7 hours*
V 7
C om pared  w ith BACA in  th is  in  vivo ex p e rim en t, AMCA had  a 
tenfo ld  in c re a s e  in  potency o v er BACA.
A nother aub jeet in g es ted  200 mg* AMCA and I gm , AMCHA on 
d iffe ren t d a y s . The ré su lta  a re  shown in  fig u re  32* w here  i t  w ill be 
Been th a t c lo se ly  s im ila r  e ffec ts  w ere  o b se rv ed  in  the u ro k in ase  
aenaitiv ity  te a t  following a d m in is tra tio n  of each  p re p a ra tio n . AMCA, 
in  th is  ex p e rim en t, th e re fo re  shows a  fivefold  in c re a s e  in  potency 
o v er AMCHA*
The re su lts  of in g estio n  of 300 m g, AMCA by 5 o th e r su b jec ts  
a re  shown in  tab le  31. In  th e se  su b jec ts , effective  antifibzdnolytic 
ac tiv ity  w as d em o n strab le  in  the u ro k in ase  sen s itiv ity  te s t  fo r  about 
13 ho u rs  a f te r  in g estio n  of the  com pound.
E ffect of AMCA in  the  T re a tm e n t of a  p a th o lo g ica l H aem osta tic  
D efect AMCA, in  a  dose of 300 m g . , was given to a pa tien t w ith 
m e ta s ta tic  c a rc in o m a  of the b re a s t  which w as a sso c ia te d  w ith abnorm al 
b leeding in to  the skin  and fro m  venepunctu re  s i te s .  The abnorm al 
b leeding  w as thought in itia lly  to  be due, in  p a r t  a t le a s t ,  to patho log ical 
fib rin o ly tic  ac tiv ity . The ev idence fo r th is  w ill be d isc u sse d  in  ch a p te r 8j 
w here  the p a tie n t 's  c a se  h is to ry  and. investig a tio n  a re  d e sc rib e d . One 
of the fe a tu re s  of the  in v es tig a tio n  of th is  pa tien t w as a c c e le ra te d  ly s is
f  u
o£ F ean iJ,ey-type d ilu te p la sm a  d o ts#  FiguiHà 33 shows the effect 
of 300 mg* AMCA, ad m in is te re d  o ra lly  to the  p a tien t, in  inh ib iting  
p la sm a  fib rin o ly tic  activity# In the  sam e fig u re  is  shown the v e ry  
s im ila r  p a tte rn , in  d u ra tio n  and ex ten t, seen  on ano ther day when the 
p a tien t w as given 2 gm# of EACA by mouth# O bserva tions on a 
con tro l day, fa lling  betw een the  ad m in is tra tio n  of AMCA and EACA, 
a re  a lso  shown*
No aide effec ts  w ere  no ted  by any of the  sub jec ts  who took 
e ith e r  AMCHA o r  AMCA#
E stim a tio n  of P la sm a  L ev e ls  of AMCA An e s tim a te  w as m ade of the 
p la sm a  lev e ls  of AMCA ach ieved  in  one pa tien t following an o ra l dose 
of 200 mg# AMCA* P la s m a  sam p les  w ere  w ithdraw n fro m  the sub jec t 
im m ed ia te ly  b efo re  ing estio n  of AMCA and a t 15 and 30 m inu tes and 
1, 2, 5, 8, 12, and 24 h o u rs  a f te r  ingestion# The concen tra tions of 
AMCA d isso lv ed  in  the  p re - in g e s tio n  p la sm a  a re  shown in  tab le  23 and 
the con tro l cu rve  in  fig u re  24# The re su lts  of te s tin g  each of the p o s t-  
ingestion  sam p les  in  the sam e sy s te m , to g e th er w ith  th e ir  M olar 
co ncen tra tions of AMCA, d e r iv e d  fro m  the co n tro l cu rv e , a re  a lso  
shown in  tab le  23* I t  w ill be seen  th a t an e s tim a te d  peak  con cen tra tio n  
of 2*0 X 10 M olar AMCA w as found 2 hours a f te r  ingestion  of the 
compound*
D is cita s ion
The re su lts  p re se n te d  in  th is  ch ap te r re v e a l th a t the 
syn thetic  am ino ac id , am inom ethyl cyclohexane carboxy lic  ac id , 
inh ib its  the fib rin o ly tic  enzym e a t two points: i t  inh ib its  both
p lasm inogen  ac tiva tion  and the p ro teo ly tic  ac itiv ity  of fo rm ed  plasm in* 
In  the ca se in o ly tic  a ssay  sy s te m  w ith  bank p la sm a  a,s the so u rce  of 
p lasm inogen , addition of AMGHA e ith e r  befo re  s trep to k in ase  o r  a f te r  
s tre p to k in a se , w ill la rg e ly  d is tin g u ish  betw een the  effec t of the 
com pound on p lasm inogen  ac tiva tion  and its  effect on the ac tiv ity  of 
fo rm ed  plasm in* T h is experixnent d em o n stra te s  th a t effective 
inh ib ition  by AMCHA of the  ac tiv a tio n  p ro c e ss  w as p roduced  by 
co nsiderab ly  low er co n cen tra tio n s  of AMCHA than  the  co n cen tra tio n  
re q u ire d  to  produce effective  inh ib ition  of the ac tiv ity  of fo rm ed  
plasm in# Inhib ition  by AMCHA of p lasm inogen  ac tiva tion  began a t a 
concen tra tion  g re a te r  than  10 M olar and of the  p ro teo ly tic  ac tiv ity  of 
fo rm e d  p lasm in  at co n cen tra tio n s  g re a te r  than  E x 10 M olar# A.t the 
h ig h e r range of co n cen tra tio n s  of AMCHA added befo re  s tre p to k in a se , 
the o b se rv ed  inh ib ition  of case in o ly tic  ac tiv ity  m u st s t i l l  be due 
p r im a rily  to  inh ib ition  of p lasm inogen  ac tiva tion , b ecause  the sam e 
concen tra tio n s added a f te r  ac tiv a tio n  did not s ign ifican tly  inh ib it the
ac tiv ity  of fo rm ed  pjLasmin*
In the  eam e cyi3tem« SAC A had  about one half the  potency of 
ÂMCÏiA» Added p r io r  to the  ac tiva tion  p rocess»  4 % 10 M olar 
SAGA p roduced  30 p e r  cen t inlTiibition of c a s e ino ly tic  activity» the 
d eg ree  of inh ib ition  p roduced  by 2 x  10 M olar AMCHA^ Added 
a f te r  activation# 14 p e r  cen t inh ib ition  of case in o ly tic  ac tiv ity  was 
p roduced  by 6 x 10 ^ M olar EAGA com pared  w ith S x 10 M olar 
AMGHAv
Since effective inh ib ition  of p lasm inogen  ac tiva tion  can  be 
achieved  by low er co n cen tra tio n s  than  those re q u ire d  to  inh ib it the 
ac tiv ity  of fo rm ed  ^ s m in »  the  a im  of th e rap y  w ith the com pound 
would be to  a d m in is te r  a dose w ith would re su lt  in  p la sm a  co n cen tra tio n s 
betw een 10 ^ and 10 ^ M o lar AMCHA-^
The k ine tic  s tu d ies  re v e a l th a t AMGHA at a  concen tra tio n  of 
0 ,2  M olar la  an uncom petitive  in h ib ito r of the p ro teo ly tic  ac tiv ity  of 
p lasm in  and th a t a t the lo w er co ncen tra tion  of 0»OS M olar i t  
com petitively  inh ib its  p lasm inogen  ac tivation  by s tre p to k in a se . One 
c r i t is ic m  of the ex p e rim en t in  w hich the k in e tic s  of inh ib ition  of 
X^lasminogen ac tiva tion  w ere  d em o n stra ted  is  th a t the  p re se n c e  of 
AMGHA m ay inh ib it p la sm in  foarmed during ac tiv a tio n . S ince the 
am ount of p lasm inogen  ac tiv a ted  in  the p re se n c e  of the in h ib ito r is  
ca lcu la ted  by a s sa y  of p la sm in  fo rm ed  fro m  it ,  any in h ib ito ry  effect of 
AMGHA on p lasm in  would m ean  th a t the to ta l am ount of p lasm in  fo rm ed
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durm g ac tiva tion  had not been  m e a su re d . H ence the tru e  k in e tic s  
of inh ib ition  would not be re p re s e n te d  by the L inew eaver-*Burk p lo ts 
of fig u re  8. In  the ex p e rim e n t, a lread y  dis cu ssed , to m e a su re  the 
inh ib ito ry  effect of AMGHA upon the case ln o ly tic  ac tiv ity  of bank 
p la sm a , i t  was seen  th a t m uch h ig h er concen tra tio n s  of AMGHA w ere  
re q u ire d  to inh ib it fo rm ed  p la sm in  than  to  inh ib it p lasm inogen  
ac tiv a tio n . In  addition  in  an o th er ex p e rim en t, the  r e s u l ts  of w hich 
a re  shown in  tab le  6, 0* OS M olar AMGHA, the concen tra tio n  u sed  to 
d em o n stra te  its  k in e tic s  of inh ib ition  of p lasm inogen  ac tiv a tio n , did 
not affect the oase ino ly tic  a s sa y  of a  range of co n cen tra tio n s  of p lasm in  
equivalen t to the po ten tia l p la sm in  w hich could be fo rm ed  by ac tiv a tio n  
of the h ig h est p lasm inogen  co n cen tra tio n  added in  the k in e tic s  ex p e rim en t, 
v a r ie d  down to neg lig ib le  am oun ts. I t ap p ears  reaso n ab le  th e i'c fo re  to 
assu m e that the L inew eav er^B u rk  p lo ts of figu re  8 do re f le c t ac cu ra te ly  
the kineticB of Iniaibition by AMGHA of p lasm inogen  ac tiva tion  by 
s tre p to k in a se . T h is  e ffec t, i . e .  com petitive inh ib ition  of p lasm inogen  
ac tiva tion , w as con firm ed  w ith the  ac tive  Iso m e r AMCA in  the sy s tem , 
w here  the p lasm in  fo rm ed  w as a ssay e d  a f te r  rem o v a l o r  d én a tu ra tion  of 
the  a c tiv a to r and in h ib ito r. W ith EAGA, non^com petitive inh ib ition  of 
the  p ro teo ly tic  ac tiv ity  of p la sm in  and com petitive  Inhibition of
p lasm inogen  ac tiva tion  by s tre p to k in a se  w ere  d em o n stra ted  a t 
EAGA. co ncen tra tions ol 0*4 and 0* 1 M olar re sp e c tiv e ly . The la t te r  
finding, to g e th e r w ith the re s u l ts  fo r  EAGA in  the ex p erim en t to 
d em o n stra te  inh ib ition  of ca se in o ly tic  ac tiv ity  of banlt p la sm a , 
w as qua lita tive ly  in  ag reem en t w ith the findings of Ablondi e t a l.
(1959) and A lkjaerB ig e t a l .  (1959 b).
The effec ts  of AMGHA on the try p sin o g en ^ try p sin  sy s tem  
w ere  shown to  be n o n -co m p etitiv e  inh ib ition  of the p ro teo ly tic  ac tiv ity  
of try p s in  w ith 0 .2  M o lar AMGHA and com petitive  inh ib ition  by AMGHA 
of try p sin o g en  ac tiva tion  by en te ro k in a se  w ith 0 .0 5  M olar A.MCHA.
As w as found w ith the plasminogen***plasmin sy s te m , the con cen tra tio n  
of AMGHA w hich wotild Inhib it fo rm ed  try p s in  w as fourfo ld  th a t which 
would inh ib it the  ac tiva tion  of try p sin o g en . F u r th e r ,  when a range 
of cone ont rationsccf try p s in , v a r ie d  fro m  the h ig h est po ten tia l 
co ncen tra tion  of try p s in  w hich could  be fo rm ed  in  the ex p e rim en t to 
in v estig a te  the  k in e tic s  of inh ib ition  of trypsinogen  ac tiva tion , to  v e ry  
low co n cen tra tio n s , w as a ssay e d  w ith and w ithout 0 .0 5  M olar AMGHA, 
the re su lts  w ere  the  sam e w ithin  the lim its  of ex p e rim en ta l e rro r*  I t  
is  again  a  f a i r  assum ption  th a t fa ilu re  to rem ove AMGHA did not affect 
the  o b se rv ed  k in e tic s  of inh ib ition  by AMGHA. of try p sin o g en  ac tiv a tio n .
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tJslng tw ice the concen tra tio n s of EACA com pared  w ith AMGHA, 
s im ila r  effects  of EACA on the  trypsinogen*^trypsin sy s tem  w ere  
o b se rv ed .
AMGHA inh ib its  p ep sin  ac tiv ity , 70 p e r  cent inh ib ition  being 
o b se rv ed  at a co n cen tra tio n  of 4 x 10 M olar com pared  w ith 57 p e r  
cen t inh ib ition  by the sam e M olar co n cen tra tio n  of EACA*
The an ticoagulan t effect on the  th ro m b o p lastin  g enera tion  te a t ,  
the on©***stage te s t  and the th ro m b in  c lo tting  tim e  w ith concen tra tions 
of AMGHA in  the  p la sm a  at o r  g re a te r  th an  2 ,5 %  10 M olar, would 
not be im p o rtan t in  v ivo , since  such co n cen tra tio n s a re  m uch h ig h er 
than  those re q u ire d  to in liib it p lasm inogen  ac tiva tion  ** the a im  of 
th erap y  w ith th is  fib rin o ly tic  inhibitor*
In the in  v itro  p la sm a  clo t sy s te m , w hich is  ac tiv a ted  by a 
s tan d a rd  am ount of u ro k in ase , the  M olar potency of AMGHA w as 
about sixfo ld  th a t of EAGA and AMCA w as about one hundred tim e s  
m o re  potent than  EACA*
The in  vivo ex p e rim e n ts  revealed, f i r s t  th a t an an tifib rino ly tic  
effect d em o n strab le  in  the u ro k in ase  sen s itiv ity  te s t  could be 
p roduced  by o ra l  adnn in istra tion  of AMGHA and of AMCA, U sing the 
u ro k in ase  sen s itiv ity  te s t ,  com parab le  an tifib rin o ly tic  e ffec ts  w ere
d e tec ted  a f te r  a d m in is tra tio n  of 200 m g. AMCA, I gm , AMCHA o r  
Z gm* EACA,
It w as a lso  shown th a t an an tifib rin o ly tic  effect could be 
p roduced  in  a p a tien t w ith a h a e m o s ta tic  defect due, in  p a r t  at le a s t ,  
to  a  patho log ical fib rin o ly tic  s ta te  (see  ch ap te r 8), and th a t tw ice 
the dose of EAGA a d m in is te re d  to  th is  pa tien t p roduced  a c lo se ly  
s im ila r  e ffec t.
The effect of AMCHA and AMCA w as m o re  p ro longed  than 
th a t of EACA, a finding possib ly  duo to slow er re n a l ex c re tio n  of 
AMCA and AMCHA com pared  w ith EACA; Me la n d e r ot a l .  (1964) 
found in  an im al s tud ies m axim um  q rin a ry  re c o v e ry  of EACA 
a f te r  in travenous a d m in is tra tio n  w as 72 p e r cen t, com pared  w ith 64 
p e r  cen t fo r AMGHA.
The m axim um  e s tim a te d  p la sm a  lev e l of AMCA in one pa tien t 
a f te r  an o ra l dose of 200 m g. w as 2 x 10 M o lar. A nders son e t a l.
(1965) u sing  th e ir  c lo se ly  s im ila r  techn ique, found le v e ls  of about
***4  §1.2  X 10 M olar in  se ru m  a f te r  a  dose of 0 ,01  gm ./k g *  body w eight,
a co ncen tra tion  w hich e ffec tive ly  inhil^ited pathological fib rin o ly tic
a c tiv ity .
I f  M
Conclusions
F ib rin o ly tic  in h ib ito rs  d e sc rib e d  p r io r  to  the  d iscovery  of 
a,minomethyl cyclohexane ca rboxy lic  ac id , have been a liphatic  am ino 
ac ids w ith carbon  chain  leng ths of  4 -  8 C atom s and the am ino
&
group in  the te rm in a l p osition , the  m o s t paten t being EACA, The 
s tru c tu ra l  re sem b lan ce  of am inom ethy l cyelohexane carboxy lic  ac id  
to  EACA is  obvious, though the  fo rm eras  s tru c tu re  m ay be m o re  rigid* 
The rig id ity  m ay be re sp o n s ib le  fo r i ts  in c re a s e  in  potency over SAGA 
as a fib rin o ly tic  in h ib ito r enabling i t  to Uc^ .**»xn* m o re  p re c ise ly  o r  
co n sis ten tly  to  the ac tive  s ite  on the ac tiv a to r m o lecu le .
E ffective inh ib ition  by AMCHA of p lasm inogen  ac tiva tion  m ay be 
p roduced  by m uch lov /er coxxcontrationa of AMCHA than  those  re q u ire d  
to inh ib it fo rm ed  p lasm in  and the  a im  of th erap y  w ith  AMGHA would 
th e re fo re  be to achieve the co n cen tra tio n s  w hich would inh ib it 
p lasm inogen  ac tiva tion  and thus p rev en t the continuing fo rm a tio n  of 
p la sm in .
In  v itro  in the k inetic  ex p e rim en ts  and in  the  in  vivo ex p e rim e n ts , 
AMGHA had  a twofold in c re a s e  in  potency o v e r EACA and in  the 
in  vivo exporim onts AMCA had  te n  tim e s  the potency of EAGA, T h is  
in c re a s e  in  potency re n d e rs  the ac tive  iso m e r  AMCA m uch m ore
a ttra c tiv e  as a  fib rin o ly tic  in h ib ito r than  EACA. A m in im um  of 
10 gm . daily  by m outh ol EACA i s  re q u ire d  to m a in ta in  effective 
inh ib ito ry  le v e ls . F ro m  the in  vivo ex p e rim en ts  d e sc rib e d  in  th is  
ch ap te r and fro m  the w ork  d e sc rib e d  by A nders son e t a l . (196S) a 
reaso n ab le  dosage schedule of AMCA would ap p ear to be a  loading 
dose of about 400 to 600 m g . w ith a  m ain tenance dose of 100 to 200 m g. 
every  five h o u rs . L ike EAGA, AMCA is  rap id ly  e x c re te d  in  the  u rin e  
and th e re fo re  low er dosage should  be re q u ire d  fo r the  tre a tm e n t of 
u rin a ry  t r a c t  h aem o sta tic  fa ilu re . A fu r th e r  a ttra c tio n  of AMCA as 
a  fib rin o ly tic  in h ib ito r is  i ts  lo w ered  tox ic ity  in  an im als com pared  
w ith EACA*
The inh ib ito ry  effec t of the com pound on trypsinogen  
ac tiva tion  m ay have re lev an ce  in  the fu tu re  in  the  tre a tm e n t of the 
p ro te o ly s is  of acu te  p an c rea titis*
The inixibitory effec t of the  com pound on pepsin  is  p robab ly  
w ithout th e ra p eu tic  va lue , becau se  of the v e ry  high concen tra tions 
w hich would be re q u ire d  to p roduce  effective inh ib ition  of pepsin  
ac tiv ity .
The e ffec ts  p roduced  on the  th ro m b o p lastin  g en e ra tio n  te s t  
and the th rom b in  clo tting  tim e  in d ica te  th a t any h aem o sta tic  effect
p roduced  by the com pound in vivo is  not ex e rted  by v ir tu e  of its  
influence on e ith e r  e x tr in s ic  oi* in tr in s ic  th ro m b o p las tin  g en era tio n  
o r  on the thrpm M n"*fibrinogen reaction*
In the  fu tu re , AMCA m ay com e to rep lace  EA.CA in the. 
treatxxient of d iso rd e re d  fib rin o ly tic  s ta te s ,
CHAPTER 5
IN VITRO AND IN ViVO STÜDIES WITH TRABYLOL
T ra sy lo l i s  a  polypeptide of m o lecu la r w eight 6 ,200 which 
w as o rig in a lly  iso la te d  fro m  bovine p a ro tid  gland (F rey  et a l* , 1950),
I t  has been shown to p o s se s s  potent an titry p tic  ac tiv ity  in  v itro  
(M oshal et al» , 1963), ejid to  p rev en t the developm ent of ex p erim en ta lly  
inchtced p a n c re a titis  in  an im ale  (M cCutcheon, 1963, 1964; M cHardy et 
a l , , 1963). B ecause of th e se  p ro p e r t ie s , i t  has been u sed  
ex tensively  in  the tre a tm e n t of acute p an c rea tic  d ise a se  (see Sky ring  
et a l. 9 1965 fo r a rev iew  of the  lite ra tu re )*  I t  h a s  a lso  been 
reco g n ised  to p o sse ss  inh ib ito ry  effec ts  on the fib rin o ly tic  enssyme 
sy s tem  (M arx e t a l . , 1959; S te iche le  and H e rsc h le in , 1961; B eck et 
a l. , 1963) and m o re  recen tly  i t  h as  been shown to inh ib it blood 
coagulation  (A m ris , 1966), On th e o re tic a l g rounds, a drug p o sse ss in g  
both an tifib rin o ly tic  and an ticoagu lan t effects  m ight have co n sid e rab le  
value in  the tre a tm e n t of spontaneous pathological b leeding s ta te s  
a sso c ia te d  w ith hypofib rinogenaem ia . Such s ta te s  m ay com plicate  
m a jo r  su rg ic a l p ro c e d u re s  e sp ec ia lly  pu lm onary  su rg e ry  (Soulier et 
a l. 9 1952) and su rg e ry  w ith e x tra c o rp o re a l c irc u la tio n  (von K aulla  
and Swan, 1958); c e r ta in  o b s te tr ic  conditions (S chneider, 1959)? 
m e ta s ta tic  ca rc in o m a p a r tic u la r ly  of the p ro s ta te  (Tagnon et a l . , 1952)
"* O i,
and hepa tic  c i r r h a s is  (Kwc^im et aL , 1956). The p re c is e  xnecham sm  
of production  of th e se  acu te  h ae m o sta tic  d e fec ts , which m ay be life*^ 
th rea ten in g , has not been elucidated* P o ss ib le  exp lanations include 
w id esp read  in tra v a sc u la r  coagu la tion , o r sy s tem ic  h y p e rp la sm in aem ia  
o r  a  com bination of th e se  two (F le tc h e r  et a l. , 1963 b; S harp , 1964). 
E m ergency  la b o ra to ry  d iffe ren tia tio n  of clotting fro m  ly s is  m ay be 
im p o ssib le  thus ren d erin g  d ifficu lt a ra tio n a l app roach  to  th erap y  ( i .e .  
h ep a rin  fo r p r im a ry  in tra v a s c u la r  coagulation  o r a  fib rin o ly tic  in h ib ito r, 
e ith e r  EACA o r  AMCA, fo r pi^im ary fib rin o ly s is ) .
The ex p e rim en ts  w ith T ra sy lo l d esc rib ed  in  th is  chap te r w ere  
u n d ertaken  to study fu r th e r  i ts  effec ts  on blood coagulation  and on the 
fib rin o ly tic  enzym e sy s te m , w ith a  view  to evaluating  its  possib le  u se  
in  the th e rap y  of defib rin a tio n  sy n d ro m es. A lim ited  investig a tio n  was 
a lso  m ade of i ts  ro le  as a try p s in  in h ib ito r.
In the in  v itro  in v estig a tiv e  w ork m ade w ith the d rug , i ts  m ode 
of action  as an in h ib ito r of the fib rin o ly tic  en^iyme sy s tem , i ts  potency 
as a fib rin o ly tic  in h ib ito r co m pared  w ith tha t of AMCA a.nd EACA, its  
effect on blood coagulation  and i ts  influence on p la te le t aggregation  
w ere  stud ied .
T ra sy lo l w as ad m in is te re d  to a num ber of n o rm a l sub jec ts  and
its  effect on physio log ical fibxdnolysie, blood coagulation  and p la te le t 
aggregation  a s s e s s e d . It w as a lso  given to two p a tien ts  w ith hypo-» 
fib rinogenaom ia  and its  e ffec t on the coagulation d iso rd e rs  s tud ied .
F in a lly , i ts  m ode of action  as a trypsiai inh ib ito r was in v es tig a ted  
a n d  a sy s tem  w as dev ised  to  de tec t changes in  an titry p tic  ac tiv ity  in  
p la sm a  following the intravenouB ad m in is tra tio n  of la rg e  doses of the 
d rug .
M a te r ia ls
T ra sy lo l The com pound is  iso la te d  co m m erc ia lly  fro m  bovine lung.
I t  w as m ade ava ilab le  in  am poules each containing E 5 ,000 K a llik re in  
in ac tiv a to r u n its  in  5 m l. of so lu tion  su itab le  fo r  in trav en o u s in jec tio n . 
One un it w as equivalen t to the K a llik re in  in a c tiv a to r  ac tiv ity  of 
0 .195  |xgm. of the p u re  c ry s ta llin e  su b stan ce . In m o st of the w ork  
p re se n te d  in  th is  c h a p te r , i ts  concen tra tion  has been  d e sc rib e d  in 
u n its  s in ce , in  c lin ica l u se , i t  is  p re sc r ib e d  in u n its . In one ex p e rim en t, 
in  w hich its  in  v itro  potency w as a s s e s s e d  re la tiv e  to tha t of AMCA and 
EACA*. its  concen tra tio n  is  given in  te rm s  of M olarity  and w eight.
M ethods
I n h ib i t io n ^  T ra sy lo l of the E a te ro ly tic  A ctiv ity  of U rok inase  on 
AcLM e The k in e tic s  of th is  re ac tio n  w ere  stud ied  using  the m ethod  of
S h e rry  et a l. ( 1964) w hich is  d e sc rib e d  in ch ap te r 3* T his m ethod 
w as sligh tly  m.odi£ied by ad justing  the volum e of A,cLMe to 2. 5 m l. 
T ra sy lo l w as contained In a volum e of 0. 5 m l. and sa lin e  $%:ibstituted 
fo r T ra sy lo l in the control, ex p e rim en t.
T h rom bop lastin  G enera tion  T e s t The effect of T ra sy lo l in v itro  on 
th ro rnbop laatin  g e n e ra tio n  w as stud ied  in  two w ays. It was added to the 
incubation  m ix tu re  as d e sc r ib e d  in  ch ap te r 4. In ano ther ex p e rim en t, 
i t  w as added to the subst'ra te  p la sm a  in  vary ing  co n cen tra tio n  so th a t 
the su b s tra ta  sy stem  w as 0, I m l. p la sm a  and 0. 1 m l. T ra sy lo l.
Saline w as su b stitu ted  fo r T ra sy lo l in  the con tro l ex p e rim en t.
O ther M a te r ia ls  and M ethods w ere  d esc rib ed  in ch ap te rs  3 and 4.
R ésu lta  
In Vitro Experim ents 
Inhibition by T rasylol of the C aseinblytic A ctivity of Bank P lasm a  
This inhibitory effect was m easured in a oaseinolytic assay  system  in 
which expired pooled bank p lasm a activated by streptokinase was the 
source of human plasm inogen. Streptokinase was used in a concentration  
of 100 N .Î .H . u n its /m i. p lasm a. This concentration of streptokinase  
gave a ly s is  tim e of 5 m inutes in the streptokinase sen sitiv ity  te st  
with the plasm a. Activation by streptokinase of plasm a plasm inogen
w as allow ed to p ro ceed  fo r 30 m inu tes at 37^C* A range of 
concen tra tions of T ra sy lo l w as added to the sy s tem  e ith e r  im m ed ia te ly  
b efo re  s trep to k in ase  o r im m ed ia te ly  a f te r  s trep to k in ase  and th e re fo re  
30 m inutes befo re  p lasm in  assay* The re s u lts  of th ese  experim en ts  
a re  shown in fig u res  25 and 36. It w ill be seen  th a t inhib ition  by 
T ra sy lo l of the case in o ly tlc  ac ltiv ity  of strep tok inase^-activated  p la sm a  
w as m o r e  effective when TraB ylol w as added a f te r  ac tiva tion  but p r io r  
to p lasm in  a ssay  than  w hen added p r io r  to  ac tiva tion . In  th is
System , inhib ition  of case in o ly tic  ac tiv ity  w as v ir tu a lly  com plete when 
T ra sy lo l w as p re se n t in  a  co n cen tra tio n  of 10 u n its /m l. of the 
d igestion  m ix tu re , co rresp o n d in g  to 300 u n its /m l. in whole p la sm a . 
Inhib ition  by T ra sy lo l of the ProteoX ytic A ctivity  of P lasm in ;
K inetic  s of the He action  C ase in  w as u sed  as su b s tra te  fo r hum an 
p lasm in  in  th is  experim ent» The ca se in  co ncen tra tion  was v a r ie d  
sevenfold , the m axim um  being 3 p e r  cen t in the  d igestion  m ixture*
The concen tra tio n  of p lasm in  w as constan tly  1. 5 ca se in  u n its /m l. of 
the d igestion  m ix tu re . T h re e  coneen tra tions of T ra sy lo l w ere  te s ted ;
5, 8 and 10 u n itb/ m l, of the d igestion  m ix tu re , In the exp erim en t in  
which T ra sy lo l, 10 u n its /m l, of the d igestion  m ix tiire  w as in co rp o ra ted , 
th e re  w as vi ru t ally  com.plete inh ib ition  of the p ro teo ly tic  ac tiv ity  of
plaçînin* The re su lts  a re  i l lu s tra te d  as double re c ip ro c a l p lots 
in  f ig u re s  Z7 and 28 and i t  can  be seen  tha t the rela^tionsMp betw een 
su b s tra te  coincent r a t  ion and re a c tio n  velocity  becam e d iso rg an ised , 
inh ib ition  being m ore  effective at low su b s tra te  c o n c e n tra tio n s ,
A ccordingly , the ex p e rim en t w as m odified to u se  a fourfold  
v a r ia tio n  in ca se in  co n cen tra tio n , the h ighest con cen tra tio n  being Z p e r  
cen t of the d igestion  mixture?. The concen tra tio n  in the d igestion  
m ix tu re  of p lasm in  w as as in  the p rev ious ex p erim en t and tha t of 
T ra sy lo l 6 un its /m l*  The re s u l ts  of this exp erim en t a re  shown in  
f ig u re  29 as double reciprocal p lo ts . The p lo ts fu lfil the L inew eavor- 
B urk  c r i te r ia  fo r non**competitive inhib ition  by T ra sy lo l of the 
p ro teo ly tic  ac tiv ity  of p la sm in .
Inhib ition  by T ra sy lo l of P lasm in o g en  A ctivation  by St r  e pt okina b © : 
K inetics of the .Reaction T h ese  k in e tic s  w ere  in v estig a ted  in a 
case in o ly tic  a ssay  sy s tem  in w hich p u rified  hum an p lasm inogen  was 
the su b s tra te  fo r s tre p to k in a se . The h ighest co n een tra tio n  of 
p lasm inogen  w as added to the d igestion  m ix tu re  fro m  a so lu tion  
containing 33 >3 c a se in  u n itb of p la sm in o g en /m l. and th is  concen tra tion  
w as v a r ie d  eightfold . S trep to ld n ase  (50 u n its /m l.)  w as the
activator*  T ra sy lo l w as in c o rp o ra te d  in  th re e  con cen tra tio n s;
2, 5 and IG u n its /m l, of the digestion m ixture. The resu lts of these
experim ents are shown as double reciprocal plots in figure 30, It 
w ill be seen  that, as in the experim ent in which the kinetics of 
iniiibition of the proteolytic activity of plasm in w ere studied, the 
relationship between substrate concentration and reaction velocity  
was d isorganised  when a wide variation in substrate concentration  
was em ployed. Inhibition by T rasylo l of plasm inogen activation by 
streptokinase was m ore effective at low concentrations of plasm inogen.
The experim ent was repeated using a threefold  variation in  
plasm inogen concentration, the maxim um  being 23 .3  casein  unit©/m l. 
and incorporating T rasylo l in a concentration of 5 u n its /m l. of the 
digestion m ixture. The data are shown a© double reciprocal plots in  
figure 31 where it can be seen  that the Lineweaver^Burk cr iter ia  for  
com petitive inhibition by T rasy lo l of plasm inogen activation by 
streptokinase are fu lfilled .
In the experim ent in  which inhibition by T rasy lo l of the 
caseinolytic activity of banlc plasm a was investigated , it was seen  that 
the sam e concentration of T rasy lo l had a greater inhibitory effect when 
added to the assay  system  after activation of p lasm a plasm inogen with 
streptokinase but prior to p lasm in assay  than when added prior to 
activation. In the above kinetic experim ents, m easurem ent of reaction
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velocity  is  dependent g>n assay  of plasm in form ed after the reaction  
between T rasy lo l, streptokinase and plasm inogen. The continuing 
presence of T rasylol in the d igestion  m ixture m ight therefore depress  
the activity of the plasm in so form ed and hence the observed data might 
not reflect accurately the true k inetics of the reaction .
The kinetic studies w ere therefore repeated using the method  
m odified from  that of A lkjaersig et a l, (1958 b), in  which the 
inhibitor is  rem oved by d ia lysis  and streptokinase denatured or 
inactivated before assay  of p lasm in. Plasm inogen was added to the 
digestion m ixture from  a solution containing 18 case in  units of 
plasm inogen/m l, and the concentration varied  threefold . The 
concentration of T rasylo l was 17 u n its /m l, of the digestion m ixture.
The concentration of the streptokinase solution added to the digestion  
m ixture was 50 N .I .H , u n its /m l. The resu lts are shown as double 
reciprocal plots in  figure 32, The plots fulfil thé L inew eaver-Burk  
cr iter ia  for com petitive inhibition and confirm  the previous observations. 
Inhibition by T rasylol of P lasm inogen Activation by Urokinase;
K inetics of the Reaction T hese k inetics w ere studied in  the casein o lytic  
assay system  used for streptokinase. The maximum concentration of 
plasm inogen was added to the digestion m ixture from  a solution containing
P O -
17, s  case in  units of plasm inogen/m l* This concentration was 
varied  threefold . The concentration of the urokinase solution  
added to the digestion m ixture was 100 C .T .A , u n its /m l. The 
concentration of T ra sy lo l was 5 u n its /m l. of the digestion mixture*
The resu lts are illu strated  in  figure 33 as double reciprocal plots 
which fulfil the Linewaaver^Burk cr iter ia  for com petitive inhibition  
by T rasylol of plasm inogen activation by urokinase.
Inhibition by T rasylo l of the E ste roly tic  Activity of Urokinase on 
A cIjMc: K inetics of the R eaction T hese kinetics w ere studied because  
the este  roly tie  activity of urokinase may represent a different 
property of the urokinase m olecule from  its role as an activator  
of plasm inogen, since AcLMe is  a com petitive inhibitor of plasm inogen  
activation by urokinase in  addition to being a substrate for urokinase 
(Sherry et al* # 1964), The m axim um  concentration of AcLMe used  
was 16,9  m g ,/m l*  of the d igestion  m ixture and its concentration was 
varied  fivefold* Urokinase was added to the digestion m ixture from  a 
solution containing 2 ,000  G, T * A* u n its /m l, T rasy lo l was present in  
a constant concentration of 400 u n its /m l, of the digestion mixture*
The observed data are shown as double reciprocal plots in figure 34, 
The effect# found in the previous kinetic experim ents# of m ore
efficient iniiibition by T rasylo l at low substrate concentration can be 
seen .
The experim ent was ^repeated using a threefold variation  
in  substrate concentration from  the maximum of 16* 9 m g ./m l. of the 
digestion m ixture , The concentration of T rasylol was in creased  to 
450 u n its /m l, of the d igestion m ixture. The resu lts are shown as 
double reciprocal plots in figure 35* The plots illu stra te  that the 
inhibition by T rasylo l of the este  roly tic  activity of urokinase is  of 
the 'mixed* type •* com petitive and non-com petitive.
The Antifibrinolytic Effect of T rasylo l In. Vitro This effect was 
investigated  by addition of increasing  concentrations of T rasylol to 
bank plasm a and by observation of the ly s is  tim es of these m ixtures  
in the urokinase sen sitiv ity  test* AMCA and EACA w ere investigated  
in the sam e manner so that a com parison of the antifibrinolytic effect 
of T rasylol could be made with the effect of these amino acid  
fibrinolytic inhibitors* The resu lts  are graphically presented in 
figure 36* It can be seen  that in term s of Molar concentration, 
T rasylo l was about one hundred tim es m ore potent than AMCA and 
one thousand tim es m ore potent than EAGA* On a weight b a sis , 
T rasylo l was about two and one-half tim es m ore potent than AMCA*
The E ffect of T ra sy lo l on the O n e-s tag e  P ro th ro m b in  T im e and 
the T hrom bin  G lottm g Tim© T ra sy lo l in  vary ing  co n cen tra tio n s w as 
added to  f r e s h  n o rm al p la sm a  which w as then  te s te d  in  the o n e -s ta g e  
px'othrom bin tim e and the  th ro m b in  clo tting  time* The data  a re  shown 
in  tab le  34 f ro m  w hich i t  w ill be seen  tha t T ra sy lo l had  no effec t on 
the o n e -s tag e  p ro th ro m b in  on the th ro m b in  clo tting  t im e .
The E ffect of T ra sy lo l in  the  T h rom bop lastin  G enera tion  T e s t 
T ra sy lo l w as added in  vary ing  concen tra tio n s to  the incubation  m ix tu re  
of a n o rm al th ro m b o p las tin  g en e ra tio n  test# The re s u l ts  a re  shown in  
tab le s  35 and 36 and g rap h ica lly  d isp layed  in  p a r t  in  fig u re  37* I t can  
be seen  th a t a  defect in  the th ro m b o p las tin  g en e ra tio n  te s t  w as 
de tec tab le  when T ra sy lo l w as p re se n t in  a con cen tra tio n  of 100 u n its /m l, 
of the incubation  m ixture# The defect# p ro longation  of the  su b s tra te  
p la sm a  clo tting  tim es# p e r s is te d  up to l6  m inutes* incubation* With 
co n cen tra tio n s of T ra sy lo l le a s  than  100 u n its /m l*  of the  incubation  
m ixture# no abnorm ality  of the  th ro m b o p las tin  genera tio n  te s t  w as 
d em o n strab le  #
T ra sy lo l w as a lso  added to  the  su b s tra te  p la sm a  in  the 
th ro m b o p lastin  g en e ra tio n  te s t .  The re su lts  a re  given in  tab le  37 and 
in  p a r t  in  fig u re  38# I t w ill be seen  th a t pro longation  of the su b s tra te
y X
p la sm a  çlotting^'tim es w as d em o n strab le  w ith T ra sy lo l p re se n t in a
y r  -V
co ncen tra tion  of SO u n i ts /m l .  of su h s tra te  p la sm a . T h is defect w as 
only d em o n strab le  up to the fo u rth  m inute of incubation  even w ith the 
m axim um  concen tra tion  of T ra sy lo l te s te d  and w as th e re fo re  le s s  
s tr ik in g  than  the defect due to  the  p re se n c e  of T ra sy lo l in  the  incubation 
m ixture*
The Effect- 0^1 F la t  el et A ggregation  of T raey lo l Added In V itro  to  
P la sm a  T ra sy lo l w as added to .p la sm a  from, each  of seven  n o rm al 
su b jec ts  in  a concen tra tio n  of 300 u n its /m l. of the plasm a# The effect 
of addition of T ra sy lo l to the  p la sm a  on p la te le t agg regation  w as 
a s s e s s e d  in  the C h an d le r 's  tube system # The da ta  a re  shown in  tab le  
38, T ra sy lo l, at th is  co n cen tra tio n , sign ifican tly  p ro longed  the  tim e 
fo r  p la te le t agg rega tion , the  m ean  tim e  fo r p la te le t agg regation  w ithout 
T ra sy lo l being 577 -  28 seconds and w ith T ra sy lo l 939 ^ 186 seconds 
( t -  4 .797 ; 0#00K p<0#005).
The ex p erim en t w as re p e a te d  w ith T ra sy lo l in a co ncen tra tion  of 
40 u n its /m l. of p la sm a  and p la sm a  fro m  each of ten  n o rm al sub jec ts  
w as u sed . The d a ta  a r e  shown in  tab le  39# T ra sy lo l, a t th is  
co n een tra tio n , s ign ifican tly  p ro longed  the tim e fo r p la te le t agg regation . 
The m ean  tim e  fo r  p la te le t ag g regation  w ithout T ra sy lo l was
439 ^ XSE seconds and w ith T ra sy lo l 572 t  227 seconds (t ™ 2*543: 
Û*02<p<0.05).
T h is la s t  ex p e rim en t w as re p ea ted  a f te r  fu r th e r  m odification*
P la te le t  agg regation  w ith T rasy lo l#  40 un its /m l*  p laem a an d  w ithout
T ra sy lo l w as a s s e s s e d  using  p la sm a  fro m  each of ten  n o rm a l subjects#
The co n tro l and te s t  sy s tem s  w ere  p re p a re d  in  the C h an d le r 's  tubes
oan^d both w ere  incubated  fo r  10 m inu tes at 37 C befo re  re c a lc if ic a tio n . 
The d a ta  a r e  shown in  tab le  40. In  th is  ex p e rim en t, the m ean  tim e  fo r  
p la te le t agg regation  w ithout T ra sy lo l w as 293 ^ 69 seconde and w ith 
T ra sy lo l w as 312 86 seconds* T his d iffe rence  is  not sign ifican t
(t %: O4 625: 0«5<p<0*6),
In  Vivo Expe r im en t a 
The an tifib rin o ly tic  and an ticoagulan t effec ts  of T ra sy lo l w ere  
in v estig a ted  following in trav en o u s  administx^ation of the com pound to 
hea lthy  adult su b jec ts ,
T able 41 su m m a rise s  the findings in  one sub jec t during a 12 hour 
T ra sy lo l infusion* The in fusion  ra te  w as 10#000 un its  of  T ra sy lo l o v er 
30 m inu tes: 3# 000 u n its /h o u r  fo r the  succeeding  two and o n e-h a lf h o u rs  
and 1,000 un its/ho txr fo r  a  fu r th e r  nine h o u rs . B lood sam p les  w ere  
ob tained  im m ed ia te ly  befo re  the in fusion , a f te r  30 m in u te s , 3 hou rs
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and 15 h o u rs . T h is la s t  sp ec im en  w as 3 h o u rs  a f te r  the end
of the in fusion . I t  can be seen  th a t during the in fusion , p lasm inogen  
ac tiv a to r ac tiv ity  in  the euglobulin  c lo t ly s is  te s t ,  F e a rn la y  dilute 
p lasm a  clo t ly s is  te s t ,  and the  f ib r in  p la te  te s t  d e c re a se d  and th a t 
th is  d e c re a se  had pex’s is te d  3 houx’s a f te r  the iixfusion had  ce a sed .
Using the u ro k in ase  sen s itiv ity  te s t ,  the T ra sy lo l in fusion  w as found 
to  have im p a rte d  in c re a s e d  an tifib rin o ly tic  ac tiv ity  to the p lasm a: th is  
effect which w as m ax im al 30 m inu tes a f te r  the s ta r t  of the infxision had 
som ew hat dec lined  3 h o u rs  a f te r  the s ta r t ,  but was s t i l l  apparen t 3 ho u rs  
a f te r  the in fusion  had  c e a se d . D uring the in fusion , no effect w as 
o b se rv e d  on the  o n e -s ta g e  p ro th ro m b in  tim e , th ro m b in  clotting tim e , 
o r  th ro m b o p las tin  g en e ra tio n  te s t .  The p la te le t count d id  not v a ry  
s igm flcan tly  during  the in fusion . T hese  re su lts  a re  shown in  p a r t  in  
fig u re  39.
Shown in  tab le  42 a re  the effec ts  ol in trav en o u s a d m in is tra tio n  of 
T ra sy lo l in  ano ther sub jec t who re ce iv ed  a sing le in jec tio n  of 50,000 
un its  ol T ra sy lo l follow ed by an in fusion  ol 50,000 un its  given o v er 30 
m in u te s . Blood sam p les  w e re  taken  im m ed ia te ly  before the in fusion  
and a f te r  40 m inu tes i . e . ,  10 m inu tes a l te r  the  in fusion  ceased* It can 
be seen  tha t th is  dosage schedule px*oduced a defect in  the th ro m b o p las tin
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generation test -  the substra,te plasm a clotting tim es being prolonged* 
There was also evidence of decreased  fibrinolytic activator activity in 
the euglobulin ly s is  te st  and of in creased  fibrinolytic inhibitory lev e ls  
in the urokinase sen sitiv ity  test* T hese resu lts are shown in part in 
figure 40,
Table 43 shows data obtained from  a patient who received  a 
single intravenous injection of T rasylo l containing 100,000 units.
Blood sam ples w ere obtained im m ediately before the injection and at 
30 m inutes and I, 2, 3, 5, 1 and 9 hours aft ex- the injection* A 
throm boplastin generation te s t , urokinase sen sitiv ity  te st and p latelet 
count wex^e perform ed on each sam ple. It w ill be seen  that a defect 
had appeared in the throm boplastin generation test at 30 minutes and 
had disappeared by 3 houx'S, In the urokinase sen sitiv ity  te st , in creased  
fibrinolytic inhibition v/as present at 30 m inutes and had p ersisted  at 9 
houx’s* P re-treatm en t lev e ls  had returned by 24 hours* P latelet 
counts did not vary significantly* T hese resu lts  ax^ e graphically  
displayed in part in figure 41.
Two subjects w ere given T rasylo l infusions at a p rogressive ly  
increasing rate of infusion over 5 hours, A constant infusion pump 
fitted with an infusion-rate se lec tor  (B. Braun, Mel sung en) v/as used
yto  d e liv e r the T ra sy lo l so lu tion . The kifusion  ra te  w as 10,000 uxxitB 
in  0*6 m l. so lu tion  during the f i r s t  hour; 20,000 un its  contained  in  
1 .2  m l, during the second hour; BO, 000 mxits in  3 ,0  m l. during the 
th ird  hour; 100,000 un its in  6 ,0  m l. during the fou rth  hour and
200,000 un its  in  12.0 m l, during  the fifth  and final h o u r. Blood 
sam p les  w ere  taken  im m ed ia te ly  befo re  the  in fusion , at the end of 
each  hour and two h o u rs  a f te r  the in fusion  ceased . The e ffec ts  of 
each infusion  w ere  a s s e s s e d  by te s tin g  each  spec im en  in  the th ro m b o ­
p la s tin  g en e ra tio n  te s t  and the  u ro k in ase  sen s itiv ity  te s t .  P la te le t  
counts w ere  a lso  c a r re d  out on each  sp ec im en . The data  fo r th e se  
e?xperiments a re  given in  tab le s  44 and 45 and g rap h ica lly  d isp layed  in  
figures 42 and 43. The e ffec ts  of the in fusions w ere  c lo se ly  s im ila r  in  
both su b jec ts . T h e re  w ere  d em o n strab le  defec ts  in  the th ro m b o p lastin  
g en era tio n  te s ta  at the end of the f ir s t  h o u r. The defects  becam e 
p ro g re ss iv e ly  wax*se w ith in c re a s in g  dosage of T ra ay lo l and had 
p e r s is te d  two h o u rs  a f te r  com pletion  of each  in fusion . In c re a se d  
fib rin o ly tic  inh ib ito ry  lev e ls  in  the  u ro k in ase  sen s itiv ity  te s ts  w ere  not 
apparen t un til the end of the  fourth hour when the dose of T ra sy lo l had 
been 100,000 un its  in  the p reced ing  h o u r. T h is effect had  d isap p ea red  
two h ou rs a f te r  com pletion  o l each  infusion*
P late let counts w ere not significantly affected in either subject.
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E feci of T raay lo l In jec tion  on P la te le t  A ggregation  M easu red  in the 
Ghand).er*b Tub© T h is w as s tud ied  in  seven  p a tien ts  each  of whom 
receiv-ed a sing le  in trav en o u s injects.on of T ra sy lo l containing 100,000 
u n its . P la te le t  ag g regation  w as m e a su re d  by the  Ç handler ' s tube 
technique using  silico n e  p la sm a  sam p les  taken  im m ed ia te ly  befo re  
in jec tio n  and 30 m inu tes a f te r  injection* The re s u lts  a re  shown in  
table. 46. The memx tim e  fo r .p latelet agg regation  befo re  the T ra sy lo l 
in jec tio n  w as 537 ^  75 seconds and a f te r  the T ra sy lo l in jec tio n  w as 
277 t  1 3 9  seco n d s. The a c c e le ra tio n  of p la te le t agg regation  a f te r  the 
T ra sy lo l in jec tion  is  s ig n ifican t (t -  4 .976 ; 0* 00Kp<0* 005),
The m ean  p la te le t count fo r  the 7 su b jec ts  im m ed ia te ly  b efo re  
in jec tio n  w as 309 -  72 thousands/ and 30 m inu tes a f te r  in jec tion  w as 
308 -  72 t h o u s a n d s / T h e s e  counts ax^e a lm o st id en tica l (tab le 47).
T h ro m b o p lastin  g en e ra tio n  te s ts  w ere  a lso  p e rfo rm ed  fo r each  
sub jec t im m ed ia te ly  b e fo re  in jec tio n  and 30 m inu tes a f te r  in jec tio n . The 
data a re  shown in  tab le  48, E ach  th ro m b o p las tin  g en era tio n  te s t  w as 
im p a ire d  a f te r  the T ra sy lo l injection* At 6 m in u te s ' incubation , the 
m ean  su b s tra te  p la sm a  clo tting  tim e  a f te r  the T ra sy lo l in jec tion  was 
15 .6  -  2 .6  seconds. C om pared  w ith the m ean value befo re  T ra sy lo l 
(12. I -  2 .1  seconds), the  proloxxgation a f te r  T ra sy lo l is  s ign ifican t 
(t Î? 4 .208 ; 0 .0 0 5 < p < 0 .0 l),
r .  ^  f
When the tim e s  in  seconds by which plate3.et agg rega tion  w as 
a c c e le ra te d  a f te r  the T rao y lo l in jec tion  w ere  p lo tted  ag a in s t the 
co rrespond ing  pro longations in  seconds of the sn b s tra te  p lasm a  
clo tting  tim e s  at 6 mimitea* incubation  in  the th ro m b o p las tin  g en era tio n  
test*  a positive  and highly s ign ifican t c o rre la tio n  w as o b serv ed  
{ t  î^- f 0 .934 ; p<0,001). T h ese  re su lts  a re  d isp layed  g raph ica lly  in  
fig u re  44. When the  ind iv idual timeai fo r p la te le t agg regation  befo re  
and a f te r  the T ra sy lo l in jec tio n  w ere  p lo tted  ag a in st the  co rresp o n d in g  
su b s tra te  p la sm a  clo tting  tim e s  a t 6 m inutes* incubation  In the thrombo*^ 
p la s tin  g en era tio n  te s t ,  a s ig n ifican t negative c o r re la tio n  w as fouaid 
{é -  0 . 005<p<0.01). T h ese  re su lts  a re  g rap h ica lly  d isp layed
■ i’
in  fig u re  45, Ho c o rre la tio n  w as o b se rv ed  when the re su lts  ob tained  
b efo re  the T ra sy lo l in jec tio n  o r a f te r  i t  w ere  handled  se p a ra te ly .
E ffect of T ra sy lo l in  the T re a tm e n t of H ypofib^inogenaem ia T ra sy lo l w as 
a d m in is te re d  to two p a tien ts  both of whom had hypofib rinogenaem ia 
a sso c ia te d  w ith m e ta s ta tic  c a rc in o m a . In  both patients* th e re  w as 
abnorm al bleeding in to  the akin and fro m  venepuncture s i te s .  In  each  
case* th e re  was evidence to suggest th a t the hypofib rinogenaem ia was 
due to in tra v a sc u la r  c lo tting  secondary  to m e ta s ta tic  c a rc in o m a . The 
evidence fo r th is  is  d isc u sse d  fully  in  ch ap te r 8, w here  th ese  patients*
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h is to r ie s  and in v estig a tio n  a re  d e sc rib e d .
In  each  patient* in  addition  to fib rinogen  dep letion , th e re  was 
dep letion  of fa c to r  V and an tihaem ophilic  globulin (A .H .G .) .
T ab le 49 shows the data  fro m  one of th ese  pa tien ts  who w as 
t re a te d  in itia lly  w ith h e p a rin  given by in travenous infusion; 1,000 
u n its /h o u r  fo r 48 h o u rs  then  1, 500 un its  / hou r fo r 7 h o u rs . D uring the 
h ep a rin  in fusion , fib rinogen , factor V and an tihaem ophilic  globulin 
(A .H .G ,)  lev e ls  ro se  p ro g re s s iv e ly . The p la te le t count rem a in ed  
s teady . T herapy  w as then  d iscon tinued  fo r 17§ h o u rs . At th is  t im e , 
fib rinogen , fa c to r  V and an tihaem ophilic  globulin (A .H .G .)  lev e ls  had  
fa llen  to the values found b e fo re  h ep a rin  w as given. T h ere  was no 
change in  the p la te le t count. T ra sy lo l was given by in travenous in fusion  
a t the ra te  of 100,000 un its  /h o u r  fo r 7 h o u rs . A fte r 7 h o u rs , th e re  had 
been no a lte ra tio n  in  the fib rinogen  lev e l though a r is e  had o c c u rre d  in  
the lev e ls  of fa c to r  Y  and an tihaem ophilic  globulin (A .H .G *). H ow ever 
the p la te le t count had  fa llen  sh a rp ly  and acco rd ing ly , T ra sy lo l th e rap y  
w as stopped. H ep a rin  in fusion  w as re s ta r te d ;  1,500 u n its /h o u r  fo r 
16|- h o u rs . At the end of th is  tim e  the leve l of fib rinogen  had r is e n  and 
th e re  had  been a  fu r th e r  in c re a s e  in  fa c to r V and an tihaem ophilic  globulin 
(A -H ,G .). The data  a re  d isp layed  in  p a r t  in  fig u re  46,
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The data  fo r  the  second  p a tien t a re  shown in  tab le  50 and in  
p a r t  in  figu re  47* T ra sy lo l w as a d m in is te red  to th is  pa tien t a t the 
ra te  of 100,000 u n its /h o u r  fo r 9 hours* At the end of th is  time* th e re  
had  been a r i s e  in  the lev e ls  of fib rinogen , fa c to r  Y  and an tihaem ophilic  
globulin (A ,H *G .) and in  the p la te le t count*
Investigation of the Antitryptic Activity of T rasylol 
Inh ib ition 'by  T rasylol of the P roteolytic  Activity of Trypsin; K inetics  
of the Réaction A caseinolytic  assay  system  was used . The 
concentration of ca se in , the substrate for trypsin , was varied  sevenfold, 
it© maximum being 2 per cent of the digestion m ixture. The 
concentration of trypsin  was constantly 45 pgm ./m l*  of the digestion  
m ix tu re  and that of T rasylo l 100 units/m l* The resu lts are given in  
f ig u re  48 as double reciprocal p lots. The plots fu lfil the U now eaver*  
B urk  cr iter ia  for non*com petitive inhibition by T rasylo l of the 
proteolytic activity of trypsin*
Addition of T rasylo l and T rypsin to Plasm a: A ssay  of the Antitryptic 
Effect of T rasylol In this experim ent, a range of concentrations of 
trypsin  was added to expired pooled bank plasm a, with and without 
T rasylol 40 u n its /m l. plasma* Tryptic activity was m easured in  a 
caseinolytic assay  system * The data are present in table 02. It w ill
be seen  th a t in  the plasma-»*trypsin d igestion  m ix tu re s , no f r e e ' 
t ry p s in  ac tiv ity  w as d e tec ted  un til the concen tra tion  o f try p s in  in  the 
sy s tem  w as 50 p g m ./m L  F ro m  concen tra tions of t i’ypsin  vary ing  in 
d iffe ren t p la sm a  sam p les  fro m  50 to 200 p g m ./m l* , try p tic  ac tiv ity  
began to ap p e a r. F ro m  200 [,igm ./m l, upw ards, try p tic  ac tiv ity  ro se  
s tead ily . Addition of 3?rasylol, 40 u n its /m l, p la sm a  to th is  sy s tem  
p roduced  inh ib ition  of try p tic  ac tiv ity , try p tic  ac tiv ity  being at l e a s t  
20 p e r  cen t le s s  in  the  p re se n c e  of T ra sy lo l than  w ithout i t ,
A n titry p tic  E ffec t of T ra sy lo l In jec tion  To each of seven  n o rm a l 
su b jec ts  w as ad m in is te re d  a sing le  in travenous in jec tio n  of T ra sy lo l 
containing 100,000 u n its . P la s m a  sam p les  w ere  obtained  fro m  each 
sub jec t im m ed ia te ly  p r io r  to the in jec tio n  and 30 m inu tes a f te rw a rd s . 
T ry p s in  w as added to each p la sm a  sam ple  to give a  co n cen tra tio n  of
1,000 {j,gm ,/m l. p la sm a . The try p tic  ac tiv ity  of each  of th e se  sam p les  
w as a ssay e d  im m ed ia te ly  in  a case in o ly tic  sy s tem . The data  a re  
p re se n te d  in  tab le  53, M ean try p s in  ac tiv ity  in  the p la sm a  sam p les  
taicen p r io r  to T ra sy lo l h ijec tio n  w as 0 ,159  % 0 ,079  op tical density  
units and a f te r  T ra sy lo l in jec tio n  w as 0 ,130 ^ 0 ,094  op tica l density  
u n i ts , The d e c re a se  in  try p s in  ac tiv ity  a f te r  the  T ra sy lo l in jec tion  
w as s ign ifican t (t 3*069, 0 . 02<p<0.05),
D iscu ssion
The resu lts presented  in this chaper show that the polypeptide 
T rasy lo l, com m ercially  extracted from  bovine lung, d ep resses  
activity of the fibrinolytic enayme system  by inhibition of both 
plasm inogen activation and the proteolytic activity of form ed plasm in.
In the investigative work concerning AMCHA, its  separate inhibitory  
effects on p lasm inogen-plasm in conversion and on the proteolytic  
activity of form ed plasm in w ere distinguishable because inhibition of 
plasm inogen activation began at a much low er concentration of AMCHA 
(10 Molar) thsui that required to depress the proteolytic activity of 
form ed plasm in (3 x  10 M olar). These properties of AMCHA w ere  
dem onstrated by its  addition to a caseinolytic a ssay  system  with bank 
plasm a either before activation of the plasm a plasm inogen with 
streptokinase or after activation but prior to plasm in assay  (figure 4). 
The effect of T rasylo l on the casein olytic  activity of bank plasm a  
differed from  that of AMCHA. When T rasylol was added to bank plasm a  
after activation of p lasm a plasm inogen with streptokinase but prior to 
plasm in a ssay , a greater degree of inhibition of casein olytic  activity  
was observed than when the sam e concentration of T rasylo l was added 
prior to activation (figures 25 and 26). From  these resu lts , it was
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concluded that T rasylo l effectively  inhibited the proteolytic activity  
of form ed plasm in but where T rasylo l had been added prior to 
activation with streptokinase, the observed inhibition of caeeino lysis  
might be due to inhibition of the plasm in form ed after plasminogen*^ 
plasm in conversion rather than to any inhibitory affect on the 
activation of plasminogen# That T rasylo l p o ssessed  an inhibitory 
effect on the activation of plasm inogen was shown in the kinetic 
experim ent in  which the plasm in form ed in a digestion m ixture 
containing streptokinase, plasm inogen and T rasylo l was assayed  in 
a casein olytic  system  after rem oval of T rasy lo l by d ia lysis and 
inactivation or dénaturation of streptokinase* In this system , 
therefore, the observed d ecrease in caseinolytic activity, com pared  
with activity in the control experim ent without T rasy lo l, was due to 
depression  by T rasylol of plasm inogen activation and not to the 
inhibitory effect of T rasylo l on form ed plasmin*
The kinetic studies with T rasy lo l show that its  inhibitory effects  
on the plasminogen4*plasmin sy stem  are neither wholly com petitive nor 
non'^competitive. In these stu d ies, when a wide variation in substrate  
concentration was used , with a rang© down to seven  or eightfold from  
dilution of the maximum concentration, a sudden sharp in crease  in  
inhibition was observed at low substrate concentrations* When th ese  
experim ents w ere m odified to u se three to fivefold  variation in the
substrate concentrations, the resu lts obtained w ere capable of 
interpretation according to the Iiineweaver^Burk criteria# In these  
m odified sy stem s, the inhibition by T rasy lo l of plasm inogen activation  
by streptokinase and by urokinase was of the com petitive type, that 
of the proteolytic activity of form ed plasm in of the non*com petivie 
type and that of the este  roly tic  activity of urokinase on AcEMe of the 
m ixed com petitive and noat-^competitive type* Com petitive inhibition  
was confirm ed by the experim ent, already d iscu ssed , in which T rasylo l 
was rem oved by d ia lysis  and streptokinase denatured or inactivated; 
the plasm in previously form ed by activation of plasm inogen in the 
presence of T rasylo l was then assayed# The findings of com petitive 
inhibition by T rasylo l of plasm inogen activation by streptokinase and 
urokinase are in  agreem ent with the resu lts  reported by S teichele and 
H erschlein  (1961)# T hese authors rej>orted that the inhibition by 
T rasylo l of the proteolytic activity of plasm in was a lso  com petitive, 
a resu lt contrary to the observations reported in th is paper* One 
explanation for the conflicting findings may be that the assay  system s  
differed, S teich ele  and H erschlein  employing a fibrin plate tehhnique 
and variation of the concentration of plasm in and not of its  substrate, 
fibrin.
One hypothesis to account for the sharp in crease  in the 
inhibitory effect of T rasy lo l at low substrate concentrations is  that 
the m olecule may be capable of combining with the substrate alone 
as w ell as either competing with the substrate for the en^iyme binding 
site  (com petitive inhibition) or combining with the ensyme**substrate 
com plex (non*-competitive inhibition). An inhibitory effect due to 
the form ation of a com plex of T rasylo l and the substrate would only be 
detected where the concentration of T rasylo l approached that of the 
substrate i . e . , at low substrate concentrations, and would be very  
difficult to detect at high substrate concentrations » T rasylo l may be 
capable of acting in this way since it is  a polypeptide and may therefore  
p o sse ss  a number of different active s ite s  with affin ities for many 
compounds *
The inhibition by T rasylo l of plasm inogen activation by 
urokinase d iffers in type from  its  inhibition of the este  roly tic activity  
of urokinase on AcLM e, the form er being com petitive and the latter  
•mixed* com petitive and non#com petitive, This d ifference suggests  
that the urokinase m olecule may p o sse ss  different binding s ite s  for  
these two a c tiv ities .
In the in vitro  plasm a clot system  containing a standard amount
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of ui*okma80 , the Molar potency of T rasylo l as a fibrinolytic  
inhibitor was about one hundred tim e s that of AMCA and one ' 
thousand tim es that of EACA. ¥7eight for weight, T rasylo l was about 
two and one**half tim es m ore potent than AMCA. As has already been  
suggested# the T rasylol m olecule# by virtue of its  greater siae and 
com plexity com pared with AMCA and EAGA# may p o sse ss  m ore 
active s ites  to account for its  greater potency as a fibrinolytic  
inhibitor.
In the coagulation studies# it was seen  that T rasylol had no 
effect in  vitro on the one#stage prothrombin tim e or on the throm bin- 
fibrinogen reaction as a sse s se d  in the thrombin clotting tim e, 
findings in agreem ent with the observations of A m ris, (1966.)
In vitro addition of T rasy lo l to the incubation m ixture of the 
throm boplastin generation te st  produced lengthening of the substrate  
plasm a clotting tim e s . The abnormality was not observed until 
T rasylo l was present in a concentration of 100 tinits/m l* of the 
incubation m ixture. T rasy lo l in vitro in the substrate plasm as produced  
a sim ilar  abnormality which was observed at a T rasylo l cone ©nitration of 
40 units/m l* of p lasm a. T hese resu lts may be due to an action of 
T rasylol im pairing throm boplastin generation; alternatively T rasylo l
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may inhibit the conversion of prothrombin to thrombin or it may act 
in both ways» A m ris (1966) has reported that T rasylol in vitro im pairs  
thrombin generation and N ordstrom  et al# (1965) have reported that 
in vivo in dogs# T rasylo l protects against the effects of intravenous 
adm inistration of form ed thromboplastin# T hese observations support 
the view  that T rasylo l prevents prothrombin conversion to thrombin  
by form ed thromboplastin# Blbmback e t al# (1966)# using partially  
purified clotting system s# found inhibition of the reaction between anti­
haem ophilic globulin (A » H » G # ) and the **serum com ponents” of in trin sic  
' throm boplastin in the p resence of Trasylol# observations supporting 
the view  that T rasylo l inhibits throm boplastin generation. In the 
experim ents reported in  th is thesis# it can be seen  that the m ore  
striking abnormality was produced when T rasy lo l was present in the 
incubationiw^tuie of the throm boplastin generation te st  than when 
present in the substrate plasma* It may be that the p resence of T rasylo l 
in the incubation m ixture with its  subsequent transfer to the substrate 
plasm as produced the m ore striking abnormality because of a 
summation of inhibitory effects on throm boplastin generation and on 
prothrombin conversion#
The effect of T rasy lo l in v itro on p latelet aggregation was
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exam ined a t two concentration© . At SOO u n ite /rn l, of pXaema,
T ra sy lo l p roduced  a highly s ig n ifican t'p ro lo n g a tio n  of p la te le t, 
aggregation?.- The effec t of T rasylo l* ' 40- unit a /m l .  of p la sm a , w as
' • ;:u.#
then  in v estig a ted  s in ce  th is  w as co n s id e red  to he a con cen tra tio n  which 
could foe, ach ieved  in  vivo by in trav en o u s ad m in is tra tio n  of.betw een
100,000 and 200*000 u n its  of T ra s y lo l ,  T his co n cen tra tio n  a lso  
p ro longed  p la te le t ag g rega tion  .significantly  though the effect .was le s s  
s tr ik in g  than, w ith  SOO u n i ts /m l .  H ow ever, when the. effect of T .rasy lo l,
40 un its  / ml# of p la sm a , w as .a ssessed  a f te r  10 m inu tes incubation  of 
the  p lasm a  w ith  T ra sy lo l, no s ign ifican t effect on p la te le t agg rega tion  
w as observed# A m ris  (1966) has suggested  th a t T ra sy lo l m ay becom e 
bound to  und ia lysab le  com ponents in  p la sm a , and one p o ssib le  
explanation  of the lo s s  of e ffec t of T ra sy lo l on p la te le t aggregation  a f te r  
incubation  m ight be a lte ra tio n  of the p h y sico -ch em ica l p ro p e r tie s  of 
T ra sy lo l during  incubation#
In  the in  vivo sttu iiea in  w hich T ra sy lo l w as a d m in is te re d  to n o rm a l 
su b je c ts , both an ticoagulan t and an tifib rin o ly tic  e ffec ts  w ere  impax’ted  to  
plasm a# The la t te r  effect w as d em o n strab le  a s  an h ie r  ea se  in  overall 
p la sm a  fib rin o ly tic  inh ib ition  in  the u ro k in ase  sen a itiv lty  te s t  and the 
fo rm e r  as a  defect in  the th ro m b o p las tin  g enera tion  te s t .  Though th e se
effects w ere observed to appear at very variable dosage lev e ls  of 
T rasy lo l in the different subjects# At lea st 100,000 units/hour seem ed  
to be n ecessary  to produce con sisten tly  significant lev e ls  of both anti- 
fibrinolytic and anticoagulant activity in any subject* The effects  
disappeared, rapidly after withdrawal of TràpyloL Accordingly, it 
would seem  reasonable to advise the u se of high doses of T rasy lo l 
to initiate therapy, with low er maintenance doses thereafter, A dosage 
of 100,000 units over one hour or 100,000 units in itia lly  as a single  
intravenous injection with 50,000 units/hour thereafter seem s  
appropriate, a recom m endation in agreem ent with the findings of A m ris 
(1966),
Thirty minutes after a single intravenous injection of 100,000  
units of T rasy lo l, acceleration  of p latelet aggregation was observed, 
a finding in apparent d iscord  with the in  vitro observations already  
cited  that T rasylo l inhibits p latelet aggregation- The discrepancy may 
be due in part at lea st to inactivation of the aggregation-inhibiting  
properties of T rasylo l in  the in terval between its  adm inistration and 
plasm a samplings a different resu lt might have been found if sam ples  
had been taken say 3 or 3 m inutes after T rasylol injection# The 
acceleration  of p latelet aggregation at 30 m inutes may also  be due to
a hom eo sta tic  re sp o n se  to  the  in jec tion  of an an tico ag u lan t. In 
sp ite  of the a c c e le ra tio n  of p la te le t agg regation , seen  30 m intites 
a f te r  T ra sy lo l in  the n o rm a l su b jec t a, th e re  w as no s ign ifican t 
v a r ia tio n  in  p la te le t counts during  o r  a f te r  adm in i$tra tio n  of T rasy lo l*
The c o rre la tio n s  o b se rv e d  betw een tim e s  fo r  p la te le t 
aggregation  and clo tting  tim es- in  the  co rrespond ing  th ro m b o p las tin  
g en e ra tio n  te a ts  suggest th a t in  th e se  in- v itro  s tu d ies  the speed  of 
p la te le t agg rega tion  W creased  p a r i  p a ssu  w ith defective th rom bo­
p la s tin  g en e ra tio n , evidence in  suppo rt of the hypo thesis  th a t the 
effect of T ra sy lo l on p la te le t agg regation  m ay be a h o m eo sta tic  re sp o n se  
to its  an ticoagu lan t effect*
In  the two p a tien ts  w ith  defib rin a tio n , th e re  w as evidence of 
in c re a se  in  som e of the dep le ted  coagulation  fa c to rs  during  a d m in is tra tio n  
of T rasy lo l*  In  one patient# how ever, h ep a rin  in fusion  produced  a  r is e  
in  fib rinogen  w ithout effec t on the  p la te le t count w h ereas  T ra sy lo l 
in fusion  w as a sso c ia te d  w ith a  fa ll in  the p la te le t count*
In the s tu d ies  w ith  try p s in , T ra sy lo l w as shown to iadxlbit the 
p ro teo ly tic  ac tiv ity  of th is  enzym e in  a non -com petitive  m anner* In 
v itro  in  p la sm a  T ra sy lo l w as o b se rv ed  to have an titry p tic  activity*
In vivo a  sing le  in trav en o u s in jec tio n  of T ra sy lo l containing 100,000
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unite  w as shown to p roduce  a  em ail but sign ifie  ant in c re a se  in anti*^ 
try p tic  ac tiv ity , TM s dose is  m uch la rg e r  than thos apparen tly  
need  by Sky ring  e t al# (1965) who .considered  th a t T ra sy lo l in a double- 
b lind  t r ia l  had no effec t in  the  tre a tm e n t of acu te  p an crea titis#  The 
ev idence p re se n te d  in  th is  p ap e r su ggests  th a t a  dose of the  o rd e r  of 
a t le a s t  100,000 u n its /h o u r  would be re q u ire d  to  produce inh ib ition  of 
try p s in  in  p la sm a . T h ese  findings a re  in  ag reem en t w ith the re p o r t  
of G o l d b e r g  a n d  R o y  (1 9 6 5 ) .
C onclusions
T ra sy lo l is  a com petitive  in h ib ito r of p lasm inogen  ac tiva tion  
by s trep to k in ase  and urokinase* The p ro teo ly tic  ac tiv ity  of p lasm in  
and try p s in  is  inh ib ited  nom*com petitively  and the e s te ro ly tic  ac tiv ity  
of u ro k in ase  is  inh ib ited  in  a  m ixed  com petitive  and non -com petitive  
m anner* T hese  inh ib ito ry  e ffec ts  a re  o b serv ed  a t high su b s tra te  
c o n c e n tra tio n s# At low su b s tra te  co n cen tra tio n s , the  inlxibitory e ffec ts  
of T ra sy lo l a re  re la tiv e ly  in creased*  T ra sy lo l is  co n sid erab ly  m o re  
effective  in  v itro  as an in h ib ito r of fib rin o ly tic  ac tiv ity  than AMCA o r  
EAGA: and in  c o n tra s t to th e se  am ino ac id  in h ib ito rs , T ra sy lo l is  m ore
effective a s  an in h ib ito r of fo rm e d  p la sm in  than  of p lasm inogen  activation* 
T ra sy lo l p o s s e s se s  an ticoagulan t effects p robably  due to
*  JL &
inh ib ition  of p ro th ro m b in  co n v ers io n  and cf in tr in s ic  th ro m b o p las tin
generation*
In vivo in  high dosage i t  im p a r ts  a n tif ib rin o ly tic , an ticoagulan t
and an titry p tic  effec ts  to  p la sm a , ■ It m ay a c c e le ra te  p la te le t 
agg regation  in- vivo »
In  one p atien t w ith hypofib rinogenaem ia , it© a d m in is tra tio n  w as 
a sso c ia te d 'w ith  a fa ll in  the  p la te le t count. In ano ther pa tien t th e re  w as 
evidence of a r i s e  in  fib rinogen , fa c to r  V, antih  aem ophili c globulin 
{A * H * G * ), and in  the p la te le t - count,. -
An in itia l dosage of 100,000 unit© as a  ©ingle in jec tion  o r  as an 
in fusion  given o ver one h o u r follow ed by m ain tenance dosage of 50,000 
u n its /h o u r  seem s a p p ro p r ia te 'in  the  tre a tm e n t of pathological fib rin o ly s is . 
F o r  the th e rap y  of in tra v a s c u la r  coagulation , h ig h er dosage m ay be 
re q u ire d , possib ly  100,000 u n its /h o u r ;  T h is la t te r  dosage would a lso  
be re q u ire d  in  the tre a tm e n t of sy s tem ic  p ro teo ly s is  due to trypsin*
CHAPTER 6
IH VITRO AND IN VIVO STUDIES OF 
A PREPARATION 0.F UROKINASE 
The physio log ical p lasm inogen  ac tiv a to r p re se n t in  hum an 
u r in e , ca lled  u ro k in ase  by Sob el e t a l, (1952), w as f i r s t  iso la ted  in 
a re la tiv e ly  pu re  s ta te  by P loug and K je ldgaard  (195?), A ctivation  
of p lasm inogen  by u ro k in ase  has been shown to be an enzym atic  
p ro c e ss  p roceed ing  w ith f i r s t - o r d e r  k in e tics  p robably  by the 
sp litting  of a rg in ine  a n d /o r  ly s in e  bonds (K jeldgaard  and P loug , 1957; 
A lk jae rs ig  e t a l# , 1958 b). P u r if ie d  u ro k in ase  is  a co lo u rle ss  
p ro te in  w hich is  s tab le  over the  pH range 1 to 10 (Ploug and K je ldgaard , 
1957). U sing DEAE- ce llu lo se  w hich adso rbs u ro k in ase  C elander and 
G uest (I960) found two elu ti$n  peaks in  u rin e  w ith u ro k in ase  ac tiv ity  
and th ese  w orkerb  have su g g ested  th a t u rin e  m ay contain  m o re  than  
one p lasm inogen  activator#  T h e re  is  som e evidence th a t a t le a s t  a  
p ro p o rtio n  of u r in a ry  u ro k in ase  m ay re p re s e n t e x c re te d  p la sm a  
p lasm inogen  ac tiv a to r (von K au lla  and R iggenbach, 1958; Smyxmiotis 
e t a l# , 1959)# M cHicol a t a l. (1961,1) have suggested  th a t u ro k in ase  m ay 
have a physio log ical ro le  in  m ain ta in ing  patency of the u rin a ry  t r a c t  by 
p rom oting  ly s is  of fib rinous deposits#
Thex*e has been  in te re s t  fox' som e y e a rs  in  the possib le  u se  of
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fib rin o ly tic  enaym es fo r  the tre a tm e n t of thi*ombo- em.bolic v a sc u la r  
d isease#  The en^syme which has been  m o st w idely em ployed fo r  this 
pu rp o se  is  the b a c te r ia l  p ro te in , strep tok inase*  As has been d iscu ssed , 
the use  of s trep to k in ase  has c e r ta in  d isadvan tages: i t  is  d ifficu lt to
%>repare p y ro g en -free ; i t  is  an tigenic  and p la sm a  in h ib ito r lev e ls  
to  i t  v a ry  w idely accord ing  to the p a t i e n t e x p o s u r e  to 
s trep to co cca l infection#
B ecause  of its  hum an o rig in , p re su m ed  non-an tigen ic ity  and 
the p red idab le  fib rin o ly tic  re sp o n se  which i t  p roduces (F le tch e r e t a l , , 
1 9 6 5 ), u ro k in ase  ap p ea rs  m o re  a ttra c tiv e  as an agent fo r th rom bo ly tic  
th e ra p y . H ow ever, the  p re p a ra tio n  of pure  u ro k in ase  has posed 
co n sid e rab le  d ifficu lty . N o rm a l u rin e  has been known fo r  m any y e a rs  
to p o sse ss  th ro m b o p las tic  ac tiv ity  (T ocantins and L indqu ist, 1947) 
and C aldw ell e t a l . (1963) have p re p a re d  and p a r tia lly  p u rified  u r in a ry  
th ro m b o p las tic  m a te r ia l ,  One co m m erc ia l p re p a ra tio n  of u ro k in ase  
has been  shown to p o sse ss  th ro m b o p las tic  p ro p e r tie s  (M cNieol e t a l . , 
1963 a). M ore re c e n tly , o th e r coxnm ercial p re p a ra tio n s  have becom e 
availab le  and i t  is  the p u rpose  of th is  ch ap te r to given an account of 
in v es tig a tio n s , in  v itro  and in  v iv o , of one of th ese  p re p a ra tio n s  w ith 
p a r tic u la r  re fe re n c e  to its  e ffec ts  on the coagulation  sy s te m . I ts
ab ility  to ac tiva te  p lasm inogen  in  vivo has a lso  been studied#.
Material©
Urokinase A purified preparation,, iso lated  from  the urine of norm al 
m aiee , was made available by Abbott L aboratories, North Chicago, 
I llin o is# The preparation w as supplied in two form s. One was the 
form  routinely prepared for ihtravasçular administration* It was a 
ster ile , w hite, lyophilissed powder. Its potency, stated by the 
manufacturer, was 40 ,000  G.T,A#. u n its/m g, of protein, Thià 
preparation contained sodium chloride, human serum  albumin and 
disodium  versen ate , A solution of one m g, of protein d isso lved  in  
one ml# s ter ile  d istilled  w ater was stated to contain 0 ,9  per cent 
H a d , 0, 5 per cent albumin and 0 ,1  per cent disodium  versenate*  
Before a ssessm en t of the effects of this preparation, in v itro , on 
the coagulation system , disodium  versenate was rem oved by d ia lysis  
with constant stirring for 24 hours against 0 ,9  per cent NaCl at 4^C, 
the dialysate being changed once at 13 hours. The second form  of 
urokinase preparation was supplied free from  sodium chloride, 
albumin and disodium  versenate* It was a white powder stated to 
contain 35,000 C.T ,A *  u n its/m g . of protein. Both preparations 
w ere freely  soluble in d istilled  water or 0* 9 per cent NaCl, The 
calcium  content of 20,000 C . T . A .  u n its /m l, solutions w ere le s s  
than 1 ,5  m, eq, / litr e .
A nother batch  of u ro k in ase  produced  by Abbott L a b o ra to r ie s , 
in  the fo rm  p re p a re d  fo r in tra v a s c u la r  ad m in is tra tio n , v/as 
in v estig a ted  in  v i t ro # T his ba tch  of u rok in ase  had  been  su b jec ted  
to  an additional p u rifica tio n  s tep  dtixdng p re p a ra tio n  com pared  w ith 
the batch  of u ro k in ase  u sed  fo r  m o s t of th,^'f:investigative w ork to be 
described* I ts  ac tiv ity  w as s ta te d  as 40,000 C .T .A . u n its /m g , 
p ro te in . I t was a lso  d la ly sed  befo re  it  was te s te d  in  vitro* #
A C .T .A , un it r e fe r s  to the s tan d a rd  u ro k in ase  unit re cen tly  
adopted by the C om m ittee on T hrom boly tic  A gen ts, of the N ational 
H e a rt Institu te* The un it is  b ased  on the ac tiv ity  of a s tan d a rd  
u ro k in ase  p re p a ra tio n  m e a su ra b le  by fib rin o ly tic  a s s a y s , A 
conversion  fa c to r w orked out in  se v e ra l independent la b o ra to r ie s  
in d ica tes  th a t one C .T .A . un itiin  te rm s  of fib rin o ly tic  a ssa y , is  
equivalen t to 0* 7 Houg units*
H um an F ib rin o g en The Iruman fib rinogen  em ployed fo r  p re p a ra tio n  
of fib rinogen  breakdow n p ro d u c ts , d e sc rib e d  below , w as lyophilized  
hum an fib rinogen  (A*B, K abi, g rad e  L ), T his was s ta te d  to be a 
v irtu a lly  e lec tro p h o re tic  ally  u n ifo rm  p re p a ra tio n  w ith about 95 p e r 
cent coagu lab ility .
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M ethods
O n e-s tag e  P ro th ro m b in  T im e . TM s te s t  was m odified  by
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substitu tion  of a 10,000 C .T .A . u n i t s / îuL  so lu tion  of u ro k in ase
fo r a 1:500 d ilu tion  of the hum an b ra in  e x tra c t in  u se  at th a t tim e
in  the labora to ry*  EAGA, 0. I m l* , was added to the sy s tem  to
-Egive a final conoentxxation of 10 Mola,r to m hib it l y s i s .
Re ca lc if ica tio n  T irne F r e s h  n o rm a l p lasm a  co llec ted  in  g lass  o r  
s ilicone  w as used# V ary ing  cone antidations of u ro k in ase  w ere  
su b stitu ted  fo r sa line  in  th is  test#  SAGA* 0* 1 m l . , w as added to 
the  sy s tem  as in  the o n e -s tag e  p ro th ro m b in  tim e . In one ex p e rim en t, 
Idagem an fa c to r  defic ien t plasm a, w as u sed  in s te a d  of f re s h  n o rm a l 
p la sm a .
T h rom bop lastin  G enera tion  T e s t T h is was m odified  by ad justing  the
final volum e of the incubation  m ix tu re  to 1 .3  m l. The volum es of
ad so rb ed  p la sm a , s e ru m , p la te le t su spension  o r p la te le t su b stitu te
and 0 .025  M olar CaCR w ere  each  0 .3  m l. FAC A, 0 .1  m l . , was
-2added to the sy s te m  to give a final co ncen tra tion  of 10 " M o lar. The 
rem ain ing  0 .2  m l. volum e con tained  vary ing  co ncen tra tions of 
u ro k in ase . Saline w as su b s titu ted  fo r  u ro k in ase  in  th e  con tro l 
ex p erim en t.
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A ntihaem opliiHc Globtilin (A .H .G .)  and C h ris tm a s  F a d e r  A ssays The 
effect of u ro k in ase  in th e se  a ssa y  sy s tem s w as in v estig a ted  by 
substitu ting  a 20,000 C .T .A . u n i ts /m l. so lu tion  of u ro k in ase  in  
each  a ssay  fo r f re s h  n o rm a l p la sm a  obtained by pooling 10 n o rm a l 
p la sm a s , The sy s tem s containing u ro k in ase  w ere  m ade up and r e ­
ca lc ified  s im u ltaneously  w ith a  con tro l d ilu tion  curve p re p a re d  fro m
the pooled f re s h  n o rm al p la sm a  and BACA, 0. 1 m l . , w as p re se n t in  the
—2a ssay  in  a final con cen tra tio n  of 10 M olar to inh ib it ly s is .
C o agul ation A ss ay & m ade during  the in  vivo stud ies w ere  p e rfo rm ed  in 
the p re se n c e  of BACA in  a  c on c ent x* at ion of 10 M olar to inhib it ly s is ,  
B1 ec tro p h o re s is  of U rok inase  T h is w as the m ethod  of M cHicol e t a l. 
(1963 a). Oxoid ce llu lo se  ace ta te  s tr ip s  (Oxo L td . ,  London) w ere  
u sed  fo r e le c tro p h o re s is . S tr ip s  w e re  run  fo r 2 ho tirs  at 150 volts 
in  a h o rizo n ta l e le c tro p h o re s is  tank  (Shandon S cien tific  Co. L td . , 
London). A ceta te  b u ffe r, pH 4 .5 ,  0 ,1  M olar, w as the buffer sy s te m . 
The fo rm  of u ro k in ase , f re e  fro m  album in and d isodium  v e rse n a te  
w as u sed  and com p ared  w ith u ro k in ase  (Leo). Twenty p l i tr e s  of 
each txx*okinase so lu tion  containing approx im ate ly  10,000 C .T .A , 
u n its /m l. w ere  applied  to s tr ip s  fo r e la c tro p h o re s is . A fter 
com pletion  of electrophox*esis, each  a tr ip  w as divided into th re e  equal
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portions at right angles to the origin* One portion wa© stained  
overnight with 0 ,001  per cent n igrosin  in  2 .0  per cent acetic acid. 
The other two w ere cut into str ip s one cm , w ide, parallel to the 
origin . The str ip s from  one of th ese portions w ere applied to the 
surface of a fibrin plate and ly s is  associated  with each ©trip 
a sse sse d  after incubation of the plate at 37^G for 16 hours. Each  
strip  from  the third portion was eluted with 0 .3  m l * , 0*9 per cent 
HaCl* in a 12 K 75 m m , te st tube, by pounding the strip  with a 
g lass rod for 5 m inutes. The strip s rem ained intact. After 30 
m inutes, 0 . 1 m l, of the eluate was tested  In the recalcification  
tim e system  described  above. The stained portions w ere scanned  
in a recording and integrating densitom eter (Chromoscan; Joyce, 
Loebl and G o . , Ltd. ,  G at es  he ad-on-T yne).
Preparation of Fibrinogen Degradation Products This was the 
method of H ussensw elg et a l. (1961), Four m l. human fibrinogen  
(50 m g , / m l . )  w ere incubated for 10 minutes at 37^0 with 1 .0  m l. 
human plasm inogen (17*5 case in  u n its /m l.)  and 0 ,1  m l, urokinase 
(40,000 G ,T , A .  u n its/m l.)*  At the end of incubation, this m ixture  
was layered  % aD E A E -cellu lose column of length 37 .5  cm , and 
internal diamfter E.5 cm . The buffer system  for the column was
• m i i y m
0 ,1  M olar, pH 8 .9  and the column flow rate 84 m l./hour*  
Elution was achieved during 6 hours using a linear concentration  
gradient beginning with the buffer alone and rising to the buffer 
with 0 ,3  Molar NaCl* The column was kept at 4^G*
The column effluent was concentrated with Sephadex, G-25  
(Pharm acia, Uppsala, Sweden) using Seitz filters* P rotein  in  the 
effluent was m easured by the method of Lowry et al* (1951).
Column chromatography was carried  out by M iss P atr ic ia
Wilson*
Other M aterials and Methods w ere described in  chapter 3*
R esults  
In Vitro Studies
Effect of Urokinase Compared with Human Brain Extract Solutions 
of both dialysed and pure urokinase, each containing 10,000 C , T . A ,  
u n its /m l* , w ere found to shorten the recalcification  tim e of fresh  
norm al plasm a by the sam e amount as a 1:500 dilution of the human 
brain extract in u se in  the laboratory at that time* T hese resu lts  
are shown in table 54*
E ffect of Urokinase on the Re ca lcification  Tim e of S ilicone  
P lasm a The effect of increasing concentrations of d ialysed and
-J . 2 Ü-
pure urokinase on the recaloification  tim e of s ilicon e plasm a is  
shown in table 55# Compared with saline con trols, there was a 
%)rogressive reduction in the p lasm a recalcification  tim e with 
increasing concentration of urokinase. T hese reductions in r e -  
calcification  tim e w ere linearly  related  to urokinase concentration in  
a sem ilogarithm iç plot as illu stra ted  in figures 49 and 50? It can foe 
seen  that both dialysed and pure urokinase had c lo se ly  sim ilar  e ffec ts .
By extrapolation of both p lots, the zero  coagulant value found for 
each form  of urokinase w as 100 C . T . A .  u n it s /m l. , i . e .  100 C.T .A*  
u n its /m l. was the maximum concentration added to the system  which 
had no coagulant effect.
Effect of D ialysed  Urokinase ou the R ecalcification  T im e of 
Hageman F actor D eficient P lasm a The effect of increasing  
concentrations of d ialysed urokinase on the reçalcification  tim e of 
Hageman factor deficient p lasm a is  shown in table 56. Again, a 
p rogressive  reduction in  reca lcification  tim e linearly  related  to urokinase 
concentration in a sem ilogarithm ic plot was observed (figure 51).
The zero  coagulant activity of the urokinase preparation in this 
experim ent was also  found by extrapolation to be 100 C.T.A* u n its /m l.
-  A A» * -
E ffect of Two Batches of D ialysed  Urokinase on the R ecalcification  
Tim e of F resh  Norm al P la sm a  In th is experim ent, the effect of 
the batch of urokinase, aubjected to an additional purification  
procedure during its  preparation, was com pared with that of the 
batch ern ^ yed  in the other investigative work for th is paper. The 
effect of increasing concentrations of each of th ese preparations on 
the re calcification  tim e of fresh  norm al plasm a is  shown in table 57, 
It can be seen  that both preparations had c lo se ly  s im ilar  coagulant 
properties*
Effect of Urokinase Preparations in the Throm boplastin Generation  
Test  Table 58 shows the effect of 4 ,000 C . T . A ,  units of both 
dialysed  and pure urokinase in the throm boplastin generation te st  
in partially correcting for deficiency of antihaemophilic globulin 
(A .H .G .)  and C hristm as factor. Both the dialysed and pure form  
of urokinase had c lo se ly  sim ilar  effects .
Table 59 shows the effect of 6 ,000 C . T . A .  units of both 
form s of urokinase in partially correcting the defect in the thrombo­
plastin  generation te st  due to absence of p la te lets . When the 
throm boplastin generation te s t  was carried  out with the standard 
dilutions of adsorbed plasm a and serum  but with a platelet
preparation diluted 1:3, no 4efect was produced. H owever, when 
the adsorbed plasm a and serum  w ere each diluted a further 1:4, a 
defect was found which was partially corrected  by addition of 4 ,000  
C , T . A .  units of either form  of urokinase. The effects of both form s  
w ere c lo se ly  s im ilar  in th ese experim ents.
Table 60 shows the partial correction  produced by dialysed  
urokinase, 6 ,000 C . T . A .  units, in the throm boplastin generation  
te st  in the absence of either adsorbed^4>la$ma or serum,.
E ffect of Urokinase in Antihaem ophilic Globulin (A.H.G,.) and 
Ghristmaa F actor A seaye Solutions containing 30,000 C . T . A .  units 
of both d ialysed  and pure urokinase w ere found to produce the sam e  
correction  as pooled norm al plasm a diluted to contain 2 per cent 
antihaemophilic globulin (A .H .G . )  or Christm as F actor in the 
respective a ssa y s . The resu lts  are shown in detail in table 61. 
E lectrophoretic {Studies with the Pure Form  of Urokinase (Abbott) 
Compared with Urokinase (E eo)  ^ T hese resu lts are illu strated  
in figure It w ill be seen  that in the acetate buffer, 0 .1  M olar, 
pH 4 . 5 ,  urokinase (Leo) separated into at lea st 4 com ponents. 
Fibrinolytic activity wae largely  associated  with slow  moving 
com ponents, w hereas the coagulative property was m ore uniformly
distributed. The pure form  of urokinase (Abbott), on the other 
hand, was eleetrophoretically  uniform  in the acetate buffer system  
and it was not p ossib le  to separate fibrinolytic and coagulative 
prop erties, both of which w ere dem onstrable *
Column Chromatography for Preparation of Fibrinogen Degradation  
Products Separate runs w ere made on the ce llu lose  column
with fibrinogen, plasîndnogen and urokinase. Each was recovered  in  
the column effluent at a concentration of about 0 .1  Molar NaCl.
With the 10 minute digestion  of urokinase, plasm inogen and 
fibrinogen, a single distinct protein peak was recovered  in the 
effluent at a concentration of 0 .035  Molar NaCl (figure 53). The 
protein recovery in the effluent concentrate was 3 m g . / m l .  This 
protein was electrophoretically  different in charge from  the human 
fibrinogen and its  m olecular weight estim ated by a su crose density  
gradient technique was 215,000 com pared with an estim ated m olecular  
weight by the sam e method for the original fibrinogen of 340,000.  
E lectrophoresis and su crose density m easurem ents w ere carried  out 
by M iss P a tr ic ia  W ilson. The protein was assum ed to be an early  
fibrinogen degradation product.
Effect ol Fibrinogen Degradation Products on In Vitro P latelet 
Aggregation The effect of these degradation products on p latelet 
aggregation was tested  by addition of 0*3 ml* of the degradation  
concentrate to each of 7 fresh  norm al plasm as in the Chandler’s 
tube system ,. The volum e of 0. 9 per cent NaGl was adjusted to 
9 .7  ml* to accom m odate the degradation concentrate in the te st  
system . This concentration of degradation products (180 pgm*/ml .  
plasm a) significantly enhanced p latelet aggregation, the tim e for 
platelet aggregation being 294 ^ 14 seconds, com pared with the 
control of 477 t  168 seconds (t “ 3. 874, 0*005 <p<O.Ol)* T hese  
resu lts are shown in  table 62,
In Vivo Studies
*WBWtaw#F*we
Urokinase Infusions The urokinase preparation was adm inistered  
by intravenous infusion to two subjects.
In the f ir s t  subject, the in itia l dose was calculated from  the 
ly s is  tim e in a urokinase sen sitiv ity  te st  m odified to use 100 ^ litres  
of urokinase (500 G*T*A. u n its /m l.)  in O.E m l, of the subjectif 
plasm a. This concentration of urokinase (250 C.TA, u n its /m l. of 
the subject’s plasm a) gave a ly s is  tim e of 15 m inutes in the te st  
system . The in itial dose was then calculated from  the subject’s 
weight (60 kg.) m ultiplied by h is plasm a volume per kg. (approximately
40 m l . )  and the previously obtained urokinase concentration  
050 C . T . A .  u n its /m l. p lasm a). This calculated in itial dose of
600,000 C . T . A .  units was adm inistered over 30 m inutes followed  
by 100,000 C . T . A .  units/hour for 12^ hours, 200,000 C . T . A ,  units 
in the succeeding hour and 400,000 C . T . A .  units during the la st hour 
of the infusion.
F ibrinolytic a ssays carried  out during the infusion and after 
its  conclusion are shown in table 63, Some of the resu lts are 
graphically displayed in figure 54. It w ill be seen  that after the 
in itial dose of 600,000 C . T . A .  units in the fir st half hour, there was 
evidence of marked activator activity in the rad io-active clot assay , 
and fibrin plate test .  N egligib le activator activity was detected during 
the infusion of 100,000 C . T . A ,  units/hour while 200,000 C . T . A ,  units/ 
hour produced a m oderate in crease  in activity and m arked activator 
activity was associated  with the infusion of 400,000 C . T . A ,  units/hour.
The lev e ls  of plasm inogen and fibrinogen fe ll during the infusion  
and the thrombin clotting tim e was prolonged. One and a half hours 
after com pletion of the infusion# there was evidence of persisting  brisk  
activator activity. No activator activity was detectable 3 hours after 
the infusion was com pleted.
A C # V '
Coagulation assays w ere carried  out during and after this 
infusion and the resu lts are shown in table 64 and in part in figure 55, 
At the end of the fir st-h a lf hour of the infusion, it can be seen that 
the recalcification  tim e w as accelerated  and there was shortening 
of the recalcification  tim e in a Hageman factor assay# The lev e l 
of factor V had fallen while there were shortened clotting tim es in 
antihaemophilic globulin ( A , H , 0 . )  and Christm as factor a ssa y s. 
During the rem ainder of the infusion, the lev e l of antihaemophilic 
globulin (A . H * G . ) f e l l .
The second subject was given 500,000 C , T , A ,  units of 
urokinase/hour for Z4 hours. The resu lts of fibrinolytic te sts  are 
shown in table 65csnd in part in  figure 56. It can be seen  that during 
the infusion, high lev e ls  of activator activity w ere detectable in the 
euglobulin ly s is  tost and the fibrin plate test and there was striking  
prolongation of the thrombin clotting tim e. The plasm inogen lev e l  
fe ll steadily to zero at 12 hours and fibrinogen had fallen  to 115 
mg, 1 100 ml* at 24 hours.
Coagulation assays in the sam e subject are shown in table 66 
and in part in figure 57, At the end of the fir s t  hour of the infusion, 
the silicone plasm a reca lcification  tim e was shortened. During the
üifusion, the lev e ls  of factor V, antihaomopMUc globulin (A,H*G*) 
and C hristm as factor fe ll.
Table 67 shows control curves for the coagulation assays  
perform ed during the two infusions# EACA was present in the control 
system  in a concentration of 10 M olar.
Effect of Urokinase Injection on In Vitro P la te let Aggregation This 
was studied in 7 norm al su bjects. To each subject was given, as a 
single intravenous injection, 80,000 C . T . A ,  units of urokinase#
Im m ediately b efore and 10 m inutes after the injection , blood sam ples
" '   ^
w ere withdrawn for p latelet counts, euglobulin ly s is  te sts  and to
m easure tim es for p latelet aggregation. The resu lts  are shown in
tables 68, 69 and 70.
After the urokinase injection , the mean tim e for p latelet 
' ^
nggvegntion (413 ♦ 113 seconds) was significantly le s s  than the mean  
tim e for p latelet aggregation before the injection (506  ^ 74 seconds)
(t « 3*800, 0 .0 2  <p<0#05) (table 68).
In each subject, euglobulin ly s is  activity was in creased  after  
the injection, mean activity being 1.61 t  0 ,5 5  units com pared with
4*
m ean activity pre^^injection (0,92 -  0 ,30 units). This in crease  in 
activity after the urokinase injection is  significant (t -  5 ,145,
0 .001  <p<0,005) (table 69).
The mean p latelet count after the injection (268, 4 ^ 85 .5  
thousands/m m  ) was low er than the mean platelet count before 
the injection (279.6 ^ 86 .0  t h o u s a n d s / T h i s  fa ll in the mean  
platelet count i s  significant (t » 2 .975 ,  0 ,02  <p<0,05) (table 70).
D iscu ssion
The resu lts  presented  in this chapter show that the urokinase 
preparation in both form s p o sse s se s  coagulative activ ity . This 
activity was readily dem onstrable in v itro . Though not potent 
(a solution of urokinase containing 10,000 C . T . A .  u n its /m l, was 
equivalent to a 1:500 dilution of human brain extract in  the on e-stage  
prothrombin time)^ the activity was very non***specific* In the 
throm boplastin generation te s t , addition of between 4 ,000 and 6*000 
C . T . A .  units of urokinase partially corrected  for defects due to 
deficiency of antihaem ophilic globulin (A.H.G,)* C hristm as factor  
or p latelets and 6 ,000 C . T . A .  units produced slight correction  
com pared with saline when substituted in  the te s t  for adsorbed plasm a  
or serum . A 20,000 C . T . A .  u n its /m l, solution was equivalent to 
plasm a containing 2 per cent antihaemophilic globulin (A .H.G.)  or 
Christm as factor in the resp ective assay  system s * Substituted for  
saline in a system  to m easure the recalcification  tim e of fresh  norm al
* A# /  ■
silicone plasma# a solution of urokinase containing ZOO C . T . A .  
u n its /m l. shortened the clotting tim e by about BO seconds. By 
extrapolation of the straight line graphs obtained in th ese experim ents#  
the ^ero coagulant value for the preparation was found to foe 100 C . T . A ,  
u n its /m l. This aame coagulant value was also found in the system  
with Hageman factor deficient p lasm a as substrate (figure 51). The 
findings w ere c lo se ly  sim ilar  for both d ia lysed  and pure form s of 
uroldnase. Coagulant activity of the dialysed  urokinase could not 
therefore be attributed to it s  content of human serum  albumin* The 
zero  coagulant value of 100 C . T . A .  u n its /m l, was a finding in  
agreem ent with the resu lts reported by A lkjaersig et a l. (1965),
Urokinase (Leo) was investigated  by M cKicol et a l. (196B a) 
who reported it to have coagulant activity at a concentration of Z Hkxug 
iin its/ m l, plasm a In a reca lcification  tim e sy stem  with Hageman factor  
deficient p lasm a as su b strate , Urokinase (Abbott) appears therefore to 
be considerably leas  coagulant than urokinase (Leo),
This d ifference was further reflected  in the electrophoretic  
studies of urokinase (Leo) and urokinase (Abbott), Urokinase (Leo) 
was not a homogeneous ^préparation# 4 components at lea st being 
dem onstrable. Its fibrinolytic activity was largely  found with slow -
• *  4 , - 3
moving components while coagulant activity was m ore uniformly  
distributed* Urokinase (Abbott) appeared to be a uniform  
preparation and it p ossib le  to separate its  fibrinolytic and
coagulant properties*
la tr id is et al* (I960) have reported investigation  of another 
preparation of urokinase which they found to p o sse ss  a ’Hagem an- 
lik e ’ effect* The electrophoretic finding with urokinase (Abbott) 
is  guggestive# though not con clu sive, evidence that its  coagulant 
activity may be due to a ’Hageman-like* property of the urokinase 
m olecule rather than to contamination of the preparation with throm bo- 
p lastic m oieties* Further evidence in support of this suggestion is  
provided by the findings with the batch of urokinase which had under­
gone an additional purification step in its  pre%)aration* This 
preparation of urokinase had a c lo se ly  sim ilar  coagulant effect to the 
ea r lier  preparation of urokinase when both w ere tested  sim ultaneously  
In the sam e reca lcification  tim e system # However# A lkjaersig  et al# 
(1965) consider the m ore purified batch to be considerably l e s s  
coagulant than the ea r lier  batch and found by a different method
, ’-s'n;-', M . . .  '
that it p o ssessed  a zero  coagulant value of 350 units/m l#
F rom  the two in vivo infusions of urokinase# it was seen  that
-  i -
400,000 C.T.A* unite of urokinase/hour were required to produce
brisk  plaem a fibrinolytic activ ity . F letcher et a l. (1965) have 
131shown 1-clot ly s is  to be m aintained at the 30 per cent lev e l
131( i . e .  the per cent ly s is  at 30 m inutes of a I-clot)* by the infusion  
of about 4,000 C.T.A*  units of urokinase/kg* of body w eight/hour.
The weight of the f ir s t  subject described  in this paper was about 
80 kg. of the second, 75 kg, so that the suggested  requirem ent 
of 400,000 C . T . A .  units/hour is  in agreem ent with the work of 
F letcher et al. (1965),
During both in fusions, plasm inogen activation and fibrinogenolysis  
w ere e v id e n c e d b y # 'p rogressive  -fall in the lev e l of plasm inogen and 
of fibrinogen*
In the f ir s t  subject, after the adm inistration of 600,000 C . T . A .  
units there was evidence of coagulative activity in  v ivo; acceleration  of 
the re calcification  tim e and apparent in crease in the lev e ls  of Hageman 
factor, antihaem ophilic globulin (A .H .G .)  and C hristm as factor. T hese  
apparent r ise s  may have been due to distortion of the assay  sy stem s by 
urokinase. The observed  d ecrease  in factor V activity may perhaps be 
explained in part by its  consumption due to in vivo clotting.
In the second subject, there was also evidence of coagulative
-  J Æ I . -
activity, there being an acceleration  ol the reca lcification  tim e and 
a fa ll in factor ¥  activity in  the end of the fir st hour#
A cceleration  of p latelet aggregation on intravenous injection  
of urokinase is  a^finding not previously reported* ' In the experim ent 
described  in this paper, the effect was found with 80,000*GiT* A* 
units of urokinase. A ssum ing, for the ? subjects, an average 
plasm a volume of 3 l i tr e s , and that 10 m inutes after the injection, 
all of the adm inistered urokinase rem ained within the vascu lar  
com partm ent, then the effect was produced by at m ost, 25 to 30 C . T . A .  
unite of u rok in ase/m l, of p lasm a. Further, it  was accom panied by a 
slight but significant fa ll in the m ean platelet count for the 7 subjects  
and by a significant in crea se  in euglobulin ly s is  activ ity . An attempt 
to provide an explanation for this mHancement of p latelet aggregation  
was made by column chromatography of a 10 minute d igest of urokinase, 
plasm inogen and fibrinogen, in  th is experim ent, a single d istinct 
protein peak was eluted at a M olarity of sodium chloride w ell separated  
from  those previously estab lished  for urokinase, plasm inogen and 
fibrinogen alone. This protein was assum ed to be an early  fibrinogen  
degradation product from  its  electrophoretic property and estim ated  
m olecular weight and when added to the Chandler’s tube system ,
Bignificantly enhanced p latelet aggregation., This effect is  
contrary to the findings of K owalski et al* (1964) and H irsch  et 
al* (196S)# H owever, the early  degradation product which these latter  
w orkers investigated  had à low er m olecular weight than the product 
tested  in the experim ents described  in this chapter. Using the sam e  
degradation concentrate, enhanced p latelet aggregation was a lso  found 
in an adenosine diphosphate sy stem  (W ilson, 1966).
The findings reported here suggest that the in vjyo effect on 
platelet aggregation may foe due to circulating early  breakdown 
products of fibrinogen following the enhanced fibrinolytic activity  
found with adm inistration of urokinase*
C onclusions
W ^ iii^ iWniiinii ,1 iiilO iy i  ...................    ,
The evidence presented in th is chapter shows that, though le s s  
thromfoopiastic than urokinase (Leo), urokinase (Abbott) both in vitro  
and in v ivo , has coagulant activity# Further, evidence has been  
presented that urokinase a cce lera tes p latelet aggregation* While it is  
lik ely  that the intense fibrinolytic activity which may foe produced by 
intravenous adm inistration of urokinase would largely  cancel out 
thromfoopiastic activity in  v iv o , the thromfoopiastic or coagulative  
properties could predispose to throm bosis or perhaps m ore particularly  
to rethrom bosis during therapy with urokinase and it would c lear ly  foe 
desirable to obtain a preparation free  from  such coagulative properties*
CHAPTER 7
THE EFFECT OF A HIGH FAT MEAL ON FIBRINOLYSIS, 
b l o o d  c o a g u l a t io n  AND PLATELET AGGREGATION
In th is chapter la presented  an account of the investigation of 
the influence of alim entary lipaem ia on fib rin o lysis , blood clotting  
and platelet aggregation* There has been in terest in this effect 
because of its  p ossib le  relationship to the estab lished  association  
of high plasm a lipoprotein lev e ls  and ischaem ic heart d isease  
(B ronte-Stew art, 1958: Albrink and Man, 19595 Dawber et a l . , 1963; 
Keys et al*, 1963).
It has been suggested  that, under physiological conditions, 
continuing patency of the vascu lar tree  may depend on a hom eostatic  
equilibrium  between the coagulation system , and the fibrinolytic  
enzym e system , the form er constantly laying down thrombi containing 
fibrin to sea l any defects of the vascu lar endothelium and the latter  
constantly removing such fibrinous deposits once they have served  
their haem ostatic function (Astrup, 1956)*
The work of Duguid and others has shown that if  intravascular  
thrombus p e r s is ts , it can becom e incorporated in the subendothelial 
layer of the arterial w all leading to the form ation of an ath erosclerotic
X>laqtie. V ascu la r occlusion  overly ing  such a s ite  m ay follow 
(Duguid, 1955)*
If i t  is  be lieved  th a t coagulation  and fib rin o ly s is  a re  
continuing com plem en tary  p ro c e s s e s  w ithin the v a sc u la r  t r e e ,  
then  any fa c to r w hich a c c e le ra te s  clo tting  o r  inh ib its  f ib rin o ly s is  
m ay p e rm it the deposition  and p e rs is te n c e  of in t r  a v a sc u la r  th ro m b i. 
One hypo thesis  fo r the re la tio n sh ip  betw een high p la sm a  lip o p ro te in  
le v e ls , th ro m b o sis  and a thesro sç lero sis  suggests  th a t high p la sm a  
lip o p ro te in  lev e ls  m ay m ove th e  postu la ted  eq u ilib riu m  of clotting 
and ly s is  tow ards th ro m b o s is  by in liib ition  of f ib rin o ly s is  o r by 
a c ce le ra tin g  c lo tting . P oo le  (1958) has rev iew ed  the  w ork  concern ing  
the effect of a lim en ta ry  lip a e m ia  on blood coagulation . The m o st 
co n sis ten t effect has been d em o n stra ted  using R u sse ll’s v ip e r venom , 
in  the p re se n c e  of th is  l ip id - f re e  coagulant, the p la sm a  clo tting  tim e  
is  sh o rten ed  during the  p e r io d  betw een th re e  and s ix  hou rs following 
a  fa tty  m ea l.
The effect of a lim en ta ry  lip a e m ia  on the  fib rin o ly tic  enzym e 
sy s te m  is  le s s  w ell estab lished*  M ost o b se rv e rs  have found an 
inh ib ito ry  e ffec t, but an ap p rec iab le  num ber of w o rk e rs  have fa iled  
to d e tec t any influence* One exp lanation  fo r th ese  conflicting  re p o r ts
m ay be the d iffering  ex p e rim en ta l design  and techn iques which 
have been u sed  (Howell, 1964).
A lim en tary  lip aem ia  has  a lso  been re p o rte d  to a c c e le ra te  
p la te le t agg regation  (PM lp and P ay  ling W right, 1965); th e re  is  
m uch evidence th a t p la te le t agg regation  in an im p o rtan t e a rly  
phase  of th rom bus fo rm a tio n  (M ustard  et a l# , 1964).
The ob ject of the s tu d ie s  to be re p o rte d  in  th is  chap te r w as 
to  exam ine the effect of a lim en ta ry  lip aem ia  on the fib rin o ly tic  
enzym e eyate?z)., p la te le t ag g rega tion  and ’Stypven* tim e , com paring  
the o b se rv a tio n s  m ade a f te r  a high fa t m eal w ith those  a f te r  a  low 
fa t m eaU  The fib rin o ly tic  enzym e sy s tem  w as stud ied , using  a  
v a r ie ty  of techn iques to  m e a su re  its  s e v e ra l com ponents. In  
p a r tic u la r ,  the ly s is  of C handler th ro m b i by exogenous ac tiv a to r in 
an a r tif ic ia l  c irc u la tio n  w as in v es tig a ted  b ecause  it  w as thought th a t 
th is  technique m ight be m o re  physio log ical than te s ts  involving 
o b se rv a tio n  of the  ly s is  of w hole blood o r p la sm a  c lo ts . An a ttem p t 
w as a lso  m ade to  c o r re la te  the  d eg ree  of e levation  of p la sm a  lij>id 
com ponents following fa t feeding w ith any o b se rv ed  changes in  
fib rin o ly tic  o r  coagulant activity#
M a te r ia ls
Rus s e l l*6 V iper Venom. ■ T h is was ’Stypven*, B urroughs W ellcom e 
and C o , , London-, One am poule w as dissolved in  0*9 pe.r cent sa line  
to  give a 1:1.0,000 d ilu tion  of venoxn.
Other M aterials w ere described intchapter 3#
Methods
Ten healthy adults, nine m ales and one fem ale, whose ages 
ranged between 36 and 36 y e a r s , w ere investigated on two occasion s, 
once after a low fat breakfast, the control situation, and once after  
the aame breakfast to which had been added 370 gm* of double cream# 
D etails of the breakfasts are provided in table 71, B efore taking a 
breakfast, each subject had fasted  and refrained from  smoking from  
the previous evening* After each breakfast, a further 3 hours’ fast  
was observed* At th is tim e, subjects rested  for 10 m inutes before  
venous blood sam ples w ere withdrawn*
Blood Sam ples With m inim al occlusion  of the proxim al circulation, 
60 ml* of venous blood w ere obtained in p lastic syrin ges, after a 
clean venepuncture using a needle of gauge number 19* The blood  
was allocated was fo llow s:- 15 ml* for preparation of the Chandler 
thrombus w ere delivered into a plain silicon e centrifuge tube; 37 ml*
to a s s e a s  speed  of p la te le t agg rega tion , fo r fib rin o ly tic  te s ts  and 
’S typven’ tim e  w ere  m ixed  in  9 m l, amountB in  th re e  s ilicone  
cen trifuge  tubes each  contain ing  one m l , , 3 .8  p e r  cen t sodium  
c i tra te ;  2. 5 m l. fo r  the p la te le t count w ere  .mixed in  a aeq u es tren c  
con ta in er (Stayne L a b o ra to r ie s , L td* , High W ycombe); 10 m l, fo r  
a ssa y  of f re e  fa tty  ac ids w ere  m ixed  in  a lith iu m  h ep a rin  bo ttle  
(Stayne L a b o ra to r ie s  L td * ,)  and the re m a in d e r co llec ted  as se ru m  
fo r  c h o le s te ro l, phospholip id  and tr ig ly c e r id e  a s sa y s .
The siliconé  sp ec im en s w ere  s to re d  on ic e . The c itra te d  
s ilico n e  spec im ens w ere  cen trifu g ed  10 m inu tes a f te r  co llec tion  
(600g* fo r 5 m inu tes at 4^C).
P re p a ra tio n  of A rtificial. T h rom bi and E stim a tio n  of T h e ir  
S trop tok in aso -in d u ced  L y s is  in  the C h an d le r’s Tube C handler (1958) 
ha,s shown th a t w hen whole blood i© ro ta ted  in  a  c lo sed  loop of p la s tic  
ttxbing, when i t  so lid if ie s , a  th ro m b u s is  fo rm ed  w ith a p la te le t head  
and a f ib r in  t a i l , Such th ro m b i w are  p re p a re d  fo r  each  sub jec t a f te r  
each  type of m eal by a m od ifica tion  of the  m ethod of C handler (M eHicol 
e t a l.*  1965). F ig u re  58 shows a C handler th ro m b u s . H isto log ica lly  
th ese  th ro m b i c lo se ly  re se m b le  pathological in  vivo a r te r ia l  th ro m b i 
(figure 59)#
F ifteen  ml* whole blood* collected  in silicon e and stored  
on ic e , w ere transferred  5 m inutes after co llection  to a Chandler’s 
tube made with transparent vinyl p lastic tubing of length 70 cm# and 
internal diam eter I #23 cm . (Portland Plastics Ltd#, Hythe) # At the 
sam e tim e a sm all quantity of radioactive iodine-tagged fibrinogen  
was added (about 0# I ml# to give approximately 1,000 counts/ second)* 
The tubing was made a continuous loop with a nylon adaptor and the 
loop rotated on the turntable of a b lood-cell suspension m ixer  
(Matburn L td ., London) revolving at 28#5 r e v s ,/m in u te . The loop  
was rotated for one hour at 37^0 and the resulting thrombus decanted  
and washed three time© with 10 m l , , 0 ,9  per cent sa lin e . Each 
washing con sisted  of four inversions of the te st tube containing the 
saline and throm bus. After washing, the thrombus was blotted dry 
gently and weighed* R adioactivity of the thrombus was determ ined  
in  a w ell-type scin tillation  counter and the thrombus transferred  to a 
Chandler’s tube containing 39 m l , , 0 .9  per cent saline to which had 
been added one ml* of streptokinase, 8 ,000 K .I .H . u n its /m l# , 
giving a final concentration of streptokinase of 200 N .t .H . units/m l*  
The thrombus was perfused with streptokinase for 24 hours by 
rotation of the tube in an incubator at 37^0. At the conclusion of the
experim ent, radioactivity of the thrombus was determ ined and, 
after correction  for decay, was exp ressed  as a percentage of the 
in itia l radioactivity of the throm bus. P er cent reduction in radio­
activity was calculated from  this* M cNicol (1965) has shown that 
there is  a good correlation  between radioactivity re lea se  and 
tyrosine re lea se  from  plasm a clots im m ersed  in  a medium containing 
plasm inogen activator* P er  cent reduction in radioactivity was 
therefore used  as a m easure of ly s is  of the thrombus* At this stage, 
the thrombus was again blotted dry and weighed and the per cent 
weight lo s s  after 24 hours perfusion calculated*
R u sse ll’s Viper Venom (’StypvenQ Clotting Tim e This was a 
m odification of the method of Maclagan et al* (1958), The plasm a
used was that co llected  in  s ilicon e and centrifuged at 600g, for 5
o ' ' * 'm inutes at 4 C* It was further centrifuged (2 ,OOOg. for 15 m inutes
at 4^C) to render it platelet^poor* To 0* I ml* of th isip |asm a at
37^C was added sim ultanebusiÿ 0 .1  m l. ’Stypven* (1:10,000) and
0 , 1 m l, 0 ,025  Molar GaCl^ and the clotting tim e recorded.
Preparation of P lasm a Thrombus This was the thrombus form ed
in the experim ent to a s s e s s  speed of p latelet aggregation. The
thrombus was rem oved from  the Chandler's tube after rotation for
Qone hdur at 37 C and its tr ig lycerid e content assayed#
Serum  C holesterol This waa m easured by a m odification of the 
method of Zlatkis et al* (1953) (Henly, 1957).
Serum  T rig lycerid es T hese w ere m easured by the method of van 
Handel and Z ilverem it (1957)*
Serum  Pho©pholipids T hese w ere  m easured by the method of 
B artlett (1959)*
P lasm a F ree  Fatty A cids T hese w ere m easured by the method of 
Dole et al# (1956) m odified to u se  N ile Blue as the indicator.
Thrombus Lipid This was extracted with chloroform -m ethanol in the 
preparation of 2:1 and tr ig lycerid e content of the extract m easured by 
the method of van Handel and Z ilversm it (1957)#
Thin Layer Chromatography The method of Robinson and Philips 
(1963) was used#
Dr# B#M. Rifkind and M iss M# Gale kindly carried  out the 
lip id  assays#
Other Methods w ere described  in chapter 3#
R esults
Plasm inogen A ssays The m ean plasm a plasm inogen lev e l for the 
10 subjects after the high fat breakfast (2*344 -  0*218 casein  u n its /m l.)
did not d iffe r sign ifican tly  f ro m  the m ean  lev e l a f te r  the  con tro l 
b re a k fa s t (2# 375 t  0 ,2 9 9  c a se in  u n its /m l* ) (t = 0*375, 0*7<p<0#S). 
T hese  re su lts  a re  shown in  tab le  72*
F ib rin o g en  A ssay s  The m ean  p la sm a  fib rinogen  lev e l fo r  the 10 
su b jec ts  a f te r  the high fa t b re aW % t (252*5 ^ 94*0 m g*/ 100 mL) w as 
a lm o st id en tica l w ith  the m ean  value a f te r  the co n tro l b reaM ast 
(253.0 t  9? .0  m g. /100  m l.)  (t + 0 .0 9 8 , 0. 90<p<0.95).% ble 73
shows th e se  re s u l ts .
Euglobulin  L y s is  T e s ts  R esu lts  of euglobulin ly s is  te a ts  fo r the ten  
su b jec ts  a f te r  both types of b re a k fa s t a re  shown in  tab le  74* M ean 
euglobulin  ly s is  ac tiv ity  a f te r  the high fa t b re a k fa s t ( 1 .10 i  0 ,51  
units) is  sign ifican tly  le s s  than  m ean  ac tiv ity  a f te r  the co n tro l 
breakfast (1 .72  t  0.88  w ilts) (t = 3 .5 7 3 , 0 .005<p<0.01).
U rok inase  S enaitiv ity  T e s ts  T able 75 shows the re s u lts  of u ro k in ase  
sen s itiv ity  te s ts  fo r  the 10 su b jec ts  a f te r  each  type of breakfast*  I t 
w ill be seen  tha t in  th is  t e s t  th e re  w as a  sign ifican t m ean  in c re a s e  in  
re s is ta n c e  to  ly s is  by u ro k in ase  of p la sm a  c lo ts  fo rm ed  a f te r  the 
high fa t b re a k fa s t (0 ,85  ^ 0 ,3 8  units) com pared  w ith the findings a f te r  
the con tro l b re a k fa s t (1*05 ^ 0*59 un its) (t « 3*087, 0*0l<p<0.02).
-L ysis of Chandler Thrombi by Streptokinase in an A rtificia l 
Circulation Table 76 shows the resu lts for the 10 subjects of per 
cent reduction in radioactivity from  the thrombi form ed after each  
type of breakfast# Mean per cent radioactivity lo st after the high 
fat breakfast (35* I t  12* 2 per cent) is  significantly decreased  
com pared with the control value (48 .6   ^ 15* 7 per cent) (t * 3*024, 
O.OKp^O.OZ).
Table 77 shows the resu lts of per cent weight lo s s  of thrombi 
form ed after each type of brealcfast for 8 subjects* Mean per cent 
weight lo ss  after the high fat breaM ast (46*8 -  14* 3 per cent) is  
significantly le s s  than m ean per cent weight lo ss  after the control 
breakfast (56*5 -  12.3 per cent) (t * 4*054, 0*00l<p<0.005).
R u sse ll's  Viper Venom (’Stypven*) Clotting T im es A consistent 
acceleration  of the 'Stypven* clotting tim e was found in each subject 
after the high fat breakfast, com pared with the findings after the low  
fat breakfast* The observations are recorded in  table 78, The 
mean 'Stypven* clotting tim e after the high fat breakfast was 
15* 6 - 4 . 9 seconds, and after the low fat brealtfast 2 2 . 9 ^ 5 * 2  
seconda* The difference is  highly significant (t * 12 .726 , p < 0 ,0 0 l). 
P la te let Aggregation T hese resu lts are shown in table 79* The mean
vaine lo r  the 10 su b jec ts  fo r  p la te le t agg regation  in  the C h an d le r 's  
tube a f te r  the low fa t b re a k fa s t w as 521 ^ 87 seconds and a f te r  the  
high fa t b re a k fa s t w as 603 t  6s seconds* The pro longation  of 
p la te le t agg regation  a f te r  the high fa t b raaM ast is  s ign ifican t 
(t a: 4*263, O* OO5<p<O*0l).
P la te le t  Counts The m ean  p la te le t count fo r the 10 Subjects 
following the co n tro l b real^fast w as 219* 7 i  51*6 th o u san d s /m m ^ , 
and a f te r  the  high fa t b re a k fa s t w as 232* 4 t  50 ,2  th o u san d s /m m  *
The d iffe rence  betw een th e se  m eans i s  not s ign ifican t (t “ 1* 178, 
0*Z<p<0i3)* The re su lts  a re  re c o rd e d  in  tab le  80*
P la s m a  L ip id  L eve ls  A fte r each  type of b re a k fa s t, the lev e ls  of 
so n u n  tr ig ly c e r id e s , s e ru m  phospholip ids, p la sm a  f re e  fa tty  ac ids 
and se ru m  c h o le s te ro l w e re  m easured*
M ean se ru m  tr ig ly c e r id e  lev e l a f te r  the high fa t b re a ld a s t 
(164 t  82 mg* / 100 m l.)  w as sign ifican tly  g re a te r  than  co n tro l 
findings (81 ^ 34 mg# / 100 m l*) (t » 4*427, 0 . 00K p<0*005). T hese  
re su lts  a re  shown in  tab le  81*
M ean se ru m  phospholip id  lev e l a f te r  fa t feeding (244 ^ 38 m g. / 
100 m l.)  w as s ign ifican tly  h ig h e r than  the m ean  lev e l a f te r  the low 
fa t b reak fae t (212 t  24 m g . / 100 m l.)  (t * 3 .5 9 6 , 0 .005< p< 0,01).
Table 82 shows th e se  re s u l ts .
A fte r the  high fa t b re a k fa s t m ean  p la sm a  f re e  fa tty  ac id  
lev e l w as 952 t  1 7 7  |xe*/litre and com pared  w ith the co n tro l findings 
( 5 6 1  180 (A e./litre) th is  r i s e  a f te r  the high fa t b realcfast is  highly
sign ifican t (t = 5*213, p<0.00l)*  T ab le  83 su m m a rise s  th ese  re su lts*
M ean se ru m  c h o le s te ro l lev e l fo r  the ten  su b jec ts  a f te r  the 
high fa t b re a k fa s t ( 2 1 0  t  4 1  m g . / 1 0 0  m l .)  did not d if fe r  sign ifican tly  
fro m  the m ean  value a f te r  the  con tro l breaîcfast (223 ^ 4 3  mg* / 1 0 0  m l.) 
(t = 1 .417 , 0* I0<p<0. 20). T hese  re su lts  a r e  shown in  fab le  84.
Thin L a y e r  C hrom atography  of the  Double C re a m  T h is  w as c a r r ie d  
out to identify  the lip id  constituen ts  of the c re a m . The c h ro m a to g ra m s , 
w hich w ere  run  with ap p ro p ria te  lip id  m a rk e r s ,  a re  shown in  
f ig u re s  60 and 61* I t  w ill be seen  th a t the constituen ts  of the  c re a m  
w ere  chiefly  trig lyceride©  w ith som e d ig ly cc rid e s , a  t ra c e  of 
ch o le s te ro l and no phospholip id .
P la sm a  T hrom bus T rig ly c e r id e  C ontent M ean th rom bus tr ig ly c e r id e  
content fo r the 10 su b jec ts  a f te r  the  high fa t b re a k fa s t ( 0 .2 9 - 0 .2 2  m g ./  
100 m l.)  w as g re a te r  than  the  m ean  con tro l th rom bus tr ig ly c e r id e  
content (0 .15  i  0, 13 m g ./  100 m l .) ,  but the d iffe ren ce  is  not fo rm a lly  
sign ifican t (t -  2. 109* 0*05<p<0,1) (tab le 85).
p is  CUB a ion
The re su lts  p re se n te d  in  th is  ch ap te r in d ica te  th a t during 
a lim en ta ry  lipaem ia# induced  by hageetlon of 95 gm* of fa t in  the 
fo rm  of 270 gm* double cream # th e re  w as both a  s ign ifican t d e c re a se  
in  spontaneous p la sm a  c lo t ly s is  a c tiv ity  (euglobulin ly s is  te s t)  and 
in c re a se d  re s is ta n c e  of p la sm a tc lo ts  to ly s is  by urokinase#
P o ss ib ly  m o s t im portant#  an in c re a s e d  re s is ta n c e  of p re fo rm ed  
C handler th ro m b i to ly s is  by e x tr in s ic  a c tiv a to r  (s trep to k in ase ) in  
an a r tif ic ia l  c irc u la tio n  w as a lso  d em o n stra ted .
G ireum stm tces w hich have been  re p o rte d  to  influence 
spontaneous- f ib rin o ly s is  such  as d iu rn a l v a r ia tio n  (Feaiudey e t a l . , 
1957)# e x e rc is e  (B iggs et al* # 1947) and c irc u la to ry  occ lusion  
b e fo re  v enesec tion  (Kwaan e t a l. # 1958>b) w are  e lim in a ted  as f a r  as 
po ss ib le  by the ex p e rim en ta l d esign .
The o b se rv ed  d e c re a se  in  physio log ical fibrinolyB is a f te r  
the  high fa t b re a k fa s t w as not due to d e c re a se  in  clo t o r th rom bus 
p lasm inogen  content o r  to  in c re a s e  in  co n cen tra tio n  of f ib rin , s ince 
the p la sm a  lev e ls  of plasminogmn and fib rinogen  w ere  c lo se ly  
s im ila r  a f te r  each  type of b re a k fa s t.
The finding of d e c re a se d  euglobulin  ly s is  ac tiv ity  during
^U m eBtary U paam ia w as to the ra su lta  ob tained  in  n o rm a l
snbjeetB by o th e r w o rk e rs  (see-H ow ell,,-1964 fo r  a  rev iew  of the 
l ite ra tu re )^  ' H ow ever, GajowSki-'(1.961)'did o b se rv e  decreased - 
ac tiv ity  in  th is  te a t  in  a  ga’oup of patien ta  w ith se v e re  a theroa  ole ro s is ,  
following- ingestion  of s a ta ra te d  fa t. .One explanation  .for th ese  
d iffering  re.anlta in  n o rm a l snb jeo ts m ay be th a t préviens- o b se rv e rs  
have s tud ied  the, euglobulin  ly s is  te s t  following m ea ls  containing 40 
to 60 gm . sa tu ra te d  fa t, w h e rea s  the ten  su b jec ts  d e sc rib e d  in  th is  
ch ap te r w ere  in v estig a ted  during  the lip aem ia  Induced by about 
tw ice th is  amount# The d e c re a se d  ac tiv ity  which G ajew ski o b se rv ed  
in  Ms a th e ro sc le ro tic  g ro u p s who v /ere  fed 40 to  60 gm# sa tu ra te d  
fa t, m ay be explained by the delay in  '^clearing” of lip aem ia  which 
is  re p o rte d  to  o ccu r in  th e se  su b jec ts  (M itchell and Bronte'*3tew art# 
1959). H igher lip id  lev e ls  m ay th e re fo re  have been  induced in  
Gajewski^a group due to fa t feeding  com pared  w ith findings in  n o rm a l 
su b je c ts . Pappenhagen e t al# (1963) exam ined the effect of ch y lo m ic ra  
an d ^ ^ lip o p ro te in  on englobuUn c lo t ly s is ,  and re p o r te d  p ro longation  of 
euglobulin ly s is  tim e s  w ith eithox’ fra c tio n  w hether added to p la sm a  
befo re  euglobulin p re c ip ita tio n  o r  to  the  euglobulin suspension  b efo re  
c lo tting , a  finding suggesting  th a t en try  of ch y lo m ic ra  orjS «^lipoprotein
into the c lo t m ay be a fa c to r  in the production  of d e c re a se d  
euglobulin  ly©is activity* T hat the  bulk of p la sm a  lip id  com ponents 
is  p re se n t in  the euglobulin  c lo t has been d em o n stra ted  by R ifkind 
{19-65) using  th in  la y e r  ch rom atog raphy  of lip id  e x tra c ts  of euglobulin 
c lo t, su p ern a tan t m % dn#w e plasm a* T ra c e s , only, of the p la sm a  
lip id  com ponents w e re  id en tified  in  the su p e rn a tan t, w h ereas  lip id  
com ponents in  the  c lo t w ere  quar^titatively s im ila r  to those  of the 
native p la sm a .
R iding and E llis  (1964) re p o rte d  th a t p u rif ie d ^  ^^lipoprotein 
p o s se s se s  s ign ifican t an tip lasm in  ac tiv ity  in v itro  in  a p lasm inogen  
a ssay  sy s tem  w ith ca se in  a s  the  s u b s tra te  fo r plasm in# The in c re a se  
in  o v e ra ll f ib rin o ly tic  iîüûM tOry lev e ls  d em o n stra ted  in  the u ro k in ase  
sen s itiv ity  te s ts  re p o r te d  in  th is  chaper m ight th e re fo re  be due to an 
an tip lasm in  effec t ofy8*«lipoprotein in  the c lo t. The u ro k in ase  
sen s itiv ity  te s t  does not d is tin g u ish  an tiac tiv a to r and aa tip la sm in  
ac tiv ity , so tha t an, in c re a s e  in  a n tia c tiv a to r ac tiv ity  during U paem ia 
is  a  fu r th e r  p o ssib le  esq^M iation of the re s u l ts .
The d e c re a se d  th ro m b o ly s is  found In the  C hand ler th ro m b i 
ex p e rim en ts  m ay have g re a te r  sign ificance  than  o b serv a tio n  of ly s is  
of whole blood o r  p la sm a  c lo ts , s in ce  the te s t  sy s te m , nam ely
a r te  l i a i  ^  like th ro m b i su b jec ted  to ly s is  in an a r tif ic ia l  c ircu la tio n , 
u se s  a m o re  physio log ical su b s tra te  than te s t  tube c lo ts . The 
d e c re a se  in ly s is  of th ro m b i p re p a re d  fro m  lip aem ic  blood as 
com pared  with those fo rm ed  fro m  non^'lipaem ic blood is  in  ag reem en t 
w ith ithe o b serv a tio n  of Bang and C liff ton {I960), who induced th ro m b i 
in  dogs during  a lim en ta ry  lip a e m ia  and d em o n stra ted  d e c re a se d  
th ro m b o ly sis  in  vivo by s trep to k in ase  com pared  w ith findings in  both 
fasting  dogs and dogs fed  a low-^fat m e a l. T h èse  w o rk e rs  a lso  
show ed, using  a  h is to ch em ica l techn ique , that th rom bus fo rm ed  during 
lip aem ia  contained la rg e  am ounts of fa t in  in tim a te  contact w ith the 
f ib rin  m esh  while th rom bus fo rm ed  in  the fasting  s ta te  contained no 
fa t. They suggested  tha t re s is ta n c e  to ly s is  of ’^l ip a e m ic ” th ro m b i 
m ight be due to a lip id  coating of the fib rin  s tra n d s  w hich p ro te c ts  
them  fro m  p ro te o ly s is . Bang (1964) prov ided  fu r th e r  evidence fo r 
th is  hypo thesis; using  e lec tro n  m ic ro sco p y , he show ed th a t during the  
conversion  of fib rinogen  to  f ib r in , lip o p ro te in  fo rm s a  la y e r  on the 
su rfa c e  of fibri%i f ib r i ls .
I t is  u sually  a ssu m ed  th a t changes in f ib rin o ly s is  o r 
coagulation follow ing fa t feeding a re  due to the a sso c ia te d  U paem ia, 
H ow ever, although th e re  w ere  sign ifican t r i s e s  in tr ig ly c e r id e ,
phospholipid  and f re e  fa tty  ac id  lev e ls  following the fa t b re a k fa s t 
in  a ll ten  sub jec to , no c o r re la tio n  w as obtained betw een the ac tual 
lev e ls  o r changes in  the lev e ls  of any of th e se  lip id  com ponents and 
the changes in  fib rin o ly tic  activity*
On the o th e r hand, R u s s e ll 's  v ip e r venom. ('S typven ') clo tting  
tim e s  w ere  c losely  re la te d  to s e ru m  tr ig ly c e r id e  levels* % hen the 
p a irs  of 3:esu its  (clotting tim e s  a f te r  the con tro l b re a k fa s t and a f te r  
the high fa t b reak fas t) w ere  p lo tted  aga in st th e ir  co rresp o n d in g  se ru m  
txdglyceride lev e ls  e x p re sse d  as lo g a rith m s , a highly sign ifican t 
in v e rse  c o rre la tio n  w as found (r  % **0*679, p<0*001; 
y = 2* 71 ** 0*03S8x)* S im ila r  c o rre la tio n s  w ere  found fo r the 
a^esulta following the co n tro l b re a k fa s t (r  » *^ 0* 823, 0* 005<p<0* 01; 
y 2= 2. 52 ** 0.0285x) and follow ing the high fa t b re a k fa s t 
(r  s: **0.872, p<0«00l; y a: 2* 82 ** 0 .0285x). The c o rre la tio n  fo r the 
com bined *fat**free' and 'a f te r  fat* re s u l ts  is  i l lu s tra te d  in fig u re  62*
It  is  of in te re s t  th a t p la sm a  clo ts  fro m  lip aem ic  blood tended  to  have 
a  h ig h er tr ig ly c e r id e  content than  co n tro l c lo ts , although the 
d iffe ren ces w ere  not s ig n ifican t.
No c o rre la tio n  v/as found betw een the lev e ls  of the  o th er 
lip id s m e a su re d  and 'Stypven* t im e s .
-  i .  4.
The COX'relation betw een *Stnwen* tim e s  and se ru m  tr ig ly c e r id e s  
suggests  th a t the a c c e le ra tio n  of 'Stypven* tim e s  during a lim en ta ry  
lip  aem ia  m ay be m ed ia ted  th rough  the en try  of tr ig ly c e r id e  into the 
circu lation#  , T he com*eXation noted between, 'Stypven* tim e s  and 
tr ig ly c e r id e  lev e ls  in  the  srxbjecta a l te r  the con tro l b re a k fa s t suggests  
tha t endog enou s ly -  de r iv e  d , c ircu la tin g  tr ig ly c e r id e  m ay also  be 
im p o rtan t in  influencing the re su lts  of the 'Stypven* tim e . T hese 
re s u lts  a re  in  ag reem en t w ith  the  re p o r t  of Jam es  et a l. (4961) th a t 
th e re  ia  a s ign ifican t negative  c o rre la tio n  (r = **0.65) betw een 'Stypven* 
tim e and U paem ia m e a su re d  as  p la sm a  tu rb id ity  w hich is  la rg e ly  due 
to  t r ig ly c e r id e - r ic h  ch y lo m ic ra . I t  is  usually  assu m ed  that 
phospholip id  o r  one of its  su b frac tio n s is  the lip id  ac tive  in coagulation  
(see  Biggs and M acfarlan e , 1962 d, fo r  a rev iew  of the l i te r a tu r e ) # 
F a ilu re  to find any c o r re la tio n  betw een 'Stypven* tim e s  and p la sm a  
lip id  com ponents o th e r than tr ig ly c e r id e s  does not preclixcle a 
c o rre la tio n  betw een 'Stypven* tim e s  and p a r tic u la r  lip id  su b frac tio n s , 
e .g .  phosphatidyl ethanol am ine (B illim o ria  et a l* , 1965).
The proglongation  of p la te le t aggregation  noted  a f te r  the Jaigh 
fa t b re a k fa s t d iffe rs  fro m  o b se rv a tio n s  m ade by P h ilp  and P ay  ling 
Wxdght (1965), who re p o rte d  increa^sed adhesiveness  of p la te le ts
during lip a e m ia  co m pared  w ith findings in  the fasting  state* One 
explanation  fo r th ese  c o n tra ry  observ a tio n s xxxay be th a t the m ethod 
u sed  in  thio th e s is  to  a s s e s s  speed  of p la te le t agg regation  d iffe red  
fro m  tha t em ployed by P h ilp  and P ay ling  W righ t, T hese  au tho rs 
a lso  re p o rte d  th a t the platelet^*count w as in  ev e ry  in s tan ce  low er 
during  U paem ia than  in the fa stin g  s ta te . In the ex p e rim en ts  
re p o rte d  in  th is  c h a p te r , p la te le t-c o u n ts  a f te r  the two types of 
b re a k fa s t (low fa t and high fat) w ere  not sign ifican tly  d iffe ren t; 
accord ing ly  re la tiv e  ths/ornbocytopenia is  unlikely  to have been a 
fa c to r  in the p ro longation  of p la te le t agg regation  which w as o b se rv ed .
One hypothesis to  account fo r  p ro longation  of p la te le t 
aggregation  during U paem ia is  th a t ch y lo m icra  m ay in te r fe re  w ith 
p la te le t c o il if to s . If th is  w ere  v a lid , it  m ight be an tic ipa ted  tha t 
th e re  would be a  c o rre la tio n  betw een tr ig ly c e r id e  lev e ls  and p la te le t 
p.ggregatioji: no such c o r re la tio n  w as found.
C u rre n t knowledge su g g ests  th a t fo rm atio n  of p la te le t m ic ro -  
th ro m b i m ay be an im p o rtan t e a r ly  s tep  in  the fo rm atio n  of m acro sco p ic  
th rom bus in  the blood v e s s e ls  and possib ly  th e re fo re , d im in ished  
speed  of p la te le t agg regation  m ight oppose the o th er 'throm bosis*" 
p rom o ting ' effects of the U paem ia i . e .  d e c re a se d  fib rin o ly s is  and 
accelerated  clotting.
Gonc'iuaions
The effect of a bigîî. fa t m eal w as in v estig a ted  in  ten  n o rm al 
su b je c ts , com pared  w ith findings a f te r  a low fa t m ea l. The aim  of 
the  investigation©  w as to exam ine the hypothesis tha t the possib le  
equJlib rm ra  of f ib rin o ly s is  and coagulation  m ay be d isp laced  tow ards 
th ro m b o sis  by ra is e d  blood lip id  le v e ls .
D e c re a se d  fib rin o ly tic  ac tiv ity  w as found a f te r  the fa t m eal 
in  the euglobulin ly s is  te s t  and in  the u ro k in ase  sen s itiv ity  test* 
A rtif ic ia l th ro m b i a lso  show ed in c re a se d  re s is ta n c e  to ly s is  by 
s trep to k in ase  - a re su lt  thought to  be m o re  s ign ifican t in  te rm s  of 
the in  vivo effect of lip a e m ia  on spontaneous fib rin o ly tic  ac tiv ity .
The a c c e le ra tio n  of 'S typven ' txm es during U paem ia o rig in a lly  
re p o rte d  by F u lle r to n  et al* (1953) w as confirm ed* A highly 
sign ifican t in v e rse  c o r re la tio n  v/as d em o n stra ted  betw een 
tStypven' tim e s  and tr ig ly c e r id e  lev e ls  e x p re sse d  as lo g a rith m s .
A part fro m  the finding of pro longation  of p la te le t agg regation , 
the  o ther effects of a fa t m eal ap p ear to move the  hypothetical 
eq u ilib riu m  of clo tting  and ly e is  tow ards throm bosis.
CHAPTER 8 
STUDIES OF SIX DEFIBRINATION SYNDROMES
Defibrination or acquired hypofibrinogenaem ia is  now 
wideJy recognised  to be associa ted  with a severe  and frequently  
life-threatening haem orrhagic d iath esis. The pathogenesis of the 
condition has not been adequately elucidated in spite of intense  
in terest in the problem  over the past 15 y ea r s . Three commonly 
accepted possib le causes of the condition are loca l re lea se  of 
tissu e  throm boplastin, loca l re lea se  of fibrinolytic activator or 
prim ary re lea se  of throm boplastin with a secondary fibrinolytic  
response which "overshoots** (Schneider, 1959# F letch er et a l . ,
1962 as Sharp, 1964).
Spontaneous pathological bleeding associa ted  with hypo- 
fibrinogenaem ia may com plicate m ajor surgical procedures 
esp ec ia lly  pulmonary surgery (Soulier et a l . , 1952) and surgery  
with Qxtracorporeal circulation  (von Kaulla and Swan* 1958); 
certain  obstetric accidents particularly abruptic placentae* 
amniotic fluid em bolism  and intrauterine death (Schneider, 1959)# 
m etastatic carcinom a, m ost com monly of the prostate (Tagnon et 
a l . ,  19'52); and hepatic c irrh o sis  (Kwaan et a l . , 1956). Adm inistration  
of streptokinase and urokinase for throm bolysis m ust a lso  be Included
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(F letcher et a l . ,  1962 a).
Sharp (1964) has suggested  that, with only occasional 
exceptions, pathological fib rin o lysis is  associated  with an episode  
of intravasGular fibrin form ation, the lytic  system  being activated to 
combat coagulation. There is  accumulating evidence to suggest 
that such a com plex in ter-rela tion sh ip  may ex ist between the 
coagulation and fibrinolytic enî^iyme sy stem s. Both system s may 
be activated by activation of Hagcman factor (Hiewiarowski and P rou - 
W artelle, 1959; la tr id is  and F erguson , 196$)# P la te lets  p o ssess  
antiplasm in activity (Johnson and Schneider, 1953; Stefanini and 
Murphy, 1956; Sherry and Alkjaersig* 1957) and proactivator 
properties (Holemans and G ross, 1961). Explosive intravascular  
fibrin form ation and pathological fibrinolysis may be associated  
with depletion of the sam e coagulation components nam ely fibrinogen  
(Schneider, 1959; F letch er et a l* , 1962 a), prothrombin and factor V 
(Greenwalt and Triantaphyllopoulos, 1954; A lagille  and Soulier, 1956) 
and antihaemophilic globulin (A .H .G .)  (Lewis et a l . , 1949; Sharp et 
a l . , 1958). Fibrinogen breakdown products inhibit fibrin  
polym erisation (Alkjaereig et a l . , 1962; F letcher et a l . , 1962 b) 
and may have an antithrombin effect (Niewiarowski and L atallo, 1957;
-  i S ' V
T riantaphyllopôulos, 1958).
When hypofibrinogenaem ia occurs,, it  may be difficult or 
im possib le to determ ine whether the main cause is  clotting or 
ly s is  and hence to adopt a rational approach to therapy.
It is  the purpose of th is chapter to describe s ix  patients in 
whom the defibrination syndronae was diagnosed. In two there was 
prolonged retentionGfmcdead foetus; in three m etastatic oarcinom a  
and one arose in the course of throm bolytic therapy,
A  section  of the chapter is  devoted to description of three 
in  vitro experim ents which w ere attempts to illu stra te  possib le  
errors in interpretation of certain  fibrinolytic te sts  which might be 
perform ed In the investigation  of defibrination syndrom es.
M aterials and Methods 
Fibrinogen The preparations used w ere Kabi human fibrinogen  
described in  chapter 6 and plasm inogen-poor human fibrinogen  
prepared by the method of Kekwick et a l. (1955)#
Prothrom bin A ssay  This was the method of Glueck et a l .
(1954) in which tosy l arginine m ethyl es ter (TAMe) is  substrate. 
A ssay of F actors VII and X  T hese w ere assayed  together by a 
method which depends on shortening of the on e-stage prothrombin  
tim e of Loco.marln plasm a (Douglas, 1955),
F actor X A ssay  TM s'v/as the on e-stage method of Bachmann et 
al, (1958) In. which oxalated ox p lasm a, S eit^ -filtered  to rem ove 
factor X, is  substrate# The method was m odified slightly by using  
cephaiin prepared as described  by B ell and Alton (1954). 
Dem onstration of F ibrin  Degradation Producte in Serum  The method 
used  was that of F e r r e ir a  and Murat (1963). This was an agar-gel 
immunodiffusion technique. F ibrin  antiserum  was prepared by D r.
B. Sweet by im m unising rabbits with a suspension of fibrin (prepared  
from  Kabi human fibrinogen) in aluminium hydroxide* The fibrin  
suspension was injected tw ice at an interval of 14 days. A ntiserum  
was adsorbed before u se with aged human serum , overnight at 4^G. 
Other M aterials and Methods w ere described  in chapter 3.
C ase 1* This patient, who was 30 years old, was in the 33rd week  
of her 5th pregnancy* She was Rhesus negative. She was known to 
have developed anti-R hesus antibodies during her 3rd pregnancy 
which term inated in the delivery of a stillborn foetus with hydrops 
foetalis* During her fourth pregnancy, labour had been induced 
because of a rising anti-R liesus antibody titre . No abnormal bleeding 
had occurred during th ese pregnancies. In her 5th pregnancy, 
intrauterine death was suspected  to have taken place between 24
and 26 weeks and adm ission to hospital was arranged to confirm  
the diagnosis and to induce labour. The parient reported the 
presence of a b lood-stained vaginal discharge during the three  
days preceding admission* F oeta l death was confirm ed rad iologically , 
A Fibrindex te st  (Ortho Pharm aceuticals Ltd. ,  Bucks*) dem onstrated  
hypofibrinogenaem ia and subsequent biochem ical estim ation of 
fibrinogen gave a resu lt of .82 mg*/: 100 ml* One pint of trip le strength  
plasm a was adm inistered (equivalent to approximately 3 * 3 gm* 
fibrinogen)* On the following day# persisten t oozing of blood was 
noted from  venepuncture s ite s .  Other investigations w ere carried  
out at th is tim e in an effort to elucidate the aetiology of her hypo­
fibrinogenaemia# The resu lts are shown in table 86 (day 0). There 
was depletion of prothrombin# factor V » antihaemophilic globulin 
( A .H .G . ) ,  factor X and plasminogen* The low plasm inogen lev e l 
and norm al p latelet count w ere thought to favour a diagnosis of 
pathological fib rin o lysis as the aetiology of her hypofibrinogenaemia* 
A ccordingly, therapy with the fibrinolytic inhibitor, BAG A, was 
com m enced, the in itia l dose being 4 gm*, followed by 1 gm* four- 
hourly. Table 86 a lso  shows the resu lts of investigations carried  
out on the 4th day of therapy (day 4) and p ost-d elivery  (days 6 and 8).
i f  w
F ig u re  63 g rap h ica lly  d isp lays som e of the more^ s tr ik in g  re s u lts  
of tab le  '86*'- ' îb w ill  be seem th a t th e rap y  w ith EAGA» w hich w as 
diacontm ued' 42  ^h o u rs  ; p o s t-d e liv e ry  '(day 5), w a s  a sso c ia te d  w ith  
re s to ra tio n  of th e  m o d e ra te  plasmimogem 'depletion to a  n o rm a l level, 
but w ith -fa ilu re  t o  c o r re c t  - depletion'^of ■affected coagu la tion  com ponents*
In  p a rtic u la r ,''p la sm a -fib rin o g e n ''re m a in e d  a t l e s s  tlian 100 m g , / 100 ml*
' ' - On th e  4th-day of H  AG A  th e ra p y , m ed ica l induction* of lab o u r 
w as com m enced*' 'T w enty  h o u rs  la ter#  w ith the  o n se t of*uterine 
co n trac tio n s th e re  w a s-b risk  v a g in a l 'b leéding, ■ D uring the subsequen t 
th re e  ho u rs  u n til-d e liv e ry  of a- s t i l lb o rn  'mace ra te d 'fo e tu s  w as accom plished , 
blood lo ss  am ounted  to  about ''2.-S l i t r e s , '  - The patient# sev e re ly  shocked  
during  this, period# re q u ire d  ■ transfusion an d  w as given w ho le  blood 
(2 l i t r e s )  and fib rinogen  (12 gm*)* On the day following d e liv ery  (day 6), 
the fib rinogen  le v e l  -and the fib rin o ly tic  a ssa y s  w ere  w ith in  ■the'norm al 
range* The dep leted  coagula tion  com ponents w ere  p a r tia lly  r e s to re d  
w hile the p la te le t count had  fa llen  to  85# 0 0 0 /m m  , ,  p o ssib ly  as a 
consequence of acute blood lo s s  and rep lacem en t transfusion*
Case 2* This patient# who w as 32 y e a rs  old# w as g rav id a  3. She 
w as R hesus negative an d  h e r  husband  w as known to  be hom ozygous fo r  
the R hesus factor* She had  had# previously# two uncom plicated
pregnancies* In the present pregnancy, anti-R hesus antibodies had 
been detected at 16 w eeks. In the 21st week, she developed p re­
eclam ptic toxaem ia (peripheral oedem a was present and her d iasto lic  
blood p ressu re was 95mm* Hg). She was treated with bed rest and 
sedation and had recovered  by the 23rd w eek. At the 25th w eek, 
the anti-R hesus titre  (indirect antiglobulin technique) had risen  
dram atically to 1:1024. Intrauterine death was suspected at that 
tim e and confirm ed at the 26th week# She was admitted early in the 
32nd week for induction of labour and at the tim e of adm ission , a 
Fibrindex teat (Ortho Pharm aceuticals Ltd#,) dem onstrated hypo- 
fibrinogenaemia# On the following day (day 0, table 87) olottable 
plasm a fibrinogen was 218 mg# / 100 m l. and the plasm inogen lev e l 
was norm al as was the p latelet count# There was evidence of a 
coagulation d efect:- factor V, antihaemophilic globulin (A .H.G. )  and 
factor X lev e ls  w ere low and the on e-stage prothrombin tim e and 
thrombin clotting tim e w ere prolonged# In view  of the norm al 
platelet count, a d iagnosis of intravascular clotting was thought to be 
unlikely and since there was a striking prolongation of the thrombin  
clotting tim e, the diagnosis of pathological fib rin o lysis was entertained# 
A ccordingly, therapy with EACA was adm inistered in the sam e dosage 
as in case  I. Table 87 a lso  shows assay  values for the second day of
th e rap y  (clay 2) a%%d the im m ed ia te  p o s t-d e liv e ry  day (day 5)*
F ig u re  64 d isp lays in  p a r t  som e of the  ré su lta  of tab le  87# EACA 
w as d iscon tinued  12 h o u rs  p o st-de livery#  On the  fou rth  clay of 
th e rap y  (day 4), spontaneous lab o u r ensued  and d e liv ery  of a  s tillb o rn  
m a c e ra te d  foetus w as■acoom piished# B lo o d le s s  a sso c ia te d  w ith 
de liv ery  did not exceed'-20Ü m L -'and  no .rep lacem ent th e rap y  was 
required#.*. .On th e  p o s t-d e liv e ry  4ay> a ll of the coagulation  and 
fib rin o ly tic  a ssa y s  w ere  n o rm a l w ith the  exception  of the lev e l of 
fa c to r  V though th is  had  risen , to 30 p e r  cent fro m  its  p re -d e liv e ry  
lev e l of 10 p e r  cent*
C asa 3 # T his fem ale  p a tien t, who w as 56 y e a rs  o ld , had a  h is to ry  
of ca rc in o m a  of the b re a s t  of. 8.y e a r s ' du ra tion  fo r  w hich the in itia l 
t re a tm e n t had  been  rad io therapy# In  1963, she p re se n te d  w ith 
m é ta s ta s é s  in  the le f t  su p ra c la v ic u la r  fo ssa  and w as tre a te d  w ith 
s te ro id s  and an d ro g en s. In  F e b ru a ry  1964# she developed o b s tru c tiv e  
jaund ice  w hich re so lv e d  rap id ly  a f te r  c e ssa tio n  of the  horm one therapy^ 
S hortly  thereafter#} she w as no ted  to  have a  re c u r re n c e  of the b re a s t  
tumour a sso c ia te d  w ith a  fixed , atony h a rd  m a ss  in  the  le f t su p ra ­
c lav icu la r fossa* In A pril 1964, she im derw ent a  s im p le  m astec tom y  
follow ed by rad io therapy*  She developed a  p e r s is te n t  wound in fec tion
and u ltim a te ly  re q u ire d  p la s tic  su rgery#  In  A ugust 1964, she waa 
rev iew ed  following the p la s tic  r e p a ir  and g e n e ra lise d  ca p illa ry  oozing 
w as noted  fro m  the s t i l l  unhea led  wound edges. She v o lu n tee red  the  
in fo rm ation -that she had  noted 'Spontaneous b ru is in g  of h e r  lim b s fo r  
som e m onths -priory ■ Shortly: th e re a f te r ,  she re q u ire d  em ergency  
ad m iss io n  to h o sp ita l b ecause  of the-sudden appearm ice of a  la rg e  
fluctuan t haem atom a of h e r  r ig h t io w e r abdom en and - u p p er p a r t  of 
rig h t thigh*' C oagulation and fib rin o ly tic  in v estig a tio n s  at the tim e  
of ad m issio n  a re  shown in  tab le  88* The low fib rinogen  leve l 
e s tab lish ed  d efib rina tion  w hile the findings of a  pro longed  th rom b in  
clo tting  tim e  a c c e le ra te d  euglobulin  c lo t ly s is  t im e , low p lasm inogen  
lev e l and n o rm a l p la te le t count w ere  thought- to favour a  d iagnosis of 
patho log ical f ib rin o ly s is  r a th e r  ^than in tra v a s c u la r  clotting* I t w as 
decided  to follow the le v e ls  of p lasm inogen  and fib rinogen  during 
th e rap y  w ith EACA (days 3 to  7, f ig u re  65), On day 4 , the fib rinogen  
lev e l w as 170 m g, / 100 m l* , and th is  ap p eared  to be a  re sp o n se  to 
th e rap y  w ith EACA, Plow ever, on day 7, the fib rinogen  lev e l w as 
again  le s s  than  100 m g, /  100 m l , , so  th a t i ts  lev e l on day 4 could 
not be co n s id e red  to  have o c c u rre d  as a re sp o n se  to  therapy* On 
day 7, i t  w as noted th a t the  p la te le t count had  fa llen  and the p o ss ib ility
of in tra v a s c u la r  c lo tting  w as co n s id e red .
In  view  of fa ilu re  of th e ra p y  w ith a fib rino ly tic ' in h ib ito r, 
i t  wa©' fe lt th a t a t r i a l  of h ep a rin  a d m in is te red  by continuous in t r a -  
venous infusion  was .ju stifiab le ' - and th a t i f  i t  should  c o r re c t  the defec t, 
th is  in fo rm atio n  would be h e lp fu ld n  handling any subsequent h a e m o rrh ag ic  
episode» H ep arin  (1 ,500 u n its /h o u r)  w as ad m in is te red * fo r 'IE  h o u rs . 
Subsequent a s sa y  of the p re -in fu s io n  fib rinogen  lev e l w as .ISO mg* / 100 m l . , 
and though, -after the in fu sion , th e  lev e l w as E40 m g ./  100 m l . ,  th is  r is e  
could no t, w ith certainty ,- be. a ttr ib u te d  to heparin*- T h e re a f te r , the 
policy  adopted w as to follow  the  fib rinogen  lev e l w ithout th e rap y  and 
to  'reco n sid er the use  of h ep arin -sh o u ld  the lev e l again  fa ll below 
100 m g ,./'100 m l. D uring th is  p e rio d  of o b se rv a tio n , the patien t 
developed sm a ll sk in  modules' su rro u n d ed  by subcutaneous h ae m o rrh ag e .
At this time,'- f ib r in  deg%*adation -products w ere  d e m o n s tra ted  in  the  
'patient*© .serum  (figure 66). B©.cause of th is  finding , it  w as decided  
to  o b se rv e  the re sp o n se  to fu r th e r  th erap y  w ith fib rin o ly tic  in h ib ito rs  
(days 30 to  59, f ig u re s  E3 and 65). D uring th is  th e ra p y , tran sfu sio n  
(whole blood, 3 l i t r e s ;  packed  ce lls  fro m  whole blood, 1 l i tr e )  was 
required to m ain ta in  the p a tie n t 's  haem oglobin . Death>"occurred on 
day 60 and post*^m ortem  findings w ere  of m ark ed  w id esp read  b ru is in g
of skin; numerous sm all m etastatic tumours in lungs, m ediastinal 
lymph nodes, r ib s, sp ine, skull and long bones; tumour infiltration  
of the left pectoralis m ajor m u scle  and extensive tumour replacem ent 
of both adrenal glands. There was no evidence of intravascular  
occlusion  or fibrin form ation and no fibrin thrombi w ere present in  
the kidneys#
Case 4 , This fem ale patient, who was SB years old, had a five  
months h istory of a continuous blood#*stained vaginal d ischarge.
Biopsy of the cerv ix  u teri confirm ed the c lin ica l diagnosis of carcinom a  
of the cerv ix  u teri. There was evidence of loca l m étastasas# Shortly  
after the diagnosis was confirm ed, there was a sudden in crease  in  
vaginal bleeding and it was noted that the blood did not c lo t. Whole 
blood (2 ,5  litres) was transfused and radiotherapy to the pelv is including 
radium im plants com m enced. Half of the radiation dose had been  
adm inistered with no d ecrease in blood lo ss  when the patient developed  
a m assive  haem atom a in the left thigh at the s ite  of an intram uscular  
injection, with gross purpuric haem orrhage into the skin distal to the 
s ite . At the sam e tim e, large  haem atom ata with d istal purpura w ere  
noted in association  with venepuncture s ite s . Investigations carried  
out at this tim e are shown in table 49# There w as hypofibrinogenaem ia
— *
in association with plasm inogen depletion and a relatively  low 
platelet count* In the light o£ these findings, th is patient was 
thought to have In travascular clotting with secondary fibrinolysis# 
Accordingly, a heparin infusion was adm inistered continuously 
for 54 hours* Results of assays ca rrie d  out during therapy are  
graphically displayed in figure 46# Rises occurred  in the levels 
of fibrinogen# factor V# antihaemophilic globulin (A*H.G.) and 
plasminogen and the platelet count was steady. A fter withdrawal 
of therapy for IB hours, these assays had retu rned  to pre#infusion 
levels. As discussed in chapter 5, X rasylol (100,000 K ,I ,E , units/ 
hour) was then infused for 7 hours. At this tim e, although the 
levels of factor V and antihaemophilic globulin (A ,H ,G .) had risen , 
the fibrinogen level was unchanged and the platelet count had fallen#
In view of this la s t featu re , d iscussed  in chapter S, T rasy lo l was 
withdrawn and heparin infusion (1 ,500 units/hour) recom menced.
A fter a further l6 hours# fibrinogen concentration had increased  
though the jp la te le t count rem ained low. Towards the end of the f ir s t  
heparin infusion, although vaginal bleeding did not dim inish, the blood 
clotted and oozing of blood from  venepuncture sites had ceased.
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Case 5, This m ale patient, who was 71 years old, had a three 
months history  of cough and haem optysis. He sought m edical 
attention because of bleeding from  gums and bruising of the skin 
overlying thq jaw# Examination revealed a number of subcutaneous 
nodules with surrounding haem orrhage; cervical lymphadenopathy; 
throm bosis of the left external jugular vein; hepatoniegaly and congestive 
cardiac fa ilu re . Haem ostatic investigations a re  shown in table 50, 
Hypofibrinogenaemia, plasminogen depletion, thrombocytopenia and 
depletion of factor V and antihaemophilic globulin (A .H .G ,) were 
found, A clinical diagnosis of bronchogenic carcinom a with 
m étastasés was made and defibrination was considéred to be due to 
in travascu lar jçlotting with secondary fibrinolysis, T rasylol 
(100,000 units/hour) was adm inistered for 9 hours and the effect is 
illu stra ted  in figure 47 where it will be seen that at the conclusion of 
this therapy, there  had been r ise s  in fibrinogen, plasminogen, factor V, 
antihaemophilic globulin (A .H .G .) and in the p latelet count. Before 
the T rasylo l infusion was commenced, the left external jugular vein 
throm bosis had disappeared clinically. The patient did not survive 
and post-m ortem  findings w ere of a bronchogenic carcinom a with 
m étastasés in liv e r, spleen, h ea rt, duodenum, kidney and skin.
m  107*"
There were many a reas where In travascular fib rin  form ation was 
found in close association with tumour# particu larly  in lungs# 
heart and duodenum* A m ajor portal venous radical was throm bosed 
and there  was centrilobular necrosis of the liv e r, Homogenates of 
some of these tissu es w ere tested  on fibrin  plates and m arked 
fibrinolytic activity was found in assocaition with kidney; m oderate 
activity with heart; m inim al activity with lung and none with liver 
or. tum our.
Case 6 , This m ale patient# who was 35 years old# had m itra l 
stenosis with a tria l fib rillation . He had required  surgical rem oval 
of an embolus lodged in the left popliteal artery# Twenty*^four hours 
following the embolectomy# throm bosis was dem onstrable radiologically 
at tlie site of the e a r lie r  occlusion# The fresh  throm bosis was 
trea ted  by adm inistration of the plasminogen activator# urokinase.
The infusion was given via an a r te r ia l cannula the tip of which was 
lodged im mediately proxim al to the occlusion# Urokinase was 
adm inistered using a constant infusion pump (B# Braun# Melsungen# 
West Germany), The in itial infusion dose of urokinase was calculated 
from  the patient's urokinase sensitivity  te s t modified to use 160 p lltre s  
of urokinase (500 Ploug u n its /m l,) . This concentration of urokinase
(400 Ploug u u its /m l, o£ the patien t's  plasma) gave a lysis tim e ol 
30 minutes and therefo re  would be a sufficient concentration to 
neutralize any antiurokinase effect of the plasm a leaving enough 
free  urokinase to produce b risk  fibrinolytic activator activity in the 
plasm a (McNicol et a l, # 1963 a). The total 'priming* dose of 
urokinase (approximately 850*000 units) was calculated from  the 
patien t's  weight (54 kg#) mnütiplied by his plasm a volume 
(approxim ately 40 m l,/kg#) and the previously estim ated concentration 
of urokinase (400 Ploug u n its /m l, plasm a). The 'priming* dose was 
adm inistered over 2 |  hours* followed by 20*000 Ploug units/hour for 
Z hours and 40,00 Ploug un its/hour for 17% hours. Due to mechanical 
failure of the pump* there  was a break in the infusion at 22 hours for 
hours. At 24% hours* the infusion was re s ta rte d  at a rate of
80,000 Ploug un its/hour for a fu rther 23-% hours at which time there 
was radiological evidence of patency of the a rte ry , H eparin (10,000 
units) was given th e reafte r every 6 hours for 36 hours and at the 
sam e tim e an o ral anticoagulant was started . Those m easures 
w ere instituted to prevent reth rom bosis.
The resu lts  of fibrinolytic assays are  shown in table 89 and 
displayed in part in figure 67, It will be seen that the 'p rim ing ' dose
of urokinase produced b risk  fibrinolytic activator activity in the 
radioactive clot assay and euglobulin lysis test# During the 
adm inistration of 20,000 Ploug un its/hour, activity fell to zero 
but increased  with 40,000 units# It had again fallen to zero one 
half-hour after the break in the infusion# After resta rtin g  with
80,000 Ploug un its/hour activity was again b risk . During the 
infusion, there  was considerable plasminogen depletion and 
progressive defibrination, the fibrinogen falling to 100 mg* / 100 m l. 
at 41% hours#
Shown also in table 89 are the resu lts of antihaemophilic 
globulin (A.H.G#) assay . It can be seen  that there was a p rogressive  
fa ll in the lev e l of antihaem ophilic globulin (A .H .G . )  during the infusion#
In V itro Experim ents
Relationship between Fibrinogen Concentration and Thrombin Clotting 
Tim e In this experim ent, varying concentrations of human fibrinogen 
dissolved in 0# 9 per cent KaCl w ere substituted for p lasm a in the 
throm bin clotting tim e. The resu lts  a re  shown in table 90* It can be 
seen that the throm bin clotting tim e was prolonged by reduced 
fibrinogen concentrations.
Relationship between Fibrinogen Concentration and Lysis Time In this 
experim ent, 0*4 m l. of varying concentrations of plasm inogen-poor 
human fibrinogen was added to 0 . 1 ml* human plasminogen (2*3 casein
u n ite /m l.) and 0*05 ml* urokinase (20 Bloug units/m l*) and the 
m ixture clotted with 0 * I m l * throm bin (20 N * I * H * units / ml*)* The
. . . r  ^ '  *
olysis  tim es of these m ixtures w ere observed at 37 G* The resu lts  
a re  shown in table 91* It can be seen that clot lysis was accelerated  
by reduced fibrinogen concentrations *
Plasm inogen Levels in P lasm a and Serum  Shown in table 92 are  the 
resu lts  of assays of plasm inogen levels in II  norm al plasm as and 
the ir corresponding ^qra* The s e ra  w ere allowed to incubate cat 37 G
1 ' ‘.V* V
for 24 hours to ensure adequate clotting before separating the s e ra  by 
centrifugation (1,000 g* fo r 10 minutes at 4^0) and assay of plasminogen* 
The mean plasminogen level in plasm a was 3*7 • 0*7 casein units/m l* 
and in serum  was 3*8 * 0*7 casein  units/m l* This difference is not 
significant (t -  1*862, 0*05<p<0. Id)*
D iscussion
Numerous laboratory  te s ts  of the coagulation and fibrinolytic 
enzyme system s are  available which might be c a rrie d  out in patients 
with defibrination syndrom es in o rder to try  to determ ine the cause 
and type of th e ir haem ostatic defect* However, as will be discussed, 
no c lear pattern  of laboratory  resu lts  em erges to differentiate from  
one another in travascu lar clotting, pathological fibrinolysis o r both
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©tatea occurring together* F ibrinogen depletion ia , of coui’se , 
common to all th ree  causes of the defibrination syndrome. When 
fibrin  and/ o r fibrinogen are  degraded by the proteolytic activity of 
plasm in, the degradation products in te rfe re  with fibrin  polym erisation 
and prolongation of the throm bin clotting tim e is  usually considered 
to be an index of the severity  of defective fibrin  polym erisation 
during hyperplasm inaem ia, (A lkjaersig et al* # 19621 F le tcher et al* #
1962 b). However, low levels of fibrinogen per se may prolong the 
throm bin clotting tim e as shown in table 90# Accordingly, 
lengthening of the throm bin clotting tim e may occur in hypofibrinogenaemia 
due to pure in travascu lar clotting* A ccelerated lysis of whole blood 
and euglobulin clots is  norm ally accepted as evidence of increased  
fibrinolytic activator activity in the blood from  which they w ere 
form ed. There a re , howevqr, two situations in which lysis tim es of 
such clots might be in te rp re ted  erroneously* F irs tly , low fibrinogen 
concentration in the clots may resu lt in accelerated  lyeis tim es in the 
absence of increased  activator activity as shown in table 91* Secondly, 
in pathological fibrinolytic s ta tes , it would appear likely that activator 
re lease  into the circulation may be a transien t phenomenon bringing 
about rapid hyperplasminaemia* Since activator has a halfUife in the
ciixulation of about 15 raiuutea (F letcher et al# # 1964)» In le a a than 
30 minutes after the re lease , there  may be plasminogen depletion 
and a fall in fibrinogen without evidence of increased  activator 
activity. In these c ircum stances, whole blood and euglobuUn clot 
lysis  tim es may be abnorm ally prolonged due to a combination of 
plasminogen depletion and absence of increased  activator activity 
and the only finding diagnostic of a recent hyparplasm inaem ic state 
would be a low plasminogen level since plasminogen levels are  
probably unaltered o r only m inim ally reduced in uncomplicated fibrin  
form ation (table 92)* Estim ation of the plasminogen level would, 
therefo re , appear to be the m ost useful diagnostic fibrinolytic te s t 
in the investigation of defibrination syndrom es, Unfortunately, 
assay of plasminogen is  a  tim e consuming procedure and the inform ation 
which it  may provide ia not im m ediately available in an emergency 
situation#
As was mentioned previously, prothrom bin, facto r V and anti-* 
haemophilic globulin (A .H .G .) a re  consumed during clotting and there  
is  evidence that these clotting factors a re  susceptible to digestion by 
plastnin though it m ust be rem em bered that assay system s for these 
coagulation components depend on fibrin  clot form ation as thdr endpoint
ând this may be d istorted  by defective fibrin  polymerisation# F o r 
this reason# the one**stage prothrom bin time may also be invalidated* 
Bougie at al* (1957) have reported  the presence of factor X in the same 
concentration in both plasm a and serum  while Biggs and M acfarlane 
( 1963 § have found it to be consumed in vitro  when plasm a is  clotted in 
the presence of tissue  extract* It is  conceivable# therefore# that 
where there  is re lease  of tissu e  throm boplastin into the circulation# 
bringing about in travascu lar fibrin  formation# the level of factor X 
may fall* I t  is  generally accepted that p latelets a re  unaffected during 
hyperplasm inaemia* Possib ly  they are  protected by th e ir antiplasm in 
activity* On the other hand# a fall in the p latelet count invariably 
accoîxrpanieè In travascu lar fibrin  form ation (Sharp et al* # 1958)* The 
platelet count# therefore# em erges as the moat useful of the 
coagulation tea ts  in the investigation of defibrination syndrom es.
Case I , This patientas defibrination syndrome was considered to be 
due to pathological fibrinolytic activity because of plasminogen 
depletion and the norm al platelet count. It was thought that absence 
of increased  activator activity could be explained by transient# 
in term itten t re lease  of tissue  activator into the circulation as d iscussed 
earlier*
. Although piasmindgan depletion was co rrec ted  during 
adm inistration of the fibrinolytic inhibitor# EA€A# levels of the 
depleted coagulation components rem ained unchanged and the ir 
raetoration; to norm al -or near- norm al levels appeared to be -a 
consequence of delivery.
■ - Following failure- of response to the fibrinolytic inhibitor 
it-was necessary  to re a sse ss  the diagnqsis* A retrospective 
diagnosis v/as made in th is patient of in travascu lar clotting and 
plasminogen- depletion was the evidence of secondary fibrinolysis. 
One explanation for the norm al platelet count might be that intra-* 
vascu lar coagulation had ceased  some tim e before investigation and 
rapid regeneration of p la tele ts in the m arrow  had res to red  the ir 
circulating num bers to norm al. The low level of factor X might
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best be explained by  its  consumption during clotting in the presence 
of tissue  thromboplastin*
Case E, In th is patient# a  diagnosis of pathological fibrinolysis 
was considered because of the striking abnorm ality of the throm bin 
clotting tim e. This abnorm ality was accepted as evidence of 
defective fibrin  polym erisation due to the presence of fibrinogen 
degradation products in the circulation . The m ain degradation
;  I
fragm ent has a hali^-life in the circulation of 9* 5 hours (F letcher 
et al, I ,l962i^ b; jMcj:aergag’ et al* # 1962) • The fibrinogen level within 
the norm al range would not exclude a degree of fibrinogenolysis 
and because of the relatively  long 50 per cent p lasm a clearance 
tim e of the m ain degradation fragm ent, it  was considered that hyper^ 
plasm inaem ia and fibrinogenolysis might have occurred  some hours 
previously so that a degree of plasminogen regeneration  could have 
occurred , sufficient to re s to re  the plasminogen level to within the 
range. of norm al *
As in case 1, therapy with EACA failed to co rrec t or prevent 
deterioration  of the patient*s haem ostatic defect# Indeed, it may 
have *unmasked* intravascular clotting since the fibrinogen level fell 
to le ss  than 100 m g ,/ 100 mj,> and throm bocytopenia developed during 
therapy# These subsequent findings and the fa ilu re  of response to the 
fibrinolytic inltibitor supported a retrospective diagnosis of in tra -  
vascu lar clotting# The abnorm al throm bin clotting tim e was 
probably due to a degree of secondary fibrinolysis since the in itia l 
level of fibrinogen per se was unlikely to be responsible for such a 
striking prolongation of the clotting time# The low level of factor X 
might be explained as in case I; it  may have been consumed during
clotting in the presence of tissue  thromboplastin#
Caee 3 * - Pathological fibrinolysis - was diagnosed-initially in
this patient'because of aceelerated■eiiglobuUn clot lysis# prolongation 
of the thrombin clotting-time.# plasminogen' depletion and the norm al 
p latelet count#- Howcyo.?, as can be seen in figure 65, fluctuations 
in the levels 'of - plasminogen# fibrinogen# throm bin clotting, tim e and 
platelet count appear tO-have occurred  as a consequence of-the natural 
history-of the p a t ie n td ia e .a s e  and not 4o m edication with fibrinolytic 
inhibitors* A ccelerated clot lysis and prolongation of the throm bin 
clotting tim e may have been due to reduced fibrinogen concentration 
(tables 90 and 9-1)* The finding of fibrin  breakdown products in this 
patientas serum  was accepted  àt .-that tim e as strong presum ptive 
evidence of pathological fibrinolysis as the p rim ary  cause of this 
patient*a defibrination. However# M erskey et al* (1966) have 
dem onstrated the presence of considerable concentrations of de* 
gradation products in defibrination states due to in travascu lar 
clotting associated with a varie ty  of d iseases.
Although heparin  was adm inistered to this patient# its  tr ia l  
cannot be considered sufficiently adequate to provide comment on its  
therapeutic or  diagnostic value in th is case.
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ïn  retrospect# in  spite of absence of evidence at post*m artem  
and. because of the lack  of response to therapy with fibrinolytic 
W iibitors#' defibrination in this patient would appear to have been 
duO’to ■intravascular clotting with secondary fibrinolysis-. F ailu re  
to' find any evidence- of clotting at post^^mortem could be-explained by 
the occurrence-of lysie  either-ante*m ortem -or x^ost^-mortem,
Qas'e' 4 , ' ' -In-this-patient# therapy-with-heparin on-two-occasions 
l>roduçed' Significant r is e s  in fibrinogen# the depleted clotting factors 
and in plasminogen* The reasons for-adm inistration of a T rasy lo i 
infusion 'air,\d th e  response to this have been d iscussed in -chapter S*
The positive response to bo& heparin infusions confirm edbhe vabie 
of the trea tm en t and supported the diagnosis of in travascu lar clotting 
as the p rim ary  cause of the patientas defibrination* The initial low 
plasminogen level was evidence of secondary fibrinolysis*
Case S, In this patient# the diagnosis of In travascular do tting  was 
confirmed at post*m.ortem, Evidence for associated fibrinolysis was 
the low plasminogen level and the clinical disappearance of external 
jugular vein thrombosis* It is  of in te res t that- tum our homogenate 
from  this kpatient showed no -activator activity on a fib rin  plate* This 
*®nggeets that pathological fibrinolysis in this patient secondary to
-1 7 8 -
in travascu lar clotting was due to a 'homeostatic* protective response 
of the fibrinolytic enzyme system  and not to coincidental re lease  
of activator from  the d iseased tis su e .
Case, 6 * This case has been included as aix example of a 
defibrination syndrome due to a 'fibrinolytic state* The case 
illu s tra te s  the difficulty which may a rise  in situations in which 
activator' re lease  and hyperplasm inaem ia have occurred  some tim e 
before biochemical investigation* In figure 67, it will be seen that 
17 hours after the end of the infusion# there  was no activator activity 
detectable in the radioactive clot assay o r in the euglobuUn lysis te s t
' ' ■ ■ ■ ■ ■ I ' ■ , , '
and at that tim e the low level of plasminogen was the only feature to 
suggest a recent b risk  fibrinolytic state* In the assay system  for 
antihaemophilic globulin (A .H.O .)# consumption of this clotting
factor was dem onstrated, EACA was added in the assay system  in a
' ' '' ' - 2 ' concentration of 10  ^ M olar to inhibit lysis *
Conclusions
It can be seen that considerable difficulty may a rise  in 
in terpreta tion  of resu lts  of coagulation and fibrinolytic tests# and 
hence in establishing the aetiology, in travascu lar clotting o r pathological 
fibrinolysis o r a combination of these two# in patients in whom the
d efib rin a tio n  syndrom© is  d iagnosed , .
Of the mimerons laboratory  te s ts  of coagulation and 
fibrlnolyols which may be ]5orlormecl# a |>Xatelct count and assay of 
Tdasminogen appear to be the m ost useful in investigation of defibrination 
syndromes  ^ f  hrombocytopenia occurring in defibrination statee due to 
in travascu lar clotting and. plasm inogen depletion where there  is 
pathological :fibrinolysis, F ro m  the evidence presented  in this chapter, 
it can be seen that thromAbocytopehia may not be consistently found in 
individual patients with the defibrination syndrome due to ,prim.ary 
in travascu lar c lo tting ,’ . Possibly  because re lease  of tissue  throm bo- 
X>lastin may occur in term ittently ,, in travascu lar coagulation may have 
ceased by the tim e investigation is  undertaken and raxrid î.'eg one ration 
of p latelets in the m arrow  may have resto red  circulating platelets to 
norm al. F ttrth er, because assay  of xdaaminogen is  a lengthy procedure, 
its  level is not im m ediately available in an em ergency situation.
Sharp (1964) has suggested that apà^^t from  iatrogenic 
defibrination arising  in the course of throm bolytic therapy, defibrination 
is  probably always due to a combination of both in travascu lar clotting 
and fibrinolysis. In the six cases described in this chaptei", apart from  
the defibrination syndrome which occurred  during throm bolytic therapy
— i  *
with uroidiiaBe# there  was evidence in the other five of both clotting 
and ly s is .
Where the defibrination .syndrome a rise s  and it is  im%jOSsible 
to establish  eithex* intravascular* clotting or pathological fibrinolysis 
ae the aetiology# it would seem  wise to tre a t such cases expectantly 
with transfusion of whole blood and if nocessary  fibrinogen and by 
adm inistration of stero ids as suggested by F letcher et al. (1962 b). 
A dm inistration of specific therapy# heparin or a fibrinolytic 
inhibitor, should be re s tr ic te d  to situations which are  of such 
seriousness as to justify the r isk  of a thex*ax>eutic tr ia l.
CHAPTER 9
SUMMARY AND CONCLUSIONS 
The availability of fibrinolytic activators and inhibitors as 
preparations suitable for u se in man has stim ulated in tensive study 
of the components and functions of the fibrinolytic enayme sy stem .
The work for this th esis  was concerned with the investigation  of 
certain  aspects of plasm inogen activation and its  inhibition.
The F ibrinolytic Engyme System
The principal components of this complex system  are  
plasminogen, plasm in, activato rs and inhibitors* Plasm inogen is a 
circulating plasm a globulin which is the inactive p recu rso r of the 
proteolytic enzyme plasmin* Conversion of plasminogen to plasm in 
may be brought about by a varie ty  of activato rs, among them  blood 
and tissue  activators; urokinase, the activator p resen t in human urine 
and streptokinase, the activator produced by certa in  s tra in s  of 
haem olytic streptococci. P lasm in  is capable of digesting a number 
of plasm a proteins including fibrinogen, fibrin , prothrom bin, facto r V 
and antihaemophilic globulin (A .H.G.)* In vivo, the proteolytic activity 
of plasm in is norm ally re s tr ic te d  to fibrin* Sherry  et a l. (1959 a) 
have proposed an hypothesis to account for the in vivo specificity of 
plasm in for fibrin . According to the concept, the level of antiplasm in
in plaoma greatly  exceeds the level of plasminogen, i .e ,  potential 
plasm in. Thus, when plasm a plasminogen is slowly converted to 
plasm in, it is  rapidly neutra lized  by plasm a antiplasm in so that 
circulating plasm a proteins susceptible to digestion by plasm in are  
protected. Conversely in throm bi, levels of plasm inogen are  said  to 
be high relative to the effective concentration of antiplasm in which is  
considered to be low* in  th is situation therefo re , free  plasm in may 
be form ed in close proxim ity to its  substra te , fib rin , which is  lyoed. 
Sherry  and his associates have suggested that one function of the 
fibrinolytic enzyme system  is  to provide any throm bi which may form  
with a m echanism  which can prom ote the ir subsequent ly s is ,
Astrup (1956) has suggested  that, under physiological 
circu m stan ces, a dynamic equilibrium  may ex ist between the 
coagulation and fibrinolytic enzym e sy stem s, the form er depositing  
fibrin  to sea l any d efic ien cies which may appear in the vascular  
endothelium and the la tter  rem oving such fibrin once it has served  its  
haem ostatic function and in tegrity  of the endothelium has been  
restored* In this way, patency of the vasculature may be m aintained. 
It is  considered  that d isordered  fibrinolytic activity may 
contribute in part at lea st to a proportion of coagulation defects which
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may com plicate m ajor surgery ; certa in  obstetric  accidents; 
hepatic c irrh o s is  and m etastatic  carcinoma# Pathological fibrinolytic 
activity may occur in such situations if la rge  quantities of plasminogen 
activator a re  re leased  into the circulation  so that conversion of 
plasminogen to plasm in is rapid# The production of la rge  amounts 
of plasm in tem porarily  overwhelms the antiplasm in 'buffering* m echanism  
and free  plasm in circu lates - hyperplasm inaem ia# A coagulation 
defect ensues which is  due in p art to digestion of prothrom bin, facto r V 
and antihaemophilic globulin (A .H .G .)i in p art to digestion of fibrinogen 
and fibrin , the degradation products of which inhibit fibrin  polym erisation 
and in part to accelerated  ly sis  of such fibrin  throm bi as do form .
T here is  evidence to suggest that adm inistration of fibrinolytic 
inlxibitors may have value in the management of coagulation defects 
arising  as a consequence of d isordered  fibrinolytic activity.
Plasm inogen Activation and its  Inhibition
The studies made for this thesis included assessm en t of 
two compounds, aminomethyl cyclohexane carboxylic acid and T rasy lo i, 
known to possess inhibitory activity against the fibrinolytic enzyme 
system . T rasy lo i was also known to possess anticoagulant and anti*** 
tryptic  activities and these p roperties  w ere fu rther investigated# A
preparation  of the plasm inogen activator, urokinase, was 
investigated in o rd er to define miy coagulant activity it  might possess 
and the im portance of such activity during intravenous infusion of the 
preparation  for the purpose of increasing  plasm a activator activity*
A study of the possible inhibitory effect on fibrinolysis and coagulation 
occurring during alim entary lipaem ia was undertaken and finally 
detailed investigation was c a rr ie d  out of a number of defibrination 
syndrom es since it  is  considered  that pathological activity of the 
fibrinolytic enzyme system  may contribute in p a rt at le ast to the 
coagulation defect of some of these syndrom es.
M aterials and Methods The account given in chapter 3 contains a 
description of the m ate ria ls  and standard fibrinolytic and coagulation 
methods used in the work for th is th e s is . Many of the methods wore 
adapted for p articu lar aspects of the work and these modifications 
have been described in the relevant chap ters. The standard methods 
fo r which details a re  provided include assays for plasminogen, 
plasminogen activator activity and fibrinogen. F ibrinolytic inhibitor 
activity was m easured  in the urokinase sensitivity te s t which is a 
p lasm a clot ly sis  system  activated by a standard  amount of urokinase. 
Also described is the throm bin clotting tim e which may be an index
o£ defective fibrin  polym erisation or of fibrinogen de%)letion. Among 
the standard coagulation te s ts  used w ere the one-stage prothrom bin 
tim e, the plasm a recalcification  tim e, the throm boplastin generation 
te s t and assays for facto r V, antihaemophilic globulin (A .H .G ,), 
C hristm as factor and Hageman fac to r, F inally a method for m easuring 
platelet aggx’egation ia given* '
Aminomethyl Cyclohexane Carboxylic Acid In chapter 4, an account 
is  given of the in v itro  and in vivo investigation of a synthetic amino 
compound with a cyclic s tru c tu re , aminomethyl cyclohexane 
carboxylic acid. This compound has been reported  to possess anti­
fibrinolytic activity and to be m ore potent than EACAi the aliphatic 
amino acid the use of which as fibrinolytic inhibitor has been m ost 
fully documented up to the p resen t tim e. The resu lts  of animal 
toxicity studies had also indicated that the compound was le ss  toxic to 
adm inister than EACA, Because of the reports  of increased  potency 
and decreased  toxicity com pared with EACA, investigation of the 
compound was undertaken. Two preparations of the compound w ere 
studied. One was a m ixture of the tran s  and cis isom ers (AMCHA) 
and the other a solution of the tran s  isom er (AMCA) which had been 
shown to possess all of the antifibrinolytic activity of the m ix tu re ,
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In v itro , in strep tok inase-activated  plasm a, AMGHA was
found to inhibit plasm inogen activation at concentrations above 
-410 M olar and the proteolytic activity of plasm in at concentrations 
above 2.0 x 10 M olar. Jn the sam e system , EACA had one-half 
the potency of AMGHA. The inhibition by both AMGHA and AMCA 
of plasminogen activation was shown to be competitive in type while 
AMCHA inhibited the proteolytic activity of plasm in non-^competitively.
The effects of AMCHA on the trypsinogen-trypsin  system  w ere 
competitive inhibition of trypsinogen activation by cnterokinase and 
non-com petitive inhibition of trypsin  activity. It was also found that, 
at very high concentrations, AMCHA inhibited pepsin activity.
Added in v itro  in the urokinase sensitivity te s t, it was 
dem onstrated that AMCA and AMCHA had antifibrinolytic effects, 
AMCA being 10 tim es m ore potent than AMGHA and 100 tim es m ore 
potent than EACA. Another cyclic compound, p-aminom ethyl benzoic 
acid (PAMBA) was com pared with AMCA in this in v itro  system  and it 
was found that AMCA had an eighteenfold increase  in  antifibrinolytic 
potency com pared with PAMBA.
- 2In v itro , at a concentration of 2*5 k 10 M olar, AMCHA 
produced slight im pairm ent of throm boplastin generation and at higher
jç. O , *•
coneentrâtipns the compound prolonged the one-^stage prothrom bin 
tim e and the throm bin clotting tim e.
In the in vivo experiments# it was found that o ra l adm inistration 
of AMCA or AMCHA produced an increase  in antifibrinolytic activity 
dem onstrable in the uroldnaso-sensitivity  teat* In y iyo , AMCA had a 
fivefold increase  in  potency com pared with AMCHA and a tenfold 
in c rease  in potency com pared w ith  EAG A » The antifibrinolytic effects 
of AMCA and AMCHA w ere slightly prolonged in vivo com pared with 
EACA,
AMCA in a dose of 200 mg. was found to inhibit pathological 
fibrinolytic activity in a patient with hypofibrinogonaemia associated  
with acce lerated  lysis of Fearnley-typo dilute plasm a clots.
An indirect m easure of levels of AMCA in  plasm a was made 
in one subject who ingested 200 mg* The highest concentration of 
AMCA found in plasm a was estim ated  to be 2 x 10 M olar, This 
level was found in plasm a withdrawn 2 hours after ingestion of AMCA,
It was concludddtthht: AMCHA and AMCA w ere m ore potent
.fi '
fibrinolytic inîübitors than EACA, The in vivo antifibrinolytic effect 
dem onstrated in  the urokinase sensitivity  te s t was considered to be due 
to competitive inhibition by AMCA or AMCHA of plasminogen activation
since no attem pt v/as made to achieve the higher concentrations 
requ ired  to inhibit p lasm in. The observed antifibrinolytic effects 
w ere not due to the influence of AMCA or AMCHA on Mood clotting 
since the higher concentrations which im paired  clotting were not 
achieved in vivo.
A suggested dosage schedule fdr AMCA, based on the 
inveBtigative. work described in chapter 4, is a loading dose of 400 
to 600 mg* followed by 100 to 200 mg, every 5 hours. Such doses 
should be adequate to inhibit pathological fibrinolytic activity by 
preventing plasminogen activation and thus the form ation of plasmin*
Because of the inhibitory effect on the trypsinogem -trypsin 
system , AMCA may have value in the trea tm en t ox the system ic 
x:>roteolysi8 due to trypsin  which is believed to accompany acute 
pancreatitis*
The effect of AMCHA on pepsin is probably without therapeutic 
relevance in view of the high concentration of the inhibitor which 
would be requ ired  in vivo to produce an effective inhibition of pepsin 
activity.
The increased  potency and decreased  toxicity of AMCA com pared 
with BACA render AMCA the m ore attractive fibrinolytic inhibitor and it
may, in thé future, come to replace BACA in the trea tm en t of 
pathological fibrinolytic state a,
T rasy lo i In chapter 5 ia described  the in v itro  and in vivo 
investigation of the polypeptide T rasy lo i, which is known to possess 
antifibrinolytic activity# Recently, it has been shown to have anti­
coagulant activity in addition to its  antifibrinolytic properties# It 
was thought that, on theo re tica l grounds, a drug possessing both anti­
coagulant and antifibrinolytic activity might have vzdue in the therapy 
of spontaneous bleeding sta tes  associated  with hypofibrinogenaemia 
since possible explanations of the aetiology of such states a re  that they 
are  due to w idespread in travascu lar clotting or to hyperplasm inaem ia 
o r to a combination of these two. The further investigation of T rasy lo i 
was undertaken with a view to assessing  its  place in the treatm ent 
of such states#
The ^preparation of T rasy lo i used in the investigative work for 
this thesis  was the form , made available for in travascu lar 
adm inistration, which is  com m ercially  p repared  from  bovine lung*
T rasy lo i was found to be an effective inliibitor of plasminogen 
activation and of the proteolytic activity of form ed plasmin# In con trast 
to the amino acid inhibitors AMCA and EACA, it was a m ore effective
iîîlrdbitor of the proteolytic activity of plasm in than of plasminogen 
activation* In purified system s, using a lim ited variation  in 
substrate  concentration i*e* low substrate  coneenti%atione were 
not employed, it was seen that Tra,sylol was a competitive inhibitor 
of plasminogen activation by e ither streptokinase o r urokinase; a 
non-com petitive Inhibitor of the proteolytic activity of jdasm in and 
a mixed com petitive and non-com petitive inhibitor of the action of 
urokinase on AcLMe* In the sam e purified sy stem s, employing a 
wide range of substrate  concentration, the inliibitory effects of 
T rasy lo i w ere found to be relatively  increased  at low concentrations 
of the substra te . In v itro , in the urokina.%'^ sensitivity  te s t, T rasy lo i 
was considerably m ore potent as an inhibitor of fibrinolytic activity 
than AMCA and EACA.
The anticoagulant props r ite s  of T rasy lo i w ere found to be due 
e ither to an inhibitory effect on the conversion of prothrom bin to 
throm bin o r to inhibition of blood throm boplastin generation or to a 
combination of these two effects.
In the in vivo experiments# it  was seen that in high dosage, 
at least 50,000 un its/hou r, T rasÿ lo l im parted antifibrinolytic and 
anticoagulant effects to p lasm a. Evidence was also presented  that
■- s. /  J.
the drtig migh enhance p latelet aggregation In vivo. This effect 
was observed 30 mimites afte r a single intravenous injection of
100.000 units#
T rasy lo i was adm inistered  as a  coiitinuous intravenous 
infusion at the ra te  of 100,000 un its/hour to two x^atients with hypo- 
fibrinogenaem ia due to in trav ascu la r clotting. In one of these 
^patients, after an infusion of 9 hours, the levels of fibrinogen, 
factor V and antihaemophilic globulin (A .H .G .) and the platelet 
count had risen . In the other patient at the end of 7 hours, there  
had been no change in the level of fibrinogen though the levels of 
factor V and antihaemophilic globulin (A.H.G*) had risen* The 
p latelet comit had fallen - an effect which might have been predicted 
from  the e a rlie r  observations of enhanced platelet aggregation after 
T rasylo i injection.
Its  effect on trypsin  activity was studied in v itro , T rasylo i 
was found to be a non-com petitive inhibitor of tryj>sin and to im part 
antitryptic activity to plasm a when added in v itro .
In vivo, 30 m inutes afte r a single intravenous injection of
100.000 units of T rasy lo i, increased  antitryi>tic activity was detectable 
in plasm a.
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F ro m  the in v itro  and in yjvo studies of T rasy lo i described 
in this thesis , a dosage X’at© of 100,000 units e ither as à single 
intravenous injection o r adm inistered  as an infusion over one hour 
followed by an infusion of 50/000 un its/hour as m aintenance therapy 
seems, appropriate in the trea tm en t of system ic proteolysis due to plasm in, 
Higher dosage, 100,000 un its/hour may be requ ired  for the trea tm en t 
of intrcivascular clotting o r system ic proteolysis due to trypsin . The 
evidence presented  was considered  sufficiently encouraging to w arran t 
fu rther investigation of the effect of T rasy lo i in defibrination states* 
Urokinase The thesis continues with an account (chapter 6) of in vitro  
and in vivo studies with a com m ercial p%'eparation of urokinase, 
the physiological plasm inogen activator p resen t in human urine. Since 
human urine is known to contain throm boplastic m a te ria l, studies 
with the p reparation  w ere made with a view to defining any coagulative 
properties it might possess and the effect of such properties during 
its  intravenous admini s t r  at ion in man with the aim of increasing 
plasm a fibrinolytic activator activity*
The preparation  was made available in two fo rm s. One was 
the form  provided for intz; avascular adm ini s t r  at ion and contained 
human serum  albumin and disodium v er senate* Die odium versenate
w as fix’s t rem oved  by d ia ly s is  befoi'o th is  form, w as exam ined  fo r 
coagulative p ro p e rtie s*  The second  fo rm  of the u ro k in ase  p re p a ra tio n  
w as f re e  fro m  album in  and die odium  v e r  sen a te .
Both fo rm s  w ere  found to have non-B pecific coagulative 
p ro p e r  tie s ; they sh o rten e d  the  re q a le ific a tio n  tim e s  of s ilico n e  n o rm a l 
p lasm a; su b stitu ted  fo r  hum an b ra in  in  the o n e -s ta g e  p ro th ro m b in  
tim e  ; and c o r re c te d  %)artially fo r  defec ts  due to  an tihaem ophilic  
globulin  (A .H .G .) , C h ris tm a s  fa c to r  and p la te le t defic iency  in  the  
th  r  ombo pi a s tin  g en e ra tio n  te s t .
On e le c tro p h o re s is  on ce llu lo se  a c e ta te , the prepay;ation of 
u ro k in ase  ap p eared  to  be hom ogeneous and i t  w as not p o ssib le  to 
se p a ra te  fib rin o ly tic  and coagulan t ac tiv ity .
The u ro k in ase  pi*eparation w as given by continuous in trav en o u s 
in fusion  to two su b jec ts  ; in  both  su b jec ts  b r is k  th ro m b o ly tic  ac tiv ity  
v/as p roduced . In the f i r s t  su b jec t 600,000 C .T .A . un its  w as 
a d m in is te re d  in  30 m in u tes  and p roduced  in ten se  fib rin o ly tic  ac tiv ity . 
S ubsequently , in fusion  of 100,000 C .T .A , u n its /h o u r  p roduced  
neg lig ib le  ac tiv ity  w hile 200,000 and 400,000 C .T .A , u n its /h o u r  
p roduced  m o d e ra te ly  in ten se  and b r is k  ac tiv ity  respectively*  In  the  
second  su b jec t, the a d m in is tra tio n  of 500,000 C .T .A . u n its /h o u r  w as
a sso c ia te d  w ith b r is k  fib rin o ly tic  ac tiv ity . Ixi both su b je c ts , th e re  
w as x^ 5.’o g re ss iv e  fibtdnogen and p lasm inogen  dep letion  and th e re  
w as a lso  defin ite  la b o ra to ry  but not c lin ica l ev idence of coagulative 
ac tiv ity .
In  a  group of 7 su b jec ts  who w ere  each given a sing le  in jec tio n  
of 80,000 C .T .A . u n its  of u ro k in a se , 10 m inutée a f te r  the in jec tio n , 
th e re  w as evidence of en h an ced ;p la te le t agg regation  in  a .C h a n d le r 's  
tube sy s te m , a sso c ia te d  w ith a fa ll in  the p la te le t count and in c re a s e  
in  euglobuUn ly s is  a c tiv ity . E vidence w as pror>eiited th a t the 
a c c e le ra te d  xdatelet agg reg a tio n  anight have been due to  an effect of 
e a r ly  fib rinogeii deg rad a tio n  p ro d u c ts  on p la te le t aggregation*
U rok inase  is  known to  p o s se s s  *H agem an-U ke' e ffec ts , 
w hich m a y  be due to  an in tr in s ic ] . p ro p e rty  of the u ro k in ase  m o lecu le  
o r  to con tam ination  w ith th ro m b o p las tic  com ponents of urine# Since 
i t  w as not p o ss ib le  to  s e p a ra te  the u ro k in ase  pi*eparatlon in to  
com ponents w ith  coagu la tive  o r  fib rin o ly tic  ac tiv ity , i t  was thought 
th a t th is  evidence wa,s suggestive  though by no m eans conclusive 
ev idence to suppo rt the  fo rm e r  h y p o th esis . F u r th e r  evidence in 
suppo rt of th is  hypo thesis  w as p rov ided  by in v estig a tio n  of a batch  
of the sam e c o m m erc ia l p re p a ra tio n  of u ro k in ase  w hich had  been
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further purified com pared with the original batch# Both the m ore  
purified batch and the original batch w ere found to poeeeee c lo se ly  
sim ilar  coagulant effects dem onstrable as shortening of the 
re calcification  tim e of fresh  norm al plasma#
A lthough it  i s  p rob ab le  at a c lin ic a l le v e l  that f ib r in o ly tic  
a c tiv ity  m ay  ca n ce l out co a g u la tiv e  a c tiv ity , the co a g u la tiv e  a c tiv ity  
m igh t p r e d isp o se  to  th r o m b o s is , m o r e  p a r tic u la r ly  to  r e th ro m b o sis  
during th era p y , and it  w ould  be d e s ir a b le , i f  p o s s ib le , to  obtain  a 
p rep a ra tio n  f r e e  fr o m  su ch  coagu lan t,activ ity#
The Effect of A lim entary L ipaem ia on F ib r in o ly sis , Blood  
Coagulation and P la te let Aggregation The object of the study reported  
in chapter 7 was to investigate the effect of alim entary lipaem ia on the 
fibrinolytic enzym e sy stem , R u sse ll's  viper venom  (*Stypven*) tim e  
and p latelet aggregation, com paring findings after a high fat 
breakfast with those after a low  fat breakfast* It has been suggested  
that ra ised  p lasm a lipoprotein  le v e ls  may move the p ossib le  
equilibrium  of clotting and ly s is  towards throm bosis by accelerating  
clotting or by inhibition of spontaneous fibrinolysis# If the deposition  
and p ersisten ce  of in travascular fibrin is  encouraged in this way by
raised  p lasm a lipoprotein le v e ls , th is would afford one explanation  
for their w ell-e sta b lish ed  associa tion  with the developm ent of 
isch aem ic  heart d isea se  since Duguid (1955) has shown that 
p ersistin g  intravascular thrombus may be incorporated in the 
arteria l w all leading to the form ation of an a th erosclerotic  plaque,
In the study reported in  chapter 7, 10 norm al subjects w ere  
investigated  on two o cca sio n s, once after a low fat breakfast and 
once after the sam e breakfast to which had been added 95 gm# of 
fat in  the form  of double cream# The effect of both types of 
breakfast on the fibrinolytic enzym e system  was studied, using a 
variety  of techniques to m easure its  severa l com ponents.., In 
particular, the ly s is  of Chandler thrombi by streptokinase in an 
artific ia l circulation  was studied since this technique was thought 
to be m ore relevant to the in vivo effect of lipaem ia  on the fibrinolytic  
enzym e system  than study of the ly s is  of whole blood or plasm a c lo ts . 
P la te let aggregation after both types of breakfast was studied; 
there is  considerable evidence that p latelet aggregation in  vivo is  an 
important early  phase of thrombus form ation. After both types of 
breakfast, lip id  le v e ls  w ere m easured  and an attempt was made to 
correlate changes in their le v e ls  with any observed  changes in
f ib r in o ly tic  and coagn lan t activ ity*
The r é su lte  p r e se n te d  in  ch ap ter 1 in d ica te  tîiat during  
a lim en ta ry  lip aem ia»  in d u ced  by in g e s t io n  of 95 g m . of fat* th ere
"  t  » t' '  '  '
w a s both a  s ig n if ic a n t  d e c r e a s e  in  spontan eou s p la sm a  c lo t  ly s i s  
a c tiv ity  (eu g lobu lin  ly s i s  te s t )  and in c r e a s e d  r e s is ta n c e  of p la sm a  
c lo ts  to  ly s i s  by u r o k in a se . P o s s ib ly  m o st  im p o rta n t, th ere  w as an 
in c r e a s e d  r e s is ta n c e  o f C handler th rom b i to ly s i s  by strei^ tok inase  
in  an a r t if ic ia l  c ircu la tion *  B e c a u se  p la sm a  le v e ls  o f p la sm in o g en  
and fib r in o g en  w e r e  c lo s e ly  s im ila r  a fter  ea ch  type o f breakfast*  it  
w as con clu d ed  that the o b se r v e d  d e c r e a s e  in  p h y s io lo g ic a l  
f ib r in o ly s is  during a lim en ta ry  lip a e m ia  w as not due to d e c r e a s e  in  
c lo t o r  throm bus p la sm in o g en  con ten t o r  to in c r e a s e  in  th e ir  
co n cen tra tio n  o f fibrin*
A fter  the h igh  fa t break fast*  *Stypven* t im e s  w e r e  a c c e le r a te d  
com p ared  w ith  fin d in gs a fter  the lo w  fat breakfast*
In h ib ition  o f p la te le t  a g g reg a tio n  w as o b se r v e d  a fter  the  
h igh  fa t breakfast*  P la te le t  cou n ts a fter  the tw o ty p es  of b rea k fa st  
did not d iffer  sign ifican tly*  a cc o rd in g ly  r e la t iv e  th rom b ocytop en ia  
w a s not r e sp o n s ib le  fo r  the p ro lon gation  of p la te le t  a g g reg a tio n  w hich  
w a s o b se r v e d .
It is  ustîaily assum ed that changes in fib rin o lysis  or 
coagulation following fat feeding are due to the associatedlix^aem ia*  
However* although there w ere significant r is e s  in tr ig lycerid e , 
phospholipid and free  fatty acid leve%a following the high fat 
breakfast in  every subject* no correlation  was obtained between  
the actual le v e ls  or changes in the le v e ls  of any of th ese lip id  
components and the changes in fibrinolytic activ ity .
On the other hand* there was a c lo se  correlation  between  
*Stypven* tim es and tr ig lycer id e  le v e ls , A highly significant* 
negative correlation  was found when *Stypven* tim es after the two 
types of breakfast w ere %)lotted against their corresponding serum  
tr ig lycerid e le v e ls  exp ressed  as logarithm s* S im ilar correlations  
w ere found for the resu lts following the low fat breakfast alone and 
following the high fat breakfast alone,
No correlations w ere found between *Stypven* tim es and the 
lev e ls  of the other lip ids which w ere m easured.
It was considered that th ese  correlations su ggested  that entry  
of tr ig lycerid e into the circu lation  during alim entary lipaem ia might 
be important in bringing about acceleration  of *Stypven* tim es and 
that endogenouslyf*derived, circulating tr ig lycerid e might a lso  be 
important in influencing the resu lts of the *Stypven* tim e.
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It was concluded that apart from  the observed  prolongation  
of p latelèt aggregation* the other effects of a fat m eal appear to 
move the p ossib le  equilibrium  of clbtting and ly s is  towards 
throm bosis and that dim inished speed  of p latelet aggr«3gation m ight 
oppose the ’thrombosis•^promoting* effects of'lipaem ia i .  e*- d ecreased  
fib rin o lysis and accelerated  clotting*
Studies of Six Defibrination Syndrom es The detailed investigation  
of s ix  patients in whom the defibrination syndrome was diagnosed is  
described  in chapter 8, In two patients* there was prolonged retention  
of a dead foetus; in  three m etastatic  carcinom a and one arose in  the 
course of throm bolytic therapy.
The reason  for undertaldng the detailed investigation  of th ese  
patients was to illu stra te  the difficulty which may a r ise  in  
interpreting the resu lts of such investigations and in determ ining  
whether the m ain cause of defibrination is  in travascular clotting or  
j:>athological fib r in o ly sis .
In the ca ses  I and 2 in  which defibrination was associa ted  with 
prolonged retention of a dead foetus, there was depletion of prothrombin* 
factor V, antihaem ophilic globulin (A ,H ,G ,) and factor X, In both 
cases* the p latelet count w as norm al. In case 1* there was plasm inogen
depletion and in case  2* m arked prolongation of the thrombin  
clotting time* The low plasm inogen lev e l in case  1 and the long 
thrombin clotting tim e in case  Z w ere thought to be evidence in  
favour of pathological fibrinolytic activity and accordingly the 
fibrinolytic inhibitor EACA w as adm inistered to th ese patients* In 
both cases* EACA failed  to correct the coagulation defects and 
restoration  to norm al appeared to be a consequence of delivery. 
B ecause of failure of response to EACA* it was thought that 
defibrination in th ese patients had been due to prim ary intravascular  
clotting, plasm inogen depletion in  case  1 and the very long thrombin 
clotting tim e in case  2 being evidence for secondary pathological 
fib rin o lysis . An explanation to account for the norm al p latelet 
counts was that the re lea se  of tissu e  throm boplastin into the 
circulation might be an interm ittent phenomenon* Intravascular  
clotting might therefore have ceased  som e tim e before investigation  
and rapid regeneration of p latelets in the m arrow might have 
restored  to norm al the number of circulating p la te lets . The 
depletion of factor X was explained by its  possib le consumption  
during clotting in the p resence of tissu e  throm boplastin since this 
has been shown to occur in  v itro .
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In case  3, a patient with defibrination associa ted  with 
m etastatic carcinom a of the b reast, the in itia l investigation  ehowed 
accoiex’ated lycia  of euglobulin clot's, plasm inogen depletion and 
prolongation of the thrombin clotting tim e. The p latelet count was
normal* This evidence was interpreted  as indicating pathological
. . . . - ,  , . ., . , - ,  ■
fib rin o lysis as the prim ary cause of defibrination* H ow ever, 
prolonged therapy with SAG A was not a ssocia ted  with a r ise  in  the 
fibrinogen level# Subsequent investigation  revealed  interixiittent 
throm bocytopenia and that the le v e ls  of fibrinogen and plasm inogen  
and the p latelet count appeared to fluctuate UjS a consequence of the 
natural h istory  of the patient*© d isea se  aixd not the m edication with 
EACA. Although heparin was adm inistered  to th is patient, its  tr ia l  
was inadequate and no conclusion could be drawn a© to its  possib le  
value in the therapy of th is patient. It was concluded that in tra- 
vascu lar clotting was the prim ary cause of defibrination in this patient 
and that plasm inogen dcpleticux was evidence Of secondary pathological 
fibrinolysis# An exi>laimtion for the accelerated  euglobulin clot ly s is  
in  the absence of in creased  plasm inogen activator activity in  the 
fibrin plate te st  was provided by the in vitro experim ent in which ly s is  
of p lasm a clot©, containing a standard amount of plasm inogen and 
urok inase, was accelerated  by reduced concentration© of fibrinogen.
It was a lso  shown in v itro that the thrombin clotting tim e was prolonged  
by reduced fibrinogen concentration per s e . Although at post'-m ortem ,
there was no evidence in th is |>utient o£ hitravascular fibrin  
fox’m ation, it was thought that this could be explained by ly s is  either  
ante-m ortem , or p ost-m ortem .
In caoes 4 and 5* defibrination was associa ted  with depletion  
of factor ¥* antihaem ophilic globulin (A ,H .G .) and plasm inogen and 
thrombocytopenia* B ecause of both plasm inogen depletion and 
throm bocytopenia I in each ca se  the* diagnosis made was intr avascular  
clotting with secondary fib r in o ly sis . In case 4 , during a heparin  
infusion, a r ise  occurred  in  fibrinogen, factor Y aiid antihaem ophilic 
globulin (a ,H ,G ,)  and the p latelet count rem ained steady. A fter  
withdrawal of heparin, their le v e ls  fe ll to those found befor^e 
treatm ent. An infusion of T rasy lo l was adm inistered  but did not 
produce a r ise  in the fibrinogen level w hile a fa ll in  the p latelet count 
occurred , A second heparin infusion was adm inistered  and again  
xdsea occurred in the le v e ls  of fibrinogen, factor Y and antihaem ophilic 
globulin (A *H ,G ,). The response to both heparin infusions was good 
evidence in favour of its  therapeutic value in th is patient and supported  
the diagnosis of in travascular clotting as the prim ary cause of the 
defibrination syndrom e.
In case  5# a T rasy lo l infusion produced r is e s  in the le v e ls  of
flb rinogen , fa c to r  V, antiliaem ophU ic globulin  (A .H .G ,)  and in  the 
p la te le t count* A t p o a t^ m o rte m , in tra v a e c iila r  f ib r in  fo rm a tio n  w as 
found in  c lo se  a sso c ia tio n  w ith tum o u r thus coxxfirming the c lin ic a l 
d iag n o sis , ,
C ase 6  v/ao included  b ecau se  i t  w as a  d e fib rin a tio n  syndrom e 
due to  a  p u re  f ib rin o ly tic  s ta te  induced  by ad m in is tra tio n  of a  u ro k in ase  
in fusion . I t  .also .illu s tra te d  the  value  of p lasm inogen  a ssay  in  the 
in v estig a tio n  of acu te  h ae m o s ta tic  d e fec ts . Seventeen.houx’s a f te r  
the end of the in fusion , p lasm inogen  depletion  w as the  only fe a tu re  
to suggest a  re c e n t b r is k  f ib rin o ly tic  s ta te .
I t  w as concluded th a t a s sa y  of p lasm inogen  and a  p la te le t 
count w ere  the m o s t u sefu l te s ts  in  the in v estig a tio n  of d efib rin a tio n  
sy n d ro m es , but th a t the  fo rm e r  is  a  tim e  co n su ltin g  a s sa y  the re s u l t  
of w hich m ay not be av a ilab le  in an  em ergency  and the la t te r  m ay not 
alw ays be found s ince  if in tr  a v a sc u la r  c lo tting  has  c e a se d  te m p o ra r ily  
a t the tim e  of in v es tig a tio n , ra p id  m a rro w  re g e n e ra tio n  of p la te lb ts  
m ay  have i-esto red  th e ir  le v e l in  the cix’cu la tion  to  norm al# I t xnaj 
th e re fo re  be im p o ss ib le  to d e te rm in e  the m ain  cau se  of d e fib rin a tio n , 
e ith e r  in tra v a s  c u la r  c lo tting  o r  patho log ical f ib r in o ly s is  o r  a 
com bination  of th e se  tw o. I t  ap p e a rs  w ise  th e re fo re  to  t r e a t  such
c a se s  w ith tra n s fu s io n  of .Mood and possib ly  fib rinogen  and 
a d m in is tra tio n  of h y d ro co rtiso n e , and to. r e s e rv e  sp ec ific  th e ra p y , 
e ith e r  a  fib rin o ly tic  in h ib ito r  o r  heparin^  fo r  lifo-^th’X*eatening .,: 
s itu a tio n s  w here  co n se rv a tiv e  m e a s u re s  have fa ile d .
C o n c lu s io n .% .
A vailab ility  of f ib rin o ly tic  a c tiv a tp ra  and in h ib ito rs  as 
p re p a ra tio n s  n n ita b le .fo r  .ad m in is tra tio n  to. m an  has. s t im u la te d . . 
in to  re s t 'W  th e  com ponents and. functions of the  fib rin o ly tic  .enzym e  
sy s te m  in  h ea lth  and d ise a se  and le a d  to  a  s e a rc h  fo r  p re p a ra tio n s  
w ith g re a te r  potency and few er side  e ffec ts  than, th o se  cux*rently 
available# -. . ■
X?art of the w ork  fo r  th is  th e s is  w as conoexmed w ith the 
iiw estig a tlo n  of two su b s tan ces  * am inom ethyl cyc lohesane  c a r  boxy lie  
a c id  and T ra s y lo l , w hich w ere  found to  be m o re  po ten t in h ib ito rs  of 
the fib rin o ly tic  ensym e sy s te m  than  EAGA, the  c u r re n tly  ava ilab le  
fib rin o ly tic  in h ib ito r #
A nother p o rtio n  of the w ork  involved in v estig a tio n  of a 
p re p a ra tio n  of urokixxase, the  p lasm inogen  a c tiv a to r  p re se n t  iîi hum an 
urine* ï jro k in a se , unlike s tre p to k in a se  which is  the  m o st com m only 
em ployed fib rin o ly tic  a c tiv a to r , is  non***antigenic but e a r l ie r  p re p a ra tio n s
have been  shown to  p o s se s s  th ro m b o p las tlc  activity# The 
%)reparatiox% in v es tig a ted  in  the  w ork  fo r th is  th e s is  w as found 
to  foe le s a  th ro m b o p las tic  than  e a r l ie r ' p re p a ra tio n s .
i'in aU y , two a sp e c ts  of the  function of fiforinolysio in  
d ise a se  w ere  studied* The effec t of high |>lasm a lip id  lev e ls  in  
apontancons f ib r in o ly s is  w as exam ined  and found to be inh ib ito ry  
and the ro le  of patho log ica l f ib r in o ly s is  ixx the developm ent of 
d e fib rin a tio n  syn d ro m es w as s tu d ied .
T h e re  re m a in s  m uch to  be le a rn e d  b e fo re  th e  c lin ica l u ses  
©f fifoxdnolytic a c tiv a to rs  and in h ib ito rs  a re  c le a r ly  defined and the  
ro le  of the f ib rin o ly tic  ensym e sy s te m  in  h ea lth  and d ise a se  is  
p re c is e ly  understood*
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TRASYLOL AMCA
c60
%{40.
EACA
30-
20-
/
MOLAR CONCENTRATION OF INHIBITOR
F igu re  36  ahoim a  oomparieo% o f  th o  a a b if ib r in o l^ t io  
e f f o e t  o f  -fa^aoylol* AMCA m à  BkQA i a  m i v i t r o  
system  ## th e  tirok ih ase  e e n e i t i v i t y  t e s t  w ith  bmik 
plasm a a s  su b s tr a te *  The h oriï^ outa l s c a l e  i s  in  
fo u r  lo g a r ith m ic  cyc3.es* The f ig u r e  i s  prepared  
from d a ta  o f  t a b le  33*
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100-1
90-
80 -
70-
60-
500u/ml
50-
40 -
30-
20-
250u/ml
SALINE
CONTROL10 ■
INCUBATION TIME (Mins.)
Pigur© 57 shows the e ffe c t o f Trasylol in  v itro  
in  the incubation mixture o f the thromboplastin
generation test#  %e figure i s  prepared from 
the data o f tab le 35*
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130.
25G0u/ml
110.
100.
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200u/ml80.
50u/ml70-
50.
SAUNE — 
CONTROL
30.
20.
10
INCUBATION TIME (Mins.)
F ig u re  38 shows th e  e f f e c t  o f  ‘X'rasyloX in  
in  th e  su toatrate  system  o f  th e  tht'ombopXaatin 
g e n e r a tio n  t e a t*  %.e f ig u r e  l a  prepared from 
th e  d a ta  o f  t a b le  37*
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THROM BOPLASTIN GENERATION
TEST70-
POST-IN FU SIO N
g  40-
p  30
P R E -IN F U S IO N ^10-
INCUBATION TIM E(mins)
50,000 u. 
TRASYLOL
.E
E
U JS
15
I '3  0'5‘
TIME(mins)
UROKINASE SENSITIVITY 
TEST
EUGLOBULIN LYSIS
Figure 40 showa tW offed ts in  a normal oubjeot o f a oinglo  
in jection  of fraey lo l followed m  infusion  of fra sy lo l 
given over 30 minutes^ B%le figure dieplaye in  part the 
data of table 4^ %
TRASYLOL, 100,000 units
THROMBOPLASTIN GENERATION
TESTLU m
8 10 24
UROKINASE SENSITIVITY TEST
4 6 8
TIME(hours)
FlgiU’e hi shows the e ffe c t o f a Blagle intravenous 
in jection  of ïr a sy lo l on the thromboplastin 
generation to s t and the uroîdLnnee Bonsitxva.ty te s t  
of a normal su b ject. ïha figure graphioaliy displays 
in  part the data of tab le h3»
TRA SY LO L(U nits/hour)
10,000
20,000
50,000
z
501 100,000
200,000
30- THROMBOPLASTIN  
GENERATION TEST
i l  I
10.
O
UROKINASE 
SENSITIVITY TEST
LU
TIME (H ours)
42 ehowe the  e f fe c t of an Infnsim i of on the
tlirombopXaatln geneii'ation to s t  and the  nrokinaee s e n s i t iv i ty  
t e s t  of a  normal su b je c t« Who figu re  g raphically  displaya 
:ln p a r t  the data  of ta b le  44*
T R A SY L O L (U nits/hour
10,000
20,000
50,000
100,000LU
50 1 200,000
0: z  40 "
si
O ÿ  30-
THOMBOPLASTIN  
GENERATION TEST
UROKINASE SENSITIVITY  
TEST
TIME (Hours)
F igu re  4^ slim m  th e  e f f e c t  o f  aa iu fu s io n  o f  on th e
tlirom bop laatin  g e n e ra tio n  t e a t  and th e  u rok in ase  s e n a i t i v i t y  
t e a t  o f  a  normal sufojoot* The f ig u r e  g r a p h ic a lly  dlaplaya
in  p a r t th e  d a ta  o f  ta b le
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Figure 49 î i^otib Linetreaver-Burk plota demonetratine 
that ïraey lo l la  a non^eoiapotitive Inhibitor o f the 
proteolytic a c t iv ity  of trypain» The upper p lot 
i s  the experiment in  which Traaylol was incorporated 
end the lower p lot i s  the control experlmont. The 
plots are constructed from the data of table 5l«
oLU
0 2
150100500
REDUCTION IN RECALCIFICATION TIME (S ecs .)
figure 49 etowe roduotion tn  o lo ttin g  time with 
inoreaeing amounts o f dialyse# urokinase added 
to s ilicon e normal plasma hefore recalcifidation<  
The figure i s  prepared from table 55•
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crt
c3
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O
010 5"
8 0-2
0 1
iO 100 150 200 250 300
REDUCTION IN RECALCIFICATION TIME (Sec.)
350 400
Figure 50 ehowa roduct3.oB in  ©lotting time 
with inoreaoing amomts of pure urokinaee 
added to eilicon e noiwal plaema before 
reoalcifioation* The figure 1© prepared 
from table 55*
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600,000u 200,000 u
UROKINASE
100.000 u / hr.
400,000u
i f
RADIOACTIVE CLOT ASSAY 
FOR ACTIVATOR 
ju g m  FIBRIN LYSED/ml/hr
FIBRIN PLATE TEST:PLASMA 
AREA OF LYSIS, mm%
PLASMINOGEN, casein 
units/ml
20-1
THROMBIN TIME, secs.
600i
FIBRINOGEN, mg/lOOml400
TIME, HOURS
Figure 54 ohowa the e f fe c t  on the fib r in o ly tic  
enayme ayatera o f an infuaion of urokineae,- 
Si-ie figure la  prepared from table 63.
600.000U 200,000u
UROKINASE
_1QP,000 u/hr 400,000 u
5 10 15
TIME, HOURS
RECALCIFICATION TIME 
SECONDS
HAGEMAN FACTOR ASSAY 
SECONDS
FACTOR 3 : ASSAY 
SECONDS
ANTIHAEMOPHILIC 
GLOBULIN ASSAY 
SECONDS
CHRISTMAS FACTOR 
ASSAY
SECONDS
Figure 55 ehowe ilm e ffeo t on the coagulation 
ayatem of m  infuaion of urokinase* # e  figure 
i s  prepared from table 64#
UROKINASE
500i000units/hr
00
20Lr -r—H  I 1 EÜGLOBÜLIN LYSIS TIME, units
1,000
500'
3i
40
THROMBIN TIME,
I secs.
600
FIBRINOGEN, mg/100ml4001
41-—I
TIME, HOURS
Figttro 56 shoxvo the e f fe c t  on the fib r in o ly tic  
enayiae system of an infusion of urokinase.
The figure i s  prepared from table 65#
UROKINASE
500.000 units/hr.
300
200
100
0
300 1 
200 
100 
0
RECALCIFICATION TIME 
IN SILICONE, SECONDS.
FACTOR % ASSAY, 
SECONDS.
140
130 i
120 i I— *  ANTIHAEMOPHILIC 
GLOBULIN ASSAY. 
SECONDS.110
100
95 1
90 4
CHRISTMAS FACTOR 
ASSAY, SECONDS.85 4
4 128 4824
TIME, HOURS.
P ig a r e  57 Bhovm th e  e f f e c t  on the o o o ^ n la tlo n  
s /s te m  o f  an in fu s io n  o f  urokinase# The  
figU3?e i s  prepared from tahie 66*
Figure 58 shows an artificial thrombus made in a Chandler* s tube 
by rotation of 15 ml whole blood for 1 hour. The i^ite head end 
the fibrin tail can be seen.
p' . Yk
“ %
Figure 59 ehowa a longitudinal section through a Chandler thrombus. 
The contrast between the platelet head end the fibrin tail c^n be 
seen. Original magnification x 500. Stain - Pioro Mallory.
(Photcmiorograph prepared by Dr. F.'Walker).
Pigore 60 shows a thin layer chromatogram of double 
cream# The solvent system was petroleum ether- 
diethyl ether • aoetio aoid 60i40il# The chroasito* 
gram shows that most of the lipid in the double cream 
was triglyceride with traces of diglyoeride and 
cholesterol#
Figure 61 shows a thin layer chromatogram of double 
cream. % e  solvent system was ohloroforawmethanol- 
water 65 1 2 5 1 4. In this qystem, neutral lipids, 
cholesterol and any free fatty acids appear 
accumulated at the top of the lane as shown here. 
Phospholipids in this system should appear in the 
ascending order, lysoleoithin, sphingomyelin, lecithin 
and phosphatidylethanolamine, this last being well 
behind the other lipids at the top of the lane. As 
shown, no phospholipid was detected in double cream.
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EUGLOBULIN LYSIS ACTIVITY, 
units.
PLASMINOGEN,casein units/ml.
THROMBIN TIME, secs.
FIBRINOGEN, mg./lOOml.
ANTIHAEMOPHILIC 
GLOBULIN, per cent.
FACTOR X  , per cent.
PLATELETS, thousands/mm^.
2 4 6
TIME, DAYS.
Piguro 65 8hov/a the resu lts o f f ib r in o ly tic  
and coagulation assays in  patient 1# chapter 
8* The patient I in  whom the defibrination
syndrome was diagnosed^ had a retained dead 
foetusf Delivery of the foetus occurred on 
day 5* Therapy with IjlAOA was administered 
from day 1 u n til 12 hours a fter the delivery*
The figure i s  prepared from the data of table 06<
150
100 ■
50 •
3
2
20 ]
FIBRIN PLATE TEST, mm";
RESUSPENDED EUGLOBULIN PRECIPITATE.
PLASMINOGEN, casein units/ml.
THROMBIN TIME, seconds.
FIBRINOGEN, m g /100ml.
ANTIHAEMOPHILIC GLOBULIN, per cent.
FACTOR per cent.
PLATELETS, thousands/m m
2 5
TIME. DAYS
Figure 64 shows the resu lts of flh r in o ly tio
and ooagLilatiorA e s s a y s  in  p a t ie n t  2# ch ap ter  
8* The p a t ie n t  I in  whom th e  d e f ib r in a t io n  
syndrome d ia g n o se d | had a r e ta in e d  dead
fo e tu s*  o f  th e  fo e tu s  oocarred  on
day 4# Therapy w ith  RA.OA was a d m in istered  
from day 1 u n t i l  12 hotix’s  a f t e r  th e  d e liv e r y *
The f ig u r e  i s  prepared from th e  d a ta  o f  ta b le  8?
EACA
2G.AM CA1G,
EACA 12 G ./O .
EA CA
5G .
HEPARIN 1,500 u /h r. 
FOR 12 hr.
AMCA
Û-2G.
2*5
20
10
0
351
30-
350-1
250-
FIBRINOGEN, mg./IOOmls.
150
250
200
150-
PLATELETS, thousands/m m ^.100-
50 -
TIME, DAYS.
Figure 65 ehowe the résulta of some fib r in o ly tic  
and coagulation assays and the therapy administered 
in  patient 3t chapter 8* This patient t in  whom 
the defibrination syndrome \tos diagnosed, had a 
oaroinoma of breast with métastasés#
-p
a  9
60 1
40 ■
6 1
4
2
T X T 1
251
20-
2
RADIOACTIVE CLOT 
ASSAY, 
yUgm. FIBRIN LYSED/ml./
hr.
EUGLOBULIN LYSIS 
TEST,
units.
PROTHROMBIN TIME, 
secs.
3001
200-
100'
PLASMINOGEN, 
casein units/ml.
FIBRINOGEN, 
mg./lOO ml.
20 40 60 80 90
TIME,HOURS
Pigmze 67  shows the re su lts  of f ib r in o ly tic  assays 
Ir. p a tie n t 6$ clmpter B* fh ie  p a tie n t had an 
Infusion  of uroki^tase# The dosage ra te  was 8501000 
Ploug u n its  over 2^ hours5 2 0 * 0 0 0  Ploug un its /h o u r
fo r  2 hours I 4 0 * 0 0 0  Ploug m ilts/hour fo r 1 7 w hours. 
At 22 hours * there  was a break in  the in fusion  fo r  
2^ - hours. The infusion  was then resumed a t  e ra te  
of 80*000 Floug u n its /h o u r for a fu r th e r  hours. 
The fig u re  i s  prepared from the data of tab le  8 9 *
TABLES
faMe. 1 . . . # 8 0  ..of ^Ayoilio, toffoi* \7l t h aeid4iaomo^ .^ lo1)i% mbstrate
ia . i . iW w — ' i ;> M > » i t i iim — i ir i i i m i i i n i i i ii i i iTin i u i ii i j i i i | i i » i  \  m i n r .  i# #  i i | f i i i i i W 'n * L j i n * # n i # i m i , i * n w i 'n  * # # . > « ' n r - ' w w ^ r w W i i u W  i i i n è ü a n m w n w j i i » » » ! * ! ! , n o - w t o i im w w n w w w »
Molar ooucejitration of 100 o f fiOid-haemofdoMn aulJBteate
im h ib ito r  iti  acld^haem oglobiE  
s u b s tr a te VAlth glyoino Wltjioat g lyclae
AMOHA
0x10*5 8.0 2.5
eisao"'^
8x10*5
2.0
8.0
2 .6
8.8
4%10*5
7x10*5
8.0
8.2
3 . 4
3 .8
7x10*^ 3»4 4.5
BAQA
SxlO* '^ 2.0 2.2
8x10*5 8.0 2.4
5x10*5 2.0 3 . 4
mPI3£l0
2k10"^
2.1
8.4
3 .7
4 . 7
2x10* '^ 2.9 5 .9
BhoTO i s  the e f fe c t  o f g ljo in e  m  a  b u ffe r fo r  the aoid- 
heemoglobin su b stra te  tîhon inoreasiag  couooutratioiis of 
îmuh BAG A were added to  it*
Of banlt nlasm a
M alar c o u a e n tr a tio n  o f  
k in  d igestion  mixture
O p tic a l d e n s ity  in  
o a d o in o ly t ld  a ssa y
3f2 X 10
6,4
9#6
1.6
10
10
10
•5
'1
4
«43*2 % 1 0 :  
6.4 3: 10 i.
$16 X
1.3 n 
2.1  %
10
10
10
iimp
-3
■ 0
4.0 X 
0 .0  3C
1.6 X
3.2 
6*4 X
9.6 X
1.3 X
2 .1  X
3.2 %
6.4 z
10 
10 
10
z  10
•5
•5
10
10
10
10'
10
10'
-4
r4
■»4
-3
•5
:-3
Gent in h ib itio n  
o f  o a s o in o ly t lo  a e t i v i t y
m
Oil65,
0.3.65,
0*3.60,
o;i66,
0.130,
0.094*
0.075,
0.049»
0.043,
0.085,
0.166,
0.165,
0.165, 
0.166i 
0.140, 
0.101, 
0.075, 
0.050, 
0.045,
0.085,
0.167
O.I69
0.170
0.166
0 .1 5 0
0 .1 0 5
0 .0 0 5
0i060
0.050
0 .0 3 0
Mcisd a fter  activation
0.155,
0.135,
0.145,
0.150,
0.145,
0.148,
0.150,
0.148,
0.156,
0 . 1 3 8 ,
0.188.
0 .1 6 5
0 .1 5 5
0 ,1 5 0
0 .1 5 0
0 .1 5 5
0 .1 5 2
0 .1 5 0
0 .1 5 0
0 ,1 6 4
0 , 1 4 a
0 .1 3 0
0.6
16
40
53
68
78
84
7.5
5
5
7
2*5
12.5
19
Shorn i s  th e  e f f e c t  in  a  c a e o in o ly t ic  a ssa y  system  o f  
in c r e a s in g  o o n ç o n tr a tio n e  o f  AIÆ0E4 added to  b W t plasma 
b e fo r e  a c t iv a t io n  w ith  s tr e p to k in a s e  and a f t e r  a c t iv a t io n  
w ith  s tr e p to k in a s e  "but p r io r  t o  p lasm in  assay*  %hesQ 
r e s u l t s  a re  i l l u s t r a t e d  in  f ig u r e  4#
W W p W j i 1! IW «l'tWM.Wi,» nM.
Wa? oonoentx*ation of 
mnh iE  d igestion  mixture
3#2 %
5*2 X
6f4 %
3,2
6*4 
1 
1,9  
1,0
,3 X
K Î
“ 1
K l%
10 f
s 10
O p tie o l d m s i t y  â»  
o o s e in o ly t lo  a ssa y
Peg o e a t  is iîv l'b ltioa  
o f  o a g e in o ly t io  a c t i v i t y
a^â4^4 'bsfoye a o t iv a t lo n
0.150,
0 ,150,
0,140,
0,183*
0,111,
0 .091,
0.075,
.0.057,
,0.035*
0,025,
0.150
0,151
0.142
,0.123
. 0,112
0.094
0.077
,0.099
0,037
0.026
49
61
63
83
0 c 0,140, 0,140
3.2 X 1KT5 0.133* 0,135 4
1.6 % lO-i 
3.8 X 10 J  
6 ,4 K 10_a
0,126,.0.188 9
0,140,,0,140 0
0.136,,0*136 3
3,2 S£ IQ J . 0*136,.0,142 0
6,4 3C 10*n 0,121,.0.123 13
1,3 X  10 p 0,120*.0.121 14
1,19 % 10" 0.112, 0,114 19
Shown l e  th e  e f f e c t  i n  a  c a e e ln o ly t ic  aeeoy  ayetom  o f  
In o rea o in g  o o n o en tra tlo n e  o f  lîàOA added t o  hahlr* plasm a  
b e fo r e  a c t iv a t io n  w ith  o tre p to k in a o e  and a f t e r  a c t iv a t io n  
w ith  s tr e p to k in a s e  h u t p r io r  to  p lasm in  a s s a y ,  
r e s u l t s  are  i l M s t m t e d  in  f ig u r e  5*
OoEoentratioE of oubetra,t0# 
casein? gm#/lOO ml. 
digestion mixture. (S).
Eeaotion velocity i n  oasoinolytio 
assays mg* tyrosine 
released/ml ./how* (?)
I
COK-trol GXPBrlmenti m  i im b l to r
8.00
1,60
1,40
0,80
0 ,4 0
0 ,2 0
1,30
1,10
0,90
0,80
0 ,4 0
0 ,3 1
l^perimont with 0*2 . Molar. AHGHA. incorporated
0,50
0,63
0,72
1 ,2 3
2 .5 0
3*57
0,8
0,9
1,1
1 , 3
2,5
3 ,2
8,00 0,45 0,50 2,2
1,60 0,41 0,63 2,4
1,40 0.40 0,72 2,5
0,80 0.38 1,85 2,6
0,40 0*89 2,50 3.4
0,28 0,23 3.57 4,3
2,00 0,37 0,50 2,7
1,60 0,34 0,63 2,9
1.40 0,32 0,72 3,1
0,80 0,25 1.25 4,0
0,40 0,19 2.50 5,3
0,88 0,16 3,57 6*3
She double reoipro.oal p lots shoiw im figure 6
for AMOHA and in  figure 7 for HAOA are
compiled frora th is  table*
Sable 5 * Inhibition by. AltGHA mià by EAOA. of '
activation.Iw otf^tokiiiaOes kinetics of. 'thèoè reactionB .
rwr#W**iK-p 'Wn':!^  Mf K
O onoentration  o f  bubetx%.tG 
plasm inogen: :c a s e in  u n it s /m l  
added to  d ig e s t io n  m ixture* ( b )
R e a ctio n  v e lo c i t y  in  G aB oin o ly tic  
a o so y i c a s e in  im it s  plasminCgen  
a c tiv a te d /m l . /m in u te . (V)
V
B
/
V
C on troi experim en t: no in h ib i t o r  '
23*3
18.7
14.0
9.3  
4*7
2.3
0.152, 0.134 0.04 7.5
0.151, 0.133 0.05 7.6
0.117, 0.117, 0.07 8.5
0.1Î5, 0.115 0.11 0.7
0.110g 0.114' - , 0*21 . 8.9
0.670, 0*074 0.4 3:.13,9
Experiment  .w ith  0*05 Miolar AMOHA in co rp o ra ted
83*3 
10.7 
14.0 
9*3 
4.7 
3.3  
, 2.3
0 .0 0 4 ,
0.076,
0.062,:
,0.041*
0.632, 
0.025,. 
0.0:19,.
0 ,0 8 5
0 .0 7 7
0.062
0 .0 4 2
0j034
0.025
0.020
0.04
0 .0 5
0 .0 7
0.11
0,21
0*29
0 .4 3
11,8
1 3 .1
16.1  
2 4 ,1
3 0 .5
40.0
5 1 .3
Experim ent w ith  0*10 Molar EAOA in co rp o ra ted
23*3 0 .1 0 4 , 0 ,104 0 .04  9 ,6
18,7 . ■ o .o p l ,  0 . 093  ^  ^ - 0 .05  10,9
i4,o 0 ,0 0 3 , 0 ,087 0,07 11 ,0
9 ,3  ^ 0,062^ 0,064. 0,11 :i5.9
4*7 . , 0 .0 3 5 , 0,035 0 ,21  28.6
. 3*3 - /: _■ 0.026 ,  0.023 0.29 37.0
2 ,3  . '- : 0*020,  0.021 ,. fl.,43 ‘ 48.8
Ato double ■rèGlprooal plots ; shown .in figure 8
for AMOEA: and in figure 9 for. EAOA ,a%'0' Compiled
"from this.';tableé • ■ ' ^ ' , , ' '
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T able 7 * I n h ib it io n  b j  AMCA of plaem inogen a c t iv a t io n  by 
streptokinase@  k in e t i c s  of th e  r e a c t io n
C on cen tration  o f  s u b s tr a te ,  
plasm inogen g o a e a in  u n i t s /m l # 
added to  d ig e s t io n  m ixture* (B )
R ea ctio n  v e lo c i t y  in  c a s e in o ly t i c  
a sea y j c a se in  u n it s  p lasm inogen  
a c t iv a te d /m l/m in u tc • (? )
/ /V
C on trol ©xperim entj no in h ib it o r
23.3 , 0.150 0.04 7.2
9.3 0,11a 0.11 0.5
6.7 0.112 0.15 0.9
4.7 0.105 0.21 9.5
3.6 0.093 0.20 10.8
wiK*afk#*ÊMW#.T*W*f%T*kWw,:^^
Experim ent w ith  0*02 M olar AHOA in co rp o ra ted
23.3 0.062 0.04 16.1
9.3 0.033 0.11 30.3
6.7 0,025 0.15 40.0
4.7 0.019 0.21 52,6
5.6 0,014 0.28 71.4
The double r e c ip r o c a l  p lo t s  shown in  f ig u r e  10 
are com piled  from t h i s  t a b le .
Table 8. Inliibition by AlOHA end by BACA of proteolytic activity
of trym int kineticg of theae reaotione
Oonoentration of substrate Reaction velocity  in  caseinolytic  
caeeini gm*/lOO ml* assay: mg, tyrosine 
digestion mixture* (s )  released/ml*/hour. (V)*
1
/
s
1
/
V
Control experiment: no inhib itor ■*
2*00 1.04 0.50 0.96
1*40 0.99 0.72 1.61
0*80 0.95 1.25 1.05
0*40 0.90 2.50 1.11
0*28 0.88 3.57 1.14
Experiment with 0 .2  Molar AMOHA incorporated
2,00 0.65 0.50 1.54
1.40 0.63 0.72 1.59
0.80 0.56 1.25 1.79
0,40 0,54 2.50 1.85
0.28 0.52 3.57 1.92
Experiment with 0 ,4  Molar BACA incorporated
2,00 0.68 0.50 1.47
1.40 0.63 0.72 1.59
0.80 0.59 1.25 1.69
0.40 0.56 2.50 1.79
0,28 0.52 3.57 1.92
The double reciprocal p lots shown in figure 11 for AMGIL4 
and in  figure 12 for BAGA are compiled froià th is  table*
Table 9,_ W i W t l o m  BACA of tryp.efAnosen aotivatiom
by ontorokinas^i kinetics of these reactions
Concentration of 
substrate# trypsinogen 
mg/lOO ml 
digestion mixture* (S)
Reaction volooity  in  
oaoeinolytio assay# 
op tica l density 
readings* (V)
/
8
Control experimentt no inhib itor
50 0.680 0,020 1.5
30 0.530 0.033 1.9
20 0.420 0.050 2.4
10 0.286 0.100 3.5
8 0.210 0.125 4.8
5 0.167 0.200 6.0
ExBerlment wiiii 0,03 Ilolaa? AMOHA incornorated
50 0.405 0.020 , 2.5
30 0.320 0.033 3.1
20 0.204 0.050 4.9
10 0.18Ô 0,100 5.6
8 0.125 0.125 8.0
5 0.070 0.200 14.3
Exoeriment with 0.10 Molar BACA incorporated
50 0,400 0.020 2.5
30 0,275 0.033 3.6
20 0.170 0.050 5.9
10 0.125 0.100 8.0
8 0.083 0.125 12.0
5 0,060 0,200 16.7
The double reciprocal plots shown in figure 15
for AMOHA and in figure I4 for BACA are compiled
from this table#
Table 10, Assay o f trypsini e ffe c t  of 0.05 Molar AMOHA and of 0*10
Molar I3AGA
Concentration of 
trypaini rag/lOO ml 
o f d igestion  mixture*
Optical density  
in  oaseinolytio  
assay.
Optical density  
in  oaaeinolytic  
assay with O.05 
Molar AMOHA 
incorporated
Optical density  
in  oaseinolytio  
assay with 0.10  
Molar BACA 
incorporated
50 0,620 ' 0.630 0,622
30 0.270 0.264 0.268
20 0.190 0.198 0.190
10 0.112 0.110 0.116
5 0.070 0.074 . 0.070
Shown are the resu lts  o f caselnolytio  aeoaye o f varying 
concentrations o f trypsin alone and of the same con^ 
centrations assayed in  the presence of 0.05 Molar AMOHA 
and of 0*10 Molar BAG A,
Table H* Inhibition of pepsin
KH f f i g w r n ~ ~ i T ~ i i t T r i i ^  T i i T T i " ^ ' n T i " 7r   r — — i  - - r - - — ' " "  -  i  i ' " i
compared v/ith inhibition by* BACA
Molar concentration Gpbioal Per cent
of AIIOHA in density l*i Inhibition of
digestion mixture pepsin assay pepsin
0 0.350, 0.350
1 X 10*^ 0.350 0
5 X lO’ ^ 0*320 9
1 X lo"® 0.300 14
2 X 10"® 0.265 24
3 X lO"® 0.160 54
4 X 10*® 0,105 70
5 X 10*® 0.060 83
6 X 10*® 0.050 86
Molar concentra.tion Optical For cent
o f BAOA in density in inh ib ition  of
digestion mixture pepsin assay pepsin
2 X 10*® 0.350 0
3 X 10*® 0,185 47
4 X 10*® 0,150 57
5 X 10*® 0.080 77
6 X 10*® 0.070 80
7.5 X 10*® 0,060 83
1 X 10*^ 0.045 87
Shown ia  the e f fe c t  bf Increasing concentrations of 
AMOHA and o f BAOA on the action of pepsin on m  acid-
haemoglobin substrate* The data are also shown in  
figures 15 and 16.
Table 12. Effect of AMCA, compared with that of AMCIIA
and of BACAt ;üi the urokinae^o sensitivity test#
Molar concentration of 
:lnhibltor In digoetion mixture
0
4 .7  % lO"'^ 
9 .4  X 10 ^
2 .0  X 10"^
4,7 X 10*
7 .5  X 10*.6
lyaia time In urokinase 
Boneltivity test
k mins 30 secs 
13 mina secs 
22 niins 30 secs 
31 mine 18 secs 
66 mine 
>300 mine
0
3.5 X 10*^
7.1 X 10*®
1 .7  X 10*^
3 . 4  K 10“*^
6.8 X 10**^  
1 .7  X 10***^
EAQA
2 ,8  X 10 
5*6 X 10*^
1.1 X 10* 
2,8  X 10*
4.4 X 10"
5*6 X 10
6 mins
6 mine 40 secs
? , 30 secs
I k mins l^O secs
21 mine 10 secs
28 mine 10 secs
48 mdns 10 secs
5 mine 45 Becs
8 mina
11 mina 10 secs
17 mine 33 secs
21 mina
27 nnUia 33 socs
46 mina 15 secs
Shovm is the ontifibrinolytio effect of increasing 
concentrations of AMCA# AMCHA and BACA in the 
urokinase sensitivity test# These results ar^ o displeiyed 
graphically in figure I7.
Table Effect of AMOA#. comparocl v;ith that 
of. PAMBA^ ;ln the uroklïiase Bensitivity test.
 . . . . . . . . . . . . .   i ■w w tin ii.i  w < iw > i> n w w i  i i w i i i i i| i i i „ # r # m # # M , , i # i W £ m iiW u » , i i * , i # w , i i W M
Molar concentration of inîiibitor 
in digestion mixture
lyoio time in urokinase 
sensitivity test
0 4 mlns
4.7 X 10"^ 15 mine
9.4 X 10”'^ 22 mlD.s 30 secs
2.0 X 10"® 30 mine
4.7 X 10"® 64 mins
PAMBA
0 6 mins
1.75 X 10"® 7 mine 30 secs
3.5 X 10"® 9 mine 15 secs
4.25 X 10"® 10 mine 30 sees
8.5 X 10"® 16 mine
1.75 X 10"^ 23 mins
3.5 X 10 28 mins 30 secs
1.75 X 10"^ 70 mins
Shorn io the antifibrinolytic effect of increasing 
concentrations of AMGA and PAI#A in the urokinase 
sensitivity test* The data are ahovjn graphically 
in figure 18*
Table 14# Thrombin clotting time and 
one-sta^ o. prothromb% time : effect of AMCHA,
Molar concentration 
AMCIîA/ml plasma 0 1.0 % 10"® 2.5x10"® 3.0 X 10"®
Clotting time, seconds, 11,5, 12.0 11.6, 11.8 11.8, 11.8 12.5, 13.0
in thrombin clotting 
time
Clotting time# secoado# 17*0 , 17#0 17.0, 17.0 17.0# l8*0 20.0# 20.0 
in one-stage 
protlirombin time
Shown is the effect of increasing c one entrâtions of AMOHA in 
the tlirombia clotting time and the ono-stage x?rothromb:ki time 
The first column shows the snliie controls.
Table 15. of AMCHA,
Incubation time, 
miîiutea
Clotting timesI seconds# at varying AMOHA 
conoentrations 
Molar concentration AMCHA/ml incubation mixture
0 1.0x10"^ X.QxlO' 5x10 2^ 5>Cbao,#«2
1 38 58 58 59 61
2 37 36 37 40 42
3 21 22 23 25 26
4 15 15 16 17 19
3 12 11 12 35 16
6 11 11 11 14 15
Bliovm is the effect of increasing concentrations of AMOHA 
added to the incubation mixture in the tîiroraboplastin generation 
test. The first column shows the saline control.
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Table, E ffect o f 1 m  AMGH4. oomporod with that o f 2 BACA
on the ttrokinaee een e itiv lty  toet o f a normal QUb.ieot
Time of withdrawal 
of plasma sample# 
hours a fter  ingestion
Lysis time in  urokinase se n s it iv ity  te s t
a fter  1 gm BllQllk I a fter  2 gm BACA
0 6 mins# 50 secs# 8 mins*
i 7 mins# 50 secs# 9 mine. 20 secs#
B 11 mins# 17 mine# 30 secs#
1 X9 mins* 50 secs# 20 mine# 20 sees*
2 22 mins# 22 mins# 30 secs#
5 X7 mins# 85 BOOS# 17 mins# 20 secs#
5 15 mins à 30 secs# 14 mins# 30 seoa#
7 11 mins# 30 secs# 7 mins#
12 6 rains* 30 oeos# 7 mins#
24 6 mins# 30 secs# 7 mine*
Shorai i s  the effect#  on the urokinase se n s it iv ity  te s t  of a normal 
subject, of ingestion of 1 gm MCHA# compared with the e ffe c t  of 
2 gm BAG A* Each compound was ingested on d ifferen t days by the
same subject# The resu lts  are displayed graphically in  figure 20.
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Table 19. Igffeot of 2|()0 w? AM#A# oomT)ared with that of 2 ^
FApAff on the urokinase aeneitivity teat of a normal aub.ieot
Tims of nïithclrawal 
of plasma oample# 
hours a fter  ingestion
Lyoie time in  urokinase se n e it iv ity  test;
a fter  200 *ng MGA after  2 gm FAGA
0 5 mins* 30 secs. B mine.
i 7 mins# 9 mins. 30 0 O O S ,
i 17 mins. 50 0 O O S # 17 mins. 33 sees.
1 19 mins. 30 secs. 20 rains. 50 secs.
2 20 mins. 25 rains. 50 secs#
3 16 mins. 20 secs.
3 19 mins. 40 sees. 9 mine. 40 secs.
7 14 mins. 5 secs, 7 mins. 20 S 0 0 8 ,
12 12 mins. 5 secs. PM
24 5 mins. 30 secs. a mins.
Shorn i s  the effect^  on the urokinase se n s it iv ity  to s t  o f a 
normal subjoot^ o f ingestion  o f 200 mg* iiMOA* compared with the 
e ffe c t  of 2 gm MCA* Each oompound was ingested on diffei*ent 
days by the some subject* The resu lts are illu stra ted  
graphically in  figure 21
Table ^0* Effect of 200 AMOA, compared with that of
1 gni AMCHA t on the urokinase sensitivity tost of a normal subjeot^
Time of wltî'idrav;al 
of plaema sample* 
hours after Ingestion
lysis time in urokinase sensitivity test, 
after 200 mg AMCA after 1 gm AMCHA
0 3 mi^ is 6 mins 30 sees
7 mii3.s 7 mins 30 secs
i 17 mins 30 secs 11 mins
1 l8 mins 30  BOOB 20 mins
2 19 mins 20 secs 22 mins 30 secs
3 19 mins 30 secs
3 18 mins 50 secs 13 mins 30 sees
7 I h mins 11 mins 20 sees
12 12 mins 6 m:lns 30 secs
Bho\m is the of feet, on the urokinase sensitivity test of a normal 
subject I of ingestion of 200 mg AMCA, compared with the effect of 
1 gm AMCHA* Mch preparation was ingested by the same subject on 
different days* The data.are shown graphically in figure 22*
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22# Effqot of 20p laff àMüké üomparod v ith  that of 
2 BACA# on the Feaxnley d ilu te pXaama c lo t  ly sia
timo o f a patient with hypofibrinogenaemia
TiniG of "ivithclraTOl 
o f plasma oampio, 
hours a fter  in^jesiion
hysis time I minutes, of X^’eaxtiley d ilu te plasma c lo t
■* WIII
after  200 rag MCA on control day a fter  2 gra BACA
0 220 110 225
l i 520 125 #
5f 450 104 265
4 m «* 298
54- 340 145 515
7 240 m 345
12 195 m 200
24 200 170 180
Showm* in  a patient who had hypofibjpinogenaemia aosooiated with accelerated  
ly s is  of Feamley d ilu te  plasma o lo ts , i s  the e f fe c t  o f ingestion of 200 rag 
AJiSAf compared with that of 2 gm BACA# The findings on a control in ter­
vening day, when no fib r in o ly tic  inh ib itor was administered, are a lso  given, 
These resu lts  are displayed graphically in  figure 2%
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%able 24» Inliib ltîon by ^raaylol of oageinolytio a c t iv ity
of bsmk -plasma
Concentration of T rasylol, Optical density in Per coat
im its/m l of incubation caselnolytio  assay inhib ition  o f
mixture oaseinolytio  a c t iv ity
Trasylol added before activation
0 0.250, 0.350 _
0.2 0.859, 0.241 4
0.4 0 . 216, 0.224 12
1.0 0.180, 0,180 28
2.0 0 . 140, 0.140 44
4.0 0.100, 0,110 58
0.0 0 . 052, 0.054 87
10,0 0.028, 0.028 99
fra sy lo l added a fter  activatiora
0 0. 165, 0.165
0 .2 0*100, 0.110 56
0.4 0.085, 0.085 49
1.0 0.078, 0.080 52
2.0 0 . 075, 0.075 54
4.0 0 . 058, 0.042 75
0.0 0,008, 0,008 55
10.0 0. 005, 0*005 99
, ......  I -1......... - r r - ......-
Shovfla ia  tho effeq t in  a oaseinolytio assay system of 
increasing concentrations of Trasylol added to banlc plasma 
before aotivation with otreptokinaGo and a fter  activation  
v/ith atroptokinase but prior to plnsmin aaaay. ïhese  
resu lts  are illu stra ted  in  figures S5 and 26.
Table 25. Inhibition by toasy lo l of ttroteolytlo a o tiv ity  of plaMlln 
with sevenfold variation in  aubstrato concentration? k inetica
0Î  the ffQaotion
Concentration of substrate| 
casein1 gm/lOO ml 
digestion mixture# (s )
Reaction ve loc ity  in  caaeinolytic 1 
assay» mg tyrosine /  
released/ml/hour. (V) S
------ - 7
1
/
V
Control experiment without Trasylol
2.00 0.97 0.50 1.0
0.80 0.61 1.25 1.6
0.50 0.41 2.00 2.4
Oi40 0.52 2.50 3.1
0455 0.29 3.03 3.5
0.285 0.25 5'50 4.0
Experiment with Trasylol# 5 units/m l digestion mixture. incorporated
2.00 0.65 0.50 1.5
0.80 0.45 1.25 2.3
0.50 0.52 2.00 3.1
0.40 0.29 2.50 3.5
0.55 0.25 5,05 4.4
0.285 0.16 5.50 6.3
Experiment with T rasylol# 8 units/m l digestion mixture. incorporated
2.00 0.22 0.50 4.6
0.60 0.20 1.25 5.0
0.50 0.18 2.00 5.6
0.40 0.145 2.50 6.9
0.55 0.11 5,05 9.1
0;285 0*09 5.50 11.1
Experiment with Trasylol. 10 units/m l digestion mixture* incorporated
2.00 0.072 0.50 13.9
0.80 0.054 1.25 18.5
0.40 0.045 2.50 22.2
0.55 0.036 5#05 27.8
0.285 0.018 5.50 55.6
The double reciprocal p lots shown in  figures 2? and 28 are compiled from th is
tab le.
\ jbXe 26. Inhibition by TraayloX of proteolytic activ ity  of plasmin with 
burfold variation in  substrate concentration > kinetics of the reaction
1
m 
: ÏI
Intration of substrate, 
ksein# gm/XOO ml 
^stion mixture# (3)
Reaction velocity in caseinolytio 1 
assay* mg tyrosine /  
released/ml/hour. (V) 3
1
/
V
i \
Control experiment without Trasylol
2,00 0.05 0.50 1.2
1.00 0*69 1.00 1.5
0,80 0.54 1.25 1.9
0.65 0*45 1.54 2.5
0.55 0.55 1.89 2.9
Experiment v/lth Traarlol# 5 miits/ml digestion mixture*. incorporated
2.00 0.41 0.50 2.4
1.00 0.36 1,00 2.8
0.00 0*32 . 1.25 5.1
0.65 0.26 1.54 3.9
0.55 0.23 1,89 4.4
The double reciprocal plots shovm in figure 29 are compiled from this table
with seycnfold variation in substrate concentration» kinetics of the reaction
Conoontration o f anbotrabe 
plasminogen! oaaeln tinita/ral 
added bo d igestion  mixture* ( s )
Réaction •volooity in  caseinolytio  
assays casein units plasminogen 
aotlvated/ml/minute. (V)
1 1
/  /
S V
Control experiment without  ^ Tras,vlol '
25.3 0.135, 0.157 0,04 7 .4
11.7 0.133» 0.135 0.09 7.5
7*9 0. 127, 0.128 0,13 7 .0
5.8 0 , 117, 0.117 0.17 8.5
4.7 0.100, 0.102 0.21 9.9
3.7 0 . 093, 0.100 0.27 10.4
2.6 0.000, 0.083 0.36 12.3
.Experiment wi.th Tras.ylol. 2 units/m l d igestion  mixture, incorporated
25.3 0 . 123, 0.123 0.04 8.1
11.7 0.110, 0.112 0.09 9 .0
7.9 0.100, 0.103 0.13 9 .9
5.8 0 . 070, 0.072 0.17 14.1
4.7 0. 047, 0.047 0.21 21.3
3.7 0 . 042, 0.042 0.27 23.8
2.8 0. 030, 0.030 0.56 33.3
■T'lxpe,riment nijfch ffraaylol. 5 units/m l d igestion  mixture, incorporated
23.5 0.108, 0,113 0,04 9.1
11.7 0.087, 0.087 0.09 11.5
7.9 0. 073, 0.078 0.15 13.4
5.8 0 . 052, 0.053 0.17 19.0
4*7 0. 023, 0.025 0.21 41.7
2.8 0.018, 0.020 0.36 52.6
jjbtperiment with yraeyloX. 10 im its/m l digestion mixture* incorporated
25.3 0.000, 0.085 0.04 12.1
11.7 0.060, 0.067 0.09 15.7
7.9 0 . 047, 0.050 0.13 20.6
5.8 0.022, 0:022 0.17 45.5
4*7 0.018, 0.018 0.21 55.6
3.7 0.012, 0.012 0.27 83.3
2.8 0. 003, 0.003 0.36 333.3
The double reoiprooal plots shown in figure 50 are oompiled from this table
Table 28. Inlilbltloa by Traeylol of plaeminofcepi motivation by stroptokinase
with threefold variation in subetrate oonoentration* kinetioa of the reaction
Concentration of substrate ^ 
plasminogen* casein ■units/ml 
added to digestion mixture# (s)
Heaction velocity in caselnclytic 
assayi casein units plasminogen 
aotlvatod/ml/rainute. (V)
1
/
S
1
/
y
Control experiment without Srasylol
23.3 0*123, 0.127 0,04 8 .0
18.7 0. 122, 0*123 0.05 3.2
16.3 0. 117, 0.117 0.06 8.5
14.0 0. 115, 0.117 0.07 8.6
11.7 0.113, 0.113 0.09 8.8
9.3 0.108, 0.108 0.11 9.3
7.9 . 0. 107, 0.107 0.13 9*4
Experiment with Traaylpl.,5 units/ml digestion mixture, incorporated
23.3 0 . 105, 0,105 0,04 9*5
18.7 0 . 097, 0.100 0.05 10.2
16.3 0, 092, 0.092 0.06 10.9
14.0 0.083, 0,087 0,07 11.8
11.7 0. 077, 0.080 0.09 12.7
9*3 0. 070, 0.073 0.11 14.0
7.9 0. 063, 0.067 0.13 15.4
The double reoiprooal plots shown in figure 31 are compiled from this table*
Table, ^ 9* Inhibition by Trasylol of TPXasmino/ten ,activg>tlon by streptokinase
with threefold variation in substrate ooncentrationt kinetlos of the réaction
Concentration of substrate,
plasminogen* casein units/ml 
added to digestion mixture# (S)
Reaction velocity in  caseinolytio 
assay* casein un its  plasminogen 
activated/ml/minute, (V)
1
/
8
1
/
V
18.0
Control experiment without Trasylol
0.036 0.06 27.8
12.6 0.028 0.08 35.7
9.0 0.022 0.11 45.5
7.2 0.020 0.14 5 0 . 0
6.1 0.015 0.16 66.7
Experiment with Trasylol. 17 unite/ml digestion mixture. Incorporated
18.0 0.027 0.06 37.0
12.6 0*022 0.08 45.5
9*0 0.015 0.11 66.7
7.2 0.013 0.14 76.9
6.1 0.010 0.16 100.0
The double reoiprooal plots shown in figure 32 are compiled from this table
m.
tirokinaaei k in etics  o f the reaction
Gonoentration of BUbstrate, Reaction Valooity in  caseinolytio  
plasminogen* casein unita/ml assay* oaaeln unite plasminogen 
added to d igestion  mixture* ( s )  aotlvated/ml/mlnute. (V)
1 1
/  /  
-S V
' "1
Control experiment without I'rasylol
17.50 1.37 0.06 0.73
12.25 1.35 0.08 0.74
a . 75 1.30 0.11 0.77
7.00 1.28 0.14 0.70
5.95 1*23 0.17 0.01
Experiment with T rasylal. 5 units/m l digestion mixture. Incorporated
17.50 1.27 0.06 0.79
12.25 1.10 0.00 0.85
8.75 1.12 0.11 0.89
7 .0 0 1.03 0.14 0.97
5.95 0 .9 s 0.17 1.02
The double reoiprooal plots shown in figure 35 are compiled from this table.
Table.51. Intiibitlon by Trasylol o f the estero ly tic  a c t iv ity  of 
urokinaee on AcbMe with fiv efo ld  variation in  eubstrate concentration»
k in etics o f the reaction*
Concentration of substrate, 
AcMe; mg/lOO ml 
digestion mixture. (S)
Reaction velocity  in  1 1
e stero ly tic  assays p. moles /  /
methyl alcohol released/ml S 1 
urokinaae/minut© * ( V ) .
Oontrol experiment without Trasylol
16,7 2.42 0.06 0.41
8,3 2,13 0.12 0.47
5,6 2.11 0.18 0.47
4*2 1,92 0.24 0.52
3,3 1,91 0,30 0.52
. iMOorporated
16.7 1.91 0.06 0.52
8,3 1,60 0.12 0.65
5,6 1.39 0.18 0,72
4 ,2 1,12 0.24 0.89
3,3 0,94 0.30 1,06
The double reciprocal plots shown in figurei 34 are compiled from this table
Table 32. InUibition hy Trasylol o f the eoterolyt ic  a o tiv ity  
of urokinase on AoIiMe with ttoeefold  variation in  
substrate ooncentrationi k in etics of the reaction
Concentration of substrate, 
AcBîei mg/ml 
digestion  mixture. (S)
Reaction ve loc ity  in  1 1
este ro ly tic  assay* p moles /  /
metljyl alcohol released/ml B 1 
urokinase/minute '
Control experiment without Trasy^,ol
16,9 1.95 0.06 0.51
11,3 1*93 0.09 0*52
0,5 1.85 0.12 0,54
7*0 1.82 0.14 0.55
5,6 1.70 0.18 0.59
Experiment with Trasylol# 5^0 units/m l digestion mixture# incorporated
16*9 1.44 0.06 0.69
11,3 1*34 0.09 0.75
0,5 1*32 0.12 0.76
7,0 1.24 0.14 0,61
_________________’ • !
1# 22 0.18 0,82
The double reciprocal plots shown in figure 35 are compiled from this
table#
Table 33# Effect of TrasyloX. compared with that of1*  ' 'i" T '    I' ' " ' ' i" i i r n  v i - i r r - m n r r r  r u r  ' i ‘7i W o ' i* i t ‘i l f r r r r r r < i i -ti‘ r rp f i» n fiffN iT * rM i TT-r-«:ir | ‘ r > r - r» > iM ir if> rtf rT » t a i i i i r i r i i .‘m i i t i i r r
AKGA and of EAGA# in the .urokinaae aens.itivity teat.
Molar concentration of inhibitor 
311 digestion mixture
IV asylol
hysia time in urokinase Gonsltivity
test
0 6 mins
1*5 % 10'*'^ 6 myjiB 4o secs
3*B X 10“"' 9 mius 10 secs
4 #5 X 10"^ 13 mine
6*0 X 10""'' 31 mills
6*8 X 10"^ >300 miltts
MCA
0 6 mins
1*0 X 10-5 13 mine
2*5 2C 10-5 19 mine 20 secs
3.0 % 10-5 31 miîjas
1*0 X 10“*^ 31 m:ins 30 secs
1*3 3: lO"*'- 64 mine
2*0 X 10"'^ 8l mine
2*3 X 10"^ ' >300 miiJis
EACA
0
2 .8  X
5 .6  3t 10,-5
1,1  % lO*^’'
2.8  X 10**^
4 .4  3«£ 10"'i'
5 .6  X lO"^
6 mine 
8 mine
11 mina 13 secs 
17 mins 53 seea 
21 roins
27 rnina 33 aeoa
46 mins 20 secs
Shoim is the antifibrinolytic effect of :lncreas:lng concentrations 
Trasylol, AHCA and EAGA in the ux‘okinase sensitivity test# These 
results are plotted in figure 3^ *
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Table 35* Tliromboplastln jseneration t e s t *
o ffee t o f Trasylol in  incubation mixture♦
Incubation time, 
minutes
Clotting tim es, seconds, at varying 
Trasylpl concentrations
Trasylol concentration, units/m l 
incubation mixture
0 100 330 300
1 4 l 83 94 100
a 11 20 64 70
3 11 11 31 4 l
4 12 12 19 23
5 10 11 16 18
6 10 11 15 18
Shown i s  the e f fe c t  of increasing concentrations of 
Trasylol added to the incubation mixturo in  the 
tteomboplastin generation test*  The f i r s t  column shows 
the sa lin e control# The resu lts  are graphically  
displayed in  figure 37#
Table 36. Thromboplastin Reneratlon test :
effect of Trasylol in incubation mixture#
Incubation time,
Glott;lng times# seconds, at varying Trasylol 
concentrations
nrlautOB Trasylol concentrâtion, imits/ml incubationmixture
0 ■ 50 80 100 200 500
1 4? 46 4? 50 100 106
2 45 45 45 46 75 84
3 39 38 38 4l 57 62
4 22 22 22 2? 35 44
5 12 12 12 16 22 33
6 12 12 12 15 16 27
e 12 12 12 15 l6 22
10 12 12 12 14 16 22
12 12 12 12 3.4 15 22
14 12 12 12 14 15 22
16 12 12 12 14 15 22
Shovm is the effect of increasing concentrations of Trasylol 
added to the incubation mixture lîja the ttoomboplastin 
generation test* The first column shows the saline control*
Table 57" Thromboplastin generation testj
f Trasylol added to substrate plast
Incubation time. Clotting times, seconds, at varying Trasylol concentrations 
minutes Trasylol concentrations, units/ml substrate plasma
0 40 50 100 200 500 1,000 2,500
1 95 100 104 104 106 106 106 140
2 66 75 84 86 86 97 97 136
3 57 57 39 45 46 55 55 76
4 14 14 l4 14 l4 20 24 24
5 14 l4 14 l4 l4 l4 l4 l4
6 14 l4 14 14 14 14 14 14
Bhox-m is the effect of Traeylol addod to the substrate plasma 
in the thromboplastin generation test* The first column shows 
the saline control* The data ore displayed in part in figure 58*
Table 58* Platelet ûffare^ atiôn in Qhandlor*a tube*
effect of Traeylol added iyi vitro to plaBwa
Subject
number
Time for platelet aggregation, seconds
Control With Trasylol
300 units/ml plasma
X 630 805
2 552 928
3 572 797
4 588 977
5 560 1273
6 582 735
7 544 1058
Meen 577 939
8#D# ± 28 t 186
Shorn i s  the e f fe c t  on p la te le t  aggregation o f  
Trasylol added to plasma from each of seven 
subjects. Mean values and standard deviations 
are a lso  shown., The mean time for p la te le t  
aggregation# when Trasylol was added to each 
plasma in  a concentration of 300 units/ml# i s  
prolonged s ig n ifica n tly  compared with the mean 
time for p la te le t  aggregation in  the absence 
of Trasylol ( t  « 4*79?# 0.001 < p < 0 .0 0 5 ).
Table 59. Platelet egg/yregation in Chandler*a tube#
effect of Trasylol added in yitro to plasma
Subject
number
Time for p la te le t  aggregation» seconde
Control With Traejrlol 
40 unite/ml plasma
1 545 605
2 501 578
3 260 290
4 410 284
5 141 381
6 653 810
7 473 621
8 430 921
9 390 420
10 590 8O5
Mean 439 572
3.1). 4 152 4 227
Shown i s  the e f fe c t  on p la te le t  aggregation of 
Trasylol added to plasma from each of ten subjects. 
Mean values and standard deviations are also shown. 
The mean time for p la te le t  aggregation, when 
Trasylol was added to each plasma in  a concentration 
of 40 units/ml# i s  prolonged sig n ifica n tly  compared 
with the mean time for p la te le t  aggregation in  the 
absence of Trasylol ( t  » 2.543# 0*02 < p < 0*05)
niable 40 Platelet a/Mreggtion in Chandler*s tube*
effect of Trasylol inojubated In vitro with plasma
Subject
number
Time for p la te le t  aggregation, seoonda
Control With Traaylol
40 unita/ml plaaraa
1 275 255
2 292 286
3 260 255
4 108 358
5 247 335
6 540 400
? 240 171
8 330 390
9 320 267
10 440 320
Mean 293 312
3*3). * 69 * 06
Bhown i s  the e f fe c t  on p la te le t  aggregation of Trasylol 
incubated for 10 minutes with plasma from each o f ten 
subjects. Mean values and standard deviations are also  
shown* The mean time for p la te le t aggregation# when 
Trasylol was incubated with plasma in a concentration 
of 40 units/ml# does not d iffe r  e ign ifioan tly  from the 
mean time for p la te le t  aggregation in  the absence of 
Trasylol ( t  » 0*625# 0*5 < P 4 0*6)*
Table 41 Bioohemiôal effeota of Trasylol infusion
Time of aampling, hours
0 5 15
One*#stage prottoombin 
time; seconds 15.0 15*4 15.0 14.0
Thrombin clotting 
times seconds 10,5 9*6 10*4 9*6
ISuglobulin clot lysis 
times minutes 41 190 360 382
Feamley plasma clot 
lysis time: minutes 230 382 1#200 1,200
Ürokinase sensitivity test# 
lysis time; minutes# seconds 7i9 15,4 10,35 10,27
1 , r . ÿ  T . . .
Fibrin plate test; mm ; plasma* 
resusponclod euglobulin precipitate
49
110
0
36
0
0
0
0
Platelet count 
thousfmds/mm3 170 157 207 212
Thromboplastisi generation test 
Incubation time# minutes Clotting ^ times* seconds
1 GiO 8*8 8*8 8*4
2 8#8 8,6 8*8 8*4
3 BkA 8,6 8*2 8*4
4 8 ,4 8*0 8*2 8*4
5 8,2 8.0 8*2 8*4
6 8,2 8.0 8.2 8*4
Shown ÎB the effect in a normal subject of an intravenous infusion 
of OJraeylol on various fibrinolytic rmd coo^ jala^ tion tests. The 
dosage schedule of Trasylol v/as 10#000 units in 30 minutes j 3,000 
units/hour for two and one*half hours tuid 1,000 units/hour for 9 
hours. The data are displayed in part iïi figure 39*
Table 42. Biochemical effects of Trasylol Infusion
Euglobulin lyeis; units 1*1 0 ,2
ÏÏrokimee sensitivity test# 
lysis time; minutes# seconds 16.39
Platelet count; 
thousands/mm) 200 186
Thromboplastin generation test. 
Incubation time# seconds times. seconds
1 65 76
2 55 68
? 15 38
4 11 17
5 11 13
6 10 12
8 10 12
Time of oampling, minutes
0 40
Shown is the effect in a normal subject of an intravenous 
infusion of Trasylol* Tha dosage schedule of Trasylol was
50,000 units 88 a single injection followed by 50,000 units 
over 30 minutes# The data are displayed in part in figure 40.
Table 43. Effeoj# of Trasylol in.iection on the thromboplastin
générai;!on test. uayokinase eenaitivity test and platelet count
0
Time of smmllng# hours
1  g  3  s   7
Incubation 
time# minutes
Thrpr^ generation test
Olottteg timoBè oeoondB
i  g i
1 51 71 56 55 51 51 51 51 51
2 36 62 41 38 56 35 56 35 36
3 17 39 as 20 17 17 18 17 17
4 11 21 n 11 11 11 11 11 11
5 11 13 11 11 11 11 11 11 11
6 11 11 11 11 11 11 11 11 11
9,40 1,25
lyaiB timet mlnubea. aeoonae
16,0 15,20 16,20 17,15 15,35 15,25 9,20
1 («II*,II,I"" I
268 862 258
Platelet count
ghoiisando/pBir^
273  2 6 5  275
i m v’.. f  i I t i  W* .  <  f * .
260 261 260
Shown is the effect of a single intravenous injection of Trasylol, 
containing 100,000 units, on the thromboplastin generation tost# 
urokinase aensitivilty test o M  platelet count of a normal subject#
The data ere displayed in por^ t in figure 41#
Tablq 44# Effect of .Trasylol in fa o io n on the tliromhoplaatin 
g e n e r a tio n  teet# ttroîcinase s e n e i t i v i t y  teat and platelet count
fe L S L S S E 2 A < itiJ iS S a  
0 1 2 3 4 5 7
In cu b a tio n  P lo t t in g  t im e , secondemirmvmytmf^ mfm-*têi'k Ar n u L # 'm jw  t. * * # #  i i i w i W m
time# socoM b
:t. 71 77 80 00 60 80 61
8 55 62 64 6b 68 75 77
3 32 39 ■ 58 60 60 62 62
4 15 17 35 40 40 43 43
5 15 16 16 2 0. 20 22 22
6 15 15 15 15 15 15 15
ïïrokinase aensitiviiy teet
, 1 : 1 » . # #  01I1*  . W  n  l i w M n t w
bysie times minutes# sec
4»30 4#30 4#50 5|0 7,30 9,0 4,50
P la te le t count
300 310 310 320 302 312
Shown ie the effect in a normal subject of a-fivo hour intra# 
venous infusion of Trasylol on the thromboplastin generation 
test, urokinase sensitiviiy tost and platelet count* The 
Trasylol infusion was aflministered at a progressively 
increasing dosage; 10,000 units in the first hours 20,000 
units in the second hour; 50,000 units in the third hour;
100,000 units in  the fourth hour and 200,000 units in the 
fifth hour* The data eire displayed in part in figure 42.
Table 45» Bffeot of TragyXol infaBion on the thrombonlaetin
generÆition test* urokinase sensitivity test and platelet count
Time o f sampling* hours
Incubation 
time, minutes
0 1 2 3 4 5 7
Thromboplastin /veneration te s t  
Clotting time, seconds
1 50 52 54 56 56 50 51
2 29 44 44 53 56 56 50
5 14 30 34 47 50 52 47
4 14 16 17 32 40 44 29
5 12 14 17 23 23 23 20
6 12 14 14 10 18 18 17
TJroItinase aen eitiv ity  te s t  
Lysis times minutes# seconds
5,0 6,5 6,35 6,40 19,0 19,0 6,10
P la te le t count 
Thouoands/mm?
210 200 218 205 210 195 204
Shown i s  the e ffe c t  in  a nprmal subject of a f iv e  hour in tra­
venous infusion o f Trasylol on the throBiboplastin generation 
t e s t ,  urokinase se n s it iv ity  te s t  end p la te le t count* The 
Trasylol infusion was administered at a progressively increasing  
dosage; 10,000 units in  the f i r s t  hour; 20,000 units in  the 
second hour; 50,000 units in  the third hour; 100,000 units in  
the fourth hour and 200,000 units in  the f i f t h  hour* The data 
are displayed in  part in  figure 45*
a^CTegation measured in  the Chandler^ g tube
Subjeot I’ime for p la te le t aggregation» seconds
number Before Trasylol After Trasylol
1 400 360
S 636 448
3 495 410
4 455 145
5 486 125
6 586 137
7 623 311
Mean 537 277
s . s . * 75 * 139
Shown for each of seven subjects i s  the e f fe c t  of a single  
intravenous in jection  o f T rasylol, containing 100,000 
u n its , on p la te le t  fjiggregation measure in  the Chandler’s 
tube* Mean values and standard deviations are a lso  
shown# The moan time for p la te le t agfjregation )0  
minutes a fter  the Trasylol in jection  was s ig n ifica n tly  
le s s  than the mean time for p la te le t aggregation 
immediately pre#injeotlon ( t  =» 4*976, 0*001 < p < 0*003)
yable 47. Effect of Trasylol injection on the platelet oount
Subject P la te le t count, thouGGnde/mm
number Before Trasylol After Trasylol
1 300 301
2 555 350
3 398 402
4 243 230
5 208 211
6 383 380
T 278 275
Mean 309 308
S. 3). * 72 # 72
Bhown for each of seven eubjeots i s  the e ffe c t  of 
a single intravenous in jection  of T rasylol, 
containing 100,000 u n its , on the p la te le t count# 
Mean values and standard deviations are a lso  shown# 
The mean p la te le t  count immediately before the 
Trasylol in jection  i s  almost id en tica l with the 
mean platelet count )0 minutes a fter  the Trasylol 
injection#
Table 48> TliromboiplaBtin generation test: 
effect of fraeylol injoction#
generation test 
Clotting times, secends
Incubation time,
m inutes j. d 3
Bubjeot
number
1 45 42 21 10 10 10
52 45 24 13 12 12
2 45 36 21 10 10 10
49 44 34 16 13 12
3 73 68 59 4 l 17 16
73 69 63 41 21 17
4 61 63 43 34 19 13
61 61 61 46 26 17
5 46 44 26 17 11 11
62 62 46 26 18 16
6 53 41 24 15 12 12
60 50 45 35 23 17
7 63 59 33 16 13 13
69 61 52 31 22 18
Bhovm for each of 7 subjects are the results of 
thromboplastin generation teats carried out before a 
single intravenous iajectimi of Trasylol containing
100,000 units and 20 minutes after the injection# The 
results of the teat before Trasylol injection for each 
subject are recorded above the results of the test after 
Trasylol Injection# At 6 minutes incubation, tha^ m^ean 
clotting time before Trasylol injection was 12j|i. - 2*1 
seconds and after Trasylol injection was 15*6 seconde 1
The prolongation of clotting times after Trasylol injection 
i s  significant (t » 5.277, 0*001 < p < 0*005).
Table 49* Effect of heparin infusion conmaref
fmfusion :î^ a patient with the defibrination ^ndrome,
Fibrinogen, 
mg/lOO ml
0 11
Time of sampling# hours 
3 #  4 ^
* 1 w w > . f c j . i i, » iV< # * ! > # r « » # 3 s * t > w » :j # i » * if e * M r « i3 # te * * # ti i
115 137 158 175 195 100 100 137
55 ?2| 79i 96
Plasminogen, 
casein units/ml 1.3 1 .3 1.8 1.4 1.7 1.9
Thrombin clotting 
time y seconds
Anti-haemophilic 
globulin, per cent 15
15 13
4 5 45
1 5
7-&
1 3 13
u i 9 e . 4 ; K î S i 4 . > # i ^ 8 i i 9 . u t * e * « « » ï " < V M i r ï a r ‘A î $ « . ' y »
25 3 2
Factor F, 
per cent
Platelet count, 
thousands/
40
116 115 110 112
Christmas factor, 
per cent 100 100
!C 42 100
;w .y M L 3a*àM * c » « . :  r A - f  .  i w o j « wt^ " i 4 n a # C i » w r t f t T g : ^ J t i
98 45 54
l ^ u g n tS r f t .
100 100 100 100
Shovjn is the effect, in a patient v/lth liypofibrjjiogenaemia 
associated with metastatic caro:lnoma, of a heparin infusion compai'ed 
v/ith a Trasylol :lnfusion* Heparin infusion v/as administered for 
55 hours; 1,000 units/hour for 48 hours then 1 ,500 units/hour for 
7 hours* No therapy v/as given thereaftei' for 17'^- hours. Tradylol 
infusion was then administered; 100,000 units/hour for ? hours*
A further heparin infusion, 1,500 units/hour for 16^ hours, followed 
the Trasylol infusion* These results are (U,splayed in part in 
figure 46.
Infusion ^  a
-nationt with the d ofito in ation ayndrome
III# # # M # I *wtm* \i w ui m  i h  i
3 o f oamplln/ïé hoara
0 5 9
.Fibrinogen 
mg/lOO ml 43 75 100
Flaaminogen 
casein unite/ml 0.9 1.5 1.5
Thrombin o lo ttin g  
time, seconds 20 18 15
Onemstage protteombin 
time, seconds 21 17 16
Anti^^haemophilic 
globulin , per cent 5 60 60
Factor V, per cent 8 80 100
P la te le t count 
thousands/om3 50 63 90
Bhown la  tiiQ effeot# in  a patient with hyi)o# 
fiteinogonaeBîia asaoolatod with metataetio 
oaroinoma# of ^j^raeylol infuBion# The infuaion  
rate was 100*000 m ilte / hour for 9 hour8*
ThoBQ results axe displayed in part in figure 47*
klneticsoiVthe reaction
Oonoentration. of substrate, Heaotion velocity in oaBeinolytio 1 1
casein3 gm/lOO ml assays mg tyrosine / /
digestion mixture. (S) ^released/ml/hom*. (V) B V
G<s&oi_sa2£lsjsaiJ2 i ^
2 , 0 0 0 , 6 7 0 . 5 0 1,5
1 . 0 0 0 , 4 6 1 . 0 0 2 , 2
0.80 0 , 4 0 1#25 2,5
0 , 6 4 0 , 5 2 1 . 5 6 3 , 1
0 , 5 2 0 . 2 9 1 . 9 2 3 . 4
0 , 4 0 0 , 2 5 2 . 5 0 4 . 0
0,28 0,18 3.57 5 , 6
Experiment with Trasylol, 100 unita/m l, di/ïestioa mixture, incorporated
2.00 0,38 0 . 5 0 2,6
1.00 0 , 3 2 1.00 5.1
0.80 0,28 1 . 2 5 3.6
0.64 0 , 2 4 1 . 5 6 4 . 2
0 . 5 2 0 . 1 9 1 . 9 2 5 . 3
0 . 4 0 0,18 2 . 5 0 5.è
0.28 0 , 1 3 5 .57 7.7
The double reciprocal plots shorn in figure 48 are compiled from this table
Table 52* Inhibition by Trasylol o f tyypain added to bank plasma
' # 1 * I ■< ÜI**M W ijfi ' i '"  i u i #
Concentration o f tiyp oln , Opti°al denelty in  trypein aeeay inhib ition
jufî/îal plasma Without Trasylol With Traoylol a c t iv ity
0 0 0 m
10 0 0 m
20 0 0
50 0 . 020, 0.020 0 100
100 0 . 020, 0,020 0 100
120 0 , 020, 0,020 0 100
160 0 , 020, 0,020 0 100
200 0 , 036, 0 , 03e 0 , 020, 0,022 43
400 0,064, 0,066 0 , 035* 0,045 30
500 0 , 090, 0,090 0 , 043, 0,055 44
600 0,110, 0,110 0.080, 0,090 23
700 0 , 150, 0,153 0 , 104, 0,105 31
800 0 . 175» 0,185 0 , 105, 0,115 39
900 0 , 275* 0,275 0 . 195, 0.205 27
1,000 0.360, 0.370 0 . 245, 0*255 32
m'Hkw¥smttf.f # i f c W 'i y - ^ w f e - M p m W r t f
Shown is the activity in  a caseinolytio assay system of increasing conoentratiaiE 
of trypsin* assayed in the presenoo of banîr. plasma. Shown also is the effect 
of Trasylqlj 40 imits/ml of plasma, on the activity of the same concentrations 
of trypsin assayed in the presence of bank plasma.
Table 53* Anti*»tryptic Botivity in pXasmat
effect of TraByloX inleotion
Subjoot
number
Mean
a^i).
optical density in trypsin assay* 
before Trasylol after Trasylol
1 0*105* 0*115 0*030* 0*030
2 0 . 170,  0*180 0*140* 0*150
3 0*175» 0*185 0*150* 0*150
4 0*160, 0*166 0*154* 0*156
5 0 , 150, 0*150 0*140* 0*044
6 0 . 300, 0.300 0*300, 0*500
7 0 . 140, 0*142 0*112, 0*118
: «XW*^«aC9tiCVlK«K
0*174
0*060
0*134
0*089
Bbown are the résulte of assay of trypsin* 
1*000 ;igm/ml of plasma* added to plasmas 
Obtained from each of 7 normal subjects 
immediately before the intravenous injection 
of Traaylolf 100*000 imits# and 50 minutes 
after the injection* Mean values and 
standard deviations are also shown* Mean 
activity of trypsin in plasma after Trasylol 
injection is significantly less than Mean 
trypsin activity in plasim before Trasylol 
injection (t ^ 3*451| 0*01 < p <0;02)
Table 54* Bffeot of dialyaed urokiyiaae and pure urokinaae
Qubstituted for human brain in the pne^stage
Plasma
number
R ecalcification  time, seconds
Human
brain
Dialysed
urokinase
Vxncù
urokinase Saline
1 7T 75 76 107
2 19 77 75 116
5 84 04 86 101
4 78 72 77 95
5 92 86 88 110
6 86 69 74 96
Shown are the résulta o f substituting 101000 
G*T*A. unita/ml solutions of dialysed and pure 
urokinase for a 11500 d ilu tion  o f  human bpain 
extract in  the one-stage prothrombin time#
The la s t  cSolum gives the saline controls.
XiîAOA was present in  the system in  a concentra­
tion  of 10*2 Molar to in h ib it ly s is .
and pure urokinase added to s ilic o n e  p-Lasma.
Oonoentration of 
uroklnaoo in  te s t  system, 
units/m l plasma
H ecalcification time, seconds
with dialyaed urokinase with pure urokinase
0 446 621
50 445 618
200 428 589
500 415 557
1,000 401 552
2,000 554 512
5,000 532 353
10,000 326 366
20,000 299 520
50,000 294 245
Bhovïn Is  the e f fe c t  o f Increasing concentrations of dialysed urokinase 
and pure urokinase on the reoa lc ifioa tion  time of s ilic o n e  plasma# In 
each case a sa lin e  controjj i s  shorn# The te s t  system contained FAGA 
at a concentration of 10*^ *^* Molar to in h ib it ly s is#  The data for the 
dialysed urokinase are graphically dieplayod in  figure 49 and the data 
for the pure urokinase in  figure 50.
'oagulativo a c tiv ity  of dialyoed uroklnase 
aMed. tQ. HaggMMyfao^or
Conceateation o f  
«i?olcinaee in  te s t  system, 
ittiits/ral plasma-
^décalcification time of 
Hageman-factor d efic ien t  
plasma, seconds
0 1,316
<)k 1,324
188 1,225
375 1,026
750 935
1,500 778
3,000 571
6,000 574
12,000 395
Bhoun i s  the e ffe c t  of increasing concontrationa of 
dialyaed urokinaae on the reca lc ifica tio n  time of 
Hagemeai-faotor d efic ien t plaania* A sa lin e control 
i s  a lso  ohown* The te s t  aystem contained FACA in a 
concentration of 10*^  ^ Molar to  in h ib it ly s is#
The data are graphically displayed in  figure 51.
Table 57* Ooagulative activity of two separate batchOB 
of dialyaed urokinaae added to fresh normal plasms?..
111X. iM Ê Vii I M  | i i N# n M i H w i i # n in f K W i  IW , » #  . J . » w
G one en tration of 
urokinase jji 
test system, 
imite/ml plasma
Recalcification time 
of fresh normal plasma, seconds* 
X-'urther purified 
itrokinase urokinase
t T^ T— H  j*.  I-
0
50
100
200
500
1,000
2,000
5,000
10,000
4l6
4l4
412
406
404
379
368
368
353
375
372
351
3 4 9
340
3 3 0
3 1 0
Shown is the effect of increasing concentrations 
of two separate batches of dialysed urokinase on 
the recalcification time of fresh normal plasma* 
A saljme control is a].so shomi* lllxe test system 
contained BAGA in a conoentratioïx of 10*2 Molar 
to inhibit lysis*
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Table ^0* The effoot of. urokinase
:m the thrombopllastiu generation teat, substituted
and seruro#
Clotting time» seconda
i» # i . '«i*# r \imytmi* w ii
Incubation time, maxuttes 1 2 h 5
Normal plasma 
Normal serum 
Normal platelets
Caline
Normal seruïiî 
Normal platelets
63 35 13 11 11 11
88 8?
93
Urokinase 
Normal serum 
Normal platelets
Normal plasma 
Baline
Normal platelets
Normal plasma 
Urokinase 
Normal platelets
92 91
86 84
63 56 53 50 49
90 90 90
76 75 71 58 55 34
Shoim is the effect of dialysed uroldlnaae in partially 
correcting the defect due to absence of plasma m d  serum 
in the thromboplastin generation test* Where urokinase 
v;as added, its concentration was 6,000 G*T*A* units in 
the incubation mixture* MAGA was present in the tost system 
at a concentration of 10*2 KoXar to inhibit lysis *
Table 61. oî_uroic2jiase in ani;nxaemqphl.lic globulin
and C hristm as fa c to r  a s s a y s «
ANTIIÎABMOPïmiC GLOBULIW ASSAY
C lo t t in g  t im e , secon de  
o f  s u b s tr a te  plasm a
C on tro l d i l u t i on c u r v e , per c e n t  d i l u t i o n o f  
c o n tr o l  plasm a
100 50 20 10 0
C lo t t in g  t im e , se c o n d s , 
o f  s u b s tr a te  plasm a
l 6 l  178 200 2 1 5 2 2 5 245 2 8 5
S u b s t itu t io n s  fo r  100 per c e n t c o n tr o l  plasm a
liaem op h ilic  Pure D ia ly se d
plasm a u ro k in a se  u ro k in a se11 É II I —I I b m i  M il  ■■■nuTii I I mil I ' t w s w n v
!71 243 244
c « 9 - '.4 n ^  *  4 » f« m 3  rr» 4 u U k  w v W V ^ ''tH  .*(1
CHHISTMAS FACTOR ASSAY
C on tro l d i lu t io n  cu r v e , per  c e n t  d llx i t io n  o f  
c o n tr o l  plasm a
100 50 20 10 5 2 0
- - •     • ■ ■• ■ <V)» W W rt a.'UWI >LTfL'W I'M.mWi**rT+'m'I*'T t e n e m / i w a »
C lo t t in g  t im e , se c o n d s ,  
o f  s u b s tr a te  plasm a l4 ? 155 179 l 84 192 203 268
C lo t t in g  t im e , se c o n d s , 
o f  s u b s tr a te  plasm a
S u b s t itu t io n s  fo r  100 per c e n t  c o n tr o l plasm a  
C hristm as Pure D isilysed
plasm a u ro k in a se  in’o k in a se
« ? ^ * M A a & rz * * A # K n K ÿ T * # ff # In a k W #
264 205
Shown are  th e  e f f e c t s  o f  pure and dia3.ysGd u rok jjiase  s u b s t i t u t e d  fo r  
100 per c e n t o f  th e  c o n tr o l  plasm a in  a n tih a em o p h ilic  g lo b u lin  and 
C hristm as fa c to r  a s s a y s ,  l a  each a s s a y ,  c o n tr o l  d i lu t io n s  were made 
from a  p o o l o f  10 norm al p la sm a s. In  each a s s a y , th e  c o n tr o ls  and 
s u b s t i t u t io n s  were px'*epared end r e c a l c i f i e d  s im u lta n e o u s ly , Ux'okinase 
was p r e se n t  in  each system  in  a  c o n c e n tr a tio n  o f  2 ,0 0 0  C,1‘,A , u n i t s . 
Both form s o f  u ro k in a se  had c lo s e l y  s im ila r  e f f e c t s ,  Bach pi-’e p a r a tio n  
had th e  same e f f e c t  in  b o th  a ssa y s  a s  th e  2 per c e n t  d i lu t io n s  o f  th e  
c o n tr o l  p lasm a, BACA,10"^ M olar, was p r e se n t in  th e  system s to  
i n h ib i t  l y s i s .
Table 62* Bffeot on platelet aggregation of fibrinogen 
degradation products added in vitro to plasma#
Subject Time for platelet aggregation. seconds
number control witli fibrinogen degradation products
1 533 303
2 4l8 286
5 270 242
4 556 289
5 255 237
6 678 356
7 629 342
Mean. 477 294
S.D* 4 168 4 h'5
Shown are the times for platelet aggregation in the 
Chandlor*s tube of plasma from each of 7 normal aubjects 
and the tiraes for platelet aggregation of the same plasmas 
to which had been added fibrinogen degradation products in 
a concentration of 180 |og/ml plasma* Mean values and 
standmrd deviations are also shown# In the presence of 
fibrinogen degradation products, platelet aggregation was 
significantly enhanced compared v;ith the control 
(t 3,874, 0 .005 < p < 0*01),
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Table 6^ ’*» Bffeot s of mroklnase infusion on the coagulation system#
R e o a lc i f io a t io n  tim e # 
seco n d s
IJagemem fa c t o r  a s s a y ,  
seco n d s
F a cto r  V a s s a y ,  
secon d s
A n tih aem op h ilic  g lo b u lin  
a s s a y , seco n d s
C hristm as f a c t o r  a s s a y ,  
secon d s
One»'*Btage prothrom bin t im e ,  
seco n d s
P la t e l e t  c o u n t ,  
thouGemdvs/mm5
0
tim e o f  Bam%)lixig, hou rs
2'  ^ 12 133* I 6 &
171 130 170 160 175
320 270 350 333 333
23 7 1 61
1 5 0
68 59
157 162
167 150 158 165
185
333
69
163
158
22,3  20.0  19,8  22,2  24,8 23,6
495 399 660 662 562 552
Bhovm rln one s u b je c t  i s  th e  e f f e c t  o f  mi In traven ou s in fu s io n  o f  
u r o k in a a e . The in f u s io n  r a te  was 6 0 0 ,0 0 0  C*T*A# u n i t s  ;m 3 0  m in u te s5
1 0 0 , 0 0 0  C*T*A# im its /h o u r  fo r  tw e lv e  hours 5 2 0 0 , 0 0 0  C*T#A# im it s  fo r
th e  n e x t  hour and 4 0 0 ,0 0 0  0,T#A# u n i t s  fo r  th e  f i n a l  hour* BACA was 
p r e se n t  :Ui a l l  c lo t ta n g  sy stem s ixi a  c o n c e n tr a tio n  o f  1 0 *^ Molar to  
i n h ib i t  l y s i s *  The d a ta  a re  d isp la y e d  isi p a r t in  f ig u r e  55* The 
d i lu t io n  cu rv es  fo r  t i ie  v a r io u s  a s s a y s  a%"0 shown :3n t a b le  6 7 #
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Table 66* Effects of urokinase infusion on the
Time of sampling, hours 
0 1 2 4 8 12 24 48
Si3.icone recalcification 160 83 226 I87 I89 I85 I65 I60
time, seconds
Factor V assay, seconds I36 295 224 286 194 20? 197 I60
Antihaemophilic globulin
assay, seconds 10? 120 125 131 140 lAO 135 119
Cliristmas factor asstxy,
seconds 80 87 88 89 94 95 85 84
One-stage prothrombin
time, seconds 22*5 25*0 27*5 30*0 43*0 26*5 23 15
Pleitelets, ^
thousaxids/mn? 275 175 24-0 290 262 290 295 375
< a w w.v" t  j g i t r j f e s a u w i  li 'J **<* »*
Shown in one subject is the effect on the coagu3.ation system of an 
Intravenous infusion of urokinase* The infusion rate was 500,000 G*T*A* 
units/hour for 24 hours* BACA v/ae present in all clotting systems in 
a concentration of 10*^  ^Molar to inhibit lysis* The data m'o dis%)layed 
in part in figure 57* The dilzxtion curves for the various assayb are 
shown in table 6?*
Table 67* Di.lution curves for copulation factor assay8 
performed on plasma samples obtained durx^ ng 
two urokinase nnfusions*
Per cent dilution
* W— i J ÿS' WP 4
tK y« \t% 3 .W W *K rW pM U  g r v W , « ' * # ' 4 W * f  lW # # t « # * X W W W  *
Hagernan factor
100 5 0  25 12
dilution curve, secs 220 362 280
i'actor V dilutioîi 
curve, sQoa
25
126
21
128
40
178
4 -6
188
50
202
Antihaemophilic 
globulin dilution 
curve, secs
142
1 0 7
162
120
179
129
1 9 8
7Î0
215
143
Christmas factor I67 178 190
dilution curve, secs 80 88 102 107 II6
Shot'ftt are dilution cm’ves for the coagulation factor 
assays %)erformed for two subjects who were given 
urokinase infusions * Bach dilution curve was made with 
the pre-jjifusion plasma of each subject* The Hageman 
factor assay was ca3;’ried out for the subject whose data 
are shorn in table 64» The other assays were carried out 
for both subjects. Those di3.ution curves recorded on the 
upper i;mes pertain to the subject whose data are shovm 
:m table 64 and those on the lower lines for the subject 
whose data are shoi^ x in table 66* EAGA was present in all 
clotting systems at a concesitratlon of 10*"^  Molar*
Table 68. Bffeot of Intmvenous Injeotion of urokinaee on
o la te la t aa-A’^ e^^ation measured in  Ohondlerf a tube#
o. Sllme for p la te le t aggregation* soopncls
mmber Before urokinase After urokinase
1 570
2 460
3 630
4 530
5 430
6 435
7 490
Pan 506
*D# Ô 74
260
502
306
350
470
412 
* 112
ShoTm for oaeh of seven normal Bubjects axe the 
resu lts  o f measuring p la te le t aggregation in  the 
Chandler*B tube iim ediately before tJxe intravenous 
in jection  of urokinase# 80*000 O.T.A. unite# and 
10 minutes a fter  the iixjeotion* Mean velxieB and 
standard deviatioxis are a lso  ^homu The sîieim time 
for p la te le t  ag^ipregation a fter the urokinaie 
in jection  i s  a ifp iificantly  le s s  # a n  the memx time 
before the in jection  ( t  « 2#800# 0#02 <p <0#05)
Table 69. Bffeot o f Intravenous _
urokinaee on
Subject
number
ISuglobulln ly a is  activity# unite#
Before urokinaoe After urokinase
1. 0*91 1.92
2 0.81 1.61
5 0.83 0,88 «
4 1.46 2,61
5 0,64 1,50
6 0,60 1,20
7 X fll 1,58
Mean 0#92 1.61
O.B* * 0#30 * 0.55
Shown for each o f seven normal subjects are the 
resu lts  of eugiobulin ly s is  tests#  immediately 
before the intravenous in jection  of urokinase #
80#000 G#T*A# units# and 10 minutes a fter  the 
Injection# Mean values and standard deviations 
are a lso  shown# Mean euglobulin ly s is  a c tiv ity  
after  the urokinase in jection  i s  s ig n ifica n tly  
greater than the mean a c t iv ity  pre-injection  
,( t  -  5. 145» 0.001 -< p <0;005) ,
T a b le  7Q Bffeot of inta^ avgnous injection of urokinase
on nlatelot coimt
Subject
x*"
P la te le t count# thousahds/mm'^
nusibor 33efore urokinase Aftes* \»rokiwase
1 250 245
2 840 210
3 810 210
4 220 200
5 4X0 400
6 289 231
7 398 383
Mean 279.6 260.4
B.D» * 86.0 ± 05,5
Shown for each of seven normal subjects are
the resu lts  of p la te le t counts immediacy 
before the intravenous in jection  of urokinase# 
SO#0(X) 0*T#A. units# and 10 minutes a fter  the 
injection# Mofui va3.UQB and standard 
deviations are also shown# The mean p la te le t  
count a fter  the urokinase in jection  i s  s ig n i­
fica n tly  le s s  than the moan p la te le t count 
IfiMediately pr0#^injection ( t   ^ 2#575» 0#02 <p 
<0#05)f
Table 71» Oontent of tho low fa t  breakfast and of tho high
fa t  breakfast
how fat, breakfast
Ooimf lakes# 1 oup
Btevæd fruit*  '& oup
Vdîite bread* 1 Blioe
Marîzzalade* 1 teaspoon
Black coffee 4» migar* 1 teaspoon
Hi^h fa t broal^:fast 
Low fa t  breakfast 
3)oublo oroma* 270 ml*
Carbohydrate# gm I Protein* gm j Fat* gm
22.1
10.0
15.8  
10.0
5.0
68.9 
0,1
1.7
2.3
4.0
6.2
0 .2
0 .4
0.6
94.5
Table Fiasminogon, leyela after the low fat
Subject
. ■—»— fr-y —-fi—.
Plaeminogon, ceioein units/m l
number Control After* fa t
1 2.84, 2.26 2. 51, 2.59
S 2.89, 2.91 2.60, 2,60
3 2. 59, 2.61 2.57, 2.63
4 2. 09, 2.11 2.19, 2.21
5 2. 25,  2.35 2.59, 2.61,
6 2. 07, 2,13 2. 30, 2.30
7 2.20, 2.20 2.28, 2.52
8 2. 15, 2.35 1 . 90, 1.90
9 2.18, 8.22 2, 25, 2.25
10 2.85, 2.85 2, 30, 2.30
Mean 2.373 2.344
8.D. t  0,299 -  0.218
Shown for each oubjoot are the rosu its of 
duplioato plasminogen assaya a fter  each 
typo of brealcfaet# Mean values and 
standard deviations are a lso  shown# 
Plasminogen le v e ls  a fter  each type of 
breakfast do not d iffer  s ig n ifica n tly
( t  = 0. 575,  0 .7  <P < 0 .8 ) .
Table 75 .Fibrinogen levels after the low fat 
breakfast and after the fat breakfast*
Sublect l^’ibrinoeen, mg/lOO ml
Number Control After fat
1 272, 278 233, 245
2 394, 408 373, 387
3 3S0 , 380 396, 404
A 363, 367 360, 360
5 236, 244 248, 252
6 160, 160 166, 174
? 158, 162 168, 172
8 147, 153 150, 150
9 200, 210 202, 208
10 190, 200 200, 200
Meim 233.0 252.5
s.D . Î97 .0  Î94.0
Shovjn for each subject are the results of 
duplicate fibrinogen assays for each type of 
breai^ fast# Mean values and standard 
deviations are also shomi# Fibrinogen levels 
after each type of breakfast are almost 
identical (t - 0*098, . 0*90 < p < 0.95).
Table 74» globulin lyais tests after the low fat breakfast
a fter  the high fa t  breakfast
l'üuglobuliu ly s is  activ ity#  units
number Oontrol After fa t
1 1.53 0.94
2 1.25 0.91
3 2,70 1.15
4 2.50 1.22
5 1,60 1.10
6 0,92 0.77
7 1.67 1.65
0 5,16 1.90
9 1,65 1.29
10 0,20 0.03
Moan 1#72 1#10
B.B. t  0.80 Î  0.51
fc»mir ‘ii w n M ii# w i i w w i
Bhovm for each subject are the resu lts  of euglobulin ly s is  te s ts  
a fter  each typo of breakfast# Bhown also are mean values and 
standard deviations# Mean euglobulin ly s is  a c t iv ity  a fter  the 
high fa t breakfast i s  s ign ifioq n tly  le s s  than mean euglobulin 
ly s is  a c t iv ity  a fter  the low fa t  breakfast ( t  « 3*573» 0#005<
p < 0#01)#
(gable 73» tîrokinaae aensitlvllv teata after the low fat
’a s t and
SubjeGM
ïîUïïiber
Urokinase sensitivity teat, nnlts
Control After fat
1 0.97 0.76
2 1.77 1,50
5 1.12 0.74
4 . 1.25 0.97
5 2,31 1.71
6 0.68 0.68
7 0,65 0.49
e 0.67 0.60
9 0.48 0.54
10 0,60 0.59
Mean 1,05 0.05
S*D* — 0.59 * 0.38
Shorn for eaoii aabjeot are the rasults of urokinase 
sensitivity tests after eaoh type of broÆfast, 
values and stm"idard deviations ar& also shown* 0?he 
mean increased resistance to lysis of the standard 
plasma clots formed in tliis test after the high fat 
breakfast la si^ ï^,if leant compared with the finding 
after the low fat breakfast (t « 5*0^7» 0*01 < p <0*02)*
(Cable 76' ÎOTiOê measured as reduction in  radioact iv i t y , 
M.,CJiand3.er a fter  the low fa t braekfaet
te a k fa a t
Subject
uuraber
1
2
3
4
5
6
7
8
9 
10
Moan
bysie of Gîmndlor thrombi ^  per cent reduction in  rad ioactiv ity
S*D,
Control After fa.t
6 7 * 8
66»0
67.;i
35.0
62.0 
26*3 
3B.4
4 1 .1
48.1
5 1 .6
48.6
t  13.7
2 9 .3
64*6
35.2
51.0
3 5 .3
2 5 .4
3 0 .7
22.7
46.4
3 0 .0
3 5 .1
-  12.2
Sho\m for each patient i s  the per cent reduction in  rad ioactiv ity  of 
^3iX*-taggod QhancD.er thrombi formed a fter each type of broalcfast and 
subjected to lyaio  by atrei^tokinaae for 24 hom^ a in  an a r t i f ic ia l  
circulation* Mean values mrid standard devia>tions are a lso  ohovm* 
The mean reduction in  rad ioactiv ity  of thrombi formed after  the high 
fa t  breakfast ia  s ig n ifica n tly  leas than the moon recluotion in  radio­
a c tiv ity  o f thrombi formed a fter  the low fa t  breakfast ( t  « 3#024, 
0.01 < p  <0.02)
Table 77* Lyaiat measured ge g reduction In weight# of Ohandler 
thrombi formed after the low fat brealcfast and after
the high fat breakfast«
V W I. ML#     n # # #
Subject lÿ'sis of Ghmdler thx'ombi, per cent reduction in weight
number
y
4
5
6
8
9
10
Control After fat
90.3 
71.0 
70.2  
72.6 
5*i-.6 
7^1’.9  
78,8 
52.8
73.7  
61.9
64.8 
66.5
28.0
66,7
57.0
4-9.3
m W f iW h I# #
s.n,
56.5
12.3
46,8
* 14.3
Shorn fo3r oabjectG number i© the per cent weight loss 
of Chandler thrombi formed aftex' each type of breakfaot and 
©ubjectod to lyeid by ©troptokinaoe fox' 24 hoiu's in an 
artificial circulation* Mean values end standard deviation© 
are also shown* Mean weight loss of tlirombi formed after the 
high fat breol^ fast ia significantly leas thtm mean weight 3.oss 
of tlirombi formed after the low fat breal^ faat (t * 4*054,
0*001 < p < 0 *0 0 5 ) .
g_abie .78;   I W a
the low fa t  breakfast and a fter  the high fa t  breakfast
Subject
number
C lotting time, 0OOOM0 
Control After fa t
1 14*7# 14*9 9. 0 ,  9 .0
2 17, 2, 17.6 9. 0 , 9.4
3 29. 0 , 29.0 21. 0 , 21.0
4 20. 2, 20.4 11. 9,  12.1
5 24. 0* 24.0 15. 5, 16,5
6 19. 8 , 20.2 16. 0 , 16.0
7 50. 0, 30.0 22*8, 23,2
8 28.4 , 29.6 21. 0,  21.0
9 21. 0 , 21.0 16. 0 , 16.0
10 23. 0 , 23.0 12. 6 , 13.4
Mean 22.9 « 15.6
S.ÏÏ. -  5 .2 t  4 .9
Shoim for each ouhjeot are Ruseell viper venom (Stypven) 
c lo ttin g  times a fter  each type of teoakfaot* Moan 
values end standard deviations are a lso  shown# Bach 
c lo tt in g  time was measured in  duplicate# The mean 
c lo tt in g  time a fter  the high f e t  hreaicfaat i e  
s ig n if lc m tly  shorter than the m m  c lo tt in g  time a fter  
the low fa t  breakfast ( t  « 12#726, p <0#00l ) .
Table 79. P3at^ erfa a^tregation in  the Chandler^ a tube after  
the low f a t , breakfast end a fter  the hlfùi fa t  breakfast
Bubjoot
number
Time for p la te le t  aggregation, seconde 
Control After fa t
1 521 568
2 518 603
3 589 665
4 530 514
5 624 699
6 519 683
7 550 605
8 530 614
9 60B 570
10 430 490
Moan 521 603
S.B, t  97 “ 68
Shovm for each eubjeat are the times for p la te le t  
aggregation in  the Chandler tube a fter  each type 
o f breakfast* Mean values and standard deviations 
are a lso  shov/n* The mean time for p la te le t  
aggregation a fter  the high fa t  breakfast i s  
sig n ifica n tly  prolonged compared with the finding  
a fter  the low fa t  breakfast ( t  » 4*^6)# 0*005 < p 
<0.01)
fable 80, Platelet coTOte after the low fat breakfast
and after tlie high fat breakfast
Bubieot Platelet ootmt, thousaacls/fimi^  
number Control After fat
2 200 272
2 171.3 198
5 230 228
4 196 258
5 250 220
6 200 201
7 103 150
8 250 236
9 174 201
10 342 352
Mean, 219.7 232.4
S»B, t  51.6 t  50.2
ShoTO for each aubjeot are platelet counts after each 
type of breaikfaot* Mean values and standard 
deviations tire aleo shown# Platelet counts after 
each typo of breakfast do not differ significantly 
( t  = 1, 178, G»2 4P 0 .3 )-
Table 81* Berum triglycéride levole after the low fat breakfast
and after the hi^ fat breakfaot
Boram
nimber
1
2
3
4
5
6
7
a
9
10
Berum tr ig ly cer id es , mg/lOO ml
GontroX
128
130
62
83
59
119
41
78
61
After fa t
304
239
87
256
193
162
5 0
120
1 1 7
1 1 4
Meai'i 81 164
B*D« 4'*• 34 08
Bhovm for each subject are serum tr ig lyceride le v e ls  a fter  each 
type of breakfast# Mean values and staxidard deviations are 
also  shown* The mean serum tr ig lyceride le v e l a fter  the high 
fa t  breakfast i s  s ig n if ica n tly  higiier than the mean lev e l  
a fter  the low fa t  bx^eokfast ( t  =» 4*427» 0*001 <p <0*005 )•
Table 02. Bertwî bhospliollpid levels after the low fat
breakfast and after the hiffb fat breakfast
Subject
Humber
Serum £?hoapholipids, ïiig/lOO ml 
Control After fat
1 209 211
2 106 225
3 204 263
4 210 188
5 165 218
6 233 306
7 241 293
8 225 239
9 239 274
10 203 226
Mean
S.B* 'hm
212
24
244
. ' M M * * * , riM | > . l  . 1 1
Shorn for each eubjeat are serum phospholipid levels 
a fter  each type of brealcfaot* Mean values and standard 
deviations are also shown* The mean serum phospholipid 
lev e l a fter  the high fa t  breakfast i s  si^ ^ ificim tly  
higher than the mecm, le v e l a fter  the low fo>t breakfast
( t  =■ 3. 596,  0,005 < » < O.ol)
TabXe83* Plasma free fatty aoid levoXa after the low fat
breakfast and after the high fat breakfast
Bubleot Plasma free fa tty  aoide, ] ie /l itr e  
BuotocK- Oontrol After fa t
W> la w  I. m M
1 389 705
2 962 1018
5 620 944
4 518 972
5 500 925
6 546 833
7 481 722
0 296 1258
9 666 1102
10 629 965
Mean 56I 952
S«B, t  180 t  177
Shovrn for each subject are plasma frees fa tty  acid lev e ls  
a fter  eaoli typo of broalcfast* Also shown are mean values 
and standard c|eviatio,no» The mean plasma free fa tty  aoid 
le v e l a fter  ‘bî^ e high fa t  breakfast i s  B ignificantly  higher 
than the mean le v e l a fter  the low fa t breal^fast ( t  « 5*215»
p < 0. 001)*
Table 84. Serum oliolesterol levels after the low fat breakfast
and after the high fa.t breakfast
Subject 8erum oholeateroli mg/lOO ml 
mmbes? (JOUtX’Ol After fat
1 227 247
2 201 195
3 174 152
4 179 209
5 201 165
6 296 296
7 242 210
0 215 214
9 292 220
10 199 188
t ; # # n É Ë M W i " W r u W l % W * iW f w # w w # * k | # a # f #
s.D , •  43 4 1
tmUt
Bhovai for each aubjeot are aemim cholesterol levels after each 
type of breakfast* Mean values and standard deviations are also 
phovm* Choiestex’ol levels after each typo of breakfast do not 
differ sigtxifioantly (t « 1*417, 0*10 -< p <0*20)*
Tgblo 65. Plasma thrombi triglycoride content after 
the low fat brealcfaot and after tli© high fat breakfast
Subjeot Plasma thrombus triglycéride content» mg/100 ml
number Oontrol After fat
1 0,31 0.36
2 0.27 0 .8 0
3 0.10 0.27
4 0.14 0.26
5 0.00 0.24
6 0 ,07 0.44
7 0 ,06 0.00
8 0.23 0*17
9 0.34 0,24
10 0,01 0 .0 9
Metm
8.D*
0*15
0*13
0 * 2 9
•0 .2 2
r # T v w w B * * o *
Shovn for ouch subject Is tho trlglycoride content of the 
plasma thrombi formed after each type of breakfast in the 
03cperiment to measure platelet aggregation* Moan values 
and standard deviations are also shovna# . The mean triglyceride 
content of the plasma thrombi formed after the high fat 
breakfast is blghex' than the mean value after the low fat 
breakfast but the difforeme is not significant 
<t ci 2*109» 0,05 < p < 0,1),
Table 86* Fibrinolytic and coagulation asG^s
ill, patient 1 * chapter 8 *
'.Pime of sampling, days
0  4 6 8
2
Fibrin plate test mïa ' t plasma 0 0 0 9
resuGpendod eugXobulin precipitate 0 4 100 30
Radioactive clot assay 0 0 0 0
ISuglobulln lysis activity» units 1*2 1*0 2*6 1*6
Plasminogen» casein units/ml 1*33 2*45 1*90 3*20
Tiircmbin time» seconde 19*3 l8*0 10,6 10*0
Fibrinogen» mg/lOO ml 76 91 193
(Me-^ stage protlirombin time» seconds 19*5 19*0 15*0 12*0
Tame assay » per cent 25 33 50 **
Factor V assay, 10 10 «* 30
Factor VII assay» per cent 100 100 100 100
Antihaemopbilic globulin assay » 
per cent 7 10 25 75
OJ'iriatmas factor assay, per cent 75 75 75 75
g y j B f c ^  * ,  t r V f # * *  #  sr*4i- . k T : P 4 * u  p :  »? «M «*W M  * M W W *W i * # t w  w * Hi* W ( # J i
Factor X assay, per cent 55 - 55 100
Platelets » thousands/mm^ 160 130 85 220
i+ il’il»arti*n».»wj< r» n » ***.%^ivnnâ i * i f t * i t*g;mw*rNW-**K*v**r^wiHimMja w M i w!*»fn;»gm i uiiM * I * i!Pmj *Wi w ,w **, m(Nwii# u *m \w #*M #e«#M *m **# 'r*(i# # # 'W W # # * # * M * * # i
Bhoim are the results of flbrinolytio and coagulation assays in 
patient 1, chapter 8* This patient had had an intivmterine death 
at least 7 weeks proced:3xig investigation* ThO-t'apy with BACA was 
commenced immediately after investigation on dsy 0# Delivery of 
a stillborn infant occurred on day 5 and therapy with BACA i^fas 
disoontinuod 12 hours post-^ delivery, on the evening of day 5*
The data are displayed in part in figure 63*
Table 8? » Flbrlmolytlç mid GoamAlation assays
In patient 2$ chapter 8*
Time of sampling, day© 
0 2 5
Fibrixt plate test, mm $ plasma 
reeuopended ouglobulin preoipitate
Radioactive clot assÊiy
Buglobulln lysiB activity, unite
Plasminogen, caaei^ i nuite/ml
Thrombin time, seconde
Fibrinogen, mg/lOO ml 
One^atage prothrombin time, seconde 
Factor V assay, per cent
Factor VII aesety, per cent 
/Ultihaefiîophilic assay, per cent 
GM*istmas factor ciaeay, i^ er cent 
Factor K assay, per cent 
Platelets, thousands/
0 0 0
146 56 44
0 0 0
0 .78 0 ,78 0 ,5 0
2.3 2.3 2,85
17.0 21.0 9.7
218 98 221
14,7 13.4 14,5
25 - 25
100 100 100
15 20 100
100 100 100
15 12 100
237 127 l6o
Shown m/e the results of fibrinolytic and coagulation assays 
‘in patient 2, chapter 8* This patient had had an intrautox'ine 
death at least 6 weeks preceding investigation* Therapy with 
BACA v;as commenced Immediately after investigation on day 0* 
Delivery of a stillborn infant occurred on day 4 and therapy 
with BACA was disoontitmod 12 hours post*-4elivery, on the 
evening of dsi^y 4# The data are displayed in part in figin/e 
64.
T able_ 88* F ib rin o ly tio  .and ^.coagulai 
in  p a tio n t 3* chapte r  8
Time of sajjipltlng, daya
2Fibrin plate test, mm’? plasma 
â/esusponded euglobulin precipitate
Buglobulin lyais activity, units
Plaeminogen, casein  unitsA >l
Tlirombln tim e, sooonda
Fibrinogen mg/100 ml
Ono^atage prothi'ombin time, 
seconds
Factor V assay, per cent
k i f i W A R # ;  w *  r  i^ i *  ,# *  W i # * m ,  ; v i i  # i'^« * # w  % A  4 * P # W # m W # C # * '! '  # W
Antihaomophilic globulin assay, 
per cent
i iK im i n n * . !#
Christmas factor assay, per cent
0 58
0 0
49 66
..85 2*0
1.8 ■ 1*3
33 16
83 80
22 20
100 12
100
ICO
260 33Platelets, thousands/
i f r r - f  <r*rii ftfiiytilitirfiT'Ti-nti^-r-fn^TiT'-iTrrrrfi'rinTim rrtiTTfr rfi"rr-'Tr"riY"'-iili''ii sitm^hq»
vShown are the a/esults of fibrinolytic assays in patieni; 3, 
chapter 8# This patient had a carcinoma of breast with 
métastasés# Other data for this patient are shovm in figures 
23 and 6g#
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aixd tlirombin clotting time*
Concentration of fibrinogen,I Thrombin clotting time,
mg/lOO ml seconds
400 11
330 12
300 13
230 15
200 17
150 25
100 30
50 60
25 100
......................................................
Shown is tho relationship, in a pwified system, 
between fibx'inogen levels and thrombin clotting 
time*
Table 91» Relationship between fibrinogen coneentration
and lyaia time»
CoEOentrâtion of fibrinogen, Plasma clot lysis time 
mg/lOO ml
400 3.5 mine
350 l4 mins
300 13 mins 30 soos
250 11 ndxas 20 secs
200 9 nijas
150 6 mine 10 secs
100 3 mails 45 secs
50 2 mine 30 secs
25 1 min 50 secs
Shown ia the relationship, in a purified system 
containing a stmidard amount of m'okinase and 
plasïïdnogen, between fibrinogen levels tmd clot 
lysis times*
Table 92# Plasminogen in plasma ami aorum
JSubjeot lllasndnqgen * casein imits/niX 
Number Plasma Serura
1 3 .6 , 3 .8 3 .55 , 3 .6
2 4 .7 , 4 .7 4.7 , 4 .7
3 3 .35 , 3.45 3 .35 , 3.45
4 4 .2 , 4 .6 4*4, 4.4
3 5 .0 , 5 .0 5 .0 , 5 .0
6 3 .0 5 , 3.15 3 .25 , 3 .3
7 3 ,9 , 3 .9 3 .8 , 3 .8
8 2 .7 , 3 .1 3 .0 , 3 .0
9 3 .05 , 3.15 3 .4 , 3.45
10 2 .8 , 2.8 3 .0 , 3 .0
 ^ 11 3 .7 , 3 .7 3 .9 , 3 .9
Mean 3.7 3 .8
8*D* ~ 0.7 -  0 ,7
Shovm are the results of duplicate assays of 
plasminogen in plasmas and sera from 11 
normal subjects* Mean values and standai'd 
deviations are also shovjn* The mean 
plasminogen 3.evel in plasma does not differ 
sign!ficantly from the mean level in 
serum (t ^ 1*862» 0 .05 < p < O.IO)*
